Document:

Exhibit 10.4

 

Execution Version

 

 

 

AGREEMENT AND PLAN OF MERGER

 

by and among

 

HPI HOLDINGS, LLC,

 

AHS GRANITE MERGER SUB, INC.,

 

SHAREHOLDER REPRESENTATIVE
SERVICES LLC

 

(solely in its capacity as Stockholders’
Representative)

 and

 

ADVANTEDGE HEALTHCARE HOLDINGS, INC.

 

September 30, 2021

 

 

 

     

     

    

 

TABLE OF CONTENTS

 

Page

 

	ARTICLE I DEFINITIONS	2
	 	 	 
	Section 1.1	Definitions	2
	 	 	 
	ARTICLE II MERGER	18
	 	 	 
	Section 2.1	The Merger	18
	Section 2.2	Closing of the
    Merger	18
	Section 2.3	Effective Time	18
	Section 2.4	Effect of the
    Merger	18
	Section 2.5	Further Actions	19
	Section 2.6	Certificate
    of Incorporation; Bylaws	19
	Section 2.7	Directors and
    Officers	19
	Section 2.8	Effect on Company
    Equity Securities	19
	Section 2.9	Purchase Price	21
	Section 2.10	Earnout Payment	25
	Section 2.11	Stock Incentive
    Plan; Warrants	26
	Section 2.12	Management Carve-out
    Program Awards	26
	Section 2.13	Letters of Transmittal	26
	Section 2.14	Additional Actions	27
	Section 2.15	Payment of Closing
    Indebtedness and Unpaid Company Stockholder Expenses	28
	Section 2.16	Appraisal Rights	28
	 	 	 
	ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY	29
	 	 	 
	Section 3.1	Organization
    and Qualification	29
	Section 3.2	Capitalization	29
	Section 3.3	Consents and
    Approvals; No Violations	30
	Section 3.4	Power and Authority;
    Enforceability	31
	Section 3.5	Financial Statements;
    No Undisclosed Liabilities	31
	Section 3.6	Material Contracts	32
	Section 3.7	Absence of Changes	34
	Section 3.8	Litigation	35
	Section 3.9	Compliance with
    Applicable Law	35
	Section 3.10	Employee Plans	36
	Section 3.11	Environmental
    Matters	37
	Section 3.12	Intellectual
    Property	38
	Section 3.13	Privacy	40
	Section 3.14	Labor Matters	40
	Section 3.15	Insurance	41
	Section 3.16	Tax Matters	41
	Section 3.17	Material Permits;
    Healthcare Matters; Billing	44
	Section 3.18	Real Property	45
	Section 3.19	Clients and
    Suppliers	46

 

    i

     

    

 

	Section 3.20	Foreign Corrupt
    Practices Act	46
	Section 3.21	Brokers	46
	Section 3.22	EXCLUSIVITY
    OF REPRESENTATIONS AND WARRANTIES	46
	 	 	 
	ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB	47
	 	 	 
	Section 4.1	Organization	47
	Section 4.2	Authority	47
	Section 4.3	Consents and
    Approvals; No Violations	48
	Section 4.4	Investment Purpose	48
	Section 4.5	Brokers	48
	Section 4.6	Financial Ability	48
	Section 4.7	Solvency	49
	Section 4.8	Merger Sub Activities	49
	Section 4.9	No Contact with
    Employees, Clients and Suppliers	49
	Section 4.10	Acknowledgment
    and Representations by Parent and Merger Sub	49
	 	 	 
	ARTICLE V [RESERVED]	50
	 	 	 
	ARTICLE VI POST-CLOSING COVENANTS	50
	 	 	 
	Section 6.1	Further Assurances	50
	Section 6.2	Intellectual
    Property Matters	50
	Section 6.3	Confidentiality	51
	Section 6.4	Directors’
    and Officers’ Indemnification and Insurance	52
	Section 6.5	Employee Benefit
    Matters	53
	Section 6.6	Documents and
    Information	53
	Section 6.7	RWI Policy	54
	Section 6.8	Parachute Payments	54
	Section 6.9	Company Stockholder
    Notice	54
	 	 	 
	ARTICLE VII CLOSING DELIVERABLES	55
	 	 	 
	Section 7.1	Closing Deliverables
    of the Company	55
	Section 7.2	Closing Deliverables
    of Parent	56
	 	 	 
	ARTICLE VIII INDEMNIFICATION	56
	 	 	 
	Section 8.1	Survival	56
	Section 8.2	Indemnification
    by the Company Stockholders	57
	Section 8.3	Indemnification
    by Parent	58
	Section 8.4	Certain Limitations	58
	Section 8.5	Procedures	58
	Section 8.6	Other Limitations	59
	Section 8.7	Escrow	60
	Section 8.8	Exclusive Remedy	60

 

    ii

     

    

 

	ARTICLE IX TAX RELATED MATTERS	61
	 	 	 
	Section 9.1	Tax Returns	61
	Section 9.2	Straddle Periods	61
	Section 9.3	Transfer Taxes	61
	Section 9.4	Cooperation	61
	Section 9.5	No Intermediary
    Transaction Tax Shelter	62
	Section 9.6	Tax Treatment	62
	 	 	 
	ARTICLE X STOCKHOLDERS’ REPRESENTATIVE	62
	 	 	 
	Section 10.1	Authorization
    of Stockholders’ Representative	62
	 	 	 
	ARTICLE XI MISCELLANEOUS	65
	 	 	 
	Section 11.1	Exclusive Remedy;
    Limitation of Liability	65
	Section 11.2	Entire Agreement;
    Assignment	66
	Section 11.3	Notices	66
	Section 11.4	Governing Law	67
	Section 11.5	Fees and Expenses	68
	Section 11.6	Press Releases
    and Announcements	68
	Section 11.7	Construction;
    Interpretation	68
	Section 11.8	Exhibits and
    Schedules	69
	Section 11.9	Parties in Interest	69
	Section 11.10	Severability	69
	Section 11.11	Amendment	70
	Section 11.12	Counterparts;
    Facsimile Signatures	70
	Section 11.13	Mutual Drafting	70
	Section 11.14	WAIVER OF JURY
    TRIAL	70
	Section 11.15	Jurisdiction
    and Venue	70
	Section 11.16	Remedies	71
	Section 11.17	Waiver of Conflicts	71
	Section 11.18	Release	72

 

    iii

     

    

 

	EXHIBITS	 
	 	 	 
	Exhibit
    A	Disclosure Schedule	 
	Exhibit
    B	Form of Escrow Agreement	 
	Exhibit
    C	Form of Letter of Transmittal	 
	Exhibit
    D	Earnout Payment Calculation	 
	 	 	 
	SCHEDULES	 
	 	 	 
	Schedule 1.1(a)	Form Working Capital Statement	 

 

    iv

     

    

 

AGREEMENT AND PLAN OF MERGER

 

THIS AGREEMENT
AND PLAN OF MERGER (including all Schedules and Exhibits attached hereto, this “Agreement”), dated as of September
30, 2021, is entered into by and among HPI Holdings, LLC, a Delaware limited liability company (“Parent”), AHS
Granite Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent (“Merger Sub”),
Shareholder Representative Services LLC, a Colorado limited liability company (the “Stockholders’ Representative”),
solely in its capacity as the representative, agent and attorney- in-fact of the Company Stockholders (as defined below), and ADVANTEDGE
HEALTHCARE HOLDINGS, INC., a Delaware corporation (the “Company”). Parent, Merger Sub, the Stockholders’
Representative (solely in its capacity as such) and the Company may be referred to herein, collectively, as the “Parties,”
and each, individually, as a “Party.”

 

RECITALS:

 

WHEREAS, upon the
terms and subject to the conditions of this Agreement and in accordance with Section 251 of the Delaware General Corporations Law (“DGCL”),
Parent, Merger Sub and the Company will enter into a business combination transaction pursuant to which Merger Sub, an entity organized
for the sole purpose of entering into the transactions contemplated hereby, will merge with and into the Company, with the Company surviving
such merger as a wholly owned subsidiary of AHS HoldCo, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Parent
(the “Merger”);

 

WHEREAS, the respective
boards of directors of each of Parent, Merger Sub and the Company have approved this Agreement, the Merger and the related transactions
contemplated hereby and thereby, and have determined that the Merger is advisable to, and in the best interests of, such Party and its
stockholders and have recommended that such Party’s stockholders, as applicable and to the extent required, consent to and approve
this Agreement, the Merger and the related transactions contemplated hereby upon the terms and subject to the conditions set forth herein;

 

WHEREAS, the Company
Stockholders who collectively own at least (i) 99% of the outstanding Preferred Shares (as defined below) and (ii) 95% of the outstanding
Company Shares (as defined below), voting together as a single class (the “Company Stockholder Approval”), have
approved this Agreement and the consummation of the Transactions (as defined below) in accordance with the DGCL, the Company’s Second
Amended and Restated Certificate of Incorporation, as amended (the “Restated Certificate”), and the Stockholders’
Agreement (as defined below), pursuant to a written consent of stockholders (the “Written Consent”);

 

WHEREAS, a portion
of the cash consideration otherwise payable by Parent to the Company Stockholders in connection with the Merger shall be placed in escrow
by Parent, the release of which shall be contingent upon certain events and conditions, all as set forth in this Agreement and the Escrow
Agreement (as defined herein); and

 

WHEREAS, Parent has purchased the RWI Policy (as defined below).

 

     

     

    

 

NOW, THEREFORE, in
consideration of the foregoing and of the mutual promises, covenants, representations, warranties, and agreements herein contained, and
intending to be legally bound hereby, the Parties agree as follows:

 

ARTICLE I

 DEFINITIONS

 

Section 1.1 Definitions.
As used herein, the capitalized terms set forth below shall have the respective meanings set forth below.

 

“Accounting Firm” has the meaning
set forth in Section 2.9(b)(ii).

 

“Action”
means any Claim, action, cause of action, demand, inquiry, notice of violation, litigation, citation, summons, subpoena, investigation,
audit, suit, assessment, arbitration, or any proceeding or investigation of any nature, civil, criminal, administrative, regulatory or
otherwise, whether at law or in equity.

 

“Actual
Adjustment” means an amount, which may be a negative number, equal to (a) the Purchase Price as finally determined pursuant
to Section 2.9(b), minus (b) the Estimated Purchase Price.

 

“Adjustment Escrow Account” has
the meaning set forth in Section 2.9(a)(i).

 

“Adjustment Escrow Amount” has the meaning set forth in Section
2.9(a)(i).

 

“Affiliate”
means, with respect to any Person, any other Person who directly or indirectly, through one or more intermediaries, controls, is controlled
by, or is under common control with, such Person. The term “control” means the possession, directly or indirectly, of the
power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities,
by contract or otherwise, and the terms “controlled” and “controlling” have meanings correlative thereto.

 

“Aggregate
Common Shares Deemed Outstanding” means the sum of (a) the aggregate number of Common Shares outstanding as of immediately
prior to the Effective Time, plus (b) the aggregate number of Preferred Shares outstanding as of immediately prior to the Effective
Time.

 

“Agreement” has the meaning set
forth in the Preamble.

 

“Ancillary
Documents” means each agreement, document, instrument and/or certificate contemplated by this Agreement to be executed in
connection with the Transactions (excluding this Agreement).

 

“Assets”
means all of the Company’s and its respective Subsidiaries’ rights, assets and properties of every kind which are used in
the operation of the Business by the Company and its Subsidiaries, including all property, tangible and intangible, real, personal or
mixed, inventory, Intellectual Property Rights, accounts receivable, prepaid expenses, Contracts, Claims, Permits and Records.

 

    2 

     

    

 

“Business”
means the business of providing outsourced revenue cycle management, billing and practice management services for specialty and other
hospital-based physician practices located throughout the United States.

 

“Business
Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be
closed in New York, New York.

 

“Carve-out Program Amount” has the
meaning set forth in Section 2.12.

 

“CARES Act” means the Coronavirus Aid, Relief, and Economic Security
Act.

 

“Cash”
means, as of a specified time, cash and cash equivalents, including the amounts of any received but uncleared checks, drafts and
wires issued prior to such time, less the amounts at such time of (a) any outstanding checks or transfers, (b) restricted cash,
including but not limited to the restricted cash in the Refund Cash Account (TB 1066 Fifth Third – Refund Account), or
deposits, in each case, determined in accordance with the Company Accounting Principles, and (c) the aggregate amount of Taxes
(including withholding Taxes) that are reasonably expected to be incurred in order to lawfully repatriate to the United States the
aggregate amount of such cash and cash equivalents that is held by any subsidiary of the Company that is not a “United States
person” (as defined in Section 7701(a)(30) of the Code).

 

“Certificate of Merger” has the
meaning set forth in Section 2.3.

 

“Certificates”
means with respect to the Company Shares, those certificates evidencing Company Shares.

 

“Claim”
means any demand, claim or complaint by any Person alleging actual or potential liability.

 

“Claim Notice” has the meaning set
forth in Section 8.5(a).

 

“Closing” has the meaning set forth in Section 2.2.

 

“Closing Cash” means the amount
of Cash as of 11:59 p.m. on the day prior to the Closing Date.

 

“Closing Date” has the meaning
set forth in Section 2.2.

 

“Closing Indebtedness” means the
amount of all Indebtedness of any of the Group Companies unpaid as of the Closing.

 

“Closing Working Capital”
means the Working Capital of the Group Companies, calculated on a consolidated basis as of 11:59 p.m. on the day prior to the Closing
Date.

 

“Code” means the Internal Revenue
Code of 1986, as amended.

 

“Common Share Purchase Warrants”
means the Common Share Purchase Warrants issued by the Company to the Warrant Holders in respect of the Warrants.

 

    3 

     

    

 

“Common
Shares” shall mean the shares of Common Stock of the Company, $0.01 par value per share.

 

“Company” has the meaning set forth
in the Preamble.

 

“Company
Accounting Principles” means, as the context requires, GAAP consistently applied in accordance with the Company’s
past accounting practices, including, the accounting practices described in the Form Working Capital Statement; provided, however,
that, in the event of an inconsistency between GAAP, on the one hand, and the principles or practices described in the Form Working Capital
Statement, on the other hand, the Form Working Capital Statement shall control.

 

“Company Board” shall mean the
board of directors of the Company.

 

“Company Financial Statements” has the meaning set forth in Section 3.3.

 

“Company Recommendation” has the meaning set forth in Section 3.4.

 

“Company
Stockholder Expenses” means, without duplication, the aggregate amount of all fees, costs and expenses due and payable,
incurred, paid or accrued by any of the Group Companies or by or on behalf of the Company Stockholders or the Stockholders’ Representative,
as a result of or related to the Transactions, or the solicitation of other potential buyers of any Group Company or any of its Affiliates
or consideration of other strategic alternatives, including any public or private offering of shares, including (i) the fees and expenses
of the Stockholders’ Representative’s and any of the Group Companies’ advisers, including Brentwood Capital Advisors,
LLC, Falcon Capital Partners, LLC, Duane Morris LLP and FEF Management Services LLC (dba Founders Equity Inc.), (ii) any success, change
of control or similar bonuses payable to any employee or director of any of the Group Companies in connection with the Transactions, paid
or accrued by any of the Group Companies in connection with the payment of such bonuses, but excluding any such amounts which are conditioned
upon termination of employment and become payable as a result of a termination of employment where notice to terminate such employment
is delivered following the Closing, (iii) any distributions payable to any employee of any of the Group Companies pursuant to an award
under the Management Carve-out Program (including the Carve-Out Program Amount), (iv) any amounts payable by the Company Stockholders
in connection with the RWI Policy; (v) any amounts payable by any of the Group Companies in connection with the directors and officers
 “tail insurance policy” pursuant to and in accordance with Section 6.3(b), and (vi) any Taxes of the Group Companies
(including all sales, use, value added, and Employment Taxes) payable in connection with the payment of any amounts described in clause
(i), (ii), (iii), (iv) or (v) of this definition.

 

“Company Shares” means all the
issued and outstanding Preferred Shares and Common Shares.

 

“Company Stockholder Approval” has the meaning
set forth in the Recitals.

 

“Company Stockholders” means, collectively,
each of the holders of the Company Shares outstanding immediately prior to the Effective Time.

 

    4 

     

    

 

“Confidential
Information” means, with respect to a particular Person and its Affiliates, all information of a confidential or proprietary
nature (whether or not specifically labeled or identified as “confidential”), in any form or medium, that relates to the business,
products, or research and development of such Person or its Affiliates, including the following: (a) internal business and financial information;
(b) identities of, individual requirements of, specific contractual arrangements with, and information about, suppliers, distributors
or customers; (c) trade secrets, know-how, analyses, techniques, systems, formulae, research and development information, Records, reports,
manuals, drawings, specifications, designs, plans, proposals, technical data, documentation, models, data and databases relating thereto,
manufacturing processes and techniques, financial and marketing plans and customer and supplier lists and information; and (d) inventions,
innovations, improvements, developments and methods (whether or not patentable). Notwithstanding the foregoing, “Confidential Information”
shall not include information, data, knowledge or know-how that (i) enters the public domain through no violation of this Agreement by
the Party (or its Affiliates), or any of their respective representatives or agents, which has the obligation of confidentiality; (ii)
is received from a third party not under obligation of confidentiality to the Party (or its Affiliates), or any of their respective representatives
or agents which has the obligation of confidentiality; or (iii) is independently developed without reliance on any Confidential Information.

 

“Confidentiality
Agreement” means that certain Confidentiality Agreement, dated May 5, 2021, executed by Health Prime International, LLC.

 

“Consideration
Spreadsheet” means a spreadsheet prepared by the Company which shall set forth, as of the Closing, the following: (i) the
names, addresses, email addresses and wire instructions of all Company Stockholders; (ii) the number and class of Company Shares held
by each such Company Stockholder; (iii) the amount of cash deliverable to each Company Stockholder at Closing; (iv) each Company Stockholder’s
Pro Rata Share; (v) the calculation of the Series A Liquidation Preference Amount, the Series A-1 Liquidation Preference Amount, the Series
A Per Share Merger Consideration and the Series A-1 Per Share Merger Consideration; (vi) a funds flow memorandum setting forth applicable
wire transfer instructions; and (vii) such other information which Parent may reasonably request.

 

“Contract”
means, with respect to a particular Person, any contract, agreement, commitment, deed, engagement letter, note, bond, pledge, lease, license,
mortgage, guaranty, indenture, option, instrument, obligation, undertaking, or commitment that is legally binding on such Person or its
property, whether written or oral.

 

“COVID-19”
means SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), coronavirus disease 2019 or COVID-19, including any future resurgence
or evolutions or mutations thereof or any related or associated epidemic, pandemic or disease outbreak.

 

“Current
Assets” means the sum of the line items of the consolidated balance sheet of the Group Companies that are listed under the
heading “Current Assets” on the Form Working Capital Statement and calculated in accordance with the Company Accounting Principles;
provided, however, that Current Assets shall exclude Cash and all Tax assets.

 

    5 

     

    

 

“Current
Liabilities” means the sum of the line items of the consolidated balance sheet of the Group Companies that are listed under
the heading “Current Liabilities” on the Form Working Capital Statement and calculated in accordance with the Company Accounting
Principles; provided, however, that Current Liabilities shall exclude all Tax liabilities, Closing Indebtedness and, to the extent
paid at Closing, Company Stockholder Expenses.

 

“DGCL” has the meaning set forth
in the Recitals.

 

“Disclosure
Schedule” means the disclosure schedules delivered in connection with the execution and delivery of this Agreement, a copy
of which is attached hereto as Exhibit A.

 

“Dissenting Shares” has the meaning
set forth in Section 2.16(a).

 

“Dissenting Stockholder” has the meaning set forth in Section 2.16(d).

 

“Earnout Escrow Account” has the meaning set forth in Section 2.9(a)(iii).

 

“Earnout Escrow
Amount” has the meaning set forth in Section 2.9(a)(iii).

 

“Effective Time” has the meaning
set forth in Section 2.3.

 

“Employee”
means any current or former employee, director or other individual service provider of a Group Company.

 

“Employee
Benefit Plan” means each “employee benefit plan” (as such term is defined in Section 3(3) of ERISA) and each
other material employee benefit plan, program or arrangement that any Group Company maintains, sponsors or contributes to or with respect
to which any Group Company has any material liability, other than any plan, program or arrangement sponsored, maintained or administered
by a Governmental Entity.

 

“Employment
Taxes” means the employer’s portion of any payroll, employment or similar Taxes payable by the Group Companies, regardless
of whether or not such amounts are currently due and payable or deferred under Section 2302 of the CARES Act (or any similar provision
of state, local or foreign Law)).

 

“Enterprise Value” means $80,000,000.

 

“Environmental
Laws” means all Laws, and any order from a Governmental Entity or binding agreement with any Governmental Entity: (a)
relating to pollution (or the cleanup thereof) or the protection of natural resources, endangered or threatened species, human
health or safety, or the environment (including ambient air, soil, surface water or groundwater, or subsurface strata); or (b)
concerning the presence of, exposure to, or the management, manufacture, use, containment, storage, recycling, reclamation, reuse,
treatment, generation, discharge, transportation, processing, production, disposal or remediation of any Hazardous Materials. The
term “Environmental Law” includes, without limitation, the following (including their implementing regulations and any
state analogs): the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended by the Superfund
Amendments and Reauthorization Act of 1986, 42 U.S.C. §§ 9601 et seq.; the Solid Waste Disposal Act, as amended by the
Resource Conservation and Recovery Act of 1976, as amended by the Hazardous and Solid Waste Amendments of 1984, 42 U.S.C.
 §§ 6901 et seq.; the Federal Water Pollution Control Act of 1972, as amended by the Clean Water Act of 1977, 33 U.S.C.
 §§ 1251 et seq.; the Toxic Substances Control Act of 1976, as amended, 15 U.S.C. §§ 2601 et seq.; the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. §§ 11001 et seq.; the Clean Air Act of 1966, as amended by the
Clean Air Act Amendments of 1990, 42 U.S.C. §§ 7401 et seq.; and the Occupational Safety and Health Act of 1970, as
amended, 29 U.S.C. §§ 651 et seq, as such of the foregoing are enacted and in effect on or prior to the Closing Date.

 

    6 

     

    

 

“Equity
Incentive Options” means the options to purchase Common Shares pursuant to a grant made under the Stock Incentive Plan.

 

“Equity
Securities” of any Person shall mean, as applicable, (a) any capital stock, membership interests or other share capital,
(b) any securities directly or indirectly convertible into or exchangeable for any capital stock, membership interests or other share
capital or containing any profit participation features, (c) any rights or options directly or indirectly to subscribe for or to purchase
any capital stock, membership interests, other share capital or securities containing any profit participation features, or to subscribe
for or to purchase any securities directly or indirectly convertible into or exchangeable for any capital stock, membership interests,
other share capital or securities containing any profit participation features, (d) any share appreciation rights, phantom share rights
or other similar rights, or (e) any securities issued or issuable with respect to the securities referred to in clauses (a) through
(d) above in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization.

 

“ERISA”
means the Employee Retirement Income Security Act of 1974, as amended, and the rules and regulations promulgated thereunder or with respect
thereto.

 

“ERISA
Affiliate” means any Person that is a member of a “controlled group of corporations” with, or is under “common
control” with, or is a member of the same “affiliated service group” with the Company, in each case, as defined in Section
414(b), (c), (m) or (o) of the Code.

 

“Escrow Agent” has the meaning set
forth in Section 2.9(a)(i).

 

“Escrow Agreement” has the meaning set forth in Section 2.9(a)(i).

 

“Escrow Amount”
means the Adjustment Escrow Amount, the Indemnity Escrow Amount and the Earnout Escrow Amount.

 

“Estimated Purchase Price” has the
meaning set forth in Section 2.9(a).

 

“Excess Dissenting Share Payments”
has the meaning set forth in Section 2.16(c).

 

“Exchange Act” means the Securities Exchange Act of 1934,
as amended, and the rules and regulations promulgated thereunder.

 

“Federal Healthcare Program” has
the meaning set forth in Section 3.17(b).

 

    7 

     

    

 

“Form
Working Capital Statement” means the Statement of Working Capital attached hereto as Schedule 1.1(a).

 

“Fraud” means actual fraud with
scienter.

 

“GAAP”
means United States generally accepted accounting principles as in effect from time to time.

 

“Governing
Documents” means the legal document(s) by which any Person (other than an individual) establishes its legal existence or
which govern its internal affairs. For example, the “Governing Documents” of a corporation are its certificate of incorporation
and bylaws, the “Governing Documents” of a limited partnership are its limited partnership agreement and certificate of limited
partnership and the “Governing Documents” of a limited liability company are its operating agreement and certificate of formation.

 

“Governmental
Entity” means any government or political subdivisions thereof, court, arbitral tribunal, administrative agency or commission
or any other governmental or regulatory body, instrumentality or authority or any self-regulated organization or other non-governmental
regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority
have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction, whether domestic (federal, state or local) or
foreign.

 

“Group Companies” means, collectively,
the Company and each of its Subsidiaries.

 

“Group Company IP Rights” has the meaning set forth in Section
3.12(a).

 

“Group
Company Software” means the Software applications owned (or purported to be owned) by or licensed to any Group Company that
are material to the Business of the Group Companies as a whole (excluding any commercially available off-the-shelf Software applications).

 

“Group Company Systems” has the
meaning set forth in Section 3.12(g).

 

“Health
Care Information Law” means the (a) Health Insurance Portability and Accountability Act of 1996, as amended by the Health
Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009), and their
implementing regulations set forth at 45 C.F.R. Parts 160-164; and (b) any federal, state and local Laws impacting protected health information,
and any federal, state and local Laws regulating the privacy and/or security of individually identifiable information, including Laws
providing for notification of breach of privacy or security of individually identifiable information, in each case with respect to the
Laws described in clauses (a) and (b) of this definition, as the same may be amended, modified or supplemented from time to time, any
successor statutes thereto, and any and all rules or regulations promulgated from time to time thereunder.

 

“HSR Act”
means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder.

 

“In-the-Money
Options” means any Equity Incentive Option other than an Out-of-the- Money Option.

 

    8 

     

    

 

“In-the-Money Warrants” means any
Warrant other than an Out-of-the-Money Warrant.

 

“Indebtedness”
means, with respect to the Group Companies, without duplication: (a) any indebtedness for borrowed money or issued in substitution for
or exchange of indebtedness for borrowed money of any Group Company; (b) any indebtedness evidenced by any note, bond, debenture or other
debt security issued or executed by any Group Company; (c) an amount equal to $275,000 of deferred capital expenditure; (d) any indebtedness
for the deferred purchase price of property or services with respect to which any Group Company is liable, contingently or otherwise,
as obligor or otherwise (other than trade payables incurred in the Ordinary Course); (e) any obligations under leases capitalized in
accordance with GAAP, with respect to which any Group Company is liable as obligor; (f) any obligations or liabilities of another Person
secured by a Lien (other than Permitted Liens) on the assets of any Group Company; (g) any dividends or distributions payable or loans/advances
payable to the Company Stockholders, which are not yet paid; (h) any letters of credit only to the extent drawn as to which any Group
Company has any obligation (other than standby letters of credit); (i) any accrued interest on any of the foregoing; (j) the Pre-Closing
Tax Amount (which includes, for the avoidance of doubt, $605,378 of Employment Taxes that have been deferred under the CARES Act); and
(k) any guarantee by any Group Company of any of the foregoing obligations of another Person; provided, however, that in no event
shall the Indebtedness of any Group Company include (x) any Indebtedness incurred or arranged by or through Parent or Merger Sub prior
to or in connection with the Closing, (y) any liabilities of any Group Company for any post-retirement benefits under any Employee Benefit
Plan which provides for such benefits; and/or (z) any lien item included within the definition of Current Liabilities and set forth on
the Form Working Capital Statement.

 

“Indemnified Parties” has the meaning
set forth in Section 8.5(a).

 

“Indemnifying Parties” has the meaning set forth in Section 8.5(a).

 

“Indemnified Persons” has the meaning set forth in Section 6.4(a).

 

“Indemnity Escrow Account”
has the meaning set forth in Section 2.9(a)(ii).

 

“Indemnity Escrow Amount” has the meaning set forth
in Section 2.9(a)(ii).

 

“Intellectual
Property Rights” means all intellectual property rights, in any jurisdiction, including all patents, patent applications
(including all reissues, divisions, renewals, extensions, provisionals, continuations and continuations in part thereof), rights in inventions
(whether or not patentable), registered and unregistered trademarks, service marks and trade names (including all goodwill associated
therewith and all registrations and applications therefor), registered and unregistered copyrights (including in Software) (including
all registrations and applications therefor), data rights, Internet domain names, trade secrets, and other proprietary confidential information
or know-how.

 

“Interim Balance Sheet Date”
has the meaning set forth in Section 3.3.

 

“Internal
Revenue Service” means the Internal Revenue Service of the United States federal government.

 

    9 

     

    

 

“International Employee Plans” has
the meaning set forth in Section 3.10(b).

 

“Knowledge”,
or words of similar import, means the actual knowledge, after due inquiry, of: (a) with respect to the Company, David H. Langsam and Terrence
Halloran, and (b) with respect to Parent, Pranil Vadgama and Christopher Wang.

 

“Law”
means any statute, law (including common law), ordinance, code, order, judgment, decree, rule or regulation, as each may be amended from
time to time.

 

“Leased
Real Property” means all leasehold or subleasehold estates and other rights to use or occupy any land, buildings, structures,
improvements, fixtures or other interest in real property held by any Group Company.

 

“Leases”
means all Contracts or other leases, subleases, licenses, concessions and other agreements (written or oral) pursuant to which any Group
Company holds any Leased Real Property, including the right to all security deposits and other amounts and instruments deposited by or
on behalf of a Group Company.

 

“Letter of Transmittal” has the
meaning set forth in Section 2.13(b).

 

“Liens”
means liens, pledges, charges, security interests, community property interests, conditions, equitable interests, mortgages, easements,
encroachments, options, deeds of trust, licenses, restriction on use or transfer or other encumbrances (other than those under applicable
federal, state and foreign securities laws), including any restriction on use, voting, transfer, receipt of income or exercise of any
other attribute of ownership.

 

“Loss”
or “Losses” means actual out-of-pocket losses, liabilities, obligations, damages, deficiencies, Actions, interest,
awards, penalties, fines, judgments, costs and expenses (including reasonable attorneys’ and experts’ fees and disbursements).

 

“Management Carve-out Amount”
has the meaning set forth in Section 2.9(b)(iii).

 

“Management Carve-out Program” means that certain
2020 Amended and Restated AdvantEdge Healthcare Holdings, Inc. Management Carve-out Program.

 

“Material
Adverse Effect” means any event, occurrence, fact, condition or change that is, or could reasonably be expected to
become, individually or in the aggregate, materially adverse to (a) the condition (financial or otherwise), business, assets or
results of operations of the Group Companies, taken as a whole, or (b) the ability of the Group Companies to consummate the
Transactions on a timely basis; provided, however, that “Material Adverse Effect” shall not include any
event, occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (a) general economic or
political conditions; (b) any national or international political or social conditions, including the engagement by the United
States in hostilities, whether or not pursuant to the declaration of a national emergency or war, or the occurrence of any military
or terrorist attack upon the United States, or any of its territories, possessions, or diplomatic or consular offices or upon any
military installation, equipment or personnel of the United States; (c) changes in GAAP; (d) changes in any laws, rules,
regulations, orders, or other binding directives issued by any Governmental Entity or any action required to be taken under any law,
rule, regulation, order or existing Contract by which any Group Company (or any of their respective assets or properties) is bound;
(e) the imposition or increase of tariffs (i) by the United States on goods or services imported from any foreign country or (ii) by
any foreign country on goods or services imported from the United States; (f) any change that is generally applicable to the
industries or markets in which the Group Companies operate, (g) any epidemic, pandemic or disease outbreak (including COVID-19), or
any Law, regulation, statute, directive, pronouncement or guideline issued by a Governmental Body (including, for the avoidance of
doubt, the Centers for Disease Control and Prevention and the World Health Organization) or industry group providing for business
closures, “sheltering-in-place,” curfews or other restrictions that relate to, or arise out of, an epidemic, pandemic or
disease outbreak (including COVID-19) or any change in such Law, statute, directive, pronouncement or guideline or interpretation
thereof following the date of this Agreement or any material worsening of such conditions threatened or existing as of the date of
this Agreement; (h) the public announcement of the transactions contemplated by this Agreement (including by reason of the identity
of Parent or Merger Sub or any communication by Parent or Merger Sub or any of their respective Affiliates regarding their
respective plans or intentions with respect to the business of any Group Company, and including the impact thereof on relationships
with clients, suppliers, distributors, partners or employees or others having relationships with any Group Company); (i) any failure
by any Group Company to meet any internal or published projections, forecasts or revenue or earnings predictions for any period
ending on or after the date of this Agreement (provided, however, that the underlying causes of such failures (subject to the
other provisions of this definition) shall not be excluded by this clause (i)); or (j) the taking of any action by the
Company that is expressly required to be taken under the terms of this Agreement and/or the Ancillary Documents.

 

    10 

     

    

 

“Material Clients” has the meaning
set forth in Section 3.19(a).

 

“Material Contracts” has the meaning set forth in Section 3.6(a).

 

“Material Permits” has the meaning set forth in Section 3.9.

 

“Material Suppliers”
has the meaning set forth in Section 3.19(b).

 

“Merger” has the meaning set forth in the Recitals.

 

“Merger
Consideration” means an amount equal to (a) the Purchase Price (as finally determined) minus (b) the Escrow Amount
minus (c) the Stockholders’ Representative Expense Amount.

 

“Merger Sub” has the meaning set
forth in the Preamble.

 

“New Plans” has the meaning set forth in Section 6.5.

 

“Non-US Employees” has the meaning
set forth in Section 3.10(a).

 

“Ordinary
Course” means, when used with reference to any Group Company or Parent, the ordinary course of their respective business,
consistent with past practices.

 

    11 

     

    

 

“Out-of-the-Money
Option” means any Equity Incentive Option having a per share exercise price in excess of the Per Share Estimated Payment,
calculated for this purpose as if the Aggregate Option Exercise Price for all Equity Incentive Options were included in the definition
of “Estimated Purchase Price” and as if all of the Equity Incentive Options were included in the definition of the “Aggregate
Common Shares Deemed Outstanding.”

 

“Out-of-the-Money
Warrant” means any Warrant having a per share exercise price in excess of the Per Share Estimated Payment, calculated for
this purpose as if the Aggregate Warrant Exercise Price for all Warrants were included in the definition of “Estimated Purchase
Price” and as if all of the Warrants were included in the definition of the “Aggregate Common Shares Deemed Outstanding.”

 

“Parent” has the meaning set forth
in the Preamble.

 

“Parent Indemnitees” has the meaning
set forth in Section 8.2.

 

“Parties” has the meaning set forth in the Preamble.

 

“Payments Administrator” has the
meaning set forth in Section 2.13(a).

 

“Per
Share Estimated Payment” means an amount equal to the (a) the Series A Per Share Merger Consideration calculated on the
basis of the Estimated Purchase Price in lieu of the Purchase Price (as finally determined) or (b) the Series A-1 Per Share Merger Consideration
calculated on the basis of the Estimated Purchase Price in lieu of the Purchase Price (as finally determined), as applicable.

 

“Permit”
means each permit, license, approval, authorization, franchise, certificate, certificate of need, accreditation, waiver, classification,
registration, variance and other similar documents, rights and authorizations of and from all Governmental Entities held by a Group Company.

 

“Permitted
Liens” means: (a) Liens for Taxes, assessments, charges, levies or other Claims not yet due and payable or being
contested in good faith and for which adequate reserves have been established in accordance with GAAP; (b) materialmen’s,
mechanics’, landlords’, carriers’, workmen’s and repairmen’s Liens arising in the Ordinary Course and
which do not, individually or in the aggregate, materially detract from the value of or impair the use of, any of the assets or
properties of any Group Company; (c) with respect to the Leased Real Property, (i) statutory, common law and contractual
landlord’s Liens under any Lease, (ii) such imperfections or irregularities of title, declarations, covenants, easements,
rights-of-way, building or use restrictions, prescriptive rights, protrusions, rights and party walls existing restrictions,
conditions, ordinances, charges or encumbrances or similar restrictions existing or of record, relating to the Leased Real Property,
or that are visible or would be disclosed by an ALTA survey of the Leased Real Property, (iii) zoning, building, entitlement and
other land use or Environmental Laws or regulations pertaining to the Leased Real Property, (iv) non-exclusive licenses of
Intellectual Property Rights granted in the Ordinary Course; and (v) any and all Liens encumbering the underlying fee interest of
the Leased Real Property; (d) Liens arising under original purchase price conditional sales contracts and equipment leases with
third parties entered into in the Ordinary Course; (e) restrictions on transfer arising under applicable state and federal
securities laws; and (f) Liens listed on Schedule 1.1(b).

 

    12 

     

    

 

“Person”
means any natural person, a sole proprietorship, a corporation, a partnership, a limited liability company, a joint venture, an association,
a trust, or any other entity or organization, including a Governmental Entity.

 

“Personal
Data” means a natural person’s name, street address, telephone number, e-mail address, photograph, social security
number, driver’s license number, credit card number, passport number, client or account number, health information, or any other
piece of information that allows, including in combination with other information, the identification of a natural person.

 

“Post-Closing
Funds” means (i) any amounts paid to the Stockholders’ Representative pursuant to Section 2.9(a)(ii), less
any reimbursement for costs of the Stockholders’ Representative pursuant to Article X, (ii) the Adjustment Escrow Amount,
plus the Actual Adjustment (which may be a negative number), (iii) any remaining amounts in the Indemnity Escrow Fund following
the Escrow Termination Date subject to Section 8.7(b), and (iv) the Earnout Escrow Amount, as applicable.

 

“Pre-Closing
Tax Amount” means an amount equal to the sum of (a) the Section 965 Amount and (b) an amount (not less than zero) equal
to the sum of the aggregate amount of current liabilities for unpaid Taxes (including any Employment Taxes and income Taxes) of the Group
Companies for all Pre-Closing Tax Periods (determined in the case of the portion of a Straddle Period ending on the Closing Date in accordance
with Section 9.2), in each case, only for: (i) Taxes for which the original Tax Return with respect to such Tax has not been filed
on or before the Closing Date, (ii) in the case of a Tax Return that was filed on or before the Closing Date, any Taxes to the extent
that such Taxes were shown as due and owing on such Tax Return and were not paid on or before the Closing Date, and (iii) any Taxes that
would have otherwise been due prior to the Closing Date but that are deferred until after the Closing Date under applicable Law (including,
without limitation, any employment Taxes that are deferred under the CARES Act). The calculation of the Pre-Closing Tax Amount shall
(A) be computed in accordance with past practices of the Group Companies, except as otherwise required under applicable Law and shall
take into account any Transaction Tax Deductions that have the effect of reducing (but not below zero) a particular Tax liability of
the applicable Group Company to which such deductions are relevant by allocating such Transaction Tax Deductions to the maximum extent
permitted under applicable Law to Pre-Closing Tax Periods, (B) take into account any estimated (or other prepaid) Tax payments and Tax
credits to the extent that such payments or credits have the effect of reducing (not below zero) the particular current Tax liability
of the applicable Group Company in respect of which such payments were made or credits are applied, (C) take into account any adjustment
pursuant to Section 481 of the Code (or any similar provision of state, local or foreign Law) required to be included in a Pre-Closing
Tax Period with respect to any accounting method change that was initiated by a Tax Authority or the Company prior to the Closing and
(D) be made without recalculating any Taxes previously shown due and payable on a final Tax Return filed by the Company on or prior to
the Closing Date. For the avoidance of doubt, the Pre-Closing Tax Amount shall not include: (1) any Taxes to the extent that such Taxes
were taken into account in the calculation of Unpaid Company Stockholder Expenses, (2) any amounts recorded as a non- Tax accounting
concept of deferred Tax liabilities or deferred Tax assets, (3) any reserve or accrual for contingent Taxes or with respect to uncertain
Tax positions, or (4) any Taxes arising from a transaction occurring on the Closing Date, but after the Closing, unless such transaction
was contemplated by this Agreement.

 

    13 

     

    

 

“Pre-Closing
Tax Period” means any taxable year or period that ends on or before the Closing Date and, with respect to any Straddle Period,
the portion of such Straddle Period ending on and including the Closing Date.

 

“Preferred
Share Purchase Warrants” means the Preferred Share Purchase Warrants issued by the Company to the Warrant Holders in respect
of the Warrants.

 

“Preferred
Shares” means, collectively, the Series A Preferred Shares and the Series A-1 Preferred Shares.

 

“Pro Rata
Share” means, with respect to a Company Stockholder, a fraction, the numerator of which is the sum of the Purchase Price
that such Company Stockholder is entitled to be paid pursuant to Section 2.8 (which, for the avoidance of doubt, excludes any payments
in respect of Dissenting Shares) and the denominator of which is the Total Merger Consideration that all Company Stockholders are entitled
to be paid pursuant to Section 2.8 (which, for the avoidance of doubt, excludes any payments in respect of Dissenting Shares).

 

“Proceeding” has the meaning set
forth in Section 8.5(a).

 

“Program Participant” has the meaning set forth in Section 2.12.

 

“Proposed Closing Date Calculations”
has the meaning set forth in Section 2.9(b).

 

“Purchase Price”
means (i) the Enterprise Value, plus (ii) the Working Capital Adjustment (which may be a negative number), plus (iii) the
amount of Closing Cash, minus (iv) the amount of Closing Indebtedness, minus (v) the amount of Company Stockholder Expenses.

 

“Purchase Price Dispute
Notice” has the meaning set forth in Section 2.9(b)(ii).

 

“Records” means all books,
records, documents and lists of the Group Company, including lists of clients, suppliers or personnel, all product, business and
marketing plans and all books, ledgers, files and business records.

 

“RWI Policy”
means a Buyer-Side Representations and Warranties Insurance Policy, obtained by Parent, the cost of which is borne 50% by the Company
Stockholders and 50% by Parent, having an aggregate policy limit not to exceed 10% of the Enterprise Value, a retention not to exceed
1% of the Enterprise Value (which for the avoidance of doubt, shall be funded by the Seller), a premium (including loss mitigation fees)
of up to 3.5% of the aggregate RWI Policy coverage limit and an underwriting fee of $35,000, and which RWI Policy takes effect at Closing
insuring against the breach by the Company of its representations or warranties set forth in this Agreement and in any Ancillary Document,
and contains a waiver of subrogation rights (except in the event of fraud, as defined in the RWI Policy) in a form acceptable to the Company.

 

    14 

     

    

 

“Section
965 Amount” means all liabilities for unpaid Taxes of any Group Company (determined as of the Closing Date and taking into
account, for the avoidance of doubt, prior payments of the net Tax liability arising as a result of Section 965 of the Code) that are
attributable to amounts includible in the income of such Group Company as a result of Section 965 of the Code (or any similar provision
of state or local Law), including any net Tax liability that is payable in a future taxable year as a result of an election under Section
965(h) of the Code (or any similar provision of state or local Law) that was made on or prior to the Closing Date.

 

“Series
A Liquidation Preference Amount” means (a) (i) the sum of all (A) unpaid accrued or accumulated Regular Dividends (as defined
in the Restated Certificate) (whether or not declared) and (B) other dividends that are declared but unpaid, in respect of each share
of the Series A Preferred Shares, plus (ii) $1.00, multiplied by (b) the number of Series A Preferred Shares issued and
outstanding as of immediately prior to the Effective Time.

 

“Series
A Merger Consideration” means the product of multiplying (a) the fraction determined by dividing (i) the Series A Liquidation
Preference Amount, by (ii) the sum of the Series A Liquidation Preference Amount and the Series A-1 Liquidation Preference Amount, by

(b) the Merger
Consideration.

 

“Series
A Per Share Merger Consideration” means the Series A Merger Consideration divided by the number of Series A Preferred Shares
the issued and outstanding as of immediately prior to the Effective Time.

 

“Series
A Preferred Shares” means, collectively, the shares of Series A Cumulative Convertible Redeemable Preferred Stock of the
Company, $0.01 par value per share.

 

“Series
A-1 Liquidation Preference Amount” means (a) (i) the sum of all (A) unpaid accrued or accumulated Regular Dividends (as
defined in the Restated Certificate) (whether or not declared) and (B) other dividends that are declared but unpaid, in respect of each
share of the Series A-1 Preferred Shares, plus (ii) $1.20, multiplied by (b) the number of Series A-1 Preferred Shares issued
and outstanding as of immediately prior to the Effective Time.

 

“Series
A-1 Merger Consideration” means (a) the product of the fraction determined by dividing (i) the Series A-1 Liquidation Preference
Amount, by (ii) the sum of the Series A Liquidation Preference Amount and the Series A-1 Liquidation Preference Amount, by (b) the Merger
Consideration.

 

“Series
A-1 Per Share Merger Consideration” means the Series A-1 Merger Consideration divided by the number of the Series A-1 Preferred
Shares issued and outstanding as of immediately prior to the Effective Time.

 

“Series
A-1 Preferred Shares” means, collectively, the shares of Series A-1 Cumulative Convertible Redeemable Preferred Stock of
the Company, $0.01 par value per share.

 

“Software”
means all (i) computer programs, applications, systems and code, including software implementations of algorithms, models and
methodologies, program interfaces, and source code and object code, (ii) Internet and intranet websites, databases and compilations,
including data and collections of data, whether machine-readable or otherwise, (iii) development and design tools, library functions
and compilers, (iv) technology supporting websites, and the contents and audiovisual displays of websites, and (v) media,
documentation and other works of authorship, including user manuals and training materials, relating to or embodying any of the
foregoing or on which any of the foregoing is recorded.

 

    15 

     

    

 

“Stock
Incentive Plan” means the AdvantEdge Healthcare Holdings, Inc. Omnibus Stock Incentive Plan.

 

“Stockholders’
Agreement” means the Amended and Restated Stockholders’ Agreement, dated November 16, 2006, by and among the Company
and the Company Stockholders party thereto, as amended.

 

“Stockholders’ Representative”
has the meaning set forth in the Preamble.

 

“Stockholders’ Representative Expense Account” has the meaning
set forth in Section 2.9(a)(ii).

 

“Stockholders’
Representative Expense Amount” means has the meaning set forth in Section 2.9(a)(ii).

 

“Stockholders’
Representative Losses” has the meaning set forth in Section 10.1(f).

 

“Straddle Periods”
means, with respect to any Group Company, any taxable period that includes, but does not end on, the Closing Date.

 

“Subsidiary”
means a corporation or other entity of which at least 50.1% of the voting power of the Equity Securities is owned, directly or indirectly,
by the specified Person.

 

“Surviving Corporation” has the
meaning set forth in Section 2.1.

 

“Surviving Corporation Bylaws” has the meaning set forth in Section
2.6(b).

 

“Surviving Corporation Certificate of Incorporation”
has the meaning set forth in Section 2.6(a).

 

“Surviving Corporation Common Share”
has the meaning set forth in Section 2.8(a).

 

“Target Closing Working Capital” means $2,094,767.

 

“Tax” or “Taxes”
means all income, corporation, gross receipts, capital gains, sales, use, value added, employment, franchise, property, inheritance,
withholding, payroll, national insurance contributions, social security, unemployment, U.S. Federal Insurance Contributions Act, U.S.
Federal Unemployment Tax Act, stamp duty, stamp duty reserve, stamp duty land, excise and occupation taxes and other taxes imposed or
collected by any Tax Authority, whether disputed or not, together with any interest and penalties, additions to tax or additional amounts
with respect thereto.

 

    16 

     

    

 

“Tax
Authority” means a Governmental Entity responsible for the administration, determination and collection of Taxes.

 

“Tax Incentive” has the meaning
set forth in Section 3.16(u).

 

“Tax
Returns” means any returns, declarations, reports, attachments, claims for refund or credit and information statements with
respect to Taxes required to be filed with a Tax Authority, including any amendment thereto.

 

“Total
Merger Consideration” means an amount equal to the Merger Consideration, together with those portions of the Escrow Funds
that the Stockholders become entitled to receive pursuant to the terms of this Agreement and the Escrow Agreement.

 

“Transaction
Tax Deductions” means, without duplication, any loss or deduction, which is “more likely than not
deductible” (or deductible at a higher confidence level) for applicable income Tax purposes (excluding, for the avoidance of
doubt, any amounts required to be capitalized for U.S. federal income tax purposes), resulting from or attributable to (a) Company
Stockholder Expenses (including, solely for purposes of Transaction Tax Deductions, any Company Stockholder Expenses paid at or
prior to the Closing); (b) transaction costs (other than the Company Stockholder Expenses) of any of the Group Companies arising
from, incurred in connection with or incident to this Agreement and the transactions contemplated hereby that were paid on or prior
to the Closing Date or included in the computation of the Working Capital; (c) bonuses,
change in control payments, severance payments, retention payments or similar payments made by any of the Group Companies in
connection with or as a direct or indirect result of the consummation of the transactions contemplated by this Agreement and that
were paid at or before the Closing Date or included in the computation of the Working Capital; (d) fees, expenses and interest
(including amounts treated as interest for Tax purposes and any breakage fees) incurred by any of the Group Companies, and any
unamortized deferred financing costs, with respect to the payment of Indebtedness in connection with the transactions contemplated
by this Agreement; and (e) Employment Taxes with respect to any compensatory payment made, or to be made, in connection with the
transactions contemplated by this Agreement; provided, however, that, in connection with the foregoing, Parent shall
cause the Group Companies to make an election under Revenue Procedure 2011-29, 2011-18 IRB 746 , to treat 70% of any success-based
fees that were paid by or on behalf of any of the Group Companies as an amount that did not facilitate the transactions contemplated
under this Agreement and therefore treat 70% of such costs as deductible in the taxable year that includes the Closing Date for U.S.
federal income tax purposes.

 

“Transactions”
means the Merger and the other transactions contemplated by this Agreement and the Ancillary Documents.

 

“Treasury
Regulations” means the regulations promulgated under the Code by the United States Department of the Treasury.

 

“United States” means the United
States of America.

 

“Unpaid
Company Stockholder Expenses” means the aggregate amount of Company Stockholder Expenses incurred and unpaid as of immediately
prior to the Effective Time.

 

    17 

     

    

 

“WARN” has the meaning set forth
in Section 3.14(b).

 

“Warrant Holder” has the meaning set forth in Section 2.8(f).

 

“Warrant
Payment” has the meaning set forth in Section 2.8(f).

 

“Warrants”
means, collectively, the warrants to purchase Common Shares pursuant to Common Share Purchase Warrants and the warrants to purchase Preferred
Shares pursuant to Preferred Share Purchase Warrants.

 

“Working
Capital” means, as of any given date, Current Assets minus Current Liabilities, in each case, as of such date.

 

“Working
Capital Adjustment” means (a) the amount by which Closing Working Capital exceeds the Target Closing Working Capital or
(b) the amount by which Closing Working Capital is less than the Target Closing Working Capital, in each case, if applicable; provided,
however, that any amount which is calculated pursuant to clause (b) above shall be deemed to be a negative number.

 

ARTICLE II

 MERGER

 

Section 2.1 The
Merger. Upon the terms and subject to the conditions set forth in this Agreement, and in accordance with the DGCL, Merger shall occur
at the Effective Time (as defined below). Following the Effective Time, the separate existence of Merger Sub shall cease and the Company
shall continue as the surviving corporation of the Merger (the “Surviving Corporation”) and shall succeed to
and assume all the rights and obligations of Merger Sub in accordance with the DGCL.

 

Section 2.2 Closing
of the Merger. Subject to the terms and conditions set forth in this Agreement, the closing of the Transactions (the “Closing”)
shall take place electronically via the electronic exchange of execution versions of this Agreement and any Ancillary Documents to be
entered into at the closing and the signature pages thereto via email by .pdf on the date hereof. The “Closing Date”
shall be the date of this Agreement.

 

Section 2.3 Effective
Time. Subject to the provisions of this Agreement, as soon as practicable on the Closing Date, the Parties shall file or cause to
be filed with the Secretary of State of the State of Delaware the certificate of merger relating to the Merger (the “Certificate
of Merger”), executed and acknowledged in accordance with the relevant provisions of the DGCL, and, as soon as practicable
on or after the Closing Date, shall make all other filings required under the DGCL or by the Secretary of State of the State of Delaware
in connection with the Merger. The Merger shall become effective at the time that the Certificate of Merger has been duly filed with the
Secretary of State of the State of Delaware, or at such later time as the Company and Parent shall agree and specify in the Certificate
of Merger (the time the Merger becomes effective being the “Effective Time”).

 

Section 2.4 Effect
of the Merger. The Merger shall, from and after the Effective Time, have all the effects provided herein, in the Certificate of
Merger and in Section 251 of the DGCL. Without limiting the generality of the foregoing, and subject thereto, from and after the
Effective Time, all property, rights, privileges, immunities, powers, franchises, licenses and authority of the Company and Merger
Sub shall vest in the Surviving Corporation, and all debts, liabilities, obligations, restrictions and duties of each of the Company
and Merger Sub shall become the debts, liabilities, obligations, restrictions and duties of the Surviving Corporation.

 

    18 

     

    

 

Section 2.5 Further
Actions. The Parties shall execute and deliver such certificates and other documents and take such other actions as may be necessary
or appropriate in order to effect the Merger, including making filings, recordings or publications required under the DGCL. If at any
time after the Effective Time any further action is necessary to vest in the Surviving Corporation the title to all property or rights
of Merger Sub or the Company, the authorized officers and directors of the Surviving Corporation are fully authorized in the name of Merger
Sub or the Company, as the case may be, to take, and shall take, any and all such lawful action.

 

Section 2.6 Certificate of Incorporation;
Bylaws.

 

(a)       At
the Effective Time, the certificate of incorporation of the Surviving Corporation shall be amended and restated to be identical to the
certificate of incorporation of Merger Sub as in effect immediately prior to the Effective Time (except for the name of the Company) (the
 “Surviving Corporation Certificate of Incorporation”) until thereafter changed or amended as provided therein
or by applicable Law, except that the Surviving Corporation Certificate of Incorporation shall comply with Section 6.4.

 

(b)       At
the Effective Time, the bylaws of Merger Sub in effect immediately prior to the Effective Time shall become the bylaws of the Surviving
Corporation (the “Surviving Corporation Bylaws”) until thereafter changed or amended as provided therein or
by applicable Law, except that the Surviving Corporation Bylaws shall comply with Section 6.4.

 

Section 2.7 Directors and Officers.

 

(a)       The
directors of Merger Sub immediately prior to the Effective Time shall be the initial directors of the Surviving Corporation, each to hold
office in accordance with the Surviving Corporation Certificate of Incorporation and the Surviving Corporation Bylaws until such director’s
successor is duly elected or appointed and qualified, or until the earlier of their death, resignation or removal.

 

(b)       The
officers of Merger Sub immediately prior to the Effective Time shall be the initial officers of the Surviving Corporation, each to hold
office in accordance with the Surviving Corporation Certificate of Incorporation and the Surviving Corporation Bylaws until such officer’s
successor is duly elected or appointed and qualified, or until the earlier of their death, resignation or removal.

 

Section 2.8 Effect on Company Equity
Securities.

 

(a)       Conversion
of Merger Sub Shares. At the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub or
the Company, each share of capital stock of Merger Sub issued and outstanding immediately prior to the Effective Time shall be converted
into one Surviving Corporation Common Share. For purposes of this Agreement, the term “Surviving Corporation Common Share”
means a share of common stock, par value $0.001 per share of the Surviving Corporation.

 

    19 

     

    

 

(b)       Conversion
of Series A Preferred Shares. At the Effective Time, each Series A Preferred Share (other than any Dissenting Shares (as defined below))
issued and outstanding as of immediately prior to the Effective Time, by virtue of the Merger and without any action on the part of Parent,
Merger Sub, the Company or the holder of such Series A Preferred Share, shall be canceled and extinguished and be converted into and shall
become the right to receive the Series A Per Share Merger Consideration, without interest, as provided herein. From and after the Effective
Time, the holders of certificates, if any, evidencing ownership of the Series A Preferred Shares outstanding immediately prior to the
Effective Time shall cease to have any rights with respect to such Series A Preferred Shares except as otherwise provided for in this
Agreement or under applicable Law.

 

(c)       Conversion
of Series A-1 Preferred Shares. At the Effective Time, each Series A-1 Preferred Share (other than any Dissenting Shares) issued and
outstanding as of immediately prior to the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger
Sub, the Company or the holder of such Series A-1 Preferred Share, shall be canceled and extinguished and be converted into and shall
become the right to receive the Series A-1 Per Share Merger Consideration, without interest, as provided herein. From and after the Effective
Time, the holders of certificates, if any, evidencing ownership of the Series A-1 Preferred Shares outstanding immediately prior to the
Effective Time shall cease to have any rights with respect to such Series A-1 Preferred Shares except as otherwise provided for in this
Agreement or under applicable Law.

 

(d)       Cancellation
of Common Shares. At the Effective Time, each Common Share (other than any Dissenting Shares) issued and outstanding as of immediately
prior to the Effective Time, by virtue of the Merger and without any action on the part of Parent, Merger Sub, the Company or the holder
of such Common Share, shall be canceled and extinguished and shall cease to exist. From and after the Effective Time, the holders of certificates
evidencing ownership of the Common Shares outstanding immediately prior to the Effective Time shall cease to have any rights with respect
to such Common Shares except as otherwise provided for in this Agreement or under applicable Law.

 

(e)       Cancellation
of Options. As of the Effective Time, all Equity Incentive Options shall no longer be outstanding and shall be automatically canceled
and retired and shall cease to exist, and each holder of any Equity Incentive Option shall cease to have any rights with respect thereto,
except as otherwise expressly provided for herein or by applicable Law. The Company has taken all actions pursuant to the Stock Incentive
Plan (and the option grant and/or stock award agreements in effect with the holders of Equity Incentive Options) or otherwise that are
necessary to give effect to the provisions of this Section 2.8(e) with respect to Equity Incentive Options as herein provided.

 

(f)       Cancellation
of Warrants. As of the Effective Time, all Warrants shall no longer be outstanding and shall be automatically canceled and
retired and shall cease to exist, and each holder of any such Warrant shall cease to have any rights with respect thereto, except as
otherwise expressly provided for herein or by applicable Law. The Company has taken all actions pursuant to the Warrants or
otherwise that are necessary to give effect to the provisions of this Section 2.8(f) with respect to Warrants as herein
provided.

 

    20 

     

    

 

(g)       Withholding.
The Surviving Corporation, Parent, Merger Sub and any authorized agent of the foregoing (including the Payments Administrator) shall be
entitled to deduct and withhold from the Purchase Price otherwise payable pursuant to this Agreement to any holder of Equity Securities
of the Company such amounts as the Surviving Corporation, Parent, Merger Sub or its agent, as the case may be, is required to deduct and
withhold with respect to such payment under the Code, or any provision of applicable state, local or foreign Law. To the extent that amounts
are so withheld, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to the holder of Equity
Securities of the Company in respect of which such deduction and withholding was made, and the Surviving Corporation, Parent, Merger Sub
or its authorized agent, as the case may be, shall timely remit such amounts to the appropriate Governmental Entity. Notwithstanding anything
in this Agreement to the contrary, any amounts to be paid pursuant to this Agreement that are treated as employee compensation for income
tax purposes, including any amounts payable under Section 2.12, shall be paid to the Surviving Corporation (at such time upon which
such payment is due), which in turn, shall pay the applicable recipient such amounts through the Surviving Corporation’s payroll
less any Tax deductions or withholdings required under Law.

 

Section 2.9 Purchase Price.

 

(a)       Estimated
Purchase Price. No later than three (3) Business Days prior to the Closing, the Company in good faith prepared and delivered to Parent
a written statement setting forth in reasonable detail, with reasonable supporting detail, its good faith estimate of the Purchase Price
(the “Estimated Purchase Price”), which sets forth (the “Estimated Purchase Price Statement”),
the Enterprise Value and estimates of (i) the amount of Closing Indebtedness, (ii) the amount of Unpaid Company Stockholder Expenses,
(iii) the amount of Closing Cash, and (iv) the Working Capital Adjustment. At the Closing, Parent shall pay, or shall cause Merger Sub
or the Surviving Corporation to pay, in cash by wire transfer of immediately available funds to the Payments Administrator, to be distributed
as follows:

 

(i)       $375,000
(such amount, the “Adjustment Escrow Amount”) shall be deposited into an escrow account (the “Adjustment
Escrow Account”), which shall be established pursuant to an escrow agreement (the “Escrow Agreement”),
which Escrow Agreement shall be (x) entered into on the Closing Date among Parent, the Stockholders’ Representative and Wilmington
Trust, N.A. (the “Escrow Agent”), as security for the Company Stockholders’ obligations pursuant to Section
2.9(c)(ii), if any, and (y) substantially in the form of Exhibit B attached hereto;

 

(ii)       $800,000
(such amount, the “Indemnity Escrow Amount”) shall be deposited into an escrow account (the “Indemnity
Escrow Account”), which shall be established pursuant to the Escrow Agreement, as security for the Company Stockholders’
obligations pursuant to Article VIII, if any;

 

(iii)       if
(A) Brevard Physician Associates (“BPA”) has not (1) signed a new agreement with substantially the same
economic terms as the Company’s existing agreement with BPA but without the early termination clause contained therein prior
to the Closing, (2) signed an amendment to the Company’s existing agreement with BPA that removes the early termination clause
contained therein prior to the Closing, or (3) otherwise confirmed in writing that BPA intends to remain a customer of the Company
following the Closing to Parent’s satisfaction in its sole discretion prior to the Closing, and (B) Indiana University Health,
Inc. (“Indiana”) has not signed an agreement with the Company prior to the Closing (the
 “Indiana Agreement”) with substantially the same pricing terms as the mark-up of the agreement sent to
Parent by Brentwood Capital Advisors, LLC on August 4, 2021, $16,800,000 (such amount, the “Earnout Escrow
Amount”) shall be deposited into an escrow account (the “Earnout Escrow Account”), which
shall be established pursuant to the Escrow Agreement, to be disbursed as the Earnout Payment (as defined below) to the Company
Stockholders in accordance with Section 2.10 and Exhibit D; provided, however, that if Indiana has signed the
Indiana Agreement prior to the Closing, the Earnout Escrow Amount shall be $6,000,000 instead of $16,800,000;

 

    21 

     

    

 

(iv)       $200,000
(such amount, the “Stockholders’ Representative Expense Amount”) shall be deposited into an account established
by the Stockholders’ Representative for purposes of satisfying costs, expenses and/or liabilities incurred in its capacity as the
Stockholders’ Representative and otherwise in accordance with this Agreement (such account, the “Stockholders’
Representative Expense Account”);

 

(v)       $1,968,000.00
(such amount, the “Management Carve-out Amount”) shall be deposited with the Company and disbursed in accordance
with Section 2.12; and;

 

(vi)       with
respect to the Preferred Shares issued and outstanding as of immediately prior to the Effective Time, an amount equal to the aggregate
Per Share Estimated Payment shall be paid by wire transfer of immediately available funds in accordance with Section 2.13.

 

The Company has provided Parent with the Consideration Spreadsheet
at least two (2) Business Days prior to the Closing Date.

 

(b)       Determination
of Final Purchase Price.

 

(i)       As
soon as practicable, but no later than sixty (60) days after the Closing Date, Parent shall prepare and deliver to the
Stockholders’ Representative Parent’s good faith proposed calculation of each of (A) the amount of Closing Indebtedness,
(B) the amount of Company Stockholder Expenses, (C) the amount of Closing Cash, (D) the Closing Working Capital, and (E) the
Purchase Price (which calculations shall collectively be referred to herein as the “Proposed Closing Date
Calculations”), in each case, including reasonably detailed calculations of the components thereof and in a manner
consistent with the definitions thereof set forth in this Agreement. The Proposed Closing Date Calculations (and each component
thereof) shall (1) exclude the impact of any decisions made or actions taken or omitted by Parent or any of the Group Companies
following the Closing, including any change in accounting principles, methods or policies with respect to the Company after the
Closing, and (2) not reflect changes in assets or liabilities as a result of purchase accounting adjustments or reflect any events,
conditions or circumstances which arise as a result of the change of control and/or ownership of the Group Companies contemplated by
this Agreement. If Parent fails to timely deliver any of the Proposed Closing Date Calculations in accordance with the foregoing,
then, at the election of the Stockholders’ Representative in its sole discretion, either (I) the Actual Adjustment shall be
deemed to equal zero (0) or (II) the Stockholders’ Representative may retain (at the expense of Parent) a nationally or
regionally recognized independent accounting firm to provide an audit or other review of each of the Group Companies’ books,
review the calculation of the Estimated Purchase Price and make any adjustments necessary thereto consistent with the provisions of
this Section 2.9(b), the determination of such accounting firm being conclusive and binding on the Parties.

 

    22 

     

    

 

(ii)       If
the Stockholders’ Representative does not give written notice of any dispute (a “Purchase Price Dispute
Notice”) to Parent within thirty (30) days after receiving the Proposed Closing Date Calculations, the Proposed
Closing Date Calculations shall be deemed to set forth the final Closing Indebtedness, Company Stockholder Expenses, Closing Cash,
Closing Working Capital and Purchase Price, in each case, for purposes of determining the Actual Adjustment, and shall be final and
binding upon the Parties. Prior to the end of such thirty (30)- day period, the Stockholders’ Representative may accept the
Proposed Closing Date Calculations by delivering written notice to that effect to Parent, in which case the Proposed Closing Date
Calculations shall be deemed to set forth the final Closing Indebtedness, Company Stockholder Expenses, Closing Cash, Closing
Working Capital, and Purchase Price, in each case, for purposes of determining the Actual Adjustment, and shall be final and binding
upon the Parties when such notice is given. If the Stockholders’ Representative gives a Purchase Price Dispute Notice to
Parent within such thirty (30)-day period, Parent and the Stockholders’ Representative shall use good faith efforts to resolve
the dispute during the thirty (30)-day period commencing on the date Parent receives the Purchase Price Dispute Notice from the
Stockholders’ Representative. Any Purchase Price Dispute Notice shall include Stockholders’ Representative’s
alternative calculations with respect to each component of the Proposed Closing Date Calculations, along with the basis for and
amount of each disputed item, together with supporting documentation. If the Stockholders’ Representative and Parent do not
agree upon a final resolution with respect to any disputed items within such thirty (30)-day period, then the remaining items in
dispute shall be submitted promptly to a mutually agreeable nationally-recognized, independent accounting firm (the
 “Accounting Firm”). Any item not specifically submitted to the Accounting Firm for evaluation shall be
deemed final and binding on the Parties (as set forth in the Proposed Closing Date Calculations, the Purchase Price Dispute Notice
or as otherwise resolved in writing by Parent and the Stockholders’ Representative). The Accounting Firm shall be requested to
render a determination of each disputed item within forty-five (45) days after referral of the matter to the Accounting Firm, which
determination must be in writing and must set forth, in reasonable detail, the basis therefor and must be based solely on (A) the
definitions and other applicable provisions of this Agreement, (B) a single presentation (which presentations shall be limited to
the remaining items in dispute set forth in the Proposed Closing Date Calculations and the Purchase Price Dispute Notice) submitted
by each of Parent and the Stockholders’ Representative to the Accounting Firm within fifteen (15) days after the engagement
thereof (which the Accounting Firm shall forward to Parent or the Stockholders’ Representative, as applicable), (C) one (1)
written response to the Stockholders’ Representative’s initial presentation, which response may be submitted to the
Accounting Firm by Parent within five (5) Business Days after receipt of the Stockholders’ Representative’s initial
presentation (which the Accounting Firm shall forward to the Stockholders’ Representative), and (D) one (1) written response
to Parent’s initial presentation, which response may be submitted to the Accounting Firm by the Stockholders’
Representative within five (5) Business Days after receipt of Parent’s initial presentation (which the Accounting Firm shall
forward to Parent), and not on independent review, which such determination shall be conclusive and binding on each Party. Ex
parte communications by the Accounting Firm with Parent or Stockholders’ Representative regarding substantive matters in
connection herewith shall be prohibited. The terms of appointment and engagement of the Accounting Firm shall be as reasonably
agreed upon between the Stockholders’ Representative and Parent, and any associated engagement fees shall be initially borne
50% by the Stockholders’ Representative (solely on behalf of the Company Stockholders) and 50% by Parent; provided, however,
that such fees shall ultimately be borne by Parent and the Stockholders’ Representative (solely on behalf of the Company
Stockholders) in the same proportion as the aggregate amount of the disputed items that is unsuccessfully disputed by each such
Party (as determined by the Accounting Firm) bears to the total amount of the disputed items submitted to the Accounting Firm.
Except as provided in the preceding sentence, all other costs and expenses incurred by the Parties in connection with resolving any
dispute hereunder before the Accounting Firm shall be borne by the Party incurring such cost and expense. The Accounting Firm shall
resolve each disputed item by choosing a value not in excess of, nor less than, the greatest or lowest value, respectively, set
forth in the presentations (and, if applicable, the responses) delivered to the Accounting Firm pursuant to this Section
2.9(b)(ii). The Proposed Closing Date Calculations shall be revised as appropriate to reflect the resolution of any objections
thereto pursuant to this Section 2.9(b)(ii) and, as so revised, such Proposed Closing Date Calculations shall be deemed to
set forth the final Closing Indebtedness, Company Stockholder Expenses, Closing Cash, Closing Working Capital and Purchase Price, in
each case, for all purposes hereunder (including the determination of the Actual Adjustment) and shall be final and binding upon the
Parties.

 

    23 

     

    

 

(iii)       Parent
shall, and shall cause each of the Group Companies to, promptly make its relevant financial records and personnel available to the Stockholders’
Representative and its accountants and other representatives at reasonable times at any time during the review by the Stockholders’
Representative of, and the resolution of any objections with respect to, the Proposed Closing Date Calculations.

 

(iv)       The
Parties agree that the procedures set forth in this Section 2.9(b) for resolving disputes with respect to the Proposed Closing
Date Calculations shall be the sole and exclusive method for resolving any such disputes; provided, however, that this provision
shall not prohibit Parent or the Stockholders’ Representative from instituting litigation to enforce any final determination of
the Purchase Price by the Accounting Firm pursuant to Section 2.9(b)(ii) in any court or other tribunal of competent jurisdiction
in accordance with Section 11.15. The substance of the Accounting Firm’s determination shall not be subject to review or
appeal, absent a showing of fraud or manifest error. It is the intent of the Parties to have any final determination of the Purchase Price
by the Accounting Firm proceed in an expeditious manner; provided, however, that any deadline or time period contained herein
may be extended or modified by the written agreement of Parent and the Stockholders’ Representative and the Parties agree that the
failure of the Accounting Firm to strictly conform to any deadline or time period contained herein shall not be a basis for seeking to
overturn any determination rendered by the Accounting Firm which otherwise conforms to the terms of this Section 2.9(b).

 

    24 

     

    

 

(c)       Adjustment
to Estimated Purchase Price.

 

(i)       If
the Actual Adjustment is a positive amount, (A) Parent shall pay, or cause the Surviving Corporation to pay, to the Payments Administrator,
for distribution to each of the Company Stockholders (pro rata based upon such Person’s Pro Rata Share), other than the Dissenting
Stockholders, an amount equal to such positive amount with respect to such Person’s Pro Rata Share, by wire transfer or delivery
of immediately available funds, within three (3) Business Days after the date on which the Purchase Price is finally determined pursuant
to Section 2.9(b) and (B) simultaneously therewith, Parent and the Stockholders’ Representative shall deliver joint written
instructions to the Escrow Agent instructing the Escrow Agent to release the Adjustment Escrow Amount from the Adjustment Escrow Account
to the Payments Administrator, for further distribution to the Company Stockholders (pro rata based upon such Person’s Pro Rata
Share), other than the Dissenting Stockholders.

 

(ii)       If
the Actual Adjustment is a negative amount, then within three (3) Business Days after the date on which the Purchase Price is finally
determined pursuant to Section 2.9(b), Parent and the Stockholders’ Representative shall deliver joint written instructions
to the Escrow Agent instructing the Escrow Agent to deliver to Parent an amount equal to the absolute value of such negative amount out
of the Adjustment Escrow Amount; provided, however, that if the Actual Adjustment is less than the Adjustment Escrow Amount,
then simultaneously with the delivery of such joint written instructions, Parent and the Stockholders’ Representative shall deliver
joint written instructions to the Escrow Agent instructing the Escrow Agent to release to the Payments Administrator, for further distribution
to the Company Stockholders (pro rata based upon such Person’s Pro Rata Share), other than the Dissenting Stockholders, any excess
funds remaining in the Adjustment Escrow Account.

 

Section 2.10 Earnout Payment.

 

(a)       Subject
to Parent’s rights to off-set any Earnout Payments for any indemnification obligations in accordance with Article VIII of
this Agreement, the Company shall be eligible to receive the amounts determined in accordance with Exhibit D (“Earnout
Payment”). Nothing in this Section 2.10 or Exhibit D shall limit in any manner Parent’s ability to operate
the Business and use the Assets in whatever manner Parent may deem appropriate, including setting the commercial terms of any products
or services; provided, however, during the Earnout Period (as defined in Exhibit D), Parent shall operate the Business in
the Ordinary Course of the Business as conducted prior to Closing and shall not intentionally take any action for the sole purpose of
reducing or avoiding the payment of the Earnout Payment; and, provided, further, however, that the Transition Services
Agreement entered into between Parent or an Affiliate thereof and David Langsam may not be terminated by Parent or such Affiliate prior
to the expiration of the term thereof. Any Earnout Payment made shall be treated as an adjustment to the Purchase Price, except as otherwise
required by applicable Law. Notwithstanding anything to the contrary in this Agreement and subject to the qualifications set forth in
Article VIII of this Agreement, the obligation of Parent to make any Earnout Payment shall be qualified in its entirety by the
right of Parent to reduce the amount of such Earnout Payment by the amount of any Losses in respect of one or more indemnification claims
to which Parent or any Parent Indemnitee is entitled pursuant to Article VIII of this Agreement.

 

    25 

     

    

 

(b)       If
the Earnout Payment is more than the amount deposited in the Earnout Escrow Account, (A) Parent shall pay, or cause the Surviving Corporation
to pay, to the Payments Administrator, for distribution to each of the Company Stockholders (pro rata based upon such Person’s Pro
Rata Share), other than the Dissenting Stockholders, an amount equal to such difference with respect to such Person’s Pro Rata Share,
by wire transfer or delivery of immediately available funds, within three (3) Business Days after the date on which the Earnout Payment
is finally determined pursuant to Exhibit D and (B) simultaneously therewith, Parent and the Stockholders’ Representative
shall deliver joint written instructions to the Escrow Agent instructing the Escrow Agent to release the Earnout Escrow Amount in full
from the Earnout Escrow Account to the Surviving Corporation, for further distribution to the Program Participants as set forth in the
Consideration Spreadsheet in accordance with the Management Carve-out Program, and the Payments Administrator, for further distribution
to the Company Stockholders (pro rata based upon such Person’s Pro Rata Share), other than the Dissenting Stockholders.

 

(c)       If
the Earnout Payment is less than the amount deposited in the Earnout Escrow Account, then within three (3) Business Days after the date
on which the Earnout Payment is finally determined pursuant to Exhibit D, Parent and the Stockholders’ Representative shall
deliver joint written instructions to the Escrow Agent instructing the Escrow Agent to deliver (A) the Earnout Payment to the Surviving
Corporation, for further distribution to the Program Participants as set forth in the Consideration Spreadsheet in accordance with the
Management Carve-out Program, and/or the Payments Administrator, for further distribution to the Company Stockholders (pro rata based
upon such Person’s Pro Rata Share), other than the Dissenting Stockholders, and (B) to Parent an amount equal to the difference
between the Earnout Escrow Amount and the Earnout Payment out of the Earnout Escrow Account.

 

Section 2.11 Stock
Incentive Plan; Warrants. The Stock Incentive Plan, all Equity Incentive Options and the Warrants shall terminate as of the Effective
Time, and no holder of Equity Incentive Options or Warrants shall have any rights thereunder, including any rights to acquire any equity
securities of the Company, the Surviving Corporation or any Subsidiaries thereof, other than as set forth herein or by applicable Law.

 

Section 2.12 Management
Carve-out Program Awards. Schedule 2.12 attached hereto sets forth the calculation of the amounts to be paid to each participant
in the Management Carve- out Program (each, a “Program Participant”), inclusive of an amount equal to any Employment
Taxes payable on such amounts and any Taxes that are required to be withheld under applicable Law with respect to an amount paid to the
Program Participants (collectively, the “Carve-out Program Amount”). The Management Carve-out Amount shall be
used for the sole purpose of disbursing the Carve-out Program Amount to Program Participants in accordance with the Management Carve-out
Program and the applicable Group Company’s customary payroll processes.

 

Section 2.13 Letters of
Transmittal.

 

(a)       Acquiom
Financial LLC, a Colorado limited liability company, or a successor appointed by Parent, shall act as a payments administrator (the “Payments
Administrator”) in the Merger.

 

    26 

     

    

 

(b)       As
promptly as practicable following the date of this Agreement, the Company shall deliver to each Company Stockholder that, immediately
prior to the Effective Time, held Company Shares a letter of transmittal substantially in the form attached as Exhibit C attached
hereto (a “Letter of Transmittal”) and instructions for use in effecting the surrender of Certificates in exchange
for the applicable portion of Purchase Price pursuant to Section 2.8(b), Section 2.8(c), Section 2.8(d), Section
2.8(e) or Section 2.8(f), as applicable. Prior to any Company Stockholder receiving any portion of the Purchase Price, such
Company Stockholder shall deliver to the Payments Administrator an executed and properly completed Letter of Transmittal, which Letter
of Transmittal shall include such Company Stockholder’s explicit agreement to be bound by the terms of this Agreement. Upon delivery
of such executed and properly completed Letter of Transmittal, together with any Certificates, held by such Person and any other customary
documents that the Payments Administrator may reasonably require in connection therewith, each such Company Stockholder shall be entitled
to receive, as soon as reasonably practicable (but in no event later than three (3) Business Days after receipt by the Payments Administrator
of such documents) payment from the Payments Administrator of the portion of Purchase Price payable to such Company Stockholder pursuant
to Section 2.9(a), without interest thereon. Provided the Letter of Transmittal has not been revoked or such Company Stockholder
is not in breach under the terms thereof, such Company Stockholder shall be entitled to receive, as soon as reasonably practicable after
any Post-Closing Funds become payable hereunder, such Company Stockholder’s respective Pro Rata Share of the Post-Closing Funds,
without interest thereon.

 

(c)       Until
surrendered, Certificates shall be deemed for all purposes to evidence only the right to receive the applicable portion of the Purchase
Price. No interest shall accrue or be paid on any cash payable upon the surrender of the Certificates.

 

(d)       In
the event any Certificate shall have been lost, stolen or destroyed, then in lieu of surrendering the same, the holder thereof may make
an affidavit setting forth that fact and granting indemnity against any Claim that may be made against the Payments Administrator, the
Company, the Surviving Corporation, Parent or the Stockholders’ Representative with respect to such Certificate(s), and the Payments
Administrator shall thereafter pay the applicable amounts required to be paid hereunder with respect to each share evidenced by such lost,
stolen or destroyed Certificate(s).

 

(e)       In
accordance with Section 2.8(g), the Payments Administrator shall be entitled to deduct and withhold, or cause to be deducted and
withheld, from the consideration otherwise payable pursuant to this Agreement such amounts as are required to be deducted and withheld
under the Code, or any provision of state, local or foreign Tax Law, with respect to the making of such payment.

 

Section 2.14 Additional
Actions. If, at any time after the Effective Time, the Surviving Corporation shall consider or be advised that any deeds, bills
of sale, assignments, assurances or any other actions or things are reasonably necessary or desirable to vest, perfect or confirm of
record or otherwise in the Surviving Corporation its right, title or interest in, to or under any of the rights, properties or
assets of Merger Sub or the Company or otherwise to carry out this Agreement, the officers of the Surviving Corporation shall be
authorized to execute and deliver, in the name and on behalf of Merger Sub or the Company, all such deeds, bills of sale,
assignments and assurances and to take and do, in the name and on behalf of Merger Sub or the Company, all such other actions and
things as may be reasonably necessary or desirable to vest, perfect or confirm any and all right, title and interest in, to and
under such rights, properties or assets in the Surviving Corporation or otherwise to carry out this Agreement.

 

    27 

     

    

 

Section 2.15 Payment
of Closing Indebtedness and Unpaid Company Stockholder Expenses. Contemporaneously with the filing of the Certificate of Merger and
on behalf of the Company and Company Stockholders, Parent shall pay, or shall cause the Surviving Corporation to pay, in cash by wire
transfer of immediately available funds to the Payments Administrator, to be distributed, the Closing Indebtedness and the Unpaid Company
Stockholder Expenses, in each case in the amounts set forth on the calculation of Estimated Purchase Price delivered hereunder and pursuant
to wire instructions provided to the Payments Administrator by the Company at least three (3) Business Days prior to the Closing Date.

 

Section
2.16 Appraisal Rights.

 

(a)       Notwithstanding
anything in this Agreement to the contrary, any Company Shares held by a Company Stockholder who has properly demanded and not effectively
withdrawn or lost such Company Stockholder’s appraisal rights for such shares under the DGCL or other similar rights (if any) under
applicable law (collectively, the “Dissenting Shares”), shall not be converted into or represent a right to
receive a portion of the consideration as set forth in Section 2.8, but the holder thereof shall only be entitled to such rights
as are provided by the DGCL or other applicable Law (if any).

 

(b)       Notwithstanding
the provisions of Section 2.16(a), if any holder of Dissenting Shares shall effectively withdraw or lose (through failure to perfect
or otherwise) such holder’s appraisal rights with respect to such shares under the DGCL (or any other similar rights under other
applicable law (if any such other rights have been purportedly invoked)), then, as of the later of the Effective Time and the occurrence
of such event, such Dissenting Shares shall automatically be converted into and represent only the right to receive the consideration
set forth in and subject to the provisions of this Agreement, upon surrender of the Certificate(s) formerly representing such shares (or
an affidavit of loss and indemnity in accordance with Section 2.13(d)).

 

(c)       The
Company shall give Parent (i) prompt notice of any written demand for appraisal (or withdrawal thereof) received by the Company
pursuant to the applicable provisions of the DGCL (and of any similar demand purportedly made under other applicable law) and (ii)
the opportunity to direct all negotiations and proceedings with respect to such demands. The Company shall not, except with the
prior written consent of Parent, (1) voluntarily make any payment, admission or statement against interest with respect to any such
objection, (2) offer to settle or settle any such objection or (3) waive any failure by a Company Stockholder to timely deliver a
written objection, or to perform any other act perfecting appraisal or dissenter’s rights in accordance with the DGCL. Any
communication to be made by the Company to any Dissenting Stockholder with respect to such demands shall be submitted to Parent in
advance and shall not be presented to any Dissenting Stockholder prior to the Company receiving Parent’s consent, not to be
unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, and subject to Parent’s compliance with Section
8.4 with respect to any appraisal demand, to the extent that Parent, the Surviving Corporation or the Company is required to
make any payment or payments in respect of any Dissenting Shares in excess of the consideration that otherwise would have been
payable in respect of such shares in accordance with this Agreement (“Excess Dissenting Share Payments”),
Parent shall be entitled to recover the amount of such Excess Dissenting Share Payments in accordance with the terms of Article
VIII hereof.

 

    28 

     

    

 

(d)       Notwithstanding
any provision of this Article II or Article VIII to the contrary, in the event that there are any Dissenting Shares, then,
for so long as they remain Dissenting Shares, (i) any payment by Parent pursuant to this Agreement (other than pursuant to Section
2.16(a) that would have been required to have been paid to, or on behalf of, such holder of Dissenting Shares (each a “Dissenting
Stockholder”) (assuming, for such purpose, that such Dissenting Stockholder had not exercised appraisal rights) shall be
retained by Parent, and (ii) such Dissenting Stockholder shall not be entitled to receive any distribution of funds from the Escrow Amount,
the Stockholders’ Representative Expense Amount or the Carve-out Program Amount and any such amounts otherwise payable to or on
behalf of such Dissenting Stockholder in respect of such Dissenting Shares pursuant to any such distribution shall be payable to Parent
in lieu of such Dissenting Stockholder.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

Subject to the exceptions
set forth in the Disclosure Schedule, the Company hereby represents and warrants, as of the date hereof (except to the extent that such
representations and warranties reference another date, in which case, as of such date), to Parent and Merger Sub as follows:

 

Section 3.1 Organization
and Qualification. The Company is a corporation, duly organized, validly existing and in good standing under the Laws of the State
of Delaware. Each other Group Company is a corporation, limited partnership, limited liability company or other business entity, as the
case may be, duly organized, validly existing and in good standing (or the equivalent thereof, if applicable) under the Laws of its respective
jurisdiction of formation or organization (as applicable). Schedule 3.1 sets forth each jurisdiction in which any of the Group
Companies is licensed or qualified to do business, and each Group Company is duly qualified or licensed to transact business and is in
good standing (if applicable) in each jurisdiction other than its jurisdiction of formation or organization in which the property and
assets owned, leased or operated by it, or the nature of the business conducted by it, makes such qualification or licensing necessary.
Each Group Company has the requisite corporate, limited partnership or other applicable power and authority to own, lease and operate
its material assets and properties and to carry on its businesses as presently conducted.

 

Section 3.2
Capitalization.

 

(a)       The
authorized Equity Securities of the Company consists of 55,000,000 Common Shares and 45,000,000 shares of Preferred Stock of the Company,
of which 40,000,000 are designated as Series A Preferred Shares and 5,000,000 are designated as Series A-1 Preferred Shares. The Company
has reserved 5,554,545 Common Shares for issuance pursuant to the exercise of Equity Incentive Options. As of the date hereof, the issued
and outstanding Equity Securities of the Company consists of 30,165,000 Series A Preferred Shares, 3,333,334 Series A-1 Preferred Shares,
3,926,377 Common Shares, no Equity Incentive Options for the purchase of Common Shares, and Warrants for the purchase of 550,000 Series
A-1 Shares. Schedule 3.2(a) sets forth a complete and accurate list of the (i) name of each holder of Company Shares, Equity Incentive
Options and Warrants, and (ii) the number of Company Shares held by each such holder and subject to Equity Incentive Options and Warrants
held by each such Holder.

 

    29 

     

    

 

(b)       Except
as set forth on Schedule 3.2(b), no Group Company owns any Equity Securities of any Person (other than a Subsidiary of a Group
Company). Except as set forth on Schedule 3.2(b) or as set forth in the Governing Documents, all outstanding Equity Securities
of each Group Company (except to the extent that such concepts are not applicable under the applicable Law of such Subsidiary’s
jurisdiction of formation or other applicable Law) have been duly authorized and validly issued and are fully paid and non-assessable,
are free and clear of any preemptive rights (except to the extent provided in the Stockholders’ Agreement or applicable Law and
other than such rights as may be held by any Group Company), restrictions on transfer (other than restrictions under applicable federal,
state and other securities Laws and to the extent provided in the Stockholders’ Agreement), or Liens (other than, with respect
to the Equity Securities of the Subsidiaries of the Company, Permitted Liens) and are owned, beneficially and of record, in the case
of the Equity Securities of the Company, by the Company Stockholders, and in the case of the Equity Securities of the Subsidiaries of
the Company, by another Group Company. Except as set forth on Schedule 3.2(b), there are (i) no outstanding Equity Securities
of any Group Company, (ii) no securities of any Group Company convertible into or exchangeable or exercisable for Equity Securities of
any Group Company, (iii) no subscriptions, calls, options, warrants or other rights to acquire from any Group Company and no obligations
of any Group Company to issue or sell, any Equity Securities or debt securities of, any Group Company and (iv) no equity equivalents,
stock appreciation rights, phantom stock ownership interests or similar rights in any Group Company.

 

(c)       There
are no outstanding obligations of any of the Group Companies to repurchase, redeem or otherwise acquire any securities or equity interests
in any Group Company. No outstanding Common Share is subject to vesting or forfeiture rights or repurchase by the Company. There are no
outstanding or authorized stock appreciation, dividend equivalent, phantom stock, profit participation or other similar rights with respect
to the Company or any of the Company Shares. All distributions, dividends, repurchases and redemptions of the capital stock (or other
equity interests) of the Company were undertaken in compliance with the Company Governing Documents then in effect, any agreement to which
the Company then was a party and in compliance with applicable Law.

 

(d)       No
Person holds any In-the-Money Options, and no Person holds any In- the-Money Warrants. All Equity Incentive Options are Out-of-the-Money
Options, and all Warrants are Out-of-the-Money Warrants. Each Equity Incentive Option outstanding immediately prior to the Effective Time
shall be canceled and extinguished at the Effective Time for no consideration pursuant to the terms of the Equity Incentive Options.

 

Section 3.3 Consents
and Approvals; No Violations. Assuming the truth and accuracy of the representations and warranties of Parent and Merger Sub set
forth in Section 4.3, other than as set forth in Schedule 3.3, no notices to, filings with, or authorizations,
consents or approvals of any Person or Governmental Entity are necessary for the execution, delivery or performance by the Company
of this Agreement or the Ancillary Documents to which the Company is a party or the consummation by the Company of the Transactions,
except for (a) compliance with and filings under the HSR Act, (b) execution and delivery of the Company Stockholder Approval, and
(c) those that may be required solely by reason of Parent’s or Merger Sub’s (as opposed to any other third
party’s) participation in the Transactions. Neither the execution, delivery or performance by the Company of this Agreement or
the Ancillary Documents to which the Company is a party nor the consummation by the Company of the Transactions (to the extent that
the Company is required to consummate any Transactions pursuant to this Agreement and/or any Ancillary Documents) (i)
conflict with or result in any breach of any provision of the Company Governing Documents,
(ii)result in a violation or breach of, or constitute (with or without due notice or lapse
of time or both) a default or give rise to any right of termination, cancellation or acceleration under, any of the terms,
conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or
obligation to which the Company is a party or by which the Company or any of the Company’s properties or assets may be bound,
(iii) violate any order, writ, injunction, decree, Law, statute, rule or regulation of any Governmental Entity applicable to the
Company or any of its properties or assets or (iv) except as contemplated by this Agreement or with respect to Permitted Liens,
result in the creation of any Lien upon any of the Company Shares or any assets of any Group Company, which in the case of any of clauses
(ii) through (iv) above, are material to the Group Companies.

 

    30 

     

    

 

Section 3.4 Power
and Authority; Enforceability. The Company has the corporate power and authority to execute and deliver this Agreement and each of
the Ancillary Documents and to consummate the Transactions. Except for the adoption and approval by the Company Stockholders of this Agreement
and the consummation of the Transactions, the execution and delivery of this Agreement and the consummation of the Transactions have been
duly authorized by all necessary corporate action on the part of the Company. Without limiting the foregoing, at a meeting of the Company
Board duly convened and held prior to the execution of this Agreement, the execution, delivery and performance of this Agreement and the
Ancillary Documents by the Company, and the consummation by it of the Transactions, have been duly authorized and approved by the Company
Board, and the Company Board has determined that the Merger is fair to and in the best interests of the Company Stockholders, declared
that the Merger is advisable and recommended the approval of the Merger and this Agreement by the Company Stockholders (such recommendation,
the “Company Recommendation”). This Agreement has been (and each of the Ancillary Documents to which the Company
is or will be a party has been or will be, as applicable) duly executed and delivered by the Company and constitute a valid, legal and
binding agreement of the Company (assuming that this Agreement has been and the Ancillary Documents to which the Company is or will be
a party have been or will be, as applicable, duly and validly authorized, executed and delivered by the other Persons party thereto),
each enforceable against the Company in accordance with their terms, except (i) to the extent that enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other Laws affecting the enforcement of creditors’ rights generally and (ii)
that the availability of equitable remedies, including specific performance, is subject to the discretion of the court before which any
Action thereof may be brought.

 

Section 3.5 Financial
Statements; No Undisclosed Liabilities. The Company has made available to Parent true and complete copies (such financial
statements, the “Company Financial Statements”) of (a) the audited consolidated balance sheet of the
Company and its consolidated Subsidiaries as of December 31, 2020, December 31, 2019 and December 31, 2018 and the related audited
consolidated statements of income, cash flows and stockholders’ equity for each fiscal year of the Company then ended and (b)
the unaudited consolidated balance sheet of the Company and its consolidated Subsidiaries (the “Interim Balance
Sheet”) as of June 30, 2021 (the “Interim Balance Sheet Date”), and the related unaudited
consolidated statements of income and cash flows for the five (5)-month period then ended. Except as set forth on Schedule
3.5, subject in the case of unaudited Financial Statements to the absence of certain footnotes not customarily included in the
unaudited quarterly financial statements and normal year-end adjustments, the Company Financial Statements (i) have been prepared in
accordance with GAAP applied on a consistent basis in all material respects throughout the periods covered thereby, except as may be
indicated in the notes thereto, and (ii) fairly present, in all material respects, the consolidated financial position of the Group
Companies as of the dates thereof and their consolidated results of operations for the periods then ended. The Company maintains a
standard system of accounting established and administered in accordance with GAAP. Except as set forth on Schedule 3.5, the
Company has no liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute
or contingent, accrued or unaccrued, matured or unmatured or otherwise, except (a) those which are adequately reflected or reserved
against in the Interim Balance Sheet as of the Interim Balance Sheet Date, and (b) those which have been incurred in the Ordinary
Course consistent with past practice since the Interim Balance Sheet Date and which are not, individually or in the aggregate,
material in amount.

 

    31 

     

    

 

Section 3.6 Material Contracts.

 

(a)       Schedule
3.6(a) sets forth a complete and accurate list of each Contract to which any of the Group Companies is a party or by which any of
the Group Companies or any of their respective properties or assets is bound as of the date of this Agreement that is of a type described
below (collectively, the “Material Contracts”):

 

(i)       any
Contract with any Material Client or Material Supplier;

 

(ii)       Contract
for the employment of any employee on a full-time, part- time or other basis providing annual base salary and guaranteed bonus (other
than any “at will” Contract that may be terminated by any Group Company upon ninety (90) days or less advance notice);

 

(iii)       (A)
any Leases and (B) any lease or agreement under which any Group Company is lessee of or holds or operates any tangible property (other
than real property), owned by any other Person, except for any lease or agreement under which the aggregate annual rental payments do
not exceed $75,000;

 

(iv)       any
Contract that licenses, permits or otherwise authorizes the use of Intellectual Property Rights, other than (A) non-exclusive licenses
granted by any Group Company to customers in the Ordinary Course and (B) non-exclusive licenses granted to any Group Company for generally
unmodified off-the-shelf Software applications, in each case for an aggregate fee, royalty or other consideration for any such Software
of no more than $10,000 (the foregoing, the “Company IP Agreements”);

 

    32 

     

    

 

(v)       any
material partnership agreements and joint venture agreements to which any Group Company is a party or is bound;

 

(vi)       any
Contract under which the counterparty is a reseller, distributor or agency involving at least $75,000 in payments during any calendar
year;

 

(vii)       any
Contract prohibiting any Group Company from freely engaging in any business, including: (A) all Contracts that require any of the Group
Companies to purchase its total requirements of any product or service from a third party or that contain “take or pay” provisions;
(B) all Contracts concerning exclusivity, noncompetition, non-solicitation, “most- favored nation”, other exclusive rights
of any type or scope in any line or lines of business enforceable against the Group Companies or any of their Affiliates (including, following
the Closing, Parent and its Affiliates), or (C) any Contract that could reasonably be expected to have the effect of prohibiting or impairing
the conduct of the business of the Group Companies or any of its Affiliates (including, following the Closing, Parent and its Affiliates);

 

(viii)     any
Contract relating to acquisitions or dispositions consummated by any of the Group Companies;

 

(ix)       any
other Contract with any current or former equityholder, officer, manager or director of the Group Companies, or any “Affiliate”
or “associate” of such persons (as such terms are defined in the rules and regulations promulgated under the Securities Act);

 

(x)
        all Contracts between or among the members of the Group Companies;

 

(xi)       any Contract relating to Indebtedness, whether incurred, assumed, guaranteed or secured by any asset, and any guaranty of any obligation
for Indebtedness or other material guaranty;

 

(xii)      any
indemnification or other similar Contract pursuant to which the Group Companies are obligated to indemnify or advance expenses on behalf
of any current or former director, manager or officer of the Group Companies in connection with any loss based on the fact that such Person
is or was a manager or officer of the Group Companies;

 

(xiii)     any
Contract under which the consequences of a default or termination would reasonably be expected to have a Material Adverse Effect;

 

(xiv)    other
than any Contracts specified in clauses (i) through (vi) above, Contracts that involve payments by or to any Group Company
of $250,000 or more in any calendar year; and

 

(xv)     any
other Contract that is otherwise material to the operations, business or finances of the Group Companies taken as a whole and which is
not otherwise disclosed in Schedule 3.6(a).

 

(b)       No
Group Company, and to the Company’s Knowledge, no other party, is in material breach of, or material default under, any
Material Contract. The Company has made available to Parent an accurate and complete copy of each Material Contract. All of such
Material Contracts are valid and binding in accordance with their terms and conditions against the Group Companies, as applicable,
and in full force and effect. To the Company’s Knowledge no event has occurred on or prior to the date hereof (with or without
notice, lapse of time or both) that would constitute a material default by the Group Companies under any Material Contract. Neither
the Company nor any Subsidiary is a party to any oral contract, agreement or other arrangement which, if reduced to written form,
would be required to be disclosed pursuant to this Section 3.6.

 

    33 

     

    

 

Section 3.7 Absence
of Changes. Except as set forth on Schedule 3.7, during the period beginning on the Interim Balance Sheet Date and ending
on the date of this Agreement, (a) there has not been any event, change, occurrence or circumstance that has had a Material Adverse
Effect, (b) each Group Company has conducted its business in the Ordinary Course
substantially consistent with past practices and (c) except as set forth on Schedule 3.7, no Group Company has taken any of
the following actions:

 

(a)       modified
or amended any of the Governing Documents of any of the Group Companies;

 

(b)       issued,
sold, pledged, encumbered or granted any (i) Equity Securities of any Group Company, (ii) securities convertible into or
exchangeable for, or any options, warrants or rights to acquire any, Equity Securities of any Group Company, or (iii) any
 “phantom” stock, “phantom” stock rights, stock appreciation rights, stock-based performance units or other
securities the value of which is derived from the price or value of the Equity Securities of any Group Company;

 

(c)       declared,
set aside or paid any dividends on or made any other distributions (whether in cash, stock or property) in respect of any of its issued
equity securities, or split, combine or reclassify any of its equity securities or issue or authorize the issuance of any other securities
in respect of, in lieu of or in substitution for equity interests, or repurchase, redeem or otherwise acquire, directly or indirectly,
any equity interests;

 

(d)       incurred
additional Indebtedness;

 

(e)       paid,
discharged or satisfied, in an amount in excess of $25,000 in the aggregate, any claim or Liability, other than in the Ordinary Course
and not in violation of this Agreement; dissolution;

 

(f)
       adopted a plan or agreement of complete or partial liquidation or

 

(g)
      acquired by merging or consolidating with, or by purchasing a substantial equity interest in or substantial portion of the assets
of, any Person, corporation, limited liability company, partnership, joint venture, association or other business organization or
division thereof;

 

(h)       amended
or modified in any material respect, renewed, terminated or granted any release or relinquishment of any material right under any Material
Contract;

 

    34 

     

    

 

(i)       except
to the extent required to comply with Law or the terms of any Employee Benefit Plan or any Material Contract, (i) granted or announced
any equity awards or the material increase in the salaries, bonuses or other compensation and benefits payable by any of the Group Companies
to any of the executive officers of any of the Group Companies outside the Ordinary Course (other than any success, change of control
or similar bonuses payable to any officer or employee that is treated as a Company Stockholder Expense); (ii) hired any new employee with
a $150,000 or greater annual base salary, or (iii) adopted, amended, materially increased benefits under, or terminated any Employee Benefit
Plan;

 

(j)       made
or changed any material election in respect of Taxes (including an election to change the U.S. federal income tax classification of any
Group Company), adopted or changed any material accounting method in respect of Taxes, entered into any Tax indemnity, allocation or sharing
agreement or similar Contract (other than any agreements entered into in the ordinary course of business principal subject matter of which
is not Taxes), settled any claim or assessment in respect of a material amount of Taxes, consented to any extension or waiver of the limitation
period applicable to any claim or assessment in respect of any material Taxes (other than an extension arising from obtaining an extension
of time to file a Tax Return), made or requested any Tax ruling with respect to a material Tax, entered into any installment sale or open
transaction sale, surrendered a right to a material credit or refund of any Tax, amend any material Tax Return or failed to timely file
a material Tax Return or pay a material Tax (in each case, taking into account valid extensions of time to file such Tax Return or pay
such Tax, as the case may be);

 

(k)       changed
its material accounting principles, methods, policies or procedures, except to the extent required to conform with GAAP or applicable
Law;

 

(l)       sold,
abandoned, allowed to lapse, failed to protect or maintain, leased or otherwise disposed of any of its properties or assets that are material
to any of the Group Companies;

 

(m)       except
non-exclusive licenses granted by any Group Company to customers in the Ordinary Course, granted or agreed to grant to any Person or amend,
waived any rights under or disposed of any license to any Intellectual Property material to any of the Group Companies;

 

(n)       changed
its fiscal year; or

 

(o)       authorized,
agreed, resolved or consented to any of the foregoing.

 

Section 3.8 Litigation.
Except as set forth on Schedule 3.8 there is no Action pending or threatened in writing or, to the Company’s Knowledge, under
investigation against any Group Company or any of their respective material assets. Except as set forth on Schedule 3.8, no Group
Company is subject to any outstanding order, writ, injunction or decree. This Section 3.8 does not relate to intellectual property
matters (which is the subject of Section 3.12) or Tax matters (which is the subject of Section 3.16).

 

Section 3.9 Compliance
with Applicable Law. Each of the Group Companies holds all material Permits required for the Company to conduct its business as
presently conducted and as presently proposed to be conducted (each, a “Material Permit”). The Business of
the Group Companies is, in all material respects, operated in compliance with all applicable Laws, rules, regulations, codes,
ordinances, and binding orders of all Governmental Entities. This Section 3.9 does not relate to Tax matters (which is the
subject of Section 3.16), environmental matters (which is the subject of Section 3.11), employee plan matters (which
is the subject of Section 3.10), intellectual property matters (which is the subject of Section 3.12), labor matters
(which is the subject of Section 3.14) or material permits and healthcare matters (which are the subject of Section
3.17).

 

    35 

     

    

 

Section 3.10 Employee Plans.

 

(a)       Schedule
3.10(a) lists all Employee Benefit Plans. The Company has provided to Parent as of the date hereof a true, correct and materially
complete copy (in each case, if applicable) of: (i) each such Employee Benefit Plan and any amendment thereto; (ii) each material summary
plan description and summary of material modifications with respect to any such Employee Benefit Plan; (iii) each funding document, including
each trust, insurance, annuity or other funding contract related thereto; (iv) the most recent financial statements and actuarial or other
valuation reports prepared with respect thereto; (v) the most recent annual report on Form 5500 required to be filed with the IRS with
respect thereto; and (vi) the most recent favorable determination letter received from the IRS regarding the qualification of each such
Employee Benefit Plan covered by Section 401(a) of the Code or, if such Employee Benefit Plan is a master/prototype or volume submitter
plan, the opinion or advisory letter which covers such Employee Benefit Plan. In relation to Employee Benefit Plans that are employment
agreements that relate to employees of any Group Company outside of the United States ("Non-US Employees”), the
Company has provided to Parent copies of all standard-form template employment agreements in use for Non-US employees. There are no Non-US
Employees whose employment agreements or other applicable terms of employment specify a notice period on termination by the employing
entity without cause of more than six months.

 

(b)       None
of the Company, any of its Subsidiaries, or any of their respective current or former ERISA Affiliates has, in the last six (6)
years, maintained, sponsored, contributed to or had any obligation to contribute to: (i) a plan subject to Title IV or Section 302
of ERISA or Section 412 or Section 4971 of the Code; or (ii) a Multiemployer Plan, and no Employee Benefit Plan provides health or
life insurance benefits to former employees of any Group Company other than health continuation coverage pursuant to Part 6 of
Subtitle B of Title I of ERISA, Section 4980B of the Code (COBRA) and any similar state law or other applicable Law. Each Employee
Benefit Plan that has been adopted or maintained by any Group Company, or with respect to which any Group Company will or may have
any liability, with respect to Non-US Employees (each an “International Employee Plan”), has been
registered or approved by a Governmental Entity (if required) and has been maintained in good standing with all applicable
Governmental Entities, and no event has occurred since the date of the most recent approval or application therefor that could
reasonably be expected to adversely affect any such approval or good standing. To the Knowledge of the Company, each International
Employee Plan that is intended to qualify for special Tax treatment meets the requirements for such treatment in all material
respects. All contributions to, and payments from, each International Employee Plan under the terms of such plan or applicable Law
have been timely made, except as would not result in material liability, and all contributions for any period ending on or before
the Closing Date that are not yet due have been accrued in accordance with country-specific accounting practices. Each International
Employee Plan that, under applicable Law, is required to be funded, is either: (i) funded in accordance therewith and to an extent
sufficient to provide for accrued benefit obligations with respect to all participants; or (ii) is fully insured, in each case,
based upon generally accepted local accounting and actuarial practices and procedures.

 

    36 

     

    

 

(c)       Except
as set forth on Schedule 3.10(c), each Employee Benefit Plan complies in all material respects with the applicable requirements
of ERISA, the Code and any other applicable Laws. Each Employee Benefit Plan that is intended to be qualified under Section 401(a) of
the Code has received a favorable determination letter from the Internal Revenue Service or is the subject of a favorable opinion letter
from the Internal Revenue Service on the form of such Employee Benefit Plan and, to the Company’s Knowledge, no events have occurred
that would be reasonably likely to adversely affect the qualified status of any such Employee Benefit Plan.

 

(d)       No
Group Company has any material liability under Title IV of ERISA nor, to the Company’s Knowledge, is any material liability under
Title IV of ERISA reasonably expected to be incurred by any Group Company.

 

(e)       To
the Company’s Knowledge, no Group Company has engaged in any transaction with respect to any Employee Benefit Plan that would be
reasonably likely to subject any Group Company to any material Tax or penalty (civil or otherwise) imposed by ERISA, the Code or other
applicable Law.

 

(f)       There
are no pending or, to the Knowledge of the Company, threatened Actions or disputes by, or on behalf of, any Employee Benefit Plan by any
employee or beneficiary covered under any such Employee Benefit Plan or otherwise involving any such Employee Benefit Plan (other than
routine claims for benefits).

 

(g)       Except
as set forth on Schedule 3.10(g), none of the execution and delivery of this Agreement, or the consummation of the transactions
contemplated hereby shall, either alone or in combination with another event or events: (i) entitle any Employee to severance pay, unemployment
compensation, a change of control payment or any other payment or benefit from the Company or any of its Subsidiaries; (ii) accelerate
the time of payment or vesting, or increase the amount of compensation (including funding of compensation or benefits through a trust
or otherwise) due any Employee from any Group Company; or (iii) result in the forgiveness of any Indebtedness. None of the execution and
delivery of this Agreement, or the consummation of the transactions contemplated hereby would result, individually or in the aggregate,
in the payment of any “excess parachute payment” for the purposes of Section 280G or Section 4999 of the Code by any Group
Company.

 

(h)       This
Section 3.10 contains the sole and exclusive representations and warranties of the Company with respect to each of the Group Companies’
Employee Benefit Plans.

 

Section 3.11 Environmental
Matters.

 

(a)       Except
as set forth on Schedule 3.11:

 

(i)       To
the Company’s Knowledge, each of the Group Companies is in material compliance with all applicable Environmental Laws;

 

    37 

     

    

 

(ii)       To
the Company’s Knowledge, each of the Group Companies holds and is in compliance with all Material Permits that are required pursuant
to applicable Environmental Laws for the operation of its businesses;

 

(iii)       No
Group Company has received any currently unresolved written notice of any violation of, or liability (including any investigatory, corrective
or remedial obligation) under, any Environmental Laws; and

 

(iv)       To
the Company’s Knowledge, no Group Company has treated, stored, disposed of, arranged for or permitted the disposal of, transported,
handled, or released any toxic or otherwise hazardous material, substance or waste at the Leased Real Property in violation of any Environmental
Laws.

 

(b)       This
Section 3.11 contains the sole and exclusive representations and warranties of the Company with respect to Environmental Laws and
any other environmental matters.

 

Section 3.12 Intellectual
Property.

 

(a)       Except
as set forth on Schedule 3.12(a), each of the Group Companies owns, licenses or otherwise has the valid right to use (subject only
to the terms of the Company IP Agreements), free and clear of all Liens except for Permitted Liens, all Intellectual Property Rights reasonably
required for the operation of the Business of the Group Companies as currently conducted or as reasonably contemplated to be conducted
(collectively, the “Group Company IP Rights”), except as would not reasonably be expected to be material to
any of the Group Companies, all of which rights shall survive unchanged upon the consummation of the Transactions. The consummation of
the Transactions will not place any Group Company or in breach or default of any Company IP Agreement.

 

(b)       Schedule
3.12(b) sets forth a list of: (i) issued patents, (ii) registered copyrights, (iii) registered trademarks, (iv) registered domain
names, (v) pending applications for any registrations of a type referred to in the immediately preceding clauses (i) through (iv), and
(vi) any other Intellectual Property Rights material to any Group Company, in each case of (i) through (v) and (vi)(A) owned by a Group
Company. Each item of Intellectual Property Rights listed or required to be listed on Schedule 3.12(b) is exclusively owned by
a Group Company (except those listed on Schedule 3.12(b)(vi)(B)), free and clear of all Liens (other than Permitted Liens), subsisting,
valid and enforceable and, as applicable, recorded as owned by a Group Company with the applicable Governmental Entity without any gaps
in the chain of title. Except as set forth on Schedule 3.12(b), within the past six (6) years (x) no Group Company has
received any written notice of any Claim currently pending or threatened, against any Group Company either (A) contesting the use, validity,
enforceability or ownership of any material Group Company IP Rights owned by any of the Group Companies, or (B) alleging that any of
the Group Companies is infringing, misappropriating or otherwise violating the Intellectual Property Rights of any other Person, and
(y) there are no Claims pending that have been brought by any of the Group Companies against any Person alleging any infringement, misappropriation
or other violation of any material Group Company IP Rights.

 

    38 

     

    

 

(c)       Except
as set forth on Schedule 3.12(c), (i) the conduct of the Business of the Group Companies (including the development, use, marketing,
offer for sale, sale or other commercialization of any Group Company Product (as defined below)) as currently conducted does not infringe,
misappropriate or otherwise violate any Intellectual Property Rights of any Person in a manner that could be material to any of the Group
Companies; and (ii) to the Knowledge of the Company, no Person is currently infringing, misappropriating or otherwise violating any material
Group Company IP Rights.

 

(d)       Each
of the Group Companies has taken commercially reasonable measures designed to protect the confidentiality of all trade secrets owned by
any of the Group Companies and other confidential Group Company IP Rights. The conduct of the Business of the Group Companies as currently
conducted complies with all applicable Laws pertaining to privacy and security of personally identifiable information, except for any
such non-compliance as has not been, and would not reasonably be expected to be, material to any of the Group Companies.

 

(e)       All
past and present employees and independent contractors of each Group Company who have contributed to or participated in the conception
or development of material Intellectual Property Rights used in or related to the conduct of the Business of any Group Company have entered
into agreements pursuant to which such employee agrees to protect the confidential information of such Group Company and validly and effectively
assign to such Group Company all right, title and interest in all Intellectual Property Rights created by such employee or independent
contractor in the course of his or her work with such Group Company, without further consideration or any restrictions or obligations
on the use or ownership of such Intellectual Property Rights.

 

(f)       No
Group Company Software is subject to any open source Software license or similar arrangement that requires any Group Company to make any
proprietary source code owned by a Group Company available to any Person or to otherwise grant any license or other permission to use
any of the Group Company IP Rights. No proprietary source code owned by a Group Company has been delivered or made available to any Person
who is not, as of the date of this Agreement, an employee or an independent contractor of a Group Company, and no Group Company has agreed
to deliver or make available such source code to any Person.

 

(g)       Each
of the Group Companies has implemented commercially reasonable measures, consistent with current industry standards, designed to
protect the confidentiality, integrity and security of the computer systems, including the Software, hardware, firmware, interfaces,
networks, and related systems, owned or operated by or on behalf of each Group Company (including Group Company Software and any of
the foregoing that constitutes a Group Company Product (as defined below)) (collectively, the “Group Company
Systems”) (and all information stored or contained therein or transmitted thereby) against any unauthorized use,
access, modification or corruption, each of the Group Companies maintains commercially reasonable disaster recovery plans, and each
of the Group Companies has taken commercially reasonable steps to test such plans and procedures on a periodic basis, and such plans
and measures have been proven reasonably effective upon such testing in all material respects. Since January 1, 2017, there have
been no failures, breakdowns, continued substandard performance, or other adverse events affecting any Group Company Systems (or any
information stored or contained therein or transmitted thereby) that have caused the material disruption or interruption in or to
the use of any Group Company Systems and/or the conduct of any Group Company’s Business or, to the Knowledge of the Company,
any unauthorized intrusions or breaches of any Group Company Systems (or any information stored or contained therein or transmitted
thereby). The Group Company Systems are (i) adequate in all material respects for the businesses of the Group Companies, (ii)
operate and perform in all material respects in accordance with their documentation and functional specifications and (iii) do not
include any disabling codes or instructions, “time bombs”, “Trojan horses”, “back doors”,
 “trap doors”, “worms”, viruses, bugs, faults or other Software routines or hardware components that (A)
disrupt or adversely affect the functionality of any Group Company Systems or (B) enable or assist any third Person to access
without authorization any Group Company System.

 

    39 

     

    

 

(h)       All
components of the Group Company Systems, other than Software or hardware licensed, leased, or provided as a service by a vendor to a Group
Company (such as, e.g., data center resources), are owned and operated by and are under the control of a Group Company. All service offerings
or products made or currently intended to be made commercially available or otherwise distributed, or currently under development, by
any Group Company, including any and all Internet or intranet websites owned and/or operated by or on behalf of any Group Company (the
foregoing, the “Group Company Products”), was developed entirely by the Group Companies. Schedule 3.12(h)
identifies all Software programs and products that have been developed by or for a Group Company and that are either incorporated into
Group Company Products or necessary for the provision, service, maintenance, marketing or sale of Group Company Products. No Group Company
has any ongoing or future obligations to pay royalties, commissions, or other fees upon the sale, licensing, or other distribution of
any Group Company Products.

 

Section 3.13 Privacy.
Each of the Group Companies has complied in all material respects with all applicable Laws (including Health Care Information Laws) and
contractual obligations (and each has complied in all material respects with its own policies) pertaining to data privacy, data protection,
and the collection and use of Personal Data collected, used, or held for use by any of the Group Companies. No Action or investigation
is pending before a Governmental Entity and no Person has threatened in writing to commence any such Action, in either case concerning
any claim that any Group Company has violated any Law or contractual obligation in connection with or relating to Personal Data. Except
as set forth on Schedule 3.13, no security breach, violation, or unauthorized access to any Personal Data that is collected, used,
or held for use by any of the Group Companies has been threatened in writing or, to the Knowledge of the Company, occurred.

 

Section 3.14 Labor
Matters.

 

(a)       Schedule
3.14(a) of the Company Disclosure Letter sets forth a complete and accurate list, as of the date hereof, of all of the current Employees
by name, title, years of service, location and annual base compensation (including annual base salary and annual target bonus), except
to the extent that such information may not be disclosed under applicable data privacy and protection Laws.

 

(b)       No
Group Company is party to any collective bargaining agreement, there is no strike, walk out, work stoppage, lockout or other
material labor dispute pending or, to the Company’s Knowledge, threatened in writing against any Group Company, and to the
Company’s Knowledge, as of the date of this Agreement no union organization campaign is in progress with respect to any
employees of any Group Company. No Group Company has implemented any location closing or employee layoffs during the one (1)-year
period prior to the date hereof in violation of the Worker Adjustment Retraining and Notification Act of 1988, as amended
(“WARN”), or any similar state or local plant closing or mass layoff statute, rule or regulation, and no
Group Company has taken any action that would reasonably be excepted to cause Parent or any of its Affiliates to have any material
Liability or other material obligation following the Closing under WARN or any similar state or local Law.

 

    40 

     

    

 

(c)       Except
as provided in Schedule 3.14(c), no investigation, review, complaint, grievance, controversy or proceeding by any Governmental
Entity or Employee with respect to any Group Company in relation to any actual or alleged violation of any Law involving any Employee
is pending or, to the Knowledge of the Company, threatened, nor has any Group Company received any notice from any Governmental Entity
indicating an intention to conduct the same.

 

(d)       All
Employees classified as exempt under applicable wage Laws satisfy the requirements of such applicable Laws. No Group Company is delinquent
in any material payments to any Employees for any wages, salaries, commissions, bonuses, severance, termination pay or other direct compensation
for any services performed for them or amounts required to be reimbursed to such employees. All independent contractors providing services
to a Group Company have been properly classified as independent contractors for purposes of applicable Laws, and to the Knowledge of the
Company, no current or former independent contractor has made any formal written claim to a Group Company that he or she is (or was) or
should be (or should have been) classified as an employee of a Group Company. In the past five (5) years, there has not been any action
relating to, nor to the Knowledge of the Company, any act or allegation of or relating to, sex-based discrimination, sexual harassment
or sexual misconduct, nor to the Knowledge of the Company, breach of any policy of any Group Company relating to the foregoing, in each
case involving any Employee, nor has there been any settlements relating to any such matters, nor to the Knowledge of the Company has
any such action been threatened.

 

Section 3.15 Insurance.
Schedule 3.15 contains a list of all material insurance policies owned or held by any of the Group Companies as of the date of
this Agreement. All such policies are, as of the date of this Agreement, in full force and effect, all premiums with respect thereto covering
all periods up to and including the Closing Date will have been paid, and no written notice of cancellation or termination has been received
by any Group Company with respect to any such policy.

 

Section 3.16 Tax Matters. Except as set forth
on Schedule 3.16:

 

(a)       each
Group Company has prepared and timely filed with the appropriate Governmental Entity (or has had so prepared and filed on its behalf)
(taking into account applicable extensions of time to file that are validly obtained) all income and other material Tax Returns required
to be filed by or with respect to such Group Company, and has timely paid (or has paid on its behalf) (taking into account applicable
extensions of time to file) all income and other material Taxes of such Group Company that are due and payable (whether or not shown on
any Tax Return);

 

    41 

     

    

 

(b)       all
Tax Returns filed by or with respect to any of the Group Companies are true, correct and complete in all material respects;

 

(c)       no
Tax Return of any Group Company is currently the subject of a Tax audit or examination;

 

(d)       during
the past five (5) years, no Group Company has received any written notification of any claim or legal proceeding proposed or threatened
against any Group Company in respect of any Tax (including any Tax filing or Tax reporting obligation);

 

(e)       there
are no Liens for Taxes upon any of the assets or properties of any Group Company, except for Permitted Liens;

 

(f)       no
power of attorney that is currently in force has been granted with respect to any matter relating to Taxes that could affect the Group
Companies after the Closing Date, other than any power of attorney granted in the ordinary course of business;

 

(g)       no
Group Company has (i) consented in writing to extend the time, or is the beneficiary of any extension of time, in which any Tax may be
assessed or collected by any Governmental Entity (other than any extension which is no longer in effect), and no such consent is pending
or has been requested in writing by a Governmental Entity, (ii) received or applied for a ruling relating to Taxes which could be binding
on Parent, the Group Companies or any of their Affiliates after the Closing Date, (iii) entered into a gain recognition agreement within
the meaning of Section 367 of the Code, or (iv) entered into a “closing agreement” as described in Section 7121 of the Code
(or any comparable provisions of state, local or foreign law) with any Governmental Entity that is currently in effect;

 

(h)       no
Group Company has received from any Governmental Entity any (i) written notice indicating an intent to open a Tax audit or other review;
(ii) written request for information related to Tax matters; or (iii) written notice of proposed adjustment, deficiency, underpayment
of a material amount of Taxes which has not since been satisfied by payment or been withdrawn;

 

(i)       within
the last five (5) years, no written claim has been made by any Tax Authority in a jurisdiction where any Group Company does not file Tax
Returns that any such Group Company is or may be subject to taxation by that jurisdiction or required to file a Tax Return in that jurisdiction;

 

(j)       no
Group Company is a party to or bound by any Tax indemnity, allocation or sharing agreement or similar Contract (other than such an agreement
solely between or among Group Companies or any agreement entered into in the Ordinary Course the principal subject matter of which is
not Tax), and after the Closing Date, no Group Company will be bound by any such Contract or have any Liability thereunder for any amounts;

 

(k)       no
Group Company (i) has been a member of an affiliated group filing a consolidated federal income Tax Return, other than a group the
common parent of which was a Group Company, or (ii) has any liability for the Taxes of any Person (other than a Group Company) under
Treasury Regulation Section 1.1502-6 (or any corresponding or similar provision of state or local Law), as a transferee or
successor, or by operation of applicable Law, or (iii) is (or has been at any time in the past three (3) years) a party to any joint
venture, partnership or other Contract that is properly treated as a partnership for U.S. federal income tax purposes;

 

    42 

     

    

 

(l)       the
Group Companies have been in substantial compliance with all applicable transfer pricing laws, including the execution and maintenance
of contemporaneous documentation substantiating the transfer pricing practice and methodology;

 

(m)       each
Group Company: (i) has complied in all material respects with all Laws relating to the payment, reporting and withholding of Taxes from
payments made to any Person and (ii) has, within the time and in the manner prescribed by applicable Law, withheld from such payments
(including employee wages or consulting compensation) and timely paid over to the proper Governmental Entities (or is properly holding
for such timely payment) all material amounts required to be so withheld and paid over under all applicable Laws;

 

(n)       no
Group Company will be required to include any material item of income in, or exclude any material item of deduction from, taxable income
for any for any taxable period (or portion thereof) ending after the Closing Date: (i) pursuant to Section 481 of the Code (or any similar
provision of state, local or foreign law) as the result of any change in a method of accounting or an impermissible use of a method of
accounting at any time prior to the Closing; (ii) as a result of any installment sale or open transaction disposition made on or prior
to the Closing; (iii) as a result of any prepaid amount received on or prior to the Closing; or (iv) as a result of intercompany transactions
or excess loss accounts described in Treasury Regulations under Section 1502 of the Code (or any similar provision of state, local, or
foreign Law with respect to Taxes) with respect to a transaction occurring prior to the Closing Date;

 

(o)       each
Group Company has (i) properly complied with all applicable Laws with respect to the deferral of the amount of the employer’s share
of any “applicable employment taxes” under Section 2302 of the CARES Act (or any similar provision of state, local or foreign
Legal Requirements), (ii) properly complied with all applicable Laws and duly accounted for any available Tax credits under Sections 7001
through 7005 of the Families First Coronavirus Response Act and Section 2301 of the CARES Act and (iii) not deferred any Taxes pursuant
to the Presidential Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing COVID-19 Disaster, issued August 8, 2020;

 

(p)       no
Group Company has engaged in a transaction or agreed to make any payment governed by Section 267A of the Code or the Treasury Regulations
promulgated thereunder (or any similar provision of state, local or foreign law);

 

(q)       (i)
no Group Company has engaged in an “extraordinary disposition” (as described in Treasury Regulation Section 1.245A-5(c)(3)(ii))
and there is no “extraordinary disposition account” with respect to any Group Company, (ii) there has not been an “extraordinary
reduction” (as defined in Treasury Regulation Section 1.245A-5(e)(2)(i)) with respect to any Group Company and (iii) there is no
 “hybrid deduction account” with respect to any share of stock (or other instrument treated as equity for U.S. federal income
tax purposes) of any Group Company, within the meaning of Proposed Treasury Regulation Section 1.245A(e)-1;

 

    43 

     

    

 

(r)       no
Group Company has made an election under Section 965(h)(1) of the Code (or any similar provision of state, local or foreign law) to pay
any net Tax Liability under Section 965 of the Code (or any similar provision of state, local or foreign law) in installments;

 

(s)       no
Group Company is, and has never been, required to pay the Tax imposed by Section 59A of the Code (relating to the “Base Erosion
and Anti-abuse Tax”);

 

(t)       within
the past six (6) years, no Group Company has incurred a dual consolidated loss within the meaning of Section 1503 of the Code (or any
comparable provisions of state, local or foreign Law);

 

(u)       each
Group Company is in compliance in all material respects with all terms and conditions of any Tax exemption, Tax holiday or other Tax reduction
Contract or order (each, a “Tax Incentive”), and no submission made to any Governmental Entity in connection
with obtaining any Tax Incentive contained any material misstatement or omission;

 

(v)       no
group Company has any outstanding equity interests that are currently subject to a “substantial risk of forfeiture” within
the meaning of Section 83 of the Code (or a corresponding or similar provision of state, local or foreign Law) for which a valid election
under Section 83(b) of the Code (or a corresponding or similar provision of state, local or foreign Law) has not been made by the holder
of such interests;

 

(w)       each
Group Company is, and has at all times since its formation been, properly treated as a corporation for U.S. federal and applicable state
income tax purposes; and

 

(x)       no
Group Company has “participated” in any transaction that, as of the date hereof, is a “listed transaction” under
Treasury Regulation Section 1.6011-4;

 

(y)       within
the last five (5) years, no Group Company has distributed stock of another Person or had its stock distributed by another Person, in each
case in a transaction that was purported or intended to be governed in whole or in part by Section 355 or Section 361 of the Code;

 

(z)       as
of the “Specified Date” (as such term is defined in subclause (d) of Explanation 6 to Section 9(1)(i) of the (Indian) Income
Tax Act, 1961), the fair market value of all the assets (tangible and intangible) held directly or indirectly by the Company that are
located in India represented, or will represent, less than fifty percent (50%) of the fair market value of all of the assets of the Company
(as determined in accordance with the Indian Income Tax Rules, 1962 and Notification No. 55/2016 (dated 28 June 2016)); and

 

(aa)     except for Section
3.7(j) and certain representations related to Taxes in Section 3.10, this Section 3.16 contains the sole and exclusive
representations and warranties of the Company with respect to Taxes.

 

Section 3.17 Material
Permits; Healthcare Matters; Billing.

 

(a)       Each
Group Company is duly licensed to engage in the Business in all states in which it does business, which states are listed in Schedule
3.17(a). Each Group Company owns and maintains in good standing all Material Permits to the extent necessary to enable it to (i)
own, occupy and lease its assets, and (ii) operate the Business. All such Material Permits are valid, binding and in full force and effect,
and each Group Company is not in default under any such Material Permit. Except as set forth on Schedule 3.17(a), the execution,
delivery and performance of this Agreement and the consummation of the Transactions shall not adversely affect any Material Permits which
are necessary to enable each Group Company to own, occupy and lease its assets and operate the Business as presently operated.

 

    44 

     

    

 

(b)       No
Group Company, nor to the Knowledge of the Company, any of the Group Companies’ employees or independent contractors (whether an
individual or entity) is or has been convicted of, charged with or, been investigated for any Medicare, Medicaid or other federal or state
health program, as defined in 42 U.S.C. § 1320a-7b(f) (each a “Federal Healthcare Program”), related offense,
or convicted of, charged with or investigated for a violation of any Law related to fraud, obstruction of an investigation of controlled
substances, or has been debarred, excluded or suspended from participation in any Federal Healthcare Program, or been subject to any order
or consent decree of, or criminal or civil fine or penalty imposed by, any Governmental Entity.

 

(c)       All
billing and claims submission practices of each Group Company, and, to the Knowledge of the Company, of any agent acting on behalf of
a Group Company, are and have been in material compliance with all applicable Laws, including all Federal Healthcare Program laws and
all policies and procedures of all third-party payors with which each Material Client have a Contract.

 

(d)       This
Section 3.17 contains the sole and exclusive representations and warranties of the Company with respect to healthcare and billing
matters.

 

Section 3.18 Real Property.

 

(a)       Schedule
3.18(a) sets forth a list of all locations of the Leased Real Property. Each Lease is valid and binding on the Group Company party
thereto, enforceable in accordance with its terms (subject to proper authorization and execution of such Lease by the other party thereto
and subject to applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting generally the enforcement of creditors’
rights and subject to general principles of equity). Except as set forth on Schedule 3.18(a), each of the Group Companies, and,
to the Company’s Knowledge, each of the other parties thereto, has performed in all material respects all obligations required to
be performed by it under each Lease. Except as disclosed on Schedule 3.18(a), there are no subleases or similar written agreements
granting to any Person other than a Group Company the right to use or occupy any Leased Real Property.

 

(b)       No Group Company owns, or has
ever owned, any real property. Section

 

    45 

     

    

 

 

3.19 Clients and
Suppliers.

 

(a)       Schedule
3.19(a) sets forth a true and complete list of the forty (40) largest clients of the Group Companies (i.e., to which any of
the Group Companies provided services), measured by the aggregate amount of sales made by any of the Group Companies to such clients
during the two most recently completed fiscal years of the Group Companies (the “Material Clients”), and the
aggregate amount of such sales made to each such Material Client during such fiscal year. Except as set forth on Schedule 3.19(a),
no Material Client has (i) had an adverse change in the business relationship, or any material dispute, between such Material Client
and the applicable Group Company; (ii) terminated, cancelled or failed to renew, or given any Group Company notice that references its
intention to terminate, cancel or fail to renew, its business relationship with such Group Company (whether or not subject to a Contract);
or (iii) ceased or materially reduced, or given any Group Company notice that references its intention to cease or materially reduce,
its business dealings with any Group Company.

 

(b)       Schedule
3.19(b) sets forth a true and complete list of the twenty (20) largest suppliers of the Group Companies (i.e., which provide
any of the Group Companies with products or services), measured by the aggregate amount of sales made by such suppliers to the Group Companies
during the two most recently completed fiscal years of the Group Companies (the “Material Suppliers”), and the
aggregate amount of such sales made by each such Material Supplier during such fiscal year. Except as set forth on Schedule 3.19(b),
no Material Supplier has (i) had an adverse change in the business relationship, or any material dispute, between such Material Supplier
and the applicable Group Company; (ii) terminated, cancelled or failed to renew, or given any Group Company notice that references its
intention to terminate, cancel or fail to renew, its business relationship with such Group Company (whether or not subject to a Contract);
or (iii) ceased or materially reduced, or given any Group Company notice that references its intention to cease or materially reduce,
its business dealings with any Group Company.

 

Section 3.20 Foreign
Corrupt Practices Act. None of the Company, any of its Subsidiaries or, to the Company’s Knowledge, any of their respective
representatives or Employees or any other Person have, with respect to the business of the Group Companies, (a) used any funds for unlawful
contributions, gifts, entertainment or other unlawful payments relating to any political activity or (b) made any unlawful payment to
any Person, any political party or campaign or violated any provision of the U.S. Foreign Corrupt Practices Act of 1977, the Organisation
for Economic Co-operation and Development’s (OECD) Convention on Combating Bribery of Foreign Public Officials in Business Transactions,
UK Bribery Act (The Bribery Act 2010 (c.23)), or any other similar Legal Requirement (collectively, “Anti-bribery Laws”).
The Company has made available to Parent the Contracts in effect, if any, as of the date of this Agreement between any Group Company,
on the one hand, and any sales agent or foreign representative thereof, on the other hand.

 

Section 3.21 Brokers.
Except for Brentwood Capital Advisors, LLC and Falcon Capital Partners, LLC, no broker, finder or investment banker is entitled to any
brokerage, finders or other fee or commission in connection with the transactions contemplated by this Agreement based upon arrangements
made by or on behalf of any Group Company.

 

Section 3.22 EXCLUSIVITY
OF REPRESENTATIONS AND WARRANTIES. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS ARTICLE III (INCLUDING THE
RELATED PORTIONS OF THE DISCLOSURE SCHEDULES) AND THE ANCILLARY DOCUMENTS, NEITHER THE COMPANY (ON BEHALF OF ITSELF AND EACH OTHER
GROUP COMPANY) NOR ANY OTHER PERSON HAS MADE OR MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, EITHER WRITTEN OR
ORAL, ON BEHALF OF THE COMPANY OR ANY OTHER GROUP COMPANY, INCLUDING ANY REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR
COMPLETENESS OF ANY INFORMATION REGARDING THE ASSETS OF THE COMPANY OR ANY OTHER GROUP COMPANY (INCLUDING ANY INFORMATION, DOCUMENTS
OR MATERIAL, MANAGEMENT PRESENTATIONS OR IN ANY OTHER FORM IN EXPECTATION OF THE TRANSACTIONS CONTEMPLATED HEREBY) OR AS TO THE
FUTURE REVENUE, PROFITABILITY OR SUCCESS OF THE COMPANY OR ANY OTHER GROUP COMPANY, OR ANY REPRESENTATION OR WARRANTY ARISING FROM
STATUTE OR OTHERWISE IN LAW.

 

    46 

     

    

 

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF PARENT
AND MERGER SUB

 

Parent and Merger
Sub hereby make the following representations and warranties as of the date hereof (except to the extent that such representations and
warranties reference another date, in which case, as of such date), to the Company as follows:

 

Section 4.1        Organization.
Parent is a Delaware limited liability company, and Merger Sub is a Delaware corporation, each of which is duly organized, validly existing
and in good standing under the laws of the jurisdiction of its formation and has all requisite power and authority to carry on its businesses
as now being conducted, except where the failure to have such power or authority would not prevent or materially delay the consummation
of the Transactions.

 

Section 4.2
        Authority.

 

(a)       Each
of Parent and Merger Sub has all necessary power and authority to execute and deliver this Agreement and the Ancillary Documents to which
each of Parent and Merger Sub is a party and to consummate the Transactions. The execution and delivery of this Agreement and the Ancillary
Documents to which each of Parent and Merger Sub is a party and the consummation of the Transactions have been (and the Ancillary Documents
to which each of Parent and Merger Sub is a party will be) duly authorized by all necessary action on the part of each of Parent and Merger
Sub and no other proceeding (including by their respective equityholders) on the part of each of Parent and Merger Sub is necessary to
authorize this Agreement and the Ancillary Documents to which each of Parent and Merger Sub is party or to consummate the transactions
contemplated hereby. No vote of Parent’s equityholders is required to approve this Agreement or for Parent or Merger Sub to consummate
the Transactions.

 

(b)       This
Agreement has been (and the Ancillary Documents to which each of Parent and Merger Sub is a party will be) duly and validly executed and
delivered by each of Parent and Merger Sub and constitutes a valid, legal and binding agreement of each of Parent and Merger Sub (assuming
this Agreement has been and the Ancillary Documents to which each of Parent and Merger Sub is a party will be duly authorized, executed
and delivered by the other parties thereto), enforceable against each of Parent and Merger Sub in accordance with its terms, except (i)
to the extent that enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other Laws affecting
the enforcement of creditors’ rights generally and (ii) that the availability of equitable remedies, including specific performance,
is subject to the discretion of the court before which any Action thereof may be brought.

 

    47 

     

    

 

Section 4.3        Consents
and Approvals; No Violations. Assuming the truth and accuracy of the Company’s representations and warranties contained in Section
3.3, no material notices to, filings with, or authorization, consent or approval of any Governmental Entity is necessary for the
execution, delivery or performance of this Agreement by either Parent or Merger Sub or the Ancillary Documents to which each of
Parent and Merger Sub is a party or the consummation by each of Parent and Merger Sub of the Transactions, except for compliance
with and filings under the HSR Act. Neither the execution, delivery and performance by each of Parent and Merger Sub of this
Agreement and the Ancillary Documents to which each of Parent and Merger Sub is a party nor the consummation by each of Parent and
Merger Sub of the Transactions (a) conflict with or result in any breach of any provision of either Parent’s or Merger
Sub’s Governing Documents, (b) result in a violation or breach of, or constitute (with or without due notice or lapse of time
or both) a default or give rise to any right of termination, cancellation or acceleration under, any of the terms, conditions or
provisions of any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which
each of Parent and Merger Sub is a party or by which either of them or any of their respective properties or assets may be bound, or
(c) violate any order, writ, injunction, decree, Law, statute, rule or regulation of any Governmental Entity applicable to either
Parent or Merger Sub or any of Parent’s other Subsidiaries or any of their respective properties or assets.

 

Section 4.4        Investment
Purpose. Each of Parent and Merger Sub is acquiring the Company Shares solely for its own account for investment purposes and not
with a view to, or for offer or sale in connection with, any distribution thereof. Each of Parent and Merger Sub acknowledges that the
Company Shares are not registered under the Securities Act of 1933, as amended, or any state securities laws, and that the Company Shares
may not be transferred or sold except pursuant to the registration provisions of the Securities Act of 1933, as amended, or pursuant to
an applicable exemption therefrom and subject to state securities laws and regulations, as applicable. Each of Parent and Merger Sub is
able to bear the economic risk of holding the Company Shares for an indefinite period (including total loss of its investment), and has
sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risk of its investment.

 

Section 4.5       Brokers.
No broker, finder, financial advisor or investment banker is entitled to any brokerage, finder’s, financial advisor’s or investment
banker’s fee or commission or similar payment in connection with the Transactions based upon arrangements made by and on behalf
of either Parent or Merger Sub or any of their respective Affiliates, in each case for which any Company Stockholders or any Group Company
may become liable.

 

Section 4.6       Financial
Ability. Parent and Merger Sub, individually or in the aggregate: (a)       have, and at the
Closing will have, sufficient unrestricted cash on hand available to pay the Purchase Price and any fees or expenses incurred by
Parent or Merger Sub in connection with the Transactions; (b) have, and at the Closing will have, the resources and capabilities
(financial or otherwise) to perform their obligations hereunder; and (c) have not incurred any obligation, commitment, restriction
or liability of any kind that would impair or adversely affect such resources and capabilities. Each of Parent and Merger Sub
acknowledges and agrees that: (x) each of the Group Companies has no responsibility for any debt financing that Parent or Merger Sub
may raise in connection with the transactions contemplated hereby; (y) it is not a condition to Closing under this Agreement, nor to
the consummation of the transactions contemplated hereby, for each of Parent or Merger Sub to obtain any equity or debt financing;
and (z) neither Parent nor Merger Sub has the right to terminate this Agreement for failure to obtain any equity or debt
financing.

 

    48 

     

    

 

Section 4.7        Solvency.
Assuming the representations and warranties of the Company contained in Article III are true in all material respects, at and immediately
after the Effective Time, and after giving effect to the Merger and the other transactions contemplated hereby, the Surviving Corporation
and its Subsidiaries (on a consolidated basis) (a) will be solvent (in that both the fair value of its assets will not be less than the
sum of its debts and that the present fair saleable value of its assets will not be less than the amount required to pay its probable
liability on its debts as they become absolute and matured), (b) will have adequate capital with which to engage in its business, and
(c) will not have incurred and does not immediately plan to incur debts beyond its ability to pay as they become absolute and matured.

 

Section 4.8        Merger
Sub Activities. Merger Sub was organized solely for the purpose of entering into this Agreement and consummating the Transactions
and has not engaged in any activities or business, and has incurred no liabilities or obligations whatsoever, in each case, other than
those incident to its organization and the execution of this Agreement and the other Ancillary Documents to which it is a party and the
consummation of the transactions contemplated hereby and thereby.

 

Section 4.9        No
Contact with Employees, Clients and Suppliers. Prior to the Closing, none of Parent, Merger Sub or any of their respective Affiliates
or any agents, representatives or lenders of the foregoing has, without the prior written consent of the Stockholders’ Representative
or the Company, directly or indirectly contacted any officer, director, employee, supplier, distributor, clients or other material business
relation of any Group Company for the purposes of discussing any Group Company or the Business in connection with the Transactions.

 

Section 4.10       Acknowledgment and Representations
by Parent and Merger Sub.

 

(a)       EXCEPT
FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS ARTICLE IV (INCLUDING THE RELATED PORTIONS OF THE DISCLOSURE SCHEDULES),
NEITHER PARENT, MERGER SUB NOR ANY OTHER PERSON HAS MADE OR MAKES ANY OTHER EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, EITHER WRITTEN
OR ORAL, ON BEHALF OF PARENT OR ANY MERGER SUB, INCLUDING ANY REPRESENTATION OR WARRANTY AS TO THE ACCURACY OR COMPLETENESS OF ANY INFORMATION
REGARDING PARENT OR MERGER SUB (INCLUDING ANY INFORMATION, DOCUMENTS OR MATERIAL, MANAGEMENT PRESENTATIONS OR IN ANY OTHER FORM IN EXPECTATION
OF THE TRANSACTIONS CONTEMPLATED HEREBY) OR AS TO THE FUTURE REVENUE, PROFITABILITY OR SUCCESS OF PARENT OR ANY GROUP COMPANY AFTER THE
CLOSING, OR ANY REPRESENTATION OR WARRANTY ARISING FROM STATUTE OR OTHERWISE IN LAW.

 

(b)       Each
of Parent and Merger Sub acknowledges and agrees that none of the Company Stockholders, the Group Companies or any of their
respective Affiliates or representatives has made any representations or warranties, express or implied, regarding any Group
Company, the Business, the Assets or operations of any Group Company or otherwise in connection with the Transactions, other than
the representations and warranties expressly made by the Company in Article III (including the related portions of the
Disclosure Schedule) and the Ancillary Documents. Without limiting the generality of the foregoing, each of Parent and Merger Sub
acknowledges and agrees that no projections, forecasts and predictions, other estimates, data, financial information, documents,
reports, statements (oral or written), summaries, abstracts, descriptions, presentations (including any management presentation or
facility tour), memoranda, or offering materials, is or shall be deemed to be a representation or warranty by any Group Company, any
Company Stockholder or any other Person to Parent or Merger Sub, under this Agreement or otherwise, unless contained in Article
III (including the related portions of the Disclosure Schedule) or the Ancillary Documents, and that each of Parent and Merger
Sub has not relied thereon in determining to execute this Agreement and proceed with the Transactions unless contained in Article
III (including the related portions of the Disclosure Schedule) or the Ancillary Documents. Each of Parent and Merger Sub
further acknowledges and agrees that materials it and its representatives and Affiliates have received from any Company Stockholder
or Group Company and their respective Affiliates and representatives, including Brentwood Capital Advisors, LLC and Falcon Capital
Partners, LLC, include projections, forecasts and predictions relating to the Group Companies or the Business, and that there are
uncertainties inherent in attempting to make such projections, forecasts and predictions; that each of Parent and Merger Sub is
familiar with such uncertainties and is taking full responsibility for making its own evaluations of the adequacy and accuracy of
all projections, forecasts, predictions and information so furnished; that each of Parent and Merger Sub shall not have any claims
against any Company Stockholder, any Group Company or their respective Affiliates and representatives, including Brentwood Capital
Advisors, LLC and Falcon Capital Partners, LLC, with respect thereto (including with respect to omissions therein), unless such
information is contained in Article III (including the related portions of the Disclosure Schedule) or the Ancillary
Documents; and that each of Parent and Merger Sub has not relied thereon, unless such information is contained in Article III
(including the related portions of the Disclosure Schedule) or the Ancillary Documents.

 

(c)       Each
of Parent and Merger Sub acknowledges and agrees that it (i) has made its own inquiry and investigation into, and, based thereon and
on the representations and warranties set forth in Article III (including the related portions of the Disclosure Schedule)
and the Ancillary Documents, has formed an independent judgment concerning each of the Group Companies, the Business and the Assets
and operations of the Group Companies, (ii) has been furnished with or given full access to such information each of the Group
Companies and each of their respective businesses and operations as it has requested, and (iii) has conducted such investigations of
the Group Companies, the Business and the Assets and operations of the Group Companies, in each case, as each of Parent and Merger
Sub deems necessary to satisfy itself as to the operations and conditions thereof, and will rely solely on such investigations and
inquiries, and the express representations and warranties set forth in Article III (and, without limitation of the foregoing,
not on the existence of any omissions) and the Ancillary Documents. Each of Parent and Merger Sub further acknowledges and agrees
that it will not at any time assert, and hereby irrevocably waives, any claim against the Stockholders’ Representative or any
Company Stockholder or any of their present and former representatives or Affiliates, including Brentwood Capital Advisors, LLC and
Falcon Capital Partners, LLC, or attempt to hold any of such Persons liable, for any inaccuracies, misstatements or omissions with
respect to the information furnished by such Persons concerning the Group Companies, the Business and the Assets and operations of
the Group Companies other than any misrepresentation of any representation or breach of warranty set forth in Article III
(subject, in each case, to the applicable limitations and expirations set forth in this Agreement) and the Ancillary Documents.

 

    49 

     

    

 

(d)       For
the purposes of this Section 4.10, references to “Parent” and “Merger Sub” shall be deemed to include its
Affiliates, officers, directors, employees, representatives, consultants, financial advisors, attorneys, accountants or other agents.

 

ARTICLE V 

[RESERVED]

 

ARTICLE VI

POST-CLOSING COVENANTS

 

Section 6.1        Further Assurances.

 

(a)       If,
at any time after the Closing, any Party reasonably determines that further action is necessary to effectuate the Transactions, the other
Parties shall take or cause to be taken all such action as may be reasonably requested and execute, deliver and file, or cause to be executed,
delivered and filed, all such documentation as may be reasonably requested; provided, however, that the Party requesting such action
shall pay the reasonable out-of-pocket costs incurred by the other Party or Parties taking such action.

 

(b)       The
Company shall, at its sole cost and expense, take or cause to be taken all such action as may be necessary or reasonably requested by
Parent and execute, deliver, file and/or record, or cause to be executed delivered, filed and/or recorded, all such documentation as may
be necessary or reasonably requested by Parent to give effect and/or evidence the payoff, discharge, termination and release of the Closing
Indebtedness and the Liens relating to the Closing Indebtedness as contemplated by Section 2.15 and Section 7.1(j).

 

Section 6.2         Intellectual Property
Matters.

 

(a)       The
Stockholders’ Representative shall, at the expense of the Advisory Committee of the Stockholders’ Representative and not the
Surviving Corporation, and to the extent not taken prior to Closing, take or cause to be taken all actions as may be necessary or reasonably
requested by Parent to (i) correct any gaps in the chain of title and (ii) release any third party security interests, including the security
interests in favor of Elm Park Capital Management, LLC dated July 14, 2017 and Fifth Third Bank dated April 15, 2014 , in each case of
(i) and (ii), existing as of the Closing with respect to any of the Intellectual Property Rights of any of the Group Companies, and, to
the extent not taken prior to Closing, prepare and file any other documentation reasonably requested by, and in a form reasonably acceptable
to, Parent to correct any such gaps or release any such third party security interests.

 

(b)       The
Stockholders’ Representative and the Company shall, at the expense of the Advisory Committee of the Stockholders’
Representative and not the Surviving Corporation, reasonably cooperate with Parent in connection with the negotiation, and in the
case of the Company, the execution, of an amendment, in a form reasonably acceptable to Parent, including for the purpose of adding
confidentiality provisions, to (i) that certain Intellectual Property Agreement, entered into on August 23, 2017 and effective as of
January 1, 2006, by and between AdvantEdge Healthcare Solutions, Inc., Emeris Corp., Accur8 Software Development LLC, Accur8
Software Solutions LLC, Accur8 Software LLP, and Salamander Inc. and (ii) that certain Consulting Agreement, by and between Accur8
Software Solutions, LLC and AdvantEdge Healthcare Solutions, Inc., effective as of August 23, 2017.

 

    50 

     

    

 

Section 6.3         Confidentiality.

 

(a)       For
a period of four (4) years following the Closing Date, each of Parent and the Surviving Corporation, on the one hand, and the Stockholders’
Representative, on the other hand, will, and will cause their respective Affiliates to, treat and hold all of the Confidential Information
of the other Parties, and refrain from using any of the Confidential Information, except: (i) to consummate the Transactions; (ii) to
satisfy any obligations pursuant to this Agreement or any other Ancillary Document; (iii) by any employee of any of the Group Companies,
in the course of performing their normal duties as an employee of any of the Group Companies; or (iv) in the case of the Stockholders’
Representative, to employees, advisors, agents or consultants of the Stockholders’ Representative and to the Company Stockholders,
in each case who have a need to know such information, provided that such persons are subject to confidentiality obligations with respect
thereto. If requested in writing to do so, each Party shall promptly deliver to the requesting Party or destroy all tangible embodiments
(and all copies) of the Confidential Information which is in its possession, except to the extent the responding Party reasonably needs
to retain any such Confidential Information to satisfy any of its obligations pursuant to this Agreement or any other agreements ancillary
hereto, including obligations which such responding Party believes could arise in the future, including its obligation to defend against
Claims brought pursuant to the indemnification obligations set forth herein. In the event that a Party is requested or required (by oral
question or request for information or documents in any legal proceeding, interrogatory, subpoena, civil investigative demand or similar
process) to disclose any such Confidential Information, to the extent permitted to do so by Laws, such Party will notify the other Parties
promptly of the request or requirement so that the other Parties may seek an appropriate protective order or waive compliance with the
provisions of this Section 6.3(a). If, in the absence of a protective order or the receipt of a waiver hereunder, a Party is, on
the advice of counsel, compelled to disclose any Confidential Information, such Party may disclose the requested information; provided,
however, that, at the request of any other Party, the first Party will cooperate with such other Party with respect to such other
Party’s attempts, if any, to limit the scope of disclosure or to obtain other assurances that confidential treatment will be accorded
to such portion of the Confidential Information required to be disclosed as the other Party designates; provided, however the requesting
Party shall pay all of the first Party’s out-of-pocket costs incurred in connection with such cooperation.

 

(b)       Each
Party acknowledges that its obligations under Section 6.3(a) are of a special, unique and extraordinary character, that they
are reasonably related to the legitimate business interests of the other Parties, and that a failure to perform any such obligation
or a violation of such obligations under Section 6.3(a) would cause irreparable harm to the other Parties, the amount of
which may not be readily ascertainable and for which adequate compensation could not be fashioned. Accordingly, each Party agrees
that the other Parties will have the right, without the need to prove irreparable injury or to post a bond, to seek an injunction
against any breach or threatened breach of Section 6.3(a) by a Party, as well as the right to pursue any and all other rights
and remedies available at law or in equity.

 

    51 

     

    

 

Section 6.4        Directors’ and Officers’
Indemnification and Insurance.

 

(a)       Parent
and Merger Sub agree that all rights to indemnification or exculpation now existing in favor of the directors, officers, employees or
agents of each Group Company or any other natural person indemnified by any Group Company as of the date of this Agreement (collectively,
 “Indemnified Persons”), as provided in such Group Company’s Governing Documents or otherwise in effect
as of the date hereof with respect to any matters occurring prior to the Closing Date, shall survive the Transactions and shall continue
in full force and effect and that Parent and Merger Sub shall, and shall cause the Surviving Corporation and each of its Subsidiaries
to, perform and discharge its obligations to provide such indemnity and exculpation after the Closing. To the maximum extent permitted
by applicable Law, such indemnification shall be mandatory rather than permissive, and the Surviving Corporation shall, and shall cause
each of its Subsidiaries to, advance expenses in connection with such indemnification as provided in the Surviving Corporation’s
and each of its Subsidiaries’ Governing Documents or other applicable agreements. The indemnification and liability limitation or
exculpation provisions of each of the Surviving Corporation’s and each of its Subsidiaries’ Governing Documents shall not
be amended, repealed or otherwise modified after the Closing Date in any manner that would adversely affect the rights thereunder of individuals
who, as of the Closing Date or at any time prior to the Closing Date, were Indemnified Persons, unless such modification is required by
Law.

 

(b)       Parent
will obtain for the Group Companies for a six-year period following the Closing Date, the cost of which is borne 50% by the Company and
50% by Parent, and, Parent shall cause the Surviving Corporation to, and the Surviving Corporation shall, maintain in effect, beginning
on the Closing and for a period of six (6) years thereafter without any lapses in coverage, a directors and officers “tail insurance
policy” providing directors’ and officers’ liability insurance coverage for the benefit of those Persons who are covered
by any Group Company’s directors’ and officers’ liability insurance policies as of the date hereof or at the Closing
with respect to matters occurring prior to the Closing. Such policy shall provide coverage that is at least equal to the coverage in effect
on the date of this Agreement under the Group Companies’ directors’ and officers’ liability insurance policies; provided,
however, that the Surviving Corporation may substitute therefor policies of at least the same coverage and duration, containing
terms and conditions which are no less advantageous to the beneficiaries thereof so long as such substitution does not result in gaps
or lapses in coverage with respect to matters occurring prior to the Closing Date.

 

(c)       In
the event that Parent, the Surviving Corporation or any of their respective successors or assigns (i) consolidates with or merges into
any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger or (ii) transfers or conveys
all or substantially all of its properties and assets to any Person, then, and in each such case, proper provision shall be made so that
the successors and assigns of Parent or the Surviving Corporation shall assume all of the obligations thereof set forth in this Section
6.4.

 

    52 

     

    

 

(d)       The
Indemnified Persons entitled to the indemnification, liability limitation, exculpation and insurance set forth in this Section 6.4
are intended to be third-party beneficiaries of this Section 6.4 having the right to enforce this Section 6.4.

 

Section 6.5        Employee
Benefit Matters. Until December 31, 2021, Parent shall provide each individual employed by any Group Company as of immediately
prior to Closing who continues to be employed by the Surviving Corporation or any of its Subsidiaries with at least the same salary
or hourly wage rate as provided to such employee immediately prior to the Closing Date, with the opportunity to earn annual
performance-based bonuses that are at least as favorable in the aggregate as those provided to such employee immediately prior to
the Closing Date and with employee benefits (excluding equity arrangements, defined benefit pension benefits and post- retirement
health benefits) that are at least as favorable in the aggregate as the Employee Benefit Plans maintained by each of the Group
Companies as of the date of this Agreement. Parent further agrees that, from and after the Closing Date, Parent shall and shall
cause the Surviving Corporation and each of its Subsidiaries to grant all of its employees credit for any service with the
applicable Group Company earned prior to the Closing Date (a) for eligibility and vesting purposes and
(b) for purposes of vacation accrual and severance benefit determinations under any benefit
or compensation plan, program, agreement or arrangement that may be established or maintained by Parent or the Surviving Corporation
or any of its Subsidiaries on or after the Closing Date (the “New Plans”). In addition, Parent shall use
commercially reasonable efforts to (i) cause to be waived all pre-existing condition exclusions and actively-at-work requirements
and similar limitations, eligibility waiting periods and evidence of insurability requirements under any New Plans to the extent
waived or satisfied by an employee under any Employee Benefit Plan as of the Closing Date. and (ii) cause any deductible,
co-insurance and covered out-of-pocket expenses paid on or before the Closing Date by any employee (or covered dependent thereof) of
any Group Company to be taken into account for purposes of satisfying the corresponding deductible, coinsurance and maximum
out-of-pocket provisions after the Closing Date under any applicable New Plan in the year of initial participation. Nothing
contained herein, express or implied, confers upon any employee of any Group Company any right to continued employment for any
period or continued receipt of any specific employee benefit, or shall constitute an amendment to or any other modification of any
New Plan or Employee Benefit Plan. Parent agrees that Parent and the Surviving Corporation shall be solely responsible for
satisfying the continuation coverage requirements of Section 4980B of the Code for all individuals who are “M&A qualified
beneficiaries” as such term is defined in Treasury Regulation Section 54.4980B-9. The Surviving Corporation shall be
responsible for any severance payments which become payable as a result of the termination of any officer, director or employee of a
Group Company (i) following the Closing and (ii) at the request of Parent or any of its Affiliates (including Merger Sub) prior to
the Closing.

 

Section 6.6        Documents
and Information. After the Closing Date, Parent shall, and shall cause the Surviving Corporation and each of its Subsidiaries
to, until the seventh (7th) anniversary of the Closing Date, retain all Records and other documents pertaining to the Business in
existence on the Closing Date and make the same available for inspection and copying by the Stockholders’ Representative (at
the Company Stockholders’ expense) during normal business hours of the Surviving Corporation or any of its Subsidiaries, as
applicable, upon reasonable request and upon reasonable notice. No such Records shall be destroyed after the seventh (7th)
anniversary of the Closing Date by Parent, the Surviving Corporation or its Subsidiaries, without first advising the
Stockholders’ Representative in writing and giving the Stockholders’ Representative a reasonable opportunity to obtain
possession thereof.

 

    53 

     

    

 

Section 6.7        RWI
Policy. Parent shall provide to the Stockholders’ Representative, concurrent with delivery to the requisite parties under the
RWI Policy, copies of all notices which relate to any claim or potential claim under the RWI Policy. Parent will not (and will cause each
of its Subsidiaries not to), without the consent of the Stockholders’ Representative, amend Article VII (Subrogation) of
the RWI Policy in a manner that is materially adverse to the Company Stockholders.

 

Section 6.8       Parachute
Payments. With respect to each Employee who is, or would reasonably be expected to be as of the Closing Date, a “disqualified
individual” (as defined in Section 280G(c) of the Code), prior to the Closing Date, each such individual has agreed to waive any
payments or economic benefit pursuant to any Employee Benefit Plan and any agreement, in each case, entered into by the Company and such
disqualified individual prior to the Closing Date that such individual is entitled in connection with the Transactions that could reasonably
be deemed to constitute an “excess parachute payment” (as defined in Section 280G(b) of the Code) with respect to such individual.
In addition, the Company has used commercially reasonable efforts to seek to obtain or cause the Company to obtain stockholder approval
in accordance with the requirements of Section 280G(b)(5)(B) of the Code and in a manner that satisfies the applicable requirements of
Section 280G(b)(5)(B) of the Code and any regulations promulgated thereunder. Within a reasonable period of time before taking such actions,
the Company has delivered to Parent for review and comment copies of any documents or agreements necessary to effect this Section 6.8,
including, but not limited to, any stockholder consent form, disclosure statement, or waiver, and the Company considered in good faith
all comments received from Parent on such documents or agreements.

 

Section 6.9        Company
Stockholder Notice. Within five (5) Business Days following the Closing Date, the Company shall prepare and mail a notice (the “Company
Stockholder Notice”) to every Company Stockholder that did not execute the Written Consent. The Company Stockholder Notice
shall (i) be a statement to the effect that the Company Board determined that the Merger is advisable in accordance with Section 251(b)
of the DGCL and in the best interests of the Company Stockholders and approved and adopted this Agreement, the Merger and the other Transactions,
(ii) provide the Company Stockholders to whom it is sent with notice of the actions taken in the Written Consent, including the approval
and adoption of this Agreement, the Merger and the other Transactions in accordance with Section 228(e) of the DGCL and the bylaws of
the Company and (iii) notify such Company Stockholders of their dissent and appraisal rights pursuant to Section 262 of the DGCL. The
Company Stockholder Notice shall include therewith a copy of Section 262 of Delaware Law and all such other information as Parent shall
reasonably request, and shall be sufficient in form and substance to start the twenty (20) day period during which a Company Stockholder
must demand appraisal of such Company Stockholder's Common Shares as contemplated by Section 262(d)(2) of the DGCL.

 

    54 

     

    

 

ARTICLE VII

CLOSING DELIVERABLES

 

Section 7.1        Closing
Deliverables of the Company. Prior to or at the Closing, the Company shall have delivered the following documents in form and substance
reasonably acceptable to Parent:

 

(a)       written
resignations, each effective as of the Closing, of (A) each of the directors of each Group Company and (B) those officers of the Group
Companies set forth on Schedule 7.1(a);

 

(b)       a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of the Company certifying that (A) attached thereto are
true and complete copies of the Governing Documents of each of the Group Companies, and that none of such Governing Documents have been
subsequently amended, terminated or otherwise modified and (B) attached thereto are true and complete copies of all resolutions adopted
by the Company Board authorizing the execution, delivery and performance of this Agreement and the Ancillary Documents to which the Company
is a party and the consummation of the Transactions, and that all such resolutions are in full force and effect and are all the resolutions
adopted in connection with the Transactions;

 

(c)       a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of the Company certifying the names and signatures of the
officers of the Company authorized to sign this Agreement, the Ancillary Documents and the other documents to be delivered hereunder and
thereunder to which the Company is a party;

 

(d)       a
certificate from the Company, in form and substance as prescribed by Treasury Regulations promulgated under Section 1445 of the Code and
properly executed by an authorized officer of the Company, stating that the Company is not, and has not been during the relevant period
specified in Section 897(c)(1)(ii) of the Code, a “United States real property holding corporation” within the meaning of
Section 897(c) of the Code;

 

(e)       a
good standing certificate (or its equivalent) from the secretary of state or similar Governmental Authority of the jurisdiction under
the Laws in which each of the Group Companies is organized;

 

(f)       the
Estimated Closing Working Capital Statement and the Consideration Spreadsheet;

 

(g)       all
approvals, consents and waivers that are listed on Schedule 7.1(g) shall have been received, and executed counterparts
thereof shall have been delivered to the Company at or prior to the Closing;

 

(h)       the
Escrow Agreement, duly executed by the Stockholders’ Representative;

 

(i)       a
copy of all documents in the electronically accessible data room provided in connection with the Transactions to Parent on a thumb drive
or DVD (which shall be delivered by the Company as soon as reasonably practicable after the Closing, notwithstanding anything to the contrary
herein); and

 

    55 

     

    

 

(j)       executed
copies of (x) each notice of prepayment and/or notice for termination of commitments delivered pursuant to, and in accordance with, the
terms of the documents governing the Closing Indebtedness, and (y) payoff letters for the payoff, discharge and termination in full on
the Closing Date of the Closing Indebtedness attaching such instruments of discharge and releases for the discharge, termination and release
of all the Liens relating to the Closing Indebtedness to be executed, delivered, filed and/or recorded promptly upon the payoff, discharge
and termination in full of the Closing Indebtedness.

 

Section 7.2        Closing
Deliverables of Parent. Prior to or at the Closing, Parent shall have delivered the following documents in form and substance reasonably
acceptable to the Company:

 

(a)       the
Escrow Agreement, duly executed by the Surviving Corporation;

 

(b)       a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Parent certifying that attached thereto are true and
correct copies of all resolutions adopted by the board of managers of Parent authorizing the execution, delivery and performance of this
Agreement and the Ancillary Documents to which Parent is a party and the consummation of the Transactions, and that all such resolutions
are in full force and effect and are all the resolutions adopted in connection with the Transactions;

 

(c)       a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Merger Sub certifying that attached thereto are true
and correct copies of all resolutions adopted by the board of directors of Merger Sub authorizing the execution, delivery and performance
of this Agreement and the Ancillary Documents to which Merger Sub is a party and the consummation of the Transactions, and that all such
resolutions are in full force and effect and are all the resolutions adopted in connection with the Transactions;

 

(d)       a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Parent certifying the names and signatures of the officers
of Parent authorized to sign this Agreement, the Ancillary Documents and the other documents to be delivered hereunder and thereunder
to which Parent is a party;

 

(e)       a
certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Merger Sub certifying the names and signatures of the
officers of Merger Sub authorized to sign this Agreement, the Ancillary Documents and the other documents to be delivered hereunder and
thereunder to which Merger Sub is a party; and

 

(f)       evidence
of the purchase by Parent of the RWI Policy, together with evidence of the payment of the premium for such RWI Policy.

 

ARTICLE VIII

INDEMNIFICATION

 

Section 8.1         Survival.
Subject to the limitations and other provisions of this Agreement, the representations and warranties contained herein shall survive
the Closing and shall remain in full force and effect until the date that is fourteen (14) months from the Closing Date (the
 “Escrow Termination Date”); provided, that the representations and warranties in Section
3.1 (Organization and Qualification), Section 3.2 (Capitalization), the second sentence of Section 3.3 (No
Violations), Section 3.4 (Power and Authority; Enforceability), Section 3.21 (Brokers), Section 4.1
(Organization and Qualification), Section 4.2 (Authority), the second sentence of Section 4.3 (No Violations) and Section
4.5 (Brokers) (collectively, the “Fundamental Representations”) shall survive for the full period of
all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus 60 days (the
 “Fundamental Rep Termination Date”). All covenants and agreements of the parties contained herein shall
survive the Closing indefinitely or for the period explicitly specified therein. Notwithstanding the foregoing, any claims asserted
in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the Indemnified Party to
the Indemnifying Party prior to the expiration date of the applicable survival period shall not thereafter be barred by the
expiration of the relevant representation or warranty and such claims shall survive until finally resolved. For purposes of this Article
VIII, any inaccuracy in or breach of any representation or warranty shall be determined without regard to any materiality,
Material Adverse Effect or other similar qualification contained in or otherwise applicable to such representation or warranty. The
Parties acknowledge and agree that immediately upon the Escrow Termination Date or the Fundamental Rep Termination Date, as
applicable, the relevant representations and warranties of the Company shall terminate and be of no further force or effect.

 

    56 

     

    

 

Section 8.2        Indemnification
by the Company Stockholders. Subject to the other limitations in this Article VIII, from and after the Closing, the Company
Stockholders shall, severally but not jointly, in accordance with their respective Pro-Rata Share (except with respect to the Indemnity
Escrow Amount, which will be available on a joint and several basis), indemnify, defend and hold harmless Parent, the Surviving Corporation,
each of their respective Affiliates and each of their respective officers, directors, employees, members, agents and representatives (collectively,
the “Parent Indemnitees”) from and against any and all Losses asserted against, imposed upon or incurred by
such Parent Indemnitee that arise out of, are related to or in connection with:

 

(a)       any
inaccuracy or breach of any of the representations or warranties of the Company contained in this Agreement (except for representations
and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such
specified date);

 

(b)       any
breach or non-fulfillment of any covenant, agreement or obligation to be performed by the Company pursuant to this Agreement;

 

(c)       any
claim made by any Company Stockholder relating to such Person’s rights with respect to the Total Merger Consideration, or the calculations
and determinations set forth on the Consideration Spreadsheet;

 

(d)       any
Excess Dissenting Share Payments (including reasonable attorneys’ fees and court costs and fees); or

 

(e)       any
Company Stockholder Expenses or Indebtedness of the Company outstanding as of the Closing to the extent not paid or satisfied by the Company
at or prior to the Closing, or if paid by Parent or Merger Sub at or prior to the Closing, to the extent not deducted in the determination
of the Purchase Price.

 

    57 

     

    

 

Section 8.3        Indemnification
by Parent. Subject to the other limitations in this Article VIII, from and after the Closing, Parent shall indemnify and hold
harmless each of the Company Stockholders from and against any and all Losses asserted against, imposed upon or incurred by the Stockholders
based upon, arising out of, with respect to or by reason of:

 

(a)       any
inaccuracy or breach of any of the representations or warranties of Parent and Merger Sub contained in this Agreement (except for representations
and warranties that expressly relate to a specified date, the inaccuracy in or breach of which will be determined with reference to such
specified date); or

 

(b)       any
breach or non-fulfillment of any covenant, agreement or obligation to be performed by Parent or Merger Sub pursuant to this Agreement.

 

Section 8.4        Certain Limitations.

 

(a)       Except
with respect to any claims for indemnification for Fraud or breach of any Fundamental Representation, the maximum aggregate amount of
Losses that may be recovered by the Parent Indemnitees pursuant to Section 8.2(a) shall be (i) from the Indemnity Escrow Account
in accordance with the Escrow Agreement and (ii) recovery under the RWI Policy.

 

(b)       Except
with respect to any claims for indemnification for Fraud or breach of any Fundamental Representation, the maximum aggregate amount
of Losses that may be recovered by the Company Stockholders pursuant to Section 8.3(a) shall be an amount equal to
$100,000.

 

(c)       In
no event shall the aggregate liability of a Company Stockholder in accordance with this Article VIII exceed the portion of the
Total Merger Consideration actually received by such Company Stockholder hereunder, except for any claims for indemnification for Fraud.

 

(d)       The
Parties acknowledge that Parent has the RWI Policy. Except for claims of Fraud on the part of the Company and breaches of
Fundamental Representations, recovery from the RWI Policy and the Indemnity Escrow Fund (subject to the limitations set forth in
this Article VIII) are the sole recourse for the Parent Indemnitees Losses pursuant to any claims or series of related claims
under Section 8.2(a).

 

(e)       Each
Indemnified Party shall take, and cause its Affiliates to take, as required by applicable Law, steps to mitigate any Losses upon becoming
aware of any event or circumstance that would be reasonably expected to, or does, give rise thereto.

 

Section 8.5        Procedures.

 

(a)       Notice
of Claim. The party making a Claim for indemnification pursuant to this Article VIII (an “Indemnified
Party”) must give the party against whom such Claims are asserted (the “Indemnifying Party”)
notice of such Claim describing such Claim and the nature and amount of such Loss, to the extent that the nature and amount thereof
are determinable at such time or an explanation if not so determinable (a “Claim Notice”), promptly after
the Indemnified Party receives any written notice of any action, lawsuit, proceeding, investigation or other Claim (a
 “Proceeding”) against or involving the Indemnified Party by a third party or otherwise discovers the
liability or facts giving rise to such Claim for indemnification; provided, however, that the failure to notify or
delay in notifying the Indemnifying Party will not relieve the Indemnifying Party of its obligations pursuant to Section 8.2
or Section 8.3, as applicable, except to the extent that the Indemnifying Party is materially prejudiced as a result
thereof.

 

    58 

     

    

 

(b)      Control
of Defense; Conditions. With respect to the defense of any Proceeding against or involving an Indemnified Party involving a
Claim for which indemnification is provided, at its option within thirty (30) days of receipt of a Claim Notice, the Indemnifying
Party (and if the Indemnifying Party comprises the Company Stockholders, then the Stockholders’ Representative) shall have the
right to participate in, or by giving written notice to the Indemnified Party, to assume the defense of any Claim at the
Indemnifying Party’s expense and by the Indemnifying Party’s own counsel, and the Indemnified Party shall cooperate in
good faith in such defense; provided, that if the Indemnifying Party is a Company Stockholder, the Stockholders’
Representative shall not have the right to defend or direct the defense of any such Claim that (x) is asserted directly by or on
behalf of a Person that is a supplier or customer of the Company, or (y) seeks an injunction or other equitable relief against the
Indemnified Parties. In the event that the Indemnifying Party assumes the defense of any Claim, it shall have the right to take such
action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Claim in the name and on
behalf of the Indemnified Party. The Indemnified Party shall have the right, at the Indemnified Party’s sole cost and expense,
to participate in the defense of any Claim with counsel selected by it subject to the Indemnifying Party’s right to control
the defense thereof so long as the Indemnifying Party acknowledges in writing the Indemnifying Party’s obligation to indemnify
the Indemnified Party for Losses related to such Proceeding or the settlement or defense thereof. The Stockholders’
Representative and Parent shall cooperate with each other in all reasonable respects in connection with the defense of any Claim,
including making available records relating to such Claim and furnishing, without expense (other than reimbursement of actual
out-of-pocket expenses) to the defending party, management employees of the non-defending party as may be reasonably necessary for
the preparation of the defense of such Claim.

 

(c)       Settlement of
Claims. The Indemnifying Party (and if the Indemnifying Party comprises the Company Stockholders, then the Stockholders’ Representative)
must obtain the prior written consent of the Indemnified Party prior to entering into any settlement of any Claim or Proceeding or ceasing
to defend any Claim or Proceeding unless the proposed settlement involves only the payment of money damages, all such money damages will
be the responsibility of, and paid by, the Indemnifying Party, and the proposed settlement does not impose an injunction or other equitable
relief on the Indemnified Parties, and the Indemnified Parties will not settle any Claim for which it has sought or is seeking recovery
without the Indemnifying Party’s (and if the Indemnifying Party comprises the Company Stockholders, then the Stockholders’
Representative’s) prior written consent.

 

Section 8.6        Other
Limitations. Where the Company Stockholders have made a payment to a Parent Indemnitee in relation to any Losses which is the
subject of a Claim and Parent or any of its Affiliates are aware that they are entitled to recover (whether by insurance, payment,
discount, credit, relief or otherwise) from a third party a sum which indemnifies or compensates Parent Indemnitees (in whole or in
part) in respect of the Loss which is the subject of such Claim, Parent or its relevant Affiliates shall (a) promptly notify the
Stockholders’ Representative of the fact and provide such information as the Stockholders’ Representative may reasonably
require, (b) take all reasonable steps or proceedings as the Stockholders’ Representative may require to enforce such right
and (c) pay to the Company Stockholders, as soon as practicable after receipt, an amount equal to the amount recovered from the
third party (not to exceed the amount of the Company Stockholders’ payment with respect to such Claim). The amount of any Loss
that shall be recovered by the Indemnified Party from the Indemnifying Party shall be net of any amounts recovered by the
Indemnified Party under insurance policies, indemnities, reimbursement arrangements, or contracts (including with respect to any
breaches thereof) pursuant to which or under which such Person or such Person’s Affiliates is a party or has rights with
respect to such Loss.

 

    59 

     

    

 

Section 8.7         Escrow.

 

(a)       Adjustment
Escrow. The Adjustment Escrow Amount shall be held by the Escrow Agent in the Adjustment Escrow Account until paid in accordance with
Section 2.9(c) and the Escrow Agreement.

 

(b)       Indemnity
Escrow. Subject to and as further provided in the Escrow Agreement, promptly following the Escrow Termination Date, upon a joint written
direction by the Stockholders’ Representative and Parent, the Escrow Agent shall release any remaining amounts in the Indemnity
Escrow Fund to the Payments Administrator (for further payment to the Company Stockholders in accordance with the terms of this Agreement),
less (i) any amounts that would be necessary to satisfy any then pending and unsatisfied or unresolved claim for indemnification pursuant
to Section 8.2 (which were the subject of a Claim Notice delivered to the Stockholders’ Representative prior to the applicable
survival period described in Section 8.1) assuming such claim(s) were resolved in full in favor of the Parent Indemnitees (which
amounts will continue to be held in the Indemnity Escrow Fund until the related claims have been finally resolved) and (ii) any applicable
withholding Tax relating to such amount. Promptly following the time that any such pending and unsatisfied or unresolved claims have been
resolved, the Escrow Agent shall deliver the remaining portion of such undistributed amount, if any, not used to satisfy such claims,
and less any applicable withholding Taxes, to the Payments Administrator for further distribution to the Stockholders as provided in the
Escrow Agreement.

 

(c)       Earnout
Escrow. The Earnout Escrow Amount shall be held by the Escrow Agent in the Earnout Escrow Account until paid in accordance with Section
2.10 and the Escrow Agreement.

 

(d)       The
fees, costs and expenses of the Escrow Agent shall be paid 50% by Parent and 50% by the Company.

 

Section 8.8        Exclusive
Remedy. Each of the Parties hereto acknowledges and agrees that from and after the Closing, Claims under this Article VIII
shall be the exclusive and sole remedy of the Parent Indemnitees with respect to Excess Dissenting Share Payments.

 

    60 

     

    

 

ARTICLE IX

TAX RELATED MATTERS

 

Section 9.1        Tax
Returns. Parent shall prepare or cause to be prepared all Tax Returns relating to any of the Group Companies that are filed after
the Closing Date, and neither the Stockholders’ Representative nor any of the Company Stockholders shall be entitled to review and
provide comments on any such Tax Returns.

 

Section 9.2        Straddle
Periods. For purposes of allocating any Taxes that are imposed on a periodic basis and are payable for a Straddle Period under
this Agreement, the portion of such Tax that relates to the portion of such Straddle Period up to, and including, the Closing Date
shall (i) in the case of any Taxes other than Taxes based upon or related to income, sales,
receipts or payroll, be deemed to be the amount of such Tax for the entire Straddle Period, multiplied by a fraction the numerator
of which is the number of days in the Straddle Period ending on, and including, the Closing Date and the denominator of which is the
number of days in the entire Straddle Period, and (ii) in the case of any Tax based upon or related to income, sales, receipts or
payroll, be deemed equal to the amount which would be payable if the relevant Straddle Period ended on, and included, the Closing
Date, provided, that (A) any Employment Taxes arising with respect to a Pre-Closing Tax Period that have been deferred pursuant to
the CARES Act or any other corresponding or similar provision of other Law with respect to Taxes shall be allocated exclusively to
the Pre-Closing Tax Period and (B) any Transaction Tax Deductions shall be allocated exclusively to the Pre-Closing Tax Period.

 

Section 9.3        Transfer
Taxes. All transfer Taxes, recording fees and other similar Taxes that are imposed on any of the Parties by any Governmental Entity
in connection with the transactions contemplated by this Agreement (excluding, for the avoidance of doubt, any income Taxes of a Company
Stockholder (whether or not collected through withholding), which shall be the responsibility of the applicable Company Stockholder) shall
be borne equally by Parent and the Company Stockholders.

 

Section 9.4        Cooperation.
The Stockholders’ Representative and Parent, and Parent agrees to ensure that the Surviving Corporation and each of its
Subsidiaries, shall cooperate fully at Parent’s expense, as and to the extent reasonably requested by such other Party, in
connection with the filing of any Tax Return, in any audit, litigation or other proceeding with respect to Taxes, and in allowing
the Stockholders’ Representative to review Tax Returns of each of the Group Companies for Pre-Closing Tax Periods and Straddle
Periods to determine or verify the proper amounts payable as refunds hereunder. Such cooperation shall include the retention and
(upon such other Party’s request) the provision of Records and information that are reasonably relevant to any such audit,
litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and
explanation of any materials provided hereunder. The Stockholders’ Representative and Parent agree, and Parent agrees to cause
the Surviving Corporation and each of its Subsidiaries, to retain all Records with respect to Tax matters pertinent to any of the
Group Companies and which relate to a Pre-Closing Tax Period or a Straddle Period until the expiration of the applicable statute of
limitations (and, if notified in writing by another Party, any extensions thereof), and to abide by all record retention agreements
entered into with any Governmental Entity. The Parties, and Parent agrees to ensure that the Surviving Corporation and each of its
Subsidiaries, agree to give each other Party reasonable written notice prior to transferring, destroying or discarding any such
Records, and if another Party so requests, to give such other Party possession of such Records.

 

    61 

     

    

 

Section 9.5        No
Intermediary Transaction Tax Shelter. Parent has no plan or intention to take any action with respect to any of the Group Companies
subsequent to the Closing that would cause the transactions under this Agreement to constitute part of a transaction that is the same
as, or substantially similar to, the “Intermediary Transaction Tax Shelter” described in Internal Revenue Service Notices
2001-16 and 2008-111.

 

Section 9.6        Tax
Treatment. The Parties agree that all payments made pursuant to Section 2.9(c) and any indemnification payments that are made
pursuant to Article VIII shall, in each case, be treated as adjustments to the Purchase Price for applicable Tax purposes, unless a different
treatment is otherwise required by applicable Law.

 

ARTICLE X

STOCKHOLDERS’
REPRESENTATIVE

 

Section 10.1      Authorization of Stockholders’
Representative.

 

(a)       Shareholder
Representative Services LLC is hereby appointed, authorized and empowered to act as the Stockholders’ Representative for the benefit
of the Company Stockholders, as the exclusive representative, agent and attorney-in-fact to act on behalf of each of the Company Stockholders,
for all purposes in connection with this Agreement and any related agreements and in connection with and to facilitate the consummation
of the Transactions, which shall include the power, authority and discretion:

 

(i)       to
enter into amendments to this Agreement and to execute and deliver any Ancillary Documents (with such modifications or changes therein
as to which the Stockholders’ Representative, in its sole discretion, shall have consented) and to agree to such amendments or modifications
thereto that the Stockholders’ Representative, in its sole discretion, determines to be desirable, in each case, whether before
or after the Closing;

 

(ii)       to
execute and deliver such waivers and consents in connection with this Agreement and any Ancillary Documents and the consummation of the
Transactions that the Stockholders’ Representative, in its sole discretion, may deem necessary or desirable;

 

(iii)       to
use the Stockholders’ Representative Expense Amount to satisfy costs, expenses and/or liabilities of the Stockholders’ Representative
in connection with matters related to this Agreement and/or the Ancillary Documents;

 

(iv)       to
enforce and protect the rights and interests of the Company Stockholders and to enforce and protect the rights and interests of the
Stockholders’ Representative arising out of or under or in any manner relating to this Agreement, and each other agreement,
document, instrument or certificate referred to herein or therein or the transactions provided for herein or therein, and to take
any and all actions which the Stockholders’ Representative believes are necessary or appropriate under this Agreement for and
on behalf of the Company Stockholders, including asserting or pursuing any Claim against Parent, Merger Sub and/or the Surviving
Corporation, consenting to, compromising or settling any such Claims, conducting negotiations with Parent, the Surviving Corporation
and their respective representatives regarding such Claims, and, in connection therewith, to: (A) assert any claim or institute any
Action; (B) investigate, defend, contest or litigate any Action initiated by Parent, the Surviving Corporation or any other Person,
or by any federal, state or local Governmental Entity against the Stockholders’ Representative or against all Company
Stockholders, and receive process on behalf of any or all Company Stockholders in any such Action and compromise or settle on such
terms as the Stockholders’ Representative shall determine to be appropriate, and give receipts, releases and discharges with
respect to, any such Action; (C) file any proofs of debt, claims and petitions as the Stockholders’ Representative may deem
advisable or necessary; and (D) file and prosecute appeals from any decision, judgment or award rendered in any such Action, it
being understood that the Stockholders’ Representative shall not (i) have any obligation to take any such actions, and shall
not have any liability for any failure to take any such actions and (ii) have the authority to investigate, defend, contest or
litigate any Action (or compromise or settlement thereof) made against one or more Company Stockholders that is not made against all
such Persons;

 

    62 

     

    

 

(v)       to
refrain from enforcing any right of the Company Stockholders and/or the Stockholders’ Representative arising out of or under or
in any manner relating to this Agreement, or any other agreement, instrument or document in connection with the foregoing; provided,
however, that no such failure to act on the part of the Stockholders’ Representative, except as otherwise provided in this
Agreement, shall be deemed a waiver of any such right or interest by the Stockholders’ Representative or by such Company Stockholder
unless such waiver is in writing signed by the waiving party or by the Stockholders’ Representative;

 

(vi)       to
make, execute, acknowledge and deliver all such other agreements, guarantees, orders, receipts, endorsements, notices, requests, instructions,
certificates, stock powers, letters and other writings, and, in general, to do any and all things and to take any and all action that
the Stockholders’ Representative, in its sole and absolute discretion, may consider necessary or proper or convenient in connection
with or to carry out the Transactions, and all other agreements, documents or instruments referred to herein or therein or executed in
connection herewith and therewith; and

 

(vii)       to
engage such counsel, experts and other agents and consultants as it shall deem necessary in connection with exercising its powers and
performing its function hereunder and (in the absence of bad faith on the part of the Stockholders’ Representative) to conclusively
rely on the opinions and advice of such Persons.

 

(b)       The
Stockholders’ Representative shall not be entitled to any fee, commission or other compensation for the performance of its
services hereunder except as provided in the Stockholders’ Representative engagement letter entered into by the
Stockholders’ Representative and certain Company Stockholders as of the date hereof, but shall be entitled to the payment of
all of its reasonable expenses incurred as the Stockholders’ Representative (provided that Company Stockholders shall be
entitled to review a written statement thereof, together with supporting documentation, upon any reasonable request therefor). In
connection with this Agreement, the Ancillary Documents and any instrument, agreement or document relating hereto or thereto, and in
exercising or failing to exercise all or any of the powers conferred upon the Stockholders’ Representative hereunder (i) the
Stockholders’ Representative shall incur no responsibility or liability whatsoever to any Company Stockholder by reason of any
error in judgment or other act or omission performed or omitted hereunder or in connection with this Agreement and any related
agreements, excepting only responsibility for any act or failure to act which represents gross negligence or willful misconduct, and
(ii) the Stockholders’ Representative shall be entitled to rely on the advice of counsel, public accountants or other
independent experts experienced in the matter at issue, and any error in judgment or other act or omission of the
Stockholders’ Representative pursuant to such advice shall in no event subject the Stockholders’ Representative to
liability to any Company Stockholders.

 

    63 

     

    

 

(c)       All
of the indemnities, immunities and powers granted to the Stockholders’ Representative under this Agreement shall survive the Closing
Date and/or any termination of this Agreement.

 

(d)       Parent
and the Surviving Corporation shall have the right to rely upon all actions taken or omitted to be taken by the Stockholders’ Representative
pursuant to this Agreement and the Escrow Agreement, all of which actions or omissions shall be legally binding upon the Company Stockholders.

 

(e)       The
grant of authority provided for herein (i) is coupled with an interest and shall be irrevocable and survive the death, incompetency, bankruptcy
or liquidation of any Company Stockholder, and (ii) shall survive the Merger.

 

(f)       The
Company Stockholders will indemnify, defend and hold harmless the Stockholders’ Representative from and against any and all
losses, liabilities, damages, claims, penalties, fines, forfeitures, actions, fees, costs and expenses (including the fees and
expenses of counsel and experts and their staffs and all expense of document location, duplication and shipment) (collectively,
 “Stockholders’ Representative Losses”) arising out of or in connection with the Stockholders’
Representative’s execution and performance of this Agreement and any agreements ancillary hereto, in each case as such
Stockholders’ Representative Loss is suffered or incurred; provided, however, that in the event that any such
Stockholders’ Representative Loss is finally adjudicated to have been directly caused by the gross negligence or willful
misconduct of the Stockholders’ Representative, the Stockholders’ Representative will reimburse the Company Stockholders
the amount of such indemnified Stockholders’ Representative Loss to the extent attributable to such gross negligence or
willful misconduct. If not paid directly to the Stockholders’ Representative by the Company Stockholders, any such
Stockholders’ Representative Losses may be recovered by the Stockholders’ Representative from (i) the funds in the
Stockholders’ Representative Expense Account, and (ii) the amounts in the Adjustment Escrow Account, the Indemnification
Escrow Account and the Earnout Escrow Account at such time as remaining amounts would otherwise be distributable to the Company
Stockholders; provided, however, that while this Section 10.1(f) allows the Stockholders’ Representative
to be paid from the aforementioned sources of funds, this does not relieve the Company Stockholders from their obligation to
promptly pay such Stockholders’ Representative Losses as they are suffered or incurred, nor does it prevent the
Stockholders’ Representative from seeking any remedies available to it at law or otherwise. In no event will the
Stockholders’ Representative be required to advance its own funds on behalf of the Company Stockholders or otherwise.
Notwithstanding anything in this Agreement to the contrary, any restrictions or limitations on liability or indemnification
obligations of the Company Stockholders set forth elsewhere in this Agreement are not intended to be applicable to the indemnities
provided to the Stockholders’ Representative under this Section 10.1(f). The foregoing indemnities will survive the
Closing, the resignation or removal of the Stockholders’ Representative or the termination of this Agreement.

 

    64 

     

    

 

(g)       The
Company Stockholders will not receive any interest or earnings on the Stockholders’ Representative Expense Amount and irrevocably
transfer and assign to the Stockholders’ Representative any ownership right that they may otherwise have had in any such interest
or earnings. The Stockholders’ Representative will not be liable for any loss of principal of the Stockholders’ Representative
Expense Amount other than as a result of its gross negligence or willful misconduct. The Stockholders’ Representative will hold
these funds separate from its corporate funds, will not use these funds for its operating expenses or any other corporate purposes and
will not voluntarily make these funds available to its creditors in the event of bankruptcy. For Tax purposes, the Stockholders’
Representative Expense Amount shall be treated as having been received and voluntarily set aside by the Company Stockholders at the time
of Closing. As soon as practicable following the completion of the Stockholders’ Representative’s responsibilities, the Stockholders’
Representative shall disburse any remaining balance of the Stockholders’ Representative Expense Amount to the Payments Administrator
for further distribution to the Company Stockholders pro rata based on the Company Stockholders’ Pro Rata Share. The Parties agree
that the Stockholders’ Representative is not acting as a withholding agent or in any similar capacity in connection with the Stockholders’
Representative Expense Amount and is not responsible for any Tax reporting or withholding with respect thereto.

 

(h)       Upon
the written request of any Company Stockholder, the Stockholders’ Representative shall provide such Person with an accounting of
all monies received and distributed by the Stockholders’ Representative from the Stockholders’ Representative Expense Amount
and shall provide such Person with such other reasonable information regarding the Stockholders’ Representative’s actions,
in its capacity as the Stockholders’ Representative, as such Person may reasonably request.

 

(i)       The
Stockholders’ Representative may resign at any time. If the Stockholders’ Representative shall resign or be removed by the
Company Stockholders, the Company Stockholders, by majority approval based on their respective Pro Rata Shares, shall, within 30 days
after such resignation or removal, appoint a successor to the Stockholders’ Representative. Any such successor shall succeed the
former Stockholders’ Representative as the Stockholders’ Representative hereunder.

 

ARTICLE XI

MISCELLANEOUS

 

Section
11.1      Exclusive Remedy; Limitation of Liability. Except with respect to any claims for
indemnification for breach of any Fundamental Representation or Fraud, recovery by Parent, Merger Sub and their respective
Affiliates (including the Surviving Corporation and each of its Subsidiaries following Closing) in respect of any and all Losses
arising or resulting from or related to a breach of any representation or warranty shall be exclusively limited to the RWI Policy
and the Indemnity Escrow Amount. Parent and Merger Sub agree, to the fullest extent permitted by Law, that the Company Stockholders
and their respective Affiliates and their respective representatives (including the Stockholders’ Representative) shall not
have any liability or responsibility whatsoever to Parent, Merger Sub or any of their respective Affiliates or representatives on
any basis (including in contract or tort, under federal or state securities laws or otherwise) based upon any information provided
or made available, or statements made (or any omissions therefrom), to Parent, Merger Sub or any of their respective Affiliates or
representatives, including in respect of the specific representations and warranties of the Company set forth in Article III,
except as and only to the extent expressly set forth in Article III with respect to such representations and warranties and
subject to the limitations and restrictions contained in this Agreement.

 

    65 

     

    

 

Section 11.2      Entire
Agreement; Assignment. This Agreement and the Ancillary Documents, together with all exhibits, schedules, attachments, appendices
and annexes hereto and thereto, as the same may from time to time be amended, modified, supplemented, or restated in accordance with the
terms hereof, and together with the Confidentiality Agreement, (a) constitute the entire agreement among the Parties with respect to the
subject matter hereof and supersedes all other prior agreements and understandings, both written and oral, among the Parties with respect
to the subject matter hereof and (b) shall not be assigned by any Party (whether by operation of law or otherwise) without the prior written
consent of each of the other Parties; provided, however, that (i) Parent and Merger Sub may (A) assign all or any of their
rights and obligations hereunder to any Affiliate of Parent without prior written consent of the other Parties, and (B) assign or pledge
this Agreement to any lender of Parent or the Surviving Corporation as security for the obligation of such lender in respect of providing
any debt financing; provided, in each case, that Parent and Merger Sub shall be obligated to provide written notice of such assignment
or pledge to the Stockholders’ Representative promptly upon effecting such assignment or pledge, but in no case later than three
(3) days thereafter, and (ii) any assignment of this Agreement shall not relieve the assigning Party of any of its obligations hereunder.
Any attempted assignment of this Agreement not in accordance with the terms of this Section 11.2 shall be void.

 

Section 11.3      Notices.
All notices, requests, consents, claims, demands, waivers and other communications hereunder shall be in writing and shall be deemed
to have been given (a) when delivered by hand (with written confirmation of receipt); (b)
when received by the addressee if sent by a nationally recognized overnight courier (receipt requested); (c) on the date sent by
facsimile or e-mail of a PDF document (with confirmation of transmission) if sent during normal business hours of the recipient, and
on the next Business Day if sent after normal business hours of the recipient or (d) on the third (3rd) day after the date mailed,
by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the respective
Parties at the following addresses (or at such other address for a Party as shall be specified in a notice given in accordance with
this Section 11.3):

 

To Parent, Merger Sub or the Surviving
Corporation:

 

HPI Holdings, LLC 

174 Waterfront, Suite 330

National Harbor, MD 20745

Attention:
Pranil Vadgama

Pranil.Vadgama@hpiinc.com

 

    66 

     

    

 

with a copy (which shall not constitute notice hereunder)
to:

 

Shearman & Sterling LLP

300 West 6th
Street, Suite 2250

Austin, TX 78701

Attention: Carmelo Gordian

E-mail:       Carmelo.Gordian@Shearman.com

 

To the Company:

 

AdvantEdge Healthcare Holdings, Inc.

9 Northeastern Blvd,
Suite 400

Salem, NH 03079

Attention: David Langsam

   Chief Executive Officer

Facsimile: (908)
791-3330

E-mail:       dlangsam@ahsrcm.com

 

with a copy (which shall not constitute notice hereunder)
to:

 

Duane Morris LLP

30 South 17th
Street

Philadelphia, PA 19103-4196

Attention: Michael P. Gallagher

Facsimile: (215) 689-4931

E-mail:       MPGallagher@duanemorris.com

 

with a copy (which shall not constitute notice hereunder)
to:

 

Founders Equity, Inc.

545 Fifth Avenue, Suite 401

New York, NY 10017

Attention:
John White

Facsimile: (212) 829-0901

E-mail:       jdwhite@fequity.com

 

To the Stockholders’ Representative:

 

Shareholder Representative Services LLC

950 17th
Street, Suite 1400

Denver, CO 80202

Attention: Managing Director

E-mail:       deals@srsacquiom.com

 

Section
11.4      Governing Law. This Agreement and any claim, controversy or dispute arising under or related to
this Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to any
choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the
application of the Law of any jurisdiction other than the State of Delaware.

 

    67 

     

    

 

Section 11.5      Fees
and Expenses. Except as otherwise set forth in this Agreement (including, for avoidance of doubt, the fees and expenses to be borne
by Parent and Merger Sub in accordance with Section 6.4), whether or not the Transactions are consummated, all fees and expenses
incurred in connection with this Agreement and the Transactions contemplated by this Agreement, including the fees and disbursements of
counsel, financial advisors and accountants, shall be paid by the Party incurring such fees or expenses. For the avoidance of doubt, in
the event that the Transactions contemplated by this Agreement are consummated, Parent shall, or shall cause any of the Group Companies
to, pay all Unpaid Company Stockholder Expenses in accordance with Section 2.15.

 

Section 11.6      Press
Releases and Announcements. None of the Parties nor any of their respective representatives shall issue any press releases or make
any public announcements with respect to this Agreement or the Transactions without the prior written consent of Parent and the Company,
if prior to Closing, or Parent and the Stockholders’ Representative, if after Closing; provided, however, that Parent may issue
a press release at Closing with respect to this Agreement or the Transactions in its sole discretion. Notwithstanding the foregoing, any
press release or public announcement may be made if required by applicable Law or a securities exchange rule; provided, however,
that the Party required to make such press release or public announcement shall, to the extent possible, confer with Parent and the Stockholders’
Representative, to the extent applicable, concerning the timing and content of such press release or public announcement before the same
is made. Notwithstanding anything herein to the contrary, following Closing and the public announcement of the Merger, the Stockholders’
Representative shall be permitted to announce that it has been engaged to serve as the Stockholders’ Representative in connection
herewith as long as such announcement does not disclose any of the other terms hereof.

 

Section
11.7      Construction; Interpretation. The term “this Agreement” means this
Agreement together with all Schedules and Exhibits hereto, as the same may from time to time be amended, modified, supplemented or
restated in accordance with the terms hereof. The headings contained in this Agreement are inserted for convenience only and shall
not affect in any way the meaning or interpretation of this Agreement. No Party, nor its respective counsel, shall be deemed the
drafter of this Agreement for purposes of construing or enforcing the provisions hereof, and all provisions of this Agreement shall
be construed according to their fair meaning and not strictly for or against any Party, and no presumption or burden of proof will
arise favoring or disfavoring any Person by virtue of its authorship of any provision of this Agreement. The headings of particular
provisions of this Agreement are inserted for convenience only and will not be construed as a part of this Agreement or serve as a
limitation or expansion on the scope of any term or provision of this Agreement. References to dollar amount thresholds in this
Agreement shall not be deemed to be evidence of materiality, nor shall it create a measure for, or further define the meaning of,
any standard of materiality or its correlative terms. Unless otherwise indicated to the contrary herein by the context or use
thereof: (a) the words, “herein,” “hereto,” “hereof”, “hereby” and words of similar
import refer to this Agreement as a whole, including the Schedules and Exhibits, and not to any particular section, subsection
paragraph, subparagraph or clause contained in this Agreement; (b) masculine gender shall also include the feminine and neutral
genders, and vice versa; (c) words importing the singular shall also include the plural, and vice versa; (d) the words
 “include,” “includes” or “including” shall be deemed to be followed by the words “without
limitation”; (e) all references to Articles, Sections, Exhibits or Schedules are to Articles, Sections, Exhibits and
Disclosure Schedule of this Agreement; (f) the word “or” is disjunctive but not necessarily exclusive; (g) the words
 “writing”, “written” and comparable terms refer to printing, typing and other means of reproducing words
(including electronic media) in a visible form; (h) references to any agreement or contract are to that agreement or contract as
amended, modified or supplemented from time to time in accordance with the terms hereof and thereof; (i) references to any Person
include the successors and permitted assigns of that Person; (j) references from or through any date mean, unless otherwise
specified, from and including or through and including, respectively; (k) any reference to “made available” means a
document or other item of information that was provided or made available to Parent, Merger Sub and their representatives in any
 “data rooms,” “virtual data rooms,” management presentations or in any other form in expectation of, or in
connection with, the Transactions; (l) the words “dollar” or “$” shall mean U.S. dollars, and all payments
to be made pursuant to this Agreement shall be made in U.S. dollars; and (m) the word “day” means calendar day unless
Business Day is expressly specified. If any action under this Agreement is required to be done or taken on a day that is not a
Business Day, then such action shall be required to be done or taken not on such day but on the first succeeding Business Day
thereafter.

 

    68 

     

    

 

Section 11.8      Exhibits
and Schedules. All Exhibits and Schedules, or documents expressly incorporated into this Agreement, are hereby incorporated into this
Agreement and are hereby made a part hereof as if set out in full in this Agreement. Any item disclosed in any Schedule referenced by
a particular Section in this Agreement shall be deemed to have been disclosed with respect to every other Section in this Agreement if
the relevance of such disclosure to such other sections is reasonably apparent. The specification of any dollar amount in the representations
or warranties contained in this Agreement or the inclusion of any specific item in any Schedule is not intended to imply that such amounts,
or higher or lower amounts or the items so included or other items, are or are not material, and no Party shall use the fact of the setting
of such amounts or the inclusion of any such item in any dispute or controversy as to whether any obligation, items or matter not described
herein or included in a Schedule is or is not material for purposes of this Agreement. Any capitalized term used in any Exhibit or Schedule
but not otherwise defined therein shall have the meaning given to such term in this Agreement.

 

Section 11.9      Parties
in Interest. This Agreement shall be binding upon and inure solely to the benefit of each Party and its successors and permitted assigns
and, except as provided in Section 6.4, Article VIII or Section 10.1, nothing in this Agreement, express or implied,
is intended to or shall confer upon any other person any rights, benefits or remedies of any nature whatsoever under or by reason of this
Agreement.

 

Section
11.10    Severability. Whenever possible, each provision of this Agreement will be interpreted in such a
manner as to be effective and valid under applicable Law, but if any term or other provision of this Agreement is held to be
invalid, illegal or unenforceable under applicable Law, all other provisions of this Agreement shall remain in full force and effect
so long as the economic or legal substance of the Transaction is not affected in any manner materially adverse to any Party. Upon
such determination that any term or other provision of this Agreement is invalid, illegal or unenforceable under applicable Law, the
Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely as
possible in an acceptable manner in order that the Transaction are consummated as originally contemplated to the greatest extent
possible.

 

    69 

     

    

 

Section 11.11    Amendment.
Subject to applicable Law, this Agreement may be amended or modified, and any term of this Agreement may be waived, only by written agreement
executed and delivered by duly authorized officers of Parent and the Stockholders’ Representative. This Agreement may not be modified
or amended except as provided in the immediately preceding sentence and any purported amendment by any Party or the Parties effected in
a manner which does not comply with this Section 11.11 shall be void. Any waiver of any term or condition shall not be construed
as a waiver of any subsequent breach or a subsequent waiver of the same term or condition, or a waiver of any other term or condition
of this Agreement. The failure of any Party to assert any of its rights hereunder shall not constitute a waiver of such rights.

 

Section 11.12    Counterparts;
Facsimile Signatures. This Agreement may be executed in one or more counterparts (including by electronic means), each of which shall
be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an executed counterpart of a signature
page to this Agreement by facsimile or .pdf shall be as effective as delivery of a manually executed and delivered counterpart to this
Agreement.

 

Section 11.13   Mutual
Drafting. The Parties have participated jointly in the negotiation and drafting of this Agreement; accordingly, in the event an ambiguity
or question of intent or interpretation arises, this Agreement shall be construed as if drafted collectively by the Parties, and no presumption
or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any provisions of this Agreement.

 

Section
11.14   WAIVER OF JURY TRIAL. THE PARTIES TO THIS AGREEMENT EACH HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW,
ANY RIGHT TO TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (A) ARISING
UNDER THIS AGREEMENT OR (B) IN ANY WAY CONNECTED WITH OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES IN RESPECT OF THIS
AGREEMENT OR ANY OF THE TRANSACTIONS RELATED HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN
CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES TO THIS AGREEMENT EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND,
ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES TO THIS AGREEMENT MAY FILE AN
ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES TO THE WAIVER OF
THEIR RIGHT TO TRIAL BY JURY.

 

Section
11.15    Jurisdiction and Venue. Each of the Parties (a) submits to the exclusive jurisdiction of the
Chancery Court of the State of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction over a
particular matter, any state or federal court sitting in Delaware) in any Action arising out of or relating to this Agreement, (b)
agrees that all claims in respect of such Action may be heard and determined in any such court and (c) agrees not to bring any
Action arising out of or relating to this Agreement in any other court. Each of the Parties waives any defense of inconvenient forum
to the maintenance of any Action so brought and waives any bond, surety or other security that might be required of any other Party
with respect thereto. Each Party agrees that service of summons and complaint or any other process that might be served in any
Action may be made on such Party by sending or delivering a copy of the process to the party to be served at the address of such
Party and in the manner provided for the giving of notices in Section 11.3. Nothing in this Section 11.15, however,
shall affect the right of any Party to serve legal process in any other manner permitted by law. Each Party agrees that a final,
non-appealable judgment in any Action so brought shall be conclusive and may be enforced by suit on the judgment or in any other
manner provided by applicable Law.

 

    70 

     

    

 

Section 11.16     Remedies.
Except as otherwise provided herein, any and all remedies provided herein will be deemed cumulative with and not exclusive of any other
remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude the exercise
of any other remedy. The Parties agree that irreparable damage for which monetary damages, even if available, would not be an adequate
remedy, would occur in the event that the Parties do not perform their respective obligations under the provisions of this Agreement (including
failing to take such actions as are required of them hereunder to consummate the Transactions) in accordance with their specific terms
or otherwise breach such provisions. Each of the Parties agrees that it will not oppose the granting of an injunction, specific performance
and other equitable relief when expressly available pursuant to the terms of this Agreement on the basis that the other Parties have an
adequate remedy at law or an award of specific performance is not an appropriate remedy for any reason at law or equity. If a court of
competent jurisdiction has declined to specifically enforce the obligations of Parent to consummate the Closing pursuant to a claim for
specific performance brought against Parent and has instead granted an award of damages for such alleged breach against Parent, Parent
agrees such damages of the Company shall include damages based upon any decrease in share value, lost premium or lost benefit of the bargain
affecting the Company Stockholders (in each case taking into account relevant matters, including the total amount payable to the Company
Stockholders under this Agreement and the time value of money).

 

Section 11.17    Waiver
of Conflicts. Recognizing that Duane Morris LLP has acted as legal counsel to the Group Companies prior to the Closing, and that
Duane Morris LLP intends to act as legal counsel to the Stockholders’ Representative and its Affiliates (which will no longer include
the Group Companies) after the Closing, Parent, Merger Sub and the Company each hereby waives, on its own behalf and agrees to cause
its Affiliates (including the Surviving Corporation and its Subsidiaries after Closing) to waive, any conflicts that may arise in connection
with Duane Morris LLP representing the Stockholders’ Representative and/or its Affiliates (or any of the other Company Stockholders)
after the Closing as such representation may relate to Parent, Merger Sub, any Group Company or the Transactions. In addition, all communications
involving attorney- client confidences between the Stockholders’ Representative, its Affiliates or any Group Company and Duane
Morris LLP in the course of the negotiation, documentation and consummation of the Transactions shall be deemed to be attorney-client
confidences that belong solely to the Stockholders’ Representative and its Affiliates (and not the Group Companies). Accordingly,
none of the Group Companies shall, without the Stockholders’ Representative’s consent, have access to any such communications,
or to the files of Duane Morris LLP relating to its engagement, whether or not the Closing shall have occurred. Without limiting the
generality of the foregoing, upon and after the Closing, (a) the Stockholders’ Representative and its Affiliates (and not the Group
Companies) shall be the sole holders of the attorney-client privilege with respect to such engagement, and none of the Group Companies
shall be a holder thereof, (b) to the extent that files of Duane Morris LLP in respect of such engagement constitute property of the
client, only the Stockholders’ Representative and its Affiliates (and not the Group Companies) shall hold such property rights
and (c) Duane Morris LLP shall have no duty whatsoever to reveal or disclose any such attorney-client communications or files to any
of the Group Companies by reason of any attorney-client relationship between Duane Morris LLP and any of the Group Companies or otherwise.

 

    71 

     

    

 

Section 11.18    Release.
Upon and subject to the Closing, in consideration of the payments made to such Company Stockholder pursuant to this Agreement and as an
inducement to Parent’s and Merger Sub’s willingness to enter into the Transactions, each Company Stockholder agrees as follows:

 

(a)       Subject
to the last sentence of this Section 11.18, the Company Stockholders, on behalf of themselves and their respective Affiliates and
its and their respective equityholders (separately and collectively, as the case may be, the “Releasor”), by
their adoption and approval of this Agreement, as well as, in certain cases, through separate instruments (including the Letters of Transmittal),
hereby irrevocably, unconditionally and completely release, acquit and forever discharge, to the fullest extent permitted by Law, each
of Parent, Merger Sub, the Surviving Corporation and the Group Companies, together with each of their respective past, present and future
officers, managers, directors, equityholders, partners, members, Affiliates, controlling persons, employees, counsel, agents and other
representatives (each, solely in their respective capacity as such, a “Releasee”) of, from and against, and
hereby irrevocably, unconditionally and completely waives and relinquishes, any and all legal proceedings, actions, causes of action,
claims, demands, damages, judgments, debts, dues, suits and Liabilities of every kind, nature and description whatsoever, which any Releasor
ever had, now has or may have in the future against any of the Releasees on account of or by reason of any matter, cause or thing whatsoever
to the extent arising prior to or at the Closing and relating to each such Releasor’s status as a Company Stockholder (all of the
foregoing being collectively referred to herein as the “Released Claims”); provided, however, that nothing
contained herein shall operate to release, and the Released Claims shall not include, (i) any right, claim or obligation under the express
terms of this Agreement or any Ancillary Document to which such Releasor is a party, (ii) if such Releasor is an employee of the Company
or any of its Subsidiaries, any rights with respect to unpaid salaries, bonuses, consulting fees, severance and reimbursement of expenses
for services provided by such Releasor, and that, in each case, has been earned and accrued in the ordinary course of business and approved
in accordance with the Company’s or any of its Subsidiaries’ standard policies (but not including compensation relating to
grants of equity or equity-based awards), (iii) any claim relating to Fraud by Parent or Merger Sub, (iv) any rights under any Plan (but
not including any benefit plans or plan provisions relating to grants of equity or equity-based awards), or (v) claims arising from any
rights of indemnification, contribution, advancement of expenses or insurance coverage or protection that any Releasor has or had pursuant
to the Organizational Documents of the Company or any of its Subsidiaries, as in effect on the date hereof. Each Company Stockholder,
on behalf of itself and each of its Affiliates and its and their respective equityholders, agrees not to, and agrees to cause its respective
officers, directors, equityholders, Subsidiaries and Affiliates, and each of their respective successors and assigns, not to, assert any
Released Claim against the Releasees.

 

    72 

     

    

 

(b)       Each
Releasor, on behalf of itself and each of its Affiliates and its and their respective equityholders, as the case may be, hereby acknowledges
that it has considered the possibility that it may not now know the nature or value of the claims that are generally released pursuant
to Section 11.18(a), and that such general release extends to all claims of every nature and kind, known or unknown, suspected
or unsuspected, past or present, however arising, and that any and all rights granted to such Releasor, as applicable, pursuant to Section
1542 of the California Civil Code or any analogous applicable Law are hereby expressly waived. Said Section 1542 of the Civil Code of
the State of California reads as follows:

 

“A GENERAL RELEASE DOES NOT EXTEND
TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN
BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”

 

(signature pages follow)

 

    73 

     

    

 

IN WITNESS WHEREOF, the parties hereto
have duly caused this Agreement and Plan of Merger to be executed on the date first written above.

 

	 	PARENT:
	 	 
	 	HPI HOLDINGS, LLC
	 	 
	 	By:	/s/ Pranil Vadgama
	 	Name:	Pranil Vadgama
	 	Title:	Treasurer
	 	 
	 	MERGER SUB:
	 	 
	 	AHS GRANITE MERGER SUB, INC.
	 	 
	 	By:	/s/ Pranil Vadgama
	 	Name:	 Pranil Vadgama
	 	Title:	President and Chief Executive Officer

 

(Signature Page to Agreement
and Plan of Merger)

 

     

     

    

 

	 	COMPANY:
	 	 
	 	ADVANTEDGE HEALTHCARE HOLDINGS, INC.
	 	 
	 	By:	/s/ David Langsam
	 	Name:	David Langsam
	 	Title:	President and Chief Executive Officer

 

(Signature Page to Agreement
and Plan of Merger)

 

     

     

    

 

	 	STOCKHOLDERS’ REPRESENTATIVE:
	 	 
	 	SHAREHOLDER REPRESENTATIVE
	 	SERVICES LLC, solely in its capacity as the 
	 	Stockholders’ Representative
	 	 
	 	By:	/s/
    Kip Wallen                                              
	 	Name:	Kip Wallen
	 	Title:	Director

 

(Signature Page to Agreement
and Plan of Merger)

 

     

     

    

 

EXHIBIT A

 

DISCLOSURE SCHEDULE

 

(see attached)

 

     

     

    

 

EXECUTION VERSION

 

Schedule 1.1(a)

Form Working Capital Statement

 

See attached.

 

AHS NWC PROPOSAL

 

	 	 	Jul-20	 	 	Aug-20	 	 	Sep-20	 	 	Oct-20	 	 	Nov-20	 	 	Dec-20	 	 	Jan-21	 	 	Feb-21	 	 	Mar-21	 	 	Apr-21	 	 	May-21	 	 	Jun-21	 	 	L6M Average	 
	1205 Accounts Receivable	 	 	4,767,600	 	 	 	4,769,728	 	 	 	4,783,099	 	 	 	4,803,129	 	 	 	5,060,784	 	 	 	5,267,738	 	 	 	4,866,268	 	 	 	5,052,273	 	 	 	4,867,282	 	 	 	4,709,462	 	 	 	4,440,820	 	 	 	4,881,567	 	 	 	4,802,945	 
	1212 Miscellaneous Receivables	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 	 	 	6,201	 
	1213 Accrued Revenue	 	 	114,179	 	 	 	60,777	 	 	 	129,979	 	 	 	154,310	 	 	 	49,099	 	 	 	120,565	 	 	 	172,697	 	 	 	229,576	 	 	 	105,017	 	 	 	156,334	 	 	 	145,068	 	 	 	89,009	 	 	 	149,617	 
	1220 Allowance for Bad Debt	 	 	(50,748	)	 	 	(50,748	)	 	 	(83,017	)	 	 	(83,017	)	 	 	(83,017	)	 	 	(93,017	)	 	 	(93,007	)	 	 	(93,007	)	 	 	(92,351	)	 	 	(69,070	)	 	 	(68,421	)	 	 	(68,421	)	 	 	(80,713	)
	1325 Prepaid Cobra Insurance	 	 	(17,897	)	 	 	(17,752	)	 	 	(23,033	)	 	 	(25,389	)	 	 	(24,696	)	 	 	8,686	 	 	 	12,939	 	 	 	10,035	 	 	 	11,803	 	 	 	13,572	 	 	 	14,361	 	 	 	5,078	 	 	 	11,298	 
	1330 Prepaid Expenses	 	 	329,950	 	 	 	352,681	 	 	 	370,426	 	 	 	423,894	 	 	 	440,054	 	 	 	374,935	 	 	 	375,875	 	 	 	347,013	 	 	 	403,417	 	 	 	405,969	 	 	 	403,344	 	 	 	401,619	 	 	 	389,539	 
	1332 Prepaid Insurance	 	 	25,633	 	 	 	23,849	 	 	 	22,066	 	 	 	9,718	 	 	 	5,153	 	 	 	16,126	 	 	 	10,037	 	 	 	21,711	 	 	 	21,149	 	 	 	14,610	 	 	 	11,626	 	 	 	5,711	 	 	 	14,141	 
	1333 Prepaid Postage	 	 	1,610	 	 	 	33,488	 	 	 	35,305	 	 	 	37,307	 	 	 	43,489	 	 	 	(2,973	)	 	 	27,363	 	 	 	30,849	 	 	 	14,181	 	 	 	17,113	 	 	 	24,891	 	 	 	17,113	 	 	 	21,918	 
	1337 Prepaid Commissions	 	 	103,848	 	 	 	118,439	 	 	 	86,170	 	 	 	83,656	 	 	 	81,142	 	 	 	76,841	 	 	 	74,318	 	 	 	71,801	 	 	 	69,283	 	 	 	67,075	 	 	 	64,867	 	 	 	62,659	 	 	 	68,334	 
	1350 A/R Suspense	 	 	65,972	 	 	 	60,978	 	 	 	(46,684	)	 	 	(49,684	)	 	 	(49,684	)	 	 	(49,684	)	 	 	(77,833	)	 	 	(49,684	)	 	 	(49,684	)	 	 	(49,684	)	 	 	(49,684	)	 	 	(49,684	)	 	 	(54,375	)
	Current Assets	 	 	5,346,347	 	 	 	5,357,641	 	 	 	5,280,514	 	 	 	5,360,125	 	 	 	5,528,525	 	 	 	5,725,418	 	 	 	5,374,859	 	 	 	5,626,767	 	 	 	5,356,299	 	 	 	5,271,582	 	 	 	4,993,073	 	 	 	5,350,851	 	 	 	5,328,905	 
	2000 Accounts Payable	 	 	(1,218,007	)	 	 	(898,392	)	 	 	(1,021,114	)	 	 	(1,381,919	)	 	 	(1,313,101	)	 	 	(1,120,641	)	 	 	(1,009,288	)	 	 	(682,926	)	 	 	(940,936	)	 	 	(1,145,336	)	 	 	(963,605	)	 	 	(997,615	)	 	 	(956,618	)
	2050 Miscellaneous Payable - Bangal	 	 	89,386	 	 	 	81,038	 	 	 	72,139	 	 	 	65,755	 	 	 	57,867	 	 	 	-	 	 	 	200	 	 	 	(3,239	)	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(507	)
	2110 401K Payable	 	 	(18,308	)	 	 	(17,348	)	 	 	(17,692	)	 	 	(17,322	)	 	 	(17,322	)	 	 	(17,322	)	 	 	(22,538	)	 	 	(19,205	)	 	 	(19,345	)	 	 	(19,170	)	 	 	(19,170	)	 	 	(13,785	)	 	 	(18,869	)
	2120 Employee Expense Payable	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)	 	 	(3,399	)
	2125 Due to NEBH	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)	 	 	(1,597	)
	2130 FSA Payable	 	 	(8,255	)	 	 	(7,971	)	 	 	(7,723	)	 	 	(8,884	)	 	 	(9,293	)	 	 	(5,330	)	 	 	(1,324	)	 	 	(1,941	)	 	 	(1,155	)	 	 	(1,768	)	 	 	(803	)	 	 	576	 	 	 	(1,069	)
	2140 Garnishment Payable	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)	 	 	(405	)
	2141 Vacation Accrual Payable	 	 	(383,682	)	 	 	(383,401	)	 	 	(385,341	)	 	 	(379,448	)	 	 	(422,566	)	 	 	(453,397	)	 	 	(452,761	)	 	 	(453,777	)	 	 	(457,564	)	 	 	(457,226	)	 	 	(457,237	)	 	 	(457,103	)	 	 	(455,945	)
	2145 Accrued Bonus Payable	 	 	(25,201	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)	 	 	(31,501	)
	2150 Net Payroll	 	 	(613,925	)	 	 	(912,593	)	 	 	(1,087,510	)	 	 	(334,786	)	 	 	(625,209	)	 	 	(610,382	)	 	 	(678,106	)	 	 	(896,086	)	 	 	(863,795	)	 	 	(334,858	)	 	 	(405,707	)	 	 	(774,250	)	 	 	(658,800	)
	2160 Payroll Clearing	 	 	(3,944	)	 	 	(3,106	)	 	 	586,279	 	 	 	(1,996	)	 	 	298	 	 	 	2,199	 	 	 	4,013	 	 	 	(52	)	 	 	612,581	 	 	 	27,436	 	 	 	23,733	 	 	 	19,625	 	 	 	114,556	 
	2170 Payroll Liabilities	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 	 	 	7,761	 
	2183 Employee Equipment Deposits	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)	 	 	(2,069	)
	2208 Credit Card Refund Liability	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)	 	 	(15,301	)
	2210 Accrued Expenses	 	 	(690,521	)	 	 	(786,488	)	 	 	(807,006	)	 	 	(657,165	)	 	 	(636,141	)	 	 	(627,829	)	 	 	(652,125	)	 	 	(695,970	)	 	 	(772,006	)	 	 	(703,997	)	 	 	(918,027	)	 	 	(762,520	)	 	 	(750,774	)
	2215 Accrued Accounting Fees	 	 	(150,734	)	 	 	(167,401	)	 	 	(184,068	)	 	 	(172,360	)	 	 	(189,027	)	 	 	(196,336	)	 	 	(213,003	)	 	 	(229,670	)	 	 	(226,337	)	 	 	(243,004	)	 	 	(259,671	)	 	 	(256,338	)	 	 	(238,004	)
	2216 Accrued Legal Fees	 	 	(23,237	)	 	 	(43,237	)	 	 	(23,237	)	 	 	(9,316	)	 	 	(6,816	)	 	 	(7,516	)	 	 	(9,516	)	 	 	(8,454	)	 	 	(11,954	)	 	 	(240,763	)	 	 	(239,863	)	 	 	(447,954	)	 	 	(159,750	)
	2220 Accrued Healthcare	 	 	154,924	 	 	 	137,969	 	 	 	184,193	 	 	 	156,207	 	 	 	171,390	 	 	 	(0	)	 	 	(0	)	 	 	(6,601	)	 	 	(9,964	)	 	 	(5,654	)	 	 	(3,925	)	 	 	168,662	 	 	 	23,753	 
	2370 Revenue Deferal	 	 	(601,133	)	 	 	(277,345	)	 	 	(253,236	)	 	 	(162,378	)	 	 	(126,985	)	 	 	(81,551	)	 	 	(88,767	)	 	 	(81,242	)	 	 	(73,717	)	 	 	(84,859	)	 	 	(77,501	)	 	 	(182,142	)	 	 	(98,038	)
	2380 Deferred Rent Liability	 	 	(464,187	)	 	 	(463,888	)	 	 	(463,128	)	 	 	(461,142	)	 	 	(459,381	)	 	 	(456,104	)	 	 	(452,396	)	 	 	(448,547	)	 	 	(444,173	)	 	 	(442,438	)	 	 	(442,335	)	 	 	(436,320	)	 	 	(444,368	)
	Current Liabilities	 	 	(3,971,834	)	 	 	(3,788,675	)	 	 	(3,453,955	)	 	 	(3,411,265	)	 	 	(3,622,798	)	 	 	(3,620,720	)	 	 	(3,622,123	)	 	 	(3,574,221	)	 	 	(3,254,875	)	 	 	(3,698,149	)	 	 	(3,810,621	)	 	 	(4,185,675	)	 	 	(3,690,944	)
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Unadjusted Net Working Capital	 	 	1,374,512	 	 	 	1,568,965	 	 	 	1,826,559	 	 	 	1,948,861	 	 	 	1,905,727	 	 	 	2,104,698	 	 	 	1,752,736	 	 	 	2,052,546	 	 	 	2,101,423	 	 	 	1,573,433	 	 	 	1,182,452	 	 	 	1,165,176	 	 	 	1,637,961	 
	Adjustments to Net Working Capital	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Transaction Costs (adjusted out of Accounts Payable)	 	 	161,068	 	 	 	161,068	 	 	 	161,068	 	 	 	161,068	 	 	 	161,068	 	 	 	36,000	 	 	 	36,000	 	 	 	72,000	 	 	 	108,000	 	 	 	144,000	 	 	 	105,000	 	 	 	(6,000	)	 	 	76,500	 
	Accrued Transaction Costs (adjusted out of Accrued Legal Fees & Accrued Expenses)	 	 	20,837	 	 	 	37,657	 	 	 	52,501	 	 	 	12,373	 	 	 	14,040	 	 	 	20,140	 	 	 	-	 	 	 	-	 	 	 	75,000	 	 	 	203,411	 	 	 	203,411	 	 	 	410,817	 	 	 	148,773	 
	Interest Expense Payable to Elm Park (adjusted out of Accounts Payable)	 	 	211,914	 	 	 	194,500	 	 	 	194,500	 	 	 	193,560	 	 	 	188,803	 	 	 	194,143	 	 	 	192,382	 	 	 	174,071	 	 	 	192,950	 	 	 	185,030	 	 	 	190,200	 	 	 	176,633	 	 	 	185,211	 
	Adjustment for Payroll Taxes (Part of Pre-Closing Tax Amount)	 	 	44,996	 	 	 	45,675	 	 	 	53,980	 	 	 	21,334	 	 	 	25,149	 	 	 	41,908	 	 	 	60,775	 	 	 	57,236	 	 	 	68,469	 	 	 	25,618	 	 	 	29,560	 	 	 	36,274	 	 	 	46,322	 
	Adjusted Net Working Capital	 	 	1,813,327	 	 	 	2,007,865	 	 	 	2,288,608	 	 	 	2,337,196	 	 	 	2,294,787	 	 	 	2,396,889	 	 	 	2,041,893	 	 	 	2,355,854	 	 	 	2,545,842	 	 	 	2,131,492	 	 	 	1,710,624	 	 	 	1,782,900	 	 	 	2,094,767	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Target	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	2,094,767	 

 

     

     

    

 

Schedule 1.1(b)

Permitted Liens

 

		1.	The Credit Agreement, dated as of July 14, 2017, by and among
the Company, certain Company subsidiaries, Elm Park Credit Opportunities Funds II, L.P. and Elm Park Credit Opportunities Funds II (Canada),
L.P.

 

     

     

    

 

Schedule 2.12

Management Carve Out Program Awards

 

The Company intends to disburse $1,968,000.00
under the Management Carve Out Program at Closing. The total amount disbursed under the Management Carve Out Program will equal 99.92%
of the amount calculated under the Management Carve Out Program. In the event any earnout thresholds are achieved, the amount to be paid
under the Management Carve-out Program will increase in accordance with the terms thereof , and such amount will be disbursed by the Surviving
Corporation’s customary payroll processes in accordance with the percentages set forth below, the Consideration Spreadsheet and
the Agreement.

 

	Program Participant	 	Carve-out Program Amount	 
	David H. Langsam	 	 	50.00	%
	J. Paul O'Haro	 	 	12.00	%
	Terence P. Halloran	 	 	10.00	%
	Jeanne Gilreath	 	 	8.00	%
	Maureen Albano	 	 	0.09	%
	Robert Boyce	 	 	0.18	%
	Raymond Cassidy	 	 	2.50	%
	Henry Choi	 	 	0.90	%
	Paulo DaSilva	 	 	1.00	%
	Crystal Starr	 	 	0.02	%
	Victoria Kern	 	 	0.02	%
	Gloria Stitley	 	 	0.14	%
	Brice Voithofer	 	 	2.50	%
	Steven Macrea	 	 	0.30	%
	Tina Pelletier	 	 	0.15	%
	Sunil Christopher	 	 	0.18	%
	Janice Kelleher	 	 	0.25	%
	Sean Munster	 	 	1.00	%
	Jill Butler	 	 	0.19	%
	Michael Hopkins	 	 	1.00	%
	Barbara Lewis	 	 	1.00	%
	Liddy Wilson	 	 	1.00	%
	Lyne Green	 	 	1.00	%
	Marie Franklin	 	 	1.00	%
	Laurie Krachenfels	 	 	1.00	%
	Rick Brozovic	 	 	1.00	%
	David Barrett	 	 	3.00	%
	Michael Montemarano	 	 	0.50	%

 

     

     

    

 

Schedule 7.1(a)

Resigning Officers

 

		1.	David Langsam
		2.	Terence Halloran
		3.	Jeanne Gilreath
		4.	Sunil Christopher

 

     

     

    

 

Schedule 7.1(g)

Approvals, Consents
and Waivers

 

1. Written Consent.

 

    

     

    

 

Disclosure Schedules Agreement and Plan of Merger

 

This Disclosure Schedule
has been prepared in connection with that certain Agreement and Plan of Merger (the “Agreement”), dated September
30, 2021, by and among HPI Holdings, LLC, a Delaware limited liability company (“Parent”), AHS Granite Merger
Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent, Shareholder Representative Services LLC, solely in its capacity
as the representative, agent and attorney-in-fact of the Company Stockholders, and AdvantEdge Healthcare Holdings, Inc., a Delaware corporation
(the “Company”). Capitalized terms used but not otherwise defined in this Disclosure Schedule shall have the
meanings given to such terms in the Agreement.

 

The representations
and warranties of the Company in the Agreement are made subject to the exceptions and qualifications set forth herein. This Disclosure
Schedule is qualified in its entirety by reference to specific provisions of the Agreement, and are not intended to constitute, and shall
not be construed as constituting, separate representations or warranties of the Company.

 

The section numbers
used herein refer to the Sections in the Agreement. Headings and subheadings have been inserted herein for convenience of reference only
and shall not have the effect of amending or changing the express description hereof as set forth in the Agreement.

 

The inclusion of
any items (including dollar amounts) in any representations and warranties in the Agreement or in any section of this Disclosure Schedule
is not intended to imply that such amounts or items so included are required to be listed in such section or is material to or outside
the ordinary course of the business of the Company, nor shall the inclusion of such items or amounts be deemed to establish a standard
of materiality. In addition, matters reflected in this Disclosure Schedule are not necessarily limited to matters required by the Agreement
to be reflected in this Disclosure Schedule. Any such additional matters are set forth for informational purposes only and do not necessarily
include (and shall not be deemed to include) other matters of a similar nature. The information contained in this Disclosure Schedule
is disclosed solely for purposes of the Agreement, and no information contained herein or therein shall be deemed to be an admission by
any party hereto to any third party of any matter whatsoever (including, without limitation, any violation of applicable law or breach
of contract).

 

Any information disclosed
in this Disclosure Schedule under any section number shall be deemed to be disclosed and incorporated in the Disclosure Schedule under
any other section to the extent the relevance of such information to such other section would be reasonably apparent on its face to a
reader of such information.

 

Subject to applicable
law, this information is disclosed in confidence for the purposes contemplated in the Agreement and is subject to the confidentiality
provisions of the Confidentiality Agreement, dated as of May 5, 2021, between the Company and Parent.

 

    1 

     

    

 

Schedule 3.1

Organization and
Qualification

 

	Group Company	Jurisdictions
	Company	Delaware 
 New York 
 New Jersey
	AdvantEdge Healthcare Solutions, Inc.	New York
 New Jersey
	AdvantEdge Healthcare Solutions, Inc.	Delaware
 New York 
 Ohio 
 Pennsylvania
 New Hampshire
 Kentucky
	Professional Management, Inc.	Maryland
 New Jersey
	Frank Hill Associates, Inc.	Massachusetts
 New Hampshire
	Medical Account Services, Inc.	Ohio
	AdvantEdge WPA Inc.	Delaware
	AHS Services, Inc.	Delaware
 New Jersey
	AdvantEdge Healthcare Solutions, S.I., Inc.	Delaware 
 New York
	AMSPlus, Inc.	Massachusetts
 Connecticut 
 New Hampshire
	Physicians’ Service Center	Illinois
	AHP Billing Services, Inc.	Delaware 
 Maine
	AdvantEdge Healthcare Solutions Private Limited	India

 

    2 

     

    

 

Schedule 3.2(a)

Capitalization

 

See attached. 

 

AdvantEdge Healthcare Holdings, Inc.

Summary of Capitalization

As of December 31, 2020

 

	 	 	Common Stock	 	 	Preferred
    Stock	 	 	FD	 	 	Total
    Shares	 	 	%
    of	 
	 	 	Shares	 	 	Options	 	 	Warrants	 	 	A	 	 	A-1	 	 	A-1
    Warrants	 	 	FD
    Total	 	 	%age	 	 	O/S	 	 	O/S	 	 	OIP	 
	Founders' Equity SBIC
    I	 	 	-	 	 	 	-	 	 	 	-	 	 	 	11,079,569	 	 	 	1,441,400	 	 	 	-	 	 	 	12,520,969	 	 	 	28.8	%	 	 	12,520,969	 	 	 	33.5	%	 	 	12,809,249	 
	Founders' Equity NY LP	 	 	 	 	 	 	 	 	 	 	-	 	 	 	8,120,431	 	 	 	691,934	 	 	 	 	 	 	 	8,812,365	 	 	 	20.2	%	 	 	8,812,365	 	 	 	23.5	%	 	 	8,950,751	 
	Founders HW LLC	 	 	 	 	 	 	 	 	 	 	-	 	 	 	10,800,000	 	 	 	1,200,000	 	 	 	 	 	 	 	12,000,000	 	 	 	27.6	%	 	 	12,000,000	 	 	 	32.1	%	 	 	12,240,000	 
	Safeguard	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	0.0	%	 	 	-	 	 	 	0.0	%	 	 	-	 
	Other Preferred	 	 	-	 	 	 	-	 	 	 	-	 	 	 	165,000	 	 	 	-	 	 	 	550,000	 	 	 	715,000	 	 	 	1.6	%	 	 	165,000	 	 	 	0.4	%	 	 	165,000	 
	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	30,165,000	 	 	 	3,333,334	 	 	 	550,000	 	 	 	34,048,334	 	 	 	78.2	%	 	 	33,498,334	 	 	 	89.5	%	 	 	34,165,000	 
	Common
    (net of treasury)	 	 	3,926,377	 	 	 	5,554,545	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	9,480,922	 	 	 	21.8	%	 	 	3,926,377	 	 	 	10.5	%	 	 	 	 
	TOTAL	 	 	3,926,377	 	 	 	5,554,545	 	 	 	-	 	 	 	30,165,000	 	 	 	3,333,334	 	 	 	550,000	 	 	 	43,529,256	 	 	 	100.0	%	 	 	37,424,711	 	 	 	100.0	%	 	 	 	 
	Options in
    the plan not yet granted	 	 	 	 	 	 	3,017,381	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Options Outstanding	 	 	 	 	 	 	2,537,164	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

Note: Total common shares outstanding
on this cap table does not tie to the audited financial statements. The difference is 4,167 and dates back to at least 12/31/12. The amount
included in the detailed cap table and this summary ties to the stock ledger report provided by counsel.

 

    3 

     

    

 

Schedule 3.2(b)

Capitalization Exceptions

 

(b)

 

(i)

 

	Group Company	Outstanding Equity Securities
	Company	Schedule 3.2(a) is incorporated by reference herein.
	AdvantEdge Healthcare Solutions, Inc. (NY)	Company (100%)
 
 70 Common Stock Units
	AdvantEdge Healthcare Solutions, Inc. (DE)	Company (100%)
 
 100 Common Stock Units
	Professional Management, Inc.	AdvantEdge Healthcare Solutions, Inc. (DE) (100%)
 
 470 Common Stock Units
	Frank Hill Associates, Inc.	AdvantEdge Healthcare Solutions, Inc. (DE (100%)
 
 1,000 Common Stock Units
	Medical Account Services, Inc.	AdvantEdge Healthcare Solutions, Inc. (DE (100%)
 
 200 Common Stock Units
	AdvantEdge WPA Inc.	AdvantEdge Healthcare Solutions, Inc. (DE
(100%) 

100 Common Stock Units
	AHS Services, Inc.	AdvantEdge Healthcare Solutions, Inc. (NY)
(100%) 

100 Common Stock Units
	AdvantEdge Healthcare Solutions, S.I., Inc.	AdvantEdge Healthcare Solutions, Inc. (NY)
(100%)

 100 Common Stock Units

 

    4 

     

    

 

	AMSPlus, Inc.	AdvantEdge Healthcare Solutions, Inc. (NY) (100%)
 
 1,125 Common Stock Units
	Physicians’ Service Center, Inc.	AdvantEdge Healthcare Solutions, Inc. (NY) (100%)
 
 100 Class A Common Stock Units
	AHP Billing Services, Inc.	AdvantEdge Healthcare Solutions, Inc. (NY) (100%)
 
 1,000 Class B Common Stock Units
	AdvantEdge
Healthcare Solutions Private Limited	AHS Services, Inc. (.01%)
 
 10 Common Stock Units
	AdvantEdge
Healthcare Solutions Private Limited	AdvantEdge Healthcare Solutions, Inc. (NY) (99.99%)
 
 405,310 Common Stock Units

 

(ii)

 

None.

 

(iii)

 

		1.	Option Agreement, dated as of December 31, 2012, by and between the Company and Jill Butler, to be canceled effective as of the Closing
pursuant to terms of Option Agreement.

 

		2.	Option Agreement, dated as of December 31, 2012, by and between the Company and Lawrence Keber, to be canceled effective as of the
Closing pursuant to terms of Option Agreement.

 

		3.	Option Agreement, dated as of December 31, 2012, by and between the Company and Layne Cargill, to be canceled effective as of the
Closing pursuant to terms of Option Agreement.

 

		4.	Option Agreement, dated as of December 31, 2012, by and between the Company and Sean Munster, to be canceled effective as of the Closing
pursuant to terms of Option Agreement.

 

		5.	Option Agreement, dated as of December 31, 2012, by and between the Company and William Sawyer, to be canceled effective as of the
Closing pursuant to terms of Option Agreement.

 

    5 

     

    

 

		6.	Option Agreement, dated as of December 31, 2012, by and between the Company and Alan Hill, to be canceled effective as of the Closing
pursuant to terms of Option Agreement.

 

		7.	Option Agreement, dated as of December 31, 2012, by and between the Company and Diane Dolan, to be canceled effective as of the Closing
pursuant to terms of Option Agreement.

 

		8.	Option Agreement, dated as of December 31, 2012, by and between the Company and Janice McHale, to be canceled effective as of the
Closing pursuant to terms of Option Agreement.

 

		9.	Option Agreement, dated as of December 31, 2012, by and between the Company and Janice Kelleher, to be canceled effective as of the
Closing pursuant to terms of Option Agreement.

 

		10.	Warrant to Purchase Stock, issued on December 30, 2010, by the Company to ORIX Finance Equity Investors, LP, as amended by that certain
Amendment No. 1, dated as of December 30, 2020.

 

		11.	Warrant to Purchase Stock, issued on May 10, 2012, by the Company to ORIX Finance Equity Investors, LP., as amended by that certain
Amendment No. 1, dated as of December 31, 2020.

 

		12.	Warrants to Purchase Stock, issued on December 31, 2012 (as amended) by the Company to ORIX Finance Equity Investors, LP.

 

 (iv)

 

None.

 

    6 

     

    

 

Schedule 3.2(d)

Equity Incentive
Options

 

Option Agreements with the following individuals will be
cancelled effective as of the Closing pursuant to the terms of Option Agreements:

 

		1.	Ray Cassidy
		2.	Henry Choi
		3.	Jeanne Gilreath
		4.	David Langsam
		5.	Janice McHale
		6.	Sean Munster
		7.	Diane Dolan
		8.	J. Paul O’Haro
		9.	Sunil Christopher
		10.	Terence Halloran
		11.	Jill Butler
		12.	Lawrence Keber
		13.	Layne Cargill
		14.	William Sawyer
		15.	Alan Hill
		16.	Janice Kelleher

 

    7 

     

    

 

Schedule 3.3

Consents and Approvals

 

The following disclosures are in response to the last sentence
of Section 3.3 of the Agreement:

 

(i)

 

None.

 

(ii)

 

		1.	Credit Agreement, dated as of July 14, 2017, by and among the Company, certain Company subsidiaries, Elm Park Credit Opportunities
Funds II, L.P. and Elm Park Credit Opportunities Funds II (Canada), L.P. – this Contract will be terminated upon the Closing of
the Transactions contemplated by the Agreement.
	 	 	 
		2.	Lease Agreement, dated as of November 14, 2003, by and between 530
22nd Street, L.L.C., as landlord, and AdvantEdge Healthcare Solutions, Inc., as tenant, as amended by that certain First Lease Amendment,
dated as of October 21, 2008, that certain Second Lease Amendment, dated as of November 26, 2013, that certain Third Lease Amendment,
dated as of September 30, 2014, and that certain Fourth Lease Amendment dated as of January 31, 2017 (the “530 22nd Street Lease”).
	 	 	 
		3.	Lease dated as of January 21, 2004, as amended by that certain First Amendment and Supplement to Lease dated as of June 15, 2009,
that certain Second Lease Amendment and Supplement to Lease dated as of March 10, 2011, that certain Third Amendment and Supplement to
Lease dated as of November 12, 2013, and that certain Fourth Amendment and Supplement to Lease dated as of November 16, 2016, by and among
Increase Your Profit, LLC and AdvantEdge Healthcare Solutions, Inc.

 

		4.	Agreement of Lease, dated as of September 19, 2018, by and between FDS Franklin 9920, LLC, as landlord, and Professional Management,
Inc., as tenant.

 

		5.	Warrant to Purchase Stock, issued on December 30, 2010, by the Company to ORIX Finance Equity Investors, LP, as amended by that certain
Amendment No. 1, dated as of December 30, 2020.

 

		6.	Warrant to Purchase Stock, issued on May 10, 2012, by the Company to ORIX Finance Equity Investors, LP., as amended by that certain
Amendment No. 1, dated as of December 31, 2020.

 

		7.	Warrants to Purchase Stock, issued on December 31, 2012 (as amended) by the Company to ORIX Finance Equity Investors, LP.

 

		8.	Third Party Vendor Agreement, dated as of June 28, 2007, by and between Medifax-EDI, LLC and AMSplus, Inc.

 

(iii)

 

None.

 

(iv)

 

None.

 

    8 

     

    

 

Schedule 3.5

No Undisclosed Liabilities

 

The following disclosures are in response to the
last two sentences of Section 3.5 of the Agreement:

 

Under GAAP, the
Company is not obligated to record on the Company Financial Statements accruals associated with certain compensation approved by the Company
Board pursuant to the Management Carve-out Program that are contingent upon the consummation of the Transactions.

 

In addition to
the Management Carve-out Program, the Company Board has approved a transaction bonus in an aggregate amount equal to $699,900.00 payable
to certain employees contingent upon the consummation of the Transactions.

 

The Company purchased
a professional liability and cyber policy with an effective date of August 28, 2021; the policy was issued by Admiral Insurance Group
and the policy number is EO000055243-01. The premium for the policy was $79,000 and was paid in full on September 22, 2021. The policy
provides for a combination limit of $1,500,000 total and $1,500,000 per occurrence. The Company has also purchased secondary insurance
from Hudson Insurance Group for excess coverage for professional liability and cyber coverage in the amount of $2,000,000 with an effective
date of August 28, 2021.

 

    9 

     

    

 

 

Schedule
3.6

Material Contracts

(a) 

 

(i)

 

Material
Clients

 

		1.	Service
                                            Agreement, dated as of July 1, 2016, by and among AdvantEdge Healthcare Solutions, Inc. and
                                            Brevard Physician Associates, as amended by the Amendment thereto, dated as of March 16,
                                            2016 but effective as of July 1, 2016 (the “BPA Services Agreement”).

 

		2.	Service
                                            Agreement, dated as of January 1, 2015, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Anesthesia Group Practice, Inc., as amended by that certain First Amendment, dated as
                                            of November 2, 2017, that certain Second Amendment, dated as of June 1, 2018, that certain
                                            Third Amendment, dated as of June 1, 2019 and that certain Fourth Amendment, dated as of
                                            July 22, 2019.

 

		3.	Service
                                            Agreement, dated January 14, 2020, by and between Physician’s Service Center, Inc.
                                            d/b/a AdvantEdge Healthcare Solutions IL and Clinical Radiologists, S.C., as amended by the
                                            Amendment thereto, dated as of June 1, 2020.

 

		4.	Billing
                                            Services Agreement, dated as of November 1, 2000, by and between Physicians’ Service
                                            Center, Inc. and Midwest Diagnostic Pathology, S.C., as amended by that certain First Amendment,
                                            dated as of February 1, 2009 and that certain Second Amendment, dated as of January 1, 2014.

 

		5.	Service
                                            Bureau and License Agreement, dated as of July 1, 2005, by and between Frank Hill Associates,
                                            Inc., d/b/a Hill Associates Healthcare Management Systems and HRI Clinics, Inc. d/b/a Arbour
                                            Counseling Services

 

		6.	Business
                                            Associate Agreement, dated as of January 21, 2015, by and between AdvantEdge Healthcare Solutions
                                            and HRI Clinics Inc., d/b/a Arbour Counseling Services.

 

		7.	Service
                                            Agreement, dated as of March 17, 2008, by and between AMS Plus, Inc. and Emerson Practice
                                            Associates, as amended on October 20, 2010.

 

		8.	Business
                                            Associate Agreement, dated September 19, 2013, between Emerson Practice Associates and AdvantEdge
                                            Healthcare Solutions.

 

		9.	Service
                                            Agreement, dated as of October 1, 2019 by and between AdvantEdge Healthcare Solutions MA
                                            and Emerson Practice Associates, as amended by that certain First Amendment, dated as of
                                            September 1, 2020.

 

		10.	Service
                                            Bureau and License Agreement, dated as of May 5, 2011, by and between Frank Hill Associates
                                            (d/b/a Lahey), Inc. and Northeast Behavioral Health Corporation, as amended by that certain
                                            First Amendment, dated as of July 1, 2013 and that certain Second Amendment, dated as of
                                            December 1, 2018.

 

    10 

     

    

 

		11.	Service
                                            Agreement, dated as of December 28, 2016, by and between AdvantEdge Healthcare Solutions,
                                            Inc. and Anesthesiology Service Network LLC, as amended by that certain First Amendment,
                                            dated as of August 1, 2017 and that certain Second Amendment, dated as of March 1, 2019.

 

		12.	Service
                                            Agreement, dated as of July 1, 2018, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Clinical Colleagues, Inc.

 

		13.	Service
                                            Agreement, dated as of July 1, 2020, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Clinical Colleagues, Inc.

 

		14.	Service
                                            Agreement, dated as of July 1, 2020, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Clinical Colleagues (KS), PA.

 

		15.	Service
                                            Agreement, dated as of May 1, 2019, by and between and Professional Management, Inc., AdvantEdge
                                            Healthcare Solutions, Inc. and Doctors Emergency Service, P.A.

 

		16.	Service
                                            Agreement, dated as of February 1, 2010, by and between AdvantEdge Healthcare Solutions and
                                            Northwest Radiology Associates, S.C., as amended by that certain First Amendment dated January
                                            1, 2015 and that certain Second Amendment, dated as of March 1, 2017.

 

		17.	Service
                                            Agreement, dated as of July 27, 2017, by and between AdvantEdge Healthcare Solutions, Inc.,
                                            Bronx-Lebanon Hospital Center and The Martin Luther King Jr. Health Center, Inc., as amended
                                            January 1, 2021.

 

		18.	Contract
                                            Continuation Agreement, dated as of December 23, 2019, by and between Bronx- Lebanon Hospital
                                            Center and AdvantEdge Healthcare Solutions, Inc.

 

		19.	Service
                                            Agreement, dated as of March 27, 2018, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Linn County Anesthesiologists, P.C.

 

		20.	Service
                                            Agreement, dated as of April 1, 2013, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Hospital for Special Surgery, as amended by that certain Amendment, dated as of January
                                            1, 2014, that certain Addendum dated December 14, 2015 and that certain Amendment, dated
                                            as of January 1, 2018.

 

		21.	Service
                                            Agreement dated as of June 4, 2021 by and between AdvantEdge Healthcare Solutions, Inc. and
                                            Hospital for Special Surgery.

 

		22.	Service
                                            Agreement, dated as of March 1, 2015, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Eliot Community Human Services.

 

    11 

     

    

  

		23.	Service
                                            Agreement, dated as of April 1, 2019, by and between Physician’s Service Center, Inc.
                                            d/b/a AdvantEdge Healthcare Solutions IL and Consolidated Pathology Consultants, S.C.

 

		24.	Billing
                                            Services Agreement, dated as of January 31, 1992, by and between AMS Plus, Inc. (dba AdvantEdge
                                            Healthcare Solutions MA) and BIH Neurology Associates, Inc., as amended by that certain First
                                            Amendment, dated as of October 1, 2012 and that certain Second Amendment dated as of July
                                            1, 2018.

 

		25.	Management
                                            Services Agreement, dated as of October 30, 2006, by and between AdvantEdge Healthcare Solutions,
                                            Inc. (formerly Anodyne Health Partners, Inc.) and Livingston Pathology Associates, LLC, as
                                            amended by that certain Amendment thereto, dated March 1, 2015.

 

		26.	Business
                                            Associate Agreement, dated as of November 21, 2013, by and between AdvantEdge Healthcare
                                            Solutions and Livingston Pathology Associates, LLC.

 

		27.	Service
                                            Agreement, dated as of July 1, 2020, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and DMC Hospitalist, PC.

 

		28.	Services
                                            Agreement, July 17, 2018, by and between Johnson County Anesthesiologists, Chartered and
                                            the Company, as amended by that certain Addendum to that Certain Service Agreement, Employee
                                            Cost Sharing Agreement, dated October 1, 2018 and that certain Amendment #2 of Service Agreement,
                                            dated as of October 1, 2021.

 

		29.	Service
                                            Agreement, dated as of November 1, 2018, by and between the Company and Doctor’s Hospital,
                                            Inc.

 

		30.	Service
                                            Agreement, dated as of June 1, 2021, by and between Hospital Pathology Associates, P.A. and
                                            Physician’s Service Center, Inc. d/b/a AdvantEdge Healthcare Solutions IL.

 

		31.	Service
                                            Agreement, dated as of September 1, 2015, by and between DuPage Pathology Associates, S.C.
                                            and AdvantEdge Healthcare Solutions, Inc.

 

		32.	Service
                                            Agreement, dated as of July 1, 2016, by and between Mercy Medical Center and AdvantEdge Healthcare
                                            Solutions, Inc.

 

		33.	Service
                                            Agreement, dated as of December 18, 2009, by and between Arlington Ridge Pathology, S.C.
                                            and AdvantEdge Healthcare Solutions, Inc., as amended by that certain Amendment #1 of Service
                                            Agreement, dated as of December 29, 2016.

 

		34.	Service
                                            Agreement, dated as of October 1, 2013, by and between Diagnostic Pathology Consultants PA
                                            and AdvantEdge Healthcare Solutions, Inc.

 

		35.	Agreement,
                                            dated as of July 16, 2020, by and between the State University of New York and AdvantEdge
                                            Healthcare Solutions, Inc.

 

    12 

     

    

 

		36.	Service
                                            Agreement, dated as of July 1, 2018, by and between HCT Pathology Associates, LLC and AdvantEdge
                                            Healthcare Solutions MD.

 

		37.	Service
                                            Agreement, dated as of July 1, 2015, by and between Associated Pathologists, S.C. and AdvantEdge
                                            Healthcare Solutions, Inc.

 

		38.	Service
                                            Agreement, dated as of February 1, 2014, by and between Steward Medical Group, Inc. and AdvantEdge
                                            Healthcare Solutions MA.

 

		39.	Service
                                            Agreement, dated as of June 1, 2017, by and between Pathology Services of Springfield, P.C.
                                            and AdvantEdge Healthcare Solutions, Inc.

 

		40.	Service
                                            Agreement, dated as of October 1, 2014, by and between Towards Independent Living and Learning
                                            and AdvantEdge Healthcare Solutions, Inc.

 

		41.	Management
                                            Services Agreement, dated as of January 1, 2000, by and between Medical Account Services,
                                            Inc. and Lima Anesthesia Consultants, Inc.

 

		42.	Service
                                            Agreement, dated as of March 12, 2019, by and between Children’s Hospital Boston Radiology
                                            Foundation, Inc., and the Children’s Hospital Corporation, d/b/a Boston Children’s
                                            Hospital, and AdvantEdge Healthcare Solutions, Inc.

 

		43.	Service
                                            Agreement, dated as of September 21, 2016, by and between University Physicians of Brooklyn,
                                            Inc. and AdvantEdge Healthcare Solutions, Inc., as amended by that certain Amendment #1 of
                                            Service Agreement, dated January 17, 2017 and that certain Amendment #2 of Service Agreement,
                                            dated August 28, 2017.

 

		44.	Service
                                            Agreement, dated as of July 1, 2017, by and between McHenry Pathology Associates, S.C. and
                                            Physician’s Service Center, Inc. d/b/a AdvantEdge Healthcare Solutions IL.

 

		45.	Service
                                            Agreement, dated as of July 1, 2018, by and between Drs. Hicken, Cranley and Taylor, PA and
                                            AdvantEdge Healthcare Solutions MD.

 

		46.	Service
                                            Agreement, dated as of January 26, 2009, by and between Physicians’ Service Center,
                                            Inc. and Addison Central Pathology, S.C., as amended by that certain Amendment of Management
                                            Services Agreement, dated as of September 1, 2011, that certain Second Amendment of Management
                                            Services Agreement, dated as of August 1, 2013, and that certain Amendment #3 of Service
                                            Agreement, dated as of January 1, 2018.

 

		47.	Service
                                            Agreement, dated as of June 1, 2002, by and between Chesapeake Open MRI and Professional
                                            Management, Inc.

 

Material
Suppliers

 

		48.	Master
                                            Services Agreement, dated as of June 6, 2014, by and between Hexplora LLC and AdvantEdge
                                            Healthcare Solutions, Inc.

 

    13 

     

    

 

		49.	Business
                                            Associate Agreement, dated as of August 8, 2018, by and between Hexplora LLC and AdvantEdge
                                            Healthcare Solutions, Inc.

 

		50.	Confidentiality
                                            Agreement, dated as of June 5, 2016, by and between Hexplora LLC and AdvantEdge Healthcare
                                            Solutions, Inc.

 

		51.	Service
                                            Agreement, dated as of January February 8, 2013, by and between AdvantEdge Healthcare Solutions
                                            and Centron Data Services, Inc.

 

		52.	Master
                                            Services Agreement for Managed Services, dated as of November 17, 2017, by and between the
                                            Company and GeBBS Healthcare Solutions, Inc., Statement of Work #1 and Statement of Work
                                            #2 related thereto, that certain Amendment, dated as of September 18, 2019, and that certain
                                            Letter Agreement, dated as of May 29, 2020.

 

		53.	Master
                                            Services Agreement, dated as of November 10, 2018, by and between Connectria, LLC and AdvantEdge
                                            Healthcare Solutions, Inc.

 

		54.	Business
                                            Associate Agreement, dated as of November 8, 2018, by and between Connectria, LLC and AdvantEdge
                                            Healthcare Solutions, Inc.

 

		55.	Master
                                            Services and License Agreement, dated as of September 27, 2020, by and between Optum360 LLC
                                            and AdvantEdge Healthcare Solutions, as supplemented by the Professional Product Schedules,
                                            dated as of September 27, 2020.

 

		56.	Intellectual
                                            Property Agreement, dated as of August 23, 2017, by and between AdvantEdge Healthcare Solutions,
                                            Inc., Emeris Corp., Accur8 Software Development LLC and Salamander Inc.,

 

		57.	Consulting
                                            Agreement, dated as of August 23, 2017, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Accur8 Software Solutions, LLC.

 

		58.	Master
                                            Services Agreement, dated as of June 15, 2017, by and between Cologix US, Inc. and AdvantEdge
                                            Healthcare Solutions, Inc., as supplemented by that Colocation Services Schedule, dated as
                                            of June 15, 2017, that Network Services Schedule, dated as of June 15, 2017.

 

		59.	Third
                                            Party Vendor Agreement, dated as of June 28, 2007, by and between Medifax-EDI, LLC and AMSplus.

 

		60.	Master
                                            Services Agreement, dated as of July 30, 2020, by and between Comcast Enterprise Services
                                            and AdvantEdge Healthcare Solutions, Inc.

 

		61.	Service
                                            Order Agreement, dated as of July 30, 2020, by and between Comcast Enterprise Services and
                                            AdvantEdge Healthcare Solutions, Inc.

 

		62.	Business
                                            Services Customer Terms and Conditions, dated as of July 30, 2020, by and between Comcast
                                            Enterprise Services and AdvantEdge Healthcare Solutions, Inc.

 

    14 

     

    

 

		63.	Premium
                                            Finance Agreement, dated as of February 9, 2021, by and between IPFS Corporation and the
                                            Company.

 

		64.	Premium
                                            Finance Agreement, dated as of August 5, 2020, by and between IPFS Corporation and the Company.

 

		65.	Certify
                                            ACH Processing Agreement, dated as of November 21, 2015, by and between Certify, Inc. and
                                            AHS Services, Inc.

 

		66.	Customer
                                            Consent Letter, undated, by and between Certify, Inc. and AdvantEdge Healthcare Solutions,
                                            Inc.

 

		67.	Pricing
                                            Proposal, dated as of December 1, 2014, by and between Certify, Inc. and AdvantEdge Healthcare
                                            Solutions, Inc., as amended by that certain Addendum A to Pricing Proposal, dated as of September
                                            12, 2019. The original Pricing Proposal has not been made available to Parent.

 

		68.	Engagement
                                            Letter, dated as of November 9, 2020, by and between the Company and UHY LLP.

 

		69.	Letter
                                            Agreement, dated as of July 22, 2009, by and between Falcon Capital Partners, LLC.

 

(ii)

 

		1.	Amended
                                            and Restated Employment Agreement, dated as of January 1, 2011, by and between the Company
                                            and David Howard Langsam.

 

		2.	Amended
                                            and Restated Employment Agreement, dated as of January 17, 2011, by and between the Company
                                            and J. Paul O’Haro.

 

		3.	Employment
                                            Agreement, dated as of September 1, 2015, by and between the Company and Terence P. Halloran.

 

		4.	Employment
                                            Agreement, dated as of April 3, 2006, by and between the Company and Jeanne Gilreath.

 

		5.	Employment
                                            Agreement, dated as of August 26, 2013, by and between the Company and Raymond Cassidy.

 

		6.	Employment
                                            Agreement, dated as of June 15, 2009, by and between the Company and Patricia Kagebein.

 

		7.	Employment
                                            Agreement, dated as of January 1, 2014 and amended February 16, 2016 by and between the Company
                                            and Brice Voithofer.

 

		8.	Employment
                                            Agreement, dated as of March 4, 2010, by and between the Company and Steven Macrea.

 

    15 

     

    

  

		9.	Employment
                                            Agreement, dated as of December 15, 2017, by and between Professional Management, Inc. and
                                            Scott Finson.

 

		10.	Employment
                                            Agreement, dated as of December 15, 2017, by and between Professional Management, Inc. and
                                            Stephanie Reynolds.

 

		11.	Employment
                                            Agreement, dated as of December 15, 2017, by and between Professional Management, Inc. and
                                            David Nicholson.

 

(iii)

 

(A)

 

		1.	The
                                            530 22nd Street Lease
	 	 	 

		2.	Lease
                                            Agreement, dated as of August 19, 2013, by and between EIP Northeastern Boulevard LLC and
                                            AdvantEdge Healthcare Solutions, Inc., as amended by that certain First Amendment to Lease,
                                            dated as of March 1, 2014.

 

		3.	Agreement
                                            of Lease, dated as of September 19, 2018, by and between FDS Franklin 9920, LLC, as landlord,
                                            and Professional Management, Inc., as tenant.

 

		4.	Lease
                                            Agreement, dated as of September 3, 2015, by and between Ground Spring LLC and AdvantEdge
                                            Healthcare Solutions, Inc., as amended by that certain Addendum, dated April 6, 2017 and
                                            that certain Addendum Extension, dated March 25, 2019.

 

		5.	Lease,
                                            dated July 8, 2016, by and between Thomas More/Hemmer IV, Ltd. And AdvantEdge Healthcare
                                            Solutions, Inc.

 

		6.	Lease
                                            Commencement Date Agreement, dated as of October 3, 2016, by and between Thomas More/Hemmer
                                            IV, Ltd. and AdvantEdge Healthcare Solutions, Inc.

 

		7.	Lease
                                            Agreement, dated as of August 4, 2006, by and between MBCC 30, LLC and AdvantEdge Healthcare
                                            Solutions, Inc., as amended as amended by that certain First Amendment to Lease Agreement
                                            dated May 3, 2007, that certain Second Amendment to Lease Agreement dated February 29, 2012,
                                            that certain Third Amendment to Lease Agreement dated May 23, 2013, that certain Fourth Amendment
                                            to Lease Agreement dated December 18, 2014, that certain Fifth Amendment to Lease Agreement
                                            dated November 30, 2016, and that certain Sixth Amendment to Lease Agreement, dated October
                                            15, 2018, and that certain Seventh Amendment of Lease Agreement, dated as of March 9, 2021.

 

		8.	Lease
                                            dated as of January 21, 2004, as amended by that certain First Amendment and Supplement to
                                            Lease dated as of June 15, 2009, that certain Second Lease Amendment and Supplement to Lease
                                            dated as of March 10, 2011, that certain Third Amendment and Supplement to Lease dated as
                                            of November 12, 2013, and that certain Fourth Amendment and Supplement to Lease dated as
                                            of November 16, 2016, by and among Increase Your Profit, LLC and AdvantEdge Healthcare Solutions,
                                            Inc.

 

    16 

     

    

 

		9.	Lease
                                            Deed, dated as of September 18, 2019, by and between Mr. H.E. Abdulla Sait, Mrs. Ayesha Bai,
                                            Mrs. Nawsheen Mohammed Naveed, Mrs. Shameela Najeeb, Mrs. Fahra Nasser, Mrs. Tabassum Sajad,
                                            Hudna Yakub, Mohamed Ameen, and AdvantEdge Healthcare Solutions Private Limited.

 

		10.	Lease
                                            Deed, dated as of September 18, 2019, by and between Mrs. Shakera Riyaz, Mrs. Almas M. Nenset,
                                            Mr. Abdul Samad Motiwala, Mr. Ebraheem Motiwala, Mr. Abdul Ahad Motiwala, Mr. Mohd Shafee
                                            Motiwala, Mrs. Almas Farid Ali, Mrs. H. Kavitha and AdvantEdge Healthcare Solutions Private
                                            Limited.

 

		11.	Office
                                            Building Lease, dated as of September 27, 2010, by and between ICV Dayton, LLC and AdvantEdge
                                            Healthcare Solutions, Inc., as amended by that certain First Amendment to Lease, dated as
                                            of November 15, 2010, that certain Second Amendment to Lease, dated as of February 1, 2011,
                                            that certain Third Amendment to Lease, dated September 30, 2011, that certain Fourth Amendment
                                            to Lease, dated as of November 14, 2012, that certain Fifth Amendment to Lease, dated as
                                            of February 27, 2013, that certain Sixth Amendment to Lease, dated of February 26, 2015.

 

		12.	Maine
                                            Commercial Lease Agreement, dated as of February 19, 2020, by and between FNT, LLC and AdvantEdge
                                            Healthcare Solutions MA.

 

		13.	Commercial
                                            Lease Agreement, dated as of August 27, 2019, by and between Terrance J. Farmer, Sandra M.
                                            Farmer, and Professional Business Services of Central Illinois, Inc.

 

		14.	Assignment
                                            of Commercial Lease Agreement, dated as of October 29, 2020, by and between Professional
                                            Business Services of Central Illinois, Inc., AdvantEdge Healthcare Solutions, Inc., Terrance
                                            Farmer and Sandra Farmer.

 

		15.	Service
                                            License Agreement, dated as of March 14, 2014, by and between Town Center Executive Suites
                                            and AdvantEdge Healthcare Solutions, Inc.

 

		16.	Monthly
                                            Rental Agreement, dated as of September 20, 2018, by and between Highland LLC and AdvantEdge
                                            Healthcare Solutions.

 

		17.	Amending
                                            the Office Building Lease, dated as of September 27, 2020, as amended by the First Amendment
                                            dated November 15, 2010, the Second Amendment dated February 1, 2011, the Third Amendment
                                            dated September 30, 2011, the Fourth Amendment dated November 2012, the Fifth Amendment dated
                                            February 27, 2013, and the Sixth Amendment to Lease dated February 26, 2015, by and between
                                            AdvantEdge Healthcare Solutions, Inc., and 3131 Dixie Drive, LLC.

 

(B)

 

		1.	Agreement
                                            to Lease Equipment, dated as of September 30, 2020, by and between AdvantEdge Healthcare
                                            Solutions Private Limited and Smart Solutions.

 

    17 

     

    

 

(iv)

 

		1.	Intellectual
                                            Property Agreement, dated as of August 23, 2017, by and between AdvantEdge Healthcare Solutions,
                                            Inc., Emeris Corp., Accur8 Software Development LLC and Salamander Inc.,

 

		2.	Master
                                            Services Agreement, dated as of June 6, 2014, by and between AdvantEdge Healthcare Solutions,
                                            Inc. and Hexplora, LLC.

 

		3.	Master
                                            Services and License Agreement, dated as of September 27, 2020, by and between Optum360 LLC
                                            and AdvantEdge Healthcare Solutions, as supplemented by the Professional Product Schedules,
                                            dated as of September 27, 2020.

 

(v)

 

None.

 

(vi)

 

None.

 

(vii)

 

(A)

 

		1.	Master
                                            Services and License Agreement, dated as of September 27, 2020, by and between Optum360 LLC
                                            and AdvantEdge Healthcare Solutions, as supplemented by the Professional Product Schedules,
                                            dated as of September 27, 2020.

 

		2.	Channel
                                            Partner Agreement, dated as of December 29, 2020, by and between AdvantEdge Healthcare Solutions
                                            and RevSpring, Inc.

 

(B)

 

		1.	Approximately
                                            220 customers have executed the Company’s template services agreement, which template
                                            includes a non-solicitation provision.

 

		2.	The
                                            template services agreement provides that AdvantEdge Healthcare Solutions will be the exclusive
                                            provider of the base services provided under the service agreement.

 

		3.	Master
                                            Services Agreement for Managed Services, dated as of November 17, 2017, by and between the
                                            Company and GeBBS Healthcare Solutions, Inc., Statement of Work #1 and Statement of Work
                                            #2 related thereto, that certain Amendment, dated as of September 18, 2019, and that certain
                                            Letter Agreement, dated as of May 29, 2020.

 

		4.	Intellectual
                                            Property Agreement, dated as of August 23, 2017, by and between AdvantEdge Healthcare Solutions,
                                            Inc., Emeris Corp., Accur8 Software Development LLC and Salamander Inc.,

 

    18 

     

    

 

		5.	Intellectual
                                            Property Purchase Agreement, dated August 6, 2020, by and between the Company and eHana,
                                            LLC.

 

		6.	Services
                                            Agreement, dated January 31, 2014, by and between AdvantEdge Healthcare Solutions, Inc. and
                                            Paradigm Technology Consulting, LLC.

 

		7.	Outsourcer
                                            Access Agreement, dated April 28, 2016, by and among AdvantEdge Healthcare Solutions, Inc.,
                                            AdvantEdge Healthcare Solutions Pvt Ltd., and Epic Systems Corporation.

 

		8.	Connectria
                                            Master Services Agreement, dated November 10, 2018, by and between AdvantEdge Healthcare
                                            Solutions, Inc. and Connectria, LLC.

 

		9.	Consulting
                                            Agreement, dated as of June 12, 2018, by and between AdvantEdge Healthcare Solutions, Inc.
                                            and Southcare Billing, Inc.

 

		10.	Consulting
                                            Agreement, dated as of October 4, 2020, by and between the Company and CVM, Inc.

 

		11.	Service
                                            Agreement, dated as of December 18, 2009, by and between Arlington Ridge Pathology, S.C.
                                            and AdvantEdge Healthcare Solutions, Inc., as amended by that certain Amendment #1 of Service
                                            Agreement, dated as of December 29, 2016.

 

		12.	Management
                                            Services Agreement, dated as of January 1, 2000, by and between Medical Account Services
                                            and Lima Anesthesia Consultants, Inc.

 

		13.	Consulting
                                            Agreement, dated as of August 23, 2017, by and between Accur8 and AdvantEdge Healthcare Solutions,
                                            Inc.

 

		14.	Service
                                            Agreement, dated as of June 1, 2002, by and between Chesapeake Open MRI and Professional
                                            Management, Inc.

 

		15.	Business
                                            Associate Addendum, dated as of May 1, 2014, by and between Chesapeake Medical Imaging and
                                            Professional Management, Inc.

 

		16.	Service
                                            Agreement, dated as of March 17, 2008, by and between AMS Plus, Inc. and Emerson Practice
                                            Associates, as amended on October 20, 2010.

 

		17.	Billing
                                            Services Agreement, dated as of November 1, 2000, by and between Physicians’ Service
                                            Center, Inc. and Midwest Diagnostic Pathology, S.C., as amended by that certain First Amendment,
                                            dated as of February 1, 2009 and that certain Second Amendment, dated as of January 1, 2014.

 

		18.	Management
                                            Services Agreement, dated as of September 9, 2008, by and between AMSPlus and Anesthetic
                                            Solutions, P.C., as amended by that certain Amendment of Management Services Agreement, dated
                                            as of February 1, 2015.

 

    19 

     

    

 

		19.	Service
                                            Bureau and License Agreement, dated as of September 22, 2005, by and between Frank Hill Associates,
                                            Inc., d/b/a Hill Associates Healthcare Management Systems and HRI Clinics, Inc. d/b/a Arbour
                                            Counseling Services.

 

		20.	Agreement,
                                            dated as of April 1, 2011, by and between AdvantEdge Healthcare Solutions MA, Inc. and Advantage
                                            Imaging Solutions, LLC.

 

		21.	Agreement,
                                            dated as of April 1, 2011, by and between Advantage Imaging Solutions, LLC and AHS MA.

 

		22.	Service
                                            Agreement, dated as of February 1, 2006, by and between Physicians’ Service Center,
                                            Inc. and 4Path, Ltd.

 

(c)

 

		1.	Management
                                            Services Agreement, dated as of January 1, 2000, by and between Medical Account Services,
                                            Inc. and Lima Anesthesia Consultants, Inc.

 

(viii)

 

		1.	Intellectual
                                            Property Purchase Agreement, dated August 6, 2020, by and between the Company and eHana,
                                            LLC.

 

(ix)

 

		1.	Stockholders’
                                            Agreement.

 

		2.	Registration
                                            Rights Agreement, dated as of April 3, 2006, by and between the Company, Founders Equity
                                            SBIC I, L.P., Founders Equity NY, LP, and Safeguard Delaware, Inc.

 

		3.	Amendment
                                            to Amended and Restated Registration Rights Agreement, dated as of December 29, 2010, by
                                            and among the Company, Founders Equity SBIC I, L.P., Founders Equity NY L.P., and Safeguard
                                            Delaware, Inc.

 

		4.	Joinder
                                            to Amended and Restated Registration Rights Agreement, dated as of November 16, 2006, by
                                            and among the Company, Founders Equity I, L.P., Founders Equity NY L.P., and Safeguard Delaware
                                            II, Inc.

 

		5.	Correspondence
                                            re AHS Board of Directors, dated as of July 19, 2020, by and between the Company and Dr.
                                            David Barrett, M.D.

 

		6.	Letter
                                            Agreement, dated as of January 15, 2018, by and between the Company and Mr. Michael Montemarano.

 

		7.	Agreement,
                                            dated as of July 19, 2010, by and between the Company and David Barrett.

 

		8.	Senior
                                            Subordinated Loan Agreement, dated as of July 14, 2017, by and among the Company, Founders
                                            Equity I, L.P., and Founders Equity NY L.P.

 

    20 

     

    

  

		9.	Subordinated
                                            Loan Agreement, dated as of March 6, 2015, by and among the Company, Founders Equity I, L.P.,
                                            Founders Equity NY L.P. and Founders HW LLC, as amended by that certain First Amendment to
                                            Subordinated Loan Agreement, dated as of July 14, 2017.

 

		10.	Subordination
                                            Agreement, dated as of July 3, 2018, by and among the Company, Founders Equity I, L.P, Founders
                                            Equity NY L.P., Founders HW LLC, and Elm Park Capital Management, LLC.

 

		11.	Senior
                                            Subordinated Promissory Note, dated as of July 14, 2017, by and between the Company and Founders
                                            Equity I, L.P.

 

		12.	Senior
                                            Subordinated Promissory Note, dated as of July 14, 2017, by and between the Company and Founders
                                            Equity NY L.P.

 

		13.	Subordinated
                                            Promissory Note, dated as of July 3, 2018, by and between the Company and Founders Equity
                                            I, L.P.

 

		14.	Subordinated
                                            Promissory Note, dated as of July 3, 2018, by and between the Company and Founders Equity
                                            NY L.P.

 

		15.	Subordinated
                                            Promissory Note, dated as of July 3, 2018, by and between the Company and Founders HW LLC.

 

		16.	Subordinated
                                            Promissory Note, dated as of March 6, 2015, by and between the Company and Founders Equity
                                            NY L.P.

 

		17.	Subordinated
                                            Promissory Note, dated as of March 6, 2015, by and between the Company and Founders Equity
                                            SBIC I, L.P.

 

		18.	Amended
                                            and Restated Management Services Agreement, dated as of December 31, 2015, by and between
                                            FEF Management LLC and the Company.

 

		19.	Management
                                            Fee Subordination Agreement, dated as of July 14, 2017, by and among FEF Management LLC,
                                            the Company and Elm Park Capital Management, LLC.

 

(x)

 

		1.	Management
                                            Services Agreement., dated as of March 1, 2012 by and between AdvantEdge Healthcare Solutions
                                            and AdvantEdge Healthcare Private Limited, as amended by that certain Amending Agreement,
                                            dated as of March 1, 2015.

 

(xi)

 

		1.	Credit
                                            Agreement, dated as of July 14, 2017, by and among the Company, the Company’s Subsidiaries,
                                            Elm Park Credit Opportunities Funds II, L.P. and Elm Park Credit Opportunities Funds II (Canada),
                                            L.P.

 

    21 

     

    

 

		2.	Subordination
                                            Agreement, dated as of July 3, 2018, by and among the Company, Founders Equity I, L.P, Founders
                                            HW LLC, and Elm Park Capital Management, LLC.

 

		3.	Senior
                                            Subordinated Promissory Note, dated as of July 14, 2017, by and between the Company and Founders
                                            Equity I, L.P.

 

		4.	Senior
                                            Subordinated Promissory Note, dated as of July 14, 2017, by and between the Company and Founders
                                            Equity NY L.P.

 

		5.	Subordinated
                                            Promissory Note, dated as of July 3, 2018, by and between the Company and Founders Equity
                                            I, L.P.

 

		6.	Subordinated
                                            Promissory Note, dated as of July 3, 2018, by and between the Company and Founders Equity
                                            NY L.P.

 

		7.	Subordinated
                                            Promissory Note, dated as of July 3, 2018, by and between the Company and Founders HW LLC.

 

		8.	Subordinated
                                            Promissory Note, dated as of March 6, 2015, by and between the Company and Founders Equity
                                            NY L.P.

 

		9.	Subordinated
                                            Promissory Note, dated as of March 6, 2015, by and between the Company and Founders Equity
                                            SBIC I, L.P.

 

		10.	Securities
                                            Sale Agreement, dated as of June 21, 2018, by and among Safeguard Delaware II, Inc., Founders
                                            Equity I, L.P., Founders Equity NY L.P., and Founders HW LLC.

 

		11.	Limited
                                            Waiver to Credit Agreement, dated as of September 28, 2020, by and between the Company, AdvantEdge
                                            Healthcare Solutions, Inc. and Elm Park Capital Management, LLC.

 

Each
of the Contracts listed on Schedule 3.6(a)(xi) of this Disclosure Schedule will be terminated upon the Closing of the Transactions contemplated
by the Agreement.

 

(xii)

 

None.

 

(xiii)

 

Arrangement
with United Healthcare Systems to provide group health insurance coverage.

 

(xiv)

 

None.

 

(xv)

 

Management
Services Agreement, dated as of March 1, 2012, by and between the Company and AdvantEdge Healthcare Private Limited, as amended by that
certain Amending Agreement, dated as of March 1, 2015.

 

    22 

     

    

 

(b)

 

The
following disclosures are in response to the third sentence of Section 3.6(b) of the Agreement:

 

		1.	On
                                            July 31, 2020, Oak Street notified the Company that Oak Street would not renew that certain
                                            Services Agreement, dated as of September 9, 2015, by and between the Company and Oak Street.
                                            The effective date of such termination is October 31, 2020.

 

		2.	On
                                            November 6, 2020, Respiratory Specialists notified the Company that Respiratory Specialists
                                            would not renew that certain Service Agreement, dated as of December 6, 2017, by and between
                                            the Company and Respiratory Specialist. The effective date of such termination is January
                                            21, 2021.

 

		3.	On
                                            June 5, 2021, Doctors Hospital, Inc. notified the Company that Doctor’s Hospital, Inc.
                                            would not renew that certain Service Agreement, dated as of November 1, 2018, by and between
                                            the Company and Doctor’s Hospital, Inc. The effective date of such termination is June
                                            30, 2021.

 

		4.	On
                                            October 2, 2020, Steward Medical Group, Inc. notified AdvantEdge Healthcare Solutions MA
                                            of its intent to terminate the Service Agreement, dated February 1, 2014. The effective date
                                            of such termination is January 1, 2021.

 

		5.	On
                                            November 13, 2020, New England Baptist Hospital notified AdvantEdge Healthcare Solutions,
                                            Inc. of its intent to terminate the Service Agreement, dated March 21, 2014. The effective
                                            date of such termination is March 21, 2021.

 

    23 

     

    

 

Schedule
3.7

Absence of Changes

 

(a)

 

None.

 

(b)

 

None. 

 

(c)

 

None.

  

(d)

 

None. 

 

(e)

 

None.

 

(f)

 

None. 

 

(g)

 

None.

 

    24 

     

    

  

(h)

 

		1.	On
                                            July 31, 2020, Oak Street notified the Company that Oak Street would not renew that certain
                                            Services Agreement, dated as of September 9, 2015, by and between the Company and Oak Street.
                                            The effective date of such termination is October 31, 2020.

 

		2.	On
                                            November 6, 2020, Respiratory Specialists notified the Company that Respiratory Specialists
                                            would not renew that certain Service Agreement, dated as of December 6, 2017, by and between
                                            the Company and Respiratory Specialist. The effective date of such termination is January
                                            21, 2021.

 

		3.	On
                                            June 5, 2021, Doctors Hospital, Inc. notified the Company that Doctor’s Hospital, Inc.
                                            would not renew that certain Service Agreement, dated as of November 1, 2018, by and between
                                            the Company and Doctor’s Hospital, Inc. The effective date of such termination is June
                                            30, 2021.

 

		4.	On
                                            October 2, 2020, Steward Medical Group, Inc. notified AdvantEdge Healthcare Solutions MA
                                            of its intent to terminate the Service Agreement, dated February 1, 2014. The effective date
                                            of such termination is January 1, 2021.

 

		5.	On
                                            November 13, 2020, New England Baptist Hospital notified AdvantEdge Healthcare Solutions,
                                            Inc. of its intent to terminate the Service Agreement, dated March 21, 2014. The effective
                                            date of such termination is March 21, 2021.

 

		6.	Amendment
                                            #2 of Service Agreement, dated as of October 1, 2021, by and between Johnson County Anesthesiologists,
                                            Chartered and the Company, to that certain Services Agreement, July 17, 2018, by and between
                                            Johnson County Anesthesiologists, Chartered and the Company, as amended by that certain Addendum
                                            to that Certain Service Agreement, Employee Cost Sharing Agreement, dated October 1, 2018.

 

		7.	The
                                            Company has offered Anesthesiologist Service Network, LLC (“ASN”)
                                            a fee concession in light of ASN’s growth, growth plans, and in consideration of a
                                            contract extension. The Company’s current agreement with ASN runs through March 2023.
                                            However, if ASN elects to renew its agreement with the Company between August 28, 2021 and
                                            December 31, 2021, the Company’s fee under the agreement will be reduced to 3.35% of
                                            Net Collections beginning the month following ASN’s notice of its intent to renew and
                                            continuing for a two-year period thereafter. ASN has not yet elected to adopt the concession.

 

(i)

 

None.

 

(j)

 

None.

 

    25 

     

    

 

(k)

 

None.

 

(l)

 

None.

 

(m)

 

None.

 

(n)

 

None.

 

(o)

 

None.

 

    26 

     

    

 

Schedule
3.8 

Litigation

 

		1.	Barbara
                                            Engel, a former employee of the Company in Lombard, Illinois, was laid off on December 31,
                                            2020, in connection with a reduction in force. The Company offered Ms. Engel a severance
                                            package in exchange for a general release of claims. Ms. Engel declined the severance package
                                            and asserted that she was terminated on the basis of her age and not paid for statutory interest
                                            on PTO which Ms. Engel earned prior to the Company’s stock purchase of her former employer
                                            in 2009 and which the Company banked after the transaction and paid out at termination. She
                                            has further asserted that she believes she could bring a class action lawsuit against the
                                            Company on behalf of similarly situated former employees of the Company relating to the statutory
                                            interest claim. To date, the Company has not received a formal wage claim or complaint from
                                            or on behalf of Ms. Engel and has not otherwise resolved the matter. The individual wage
                                            claim for Ms. Engel is approximately $10,000.

 

		2.	On
                                            February 26, 2021, Rebecca Dean communicated her intention to resign when provided with a
                                            poor performance review. When HR contacted her to discuss her resignation, Ms. Dean alleged
                                            that the poor performance review was in retaliation for a claim she allegedly made in September
                                            2020 to her supervisor and/or the Company’s compliance officer alleging that the Company
                                            was engaged in false billing. A search of Ms. Dean’s emails revealed that she sent
                                            dozens of Company-related emails/documents to her personal email account, including client
                                            billing information and client contact information, among other confidential information,
                                            in violation of Company policy. No sensitive information, including information covered by
                                            any data protection Laws or Health Care Information Laws, was included in these emails/documents.
                                            None of these emails/documents were disclosed beyond Ms. Dean’s personal email account
                                            and were deleted from such account without any further misuse of any information contained
                                            therein. As a result of this policy violation, on March 2, 2021, the Company terminated Ms.
                                            Dean. The Company’s compliance office investigated Ms. Dean’s allegation of false
                                            billing and determined that it had no merit. It is possible that Ms. Dean will bring a wrongful
                                            termination claim against the Company, as well as a claim against the Company under the False
                                            Claims Act. The Company is confident that there is no merit to the allegations of false claims
                                            and thus nothing to remedy or pay. Given Ms. Dean’s admission to violating the Company’s
                                            policy, any wrongful termination claim is unlikely to succeed. Thus, the Company’s
                                            attorneys’ fees are the primary potential liability for any claim by Ms. Dean.

 

		3.	On
                                            March 2, 2021, the Company received a letter from attorneys representing Community Services
                                            Institute, Inc. (“CSI”), a customer of the Company, alleging that
                                            CSI had suffered a substantial loss in income since December 2020 that was “directly
                                            attributable” to a backlog of claims the Company had failed to process on CSI’s
                                            behalf. The Company has continued corresponding with CSI regarding this matter since receipt
                                            of the letter and has corrected the associated technical issues that created the backlog
                                            of these claims. As of the date hereof, the Company has completed the billing backlog, is
                                            up to date on the billing for CSI and made certain software fixes to the interface engine
                                            and the platform.

 

    27 

     

    

 

Schedule
3.9

Compliance with Applicable Law

 

None.

 

    28 

     

    

 

Schedule
3.10

Employment Plans

 

(a)

 

		1.	AdvantEdge
                                            Healthcare Solutions Health and Welfare Plan

 

		2.	AHH,
                                            Inc. 401(k) Plan.

 

		3.	AdvantEdge
                                            Healthcare Holdings, Inc. Omnibus Stock Incentive Plan.

 

		4.	AdvantEdge
                                            Healthcare Holdings, Inc. Management Carve-out Program.

 

		5.	Management
                                            Carve-out Program Participation Letter Agreements by and between AdvantEdge Healthcare Holdings,
                                            Inc. and:

 

		o	David
                                            Langsam
	 	 	 

		o	J.
                                            Paul O’Haro
	 	 	 

		o	Terence
                                            Halloran
	 	 	 

		o	Jeanne
                                            Gilreath
	 	 	 

		o	Raymond
                                            Cassidy
	 	 	 

		o	Henry
                                            Choi
	 	 	 

		o	Paulo
                                            DaSilva
	 	 	 

		o	Brice
                                            Voithofer
	 	 	 

		o	Sean
                                            Munster
	 	 	 

		o	Michael
                                            Hopkins
	 	 	 

		o	Barbara
                                            Lewis
	 	 	 

		o	Liddy
                                            Wilson
	 	 	 

		o	Lyne
                                            Green
	 	 	 

		o	Marie
                                            Franklin
	 	 	 

		o	Laurie
                                            Krachenfels
	 	 	 

		o	Rick
                                            Brozovic
	 	 	 
		o	David
                                            Barrett

 

    29 

     

    

 

		6.	Employment
                                            Agreement by and between AdvantEdge Healthcare Holdings, Inc. and J. Paul O’Haro, dated
                                            January 17, 2011.

 

		7.	Employment
                                            Agreement by and between AdvantEdge Healthcare Holdings, Inc. and Jeanne Gilreath, dated
                                            as of April 3, 2006.

 

		8.	Employment
                                            Agreement by and between AdvantEdge Healthcare Holdings, Inc. and Raymond Cassidy, dated
                                            as of August 26, 2013.

 

		9.	Employment
                                            Agreement by and between AdvantEdge Healthcare Holdings, Inc. and Terence Halloran, dated
                                            as of September 1, 2015.

 

		10.	Amended
                                            and Restated Employment Agreement by and between AdvantEdge Healthcare Holdings, Inc. and
                                            David Howard Langsam, dated as of January 1, 2011.

 

		11.	Employment
                                            Agreement, dated as of June 15, 2009, by and between the Company and Patricia Kagebein.

 

		12.	Employment
                                            Agreement, dated as of January 1, 2014 and amended February 16, 2016 by and between the Company
                                            and Brice Voithofer.

 

		13.	Employment
                                            Agreement, dated as of March 4, 2010, by and between the Company and Steven Macrea.

 

		14.	Employment
                                            Agreement, dated as of December 15, 2017, by and between Professional Management, Inc. and
                                            Scott Finson.

 

		15.	Employment
                                            Agreement, dated as of December 15, 2017, by and between Professional Management, Inc. and
                                            Stephanie Reynolds.

 

		16.	Employment
                                            Agreement, dated as of December 15, 2017, and amended from time to time as to compensation
                                            and duties, by and between Professional Management, Inc. and David Nicholson.

 

		17.	United
                                            Healthcare Choice Plus Plan.

 

		18.	AdvantEdge
                                            High Deductible Health Plan with Health Savings Account.

 

		19.	Hospital
                                            Indemnity Plan.

 

		20.	Aetna
                                            Dental Preferred Provider Organization Plan.

 

		21.	Aetna
                                            Dental Maintenance Organization.

 

		22.	EyeMed
                                            Vision Care Benefits.

 

		23.	Life
                                            and AD&D Benefits.

 

    30 

     

    

  

		24.	Short-Term
                                            and Long- Term Disability Plan.

 

		25.	Flexible
                                            Spending Accounts.

 

		26.	Health
                                            Spending Accounts.

 

		27.	Health
                                            Advocate Benefits.

 

		28.	Sales
                                            Commission Plan

 

		29.	Vacation,
                                            personal, sick, and holiday time off.

 

(b)

 

None.

 

(c)

 
None.

 

(d)

 

None.

 

(e)

 

None.

 

(f)

 
None.

 

(g)

 

(i)

 

		1.	Payments
                                            under the Management Carve-out Program.

 

    31 

     

    

 

		2.	In
                                            addition to the Management Carve-out Program, the Company’s Board of Directors has
                                            approved a transaction bonus for certain employees in an aggregate amount equal to $699,900.00.
                                            The Company Board has authorized the officers of the Company to allocate the bonus as follows:

 

	Transaction Bonus
    Participants	 	Bonus Amount	 
	David Langsam	 	$	156,400.00	 
	J. Paul O'Haro	 	$	100,500.00	 
	Terence Halloran	 	$	94,000.00	 
	Jeanne Gilreath	 	$	34,100.00	 
	Maureen Albano	 	$	1,000.00	 
	Robert Boyce	 	$	5,000.00	 
	Raymond Cassidy	 	$	15,000.00	 
	Henry Choi	 	$	2,500.00	 
	Paulo DaSilva	 	$	18,500.00	 
	Steven Macrea	 	$	1,500.00	 
	Tina Pelletier	 	$	7,500.00	 
	Sunil Christopher	 	$	70,000.00	 
	Janice Kelleher	 	$	1,600.00	 
	Sean Munster	 	$	14,350.00	 
	Hopkins, Michael	 	$	20,000.00	 
	Lewis, Barbara	 	$	23,000.00	 
	Wilson, Liddy	 	$	15,000.00	 
	Green, Lyne	 	$	15,000.00	 
	Franklin, Marie	 	$	15,000.00	 
	Krachenfels, Laurie	 	$	15,000.00	 
	Brozovic, Rick	 	$	7,500.00	 
	Finson, Scott	 	$	7,500.00	 
	Kagebein, Patricia	 	$	15,000.00	 
	Reynolds, Stephanie	 	$	7,500.00	 
	Laden, Joe	 	$	5,000.00	 
	Rowe, Nicole	 	$	1,000.00	 
	Budgett, Alisha	 	$	2,000.00	 
	Carsoni, Susan	 	$	4,000.00	 

 

    32 

     

    

 

	Johns, Ryan	 	$	500.00	 
	McKallagat, Shelagh	 	$	2,000.00	 
	Sumara, Marek	 	$	500.00	 
	Laughlin, Jessica	 	$	2,000.00	 
	Bertuca, Nicole	 	$	500.00	 
	Collins, Veronica	 	$	500.00	 
	Perry, Jennifer	 	$	2,000.00	 
	Bouzakine, Alexander	 	$	750.00	 
	Cruz, Crispin	 	$	750.00	 
	Dolitskay, Galina	 	$	750.00	 
	Horine, Lorraine	 	$	1,000.00	 
	Kidd, Stephanie	 	$	1,250.00	 
	Koneieczna, Anna	 	$	3,000.00	 
	McDougall, Blaise	 	$	750.00	 
	Plante, Deborah	 	$	500.00	 
	Reed, Diedre	 	$	500.00	 
	Shriver, Daniel	 	$	1,200.00	 
	Sierak, Dorota	 	$	1,200.00	 
	Stine, Dennis	 	$	1,800.00	 
	Morowski, Mary	 	$	2,000.00	 
	Connelly, Gail	 	$	2,000.00	 

 

(ii)

 

Items
(1) and (2) set forth in Schedule 3.10(g)(i) are incorporated by reference herein.

 

(iii)

 

None.

 

    33 

     

    

 

Schedule
3.11

Environmental Matters

 

(a)

 

(i)

 

None.

 

(ii)

 

None.

 

(iii)

 

None.

 

(iv)

 

None.

 

    34 

     

    

 

Schedule
3.12

Intellectual Property

 

(a)

 

None.

 

(b)

 

(i)

 

None.

 

(ii)

 

	Copyright
    Title	Reg.
    No. / Date	Owner	Status
	PROFESSIONAL
    BILLING SYSTEM/LEGAL.	TX0002896516

    19900820
	Professional

    Management,
    Inc.
	Registered
	THE
                                            MEDEXPERT MEDICAL GROUP, INC. MONTHLY

    MOCK-UP
    REPORTS, AUGUST 1989.
	TX0002723552

    19891218
	AMSPLUS,
    Inc.	Registered
	AMSI.	TX0001789145

    19860403
	Automated
                                            Medical

    Systems,
    Inc.1
	Registered
	AUTOMATED
                                            MEDICAL OFFICE SYSTEM : A*M*O*S :

    SCRIVENS
    MEDICAL INFORMATION SYSTEM.
	TX0001248006

    19831013
	Automated
                                            Medical

    Systems,
    Inc. 2
	Registered
	ER
    PATIENT RETRIEVAL SYSTEM.	TX0001789144

    19860403
	Automated
                                            Medical

    Systems,
    Inc.3
	Registered

 

(iii)

 

	Trademark	Country	Reg.
    No. / Date	App.
                                            No.

    /
    Filed
	Owner	Status	Liens
    / Issues
	ADVANTAGE
    HEALTH	U.S.
    State	4008256	N/A	Medical
    Account	Registered	None
	CARE
    SOLUTIONS	(OH)	23-MAR-	 	Services,
    Inc.	 	 
	 	 	2017	 	 	 	 

 

(iv)

 

 

 

1
Note to Draft: Filing has been submitted to the United States Copyright Office to update the record owner to AMSPLUS, Inc.

2
Note to Draft: Filing has been submitted to the United States Copyright Office to update the record owner to AMSPLUS, Inc.

3
Note to Draft: Filing has been submitted to the United States Copyright Office to update the record owner to AMSPLUS, Inc.

 

    35 

     

    

 

	Domain
Name	Status	Expiration

Date	Auto-renew
	activepatient.com	Active	3/7/2022	On
	advantedge-a2.com	Active	6/13/2022	On
	AHPBS.COM	Active	9/25/2021	On
	ahsarplus.com	Active	10/19/2022	On
	AHSBILLINGCORP.COM	Active	10/12/2022	On
	AHSCORPORATE.COM	Active	10/12/2022	On
	AHSFORRESULTS.COM	Active	10/12/2022	On
	AHSGLOBAL.COM	Active	10/12/2022	On
	AHSNEWYORK.COM	Active	5/15/2021	On
	AHSRCM.COM	Active	1/16/2023	On
	AHSRCM.NET	Active	1/18/2023	On
	AHSRCM.ORG	Active	1/18/2023	On
	AHSRESULTS.COM	Active	10/12/2022	On
	AHSSOFTWARE.COM	Active	10/12/2022	On
	AHSSOLUTIONS.COM	Active	10/12/2022	On
	AHSVM.COM	Active	10/12/2022	On
	AHSWINS.COM	Active	10/12/2022	On
	amsplus.com	Active	8/12/2022	On
	amsplus.info	Active	12/20/2021	On
	AMSWORX.COM	Active	4/25/2022	On
	automatedmedical.com	Active	11/13/2021	On
	COMPUDATAINC.NET	Active	2/18/2023	On
	medicalaccountservices.com	Active	9/20/2022	On
	MIRRUSSYSTEMS.COM	Active	2/15/2022	On
	PROASSOC.COM	Active	4/15/2022	On
	PSCONLINE.COM	Active	7/23/2021	On
	THEMEDICALBILLINGCOMPANY.COM	Active	4/15/2022	On
	VIRTUALMANAGERONLINE.COM	Active	10/12/2022	On

 

(v)

 

None.

 

    36 

     

    

 

(vi)

 

(A)

 

		1.	All
                                            Intellectual Property Rights included in the items 1-4 and 6-10 on Schedule 3.12(h).

 

		2.	All
                                            Intellectual Property Rights in the AHS Software, as that term is defined in the Intellectual
                                            Property Agreement, dated as of August 23, 2017, by and between AdvantEdge Healthcare Solutions,
                                            Inc. and Accur8.

 

		3.	Unregistered
                                            trademark: ADVANTEDGE HEALTHCARE SOLUTIONS

 

(B)

 

		1.	All
                                            Intellectual Property Rights included in the item 5 on Schedule 3.12(h).

 

		2.	All
                                            Intellectual Property Rights in the Accur8 Software, as that term is defined in the Intellectual
                                            Property Agreement, dated as of August 23, 2017, by and between AdvantEdge Healthcare Solutions,
                                            Inc., Emeris Corp., Accur8 Software Development LLC and Salamander Inc.

 

(c)

 

None.

 

(d)

 

None.

 

(e)

 

Hexplora,
LLC developed intellectual property (including intellectual property in software) that forms part of the underlying platform for the
reporting tool, AdvantEdge Analytics (A2), pursuant to a Master Services Agreement between Hexplora, LLC and AdvantEdge Solutions (or
AdvantEdge Healthcare Solutions, Inc., a New York corporation and a wholly-owned subsidiary of AdvantEdge) on June 6, 2014, but Hexplora,
LLC has not assigned such intellectual property to any Group Company.

 

(f)

 

None.

 

    37 

     

    

 

(g)

 

None.

 

	(h)	(second
                                            to last sentence)

 

		1.	Virtual
                                            Manager Billing Platform

 

		2.	InfoEdgeBI

 

		3.	InfoEdge
                                            File Exchange

 

		4.	PerformanceEdge

 

		5.	ARPlus

 

		6.	ProductionEdge

 

		7.	WorklogEdge

 

		8.	DeployEdge

 

		9.	Worx

 

		10.	Interface
                                            Engine (v1 and v2)

 

    38 

     

    

 

Schedule
3.13

Privacy

 

None.

 

    39 

     

    

 

Schedule
3.14

Labor Matters

 

(a)

 

See
attached.

 

(b)

 

None.

 

(c)

 

Items
(1) and (2) set forth in Schedule 3.8 of this Disclosure Schedule are incorporated by reference herein.

 

(d)

 

None.

 

    40 

     

    

 

AdvantEdge
Healthcare Solutions Census

 

	Last,
    First	 	Job
    Title	 	Hire
    Date	 	Work
    Location	 	Annual
    Salary	 	 	Bonus
    eligibility	 	Other Compensation
	Aksyonova, Iryna	 	Depositing Rep	 	07/08/2013	 	Salem	 	$	29,120.00	 	 	 	 	 
	Albano, Ma. Theresa	 	Senior Programmer	 	10/13/2008	 	Warren	 	$	98,554.04	 	 	 	 	 
	Ali, Zeenat	 	Banker	 	10/07/2019	 	Lombard	 	$	33,280.00	 	 	 	 	 
	Alvarado, Alondra	 	Clerical	 	11/17/2020	 	Lombard	 	 	 	 	 	 	 	 
	Amaro, Ruben	 	Mailroom Clerk	 	11/17/2020	 	Lombard	 	$	29,120.00	 	 	 	 	 
	Amiss, Leigha	 	Customer Care Team Leader	 	05/07/2012	 	Salem	 	$	46,300.80	 	 	 	 	 
	Anderson, Laura	 	Coder	 	02/16/2021	 	 	 	$	52,000.00	 	 	 	 	 
	Apke, Heather	 	A/R Representative	 	03/09/2020	 	Crestview Hills	 	$	37,960.00	 	 	 	 	 
	Askounes, Michael	 	A/R Manager	 	04/12/2021	 	Chambersburg	 	$	72,000.24	 	 	 	 	 
	Atkins, Brittany	 	Trainer	 	10/03/2013	 	Lombard	 	$	47,320.00	 	 	 	 	 
	Bailey, Darcy	 	A/R Representative	 	08/11/2008	 	Salem	 	$	42,057.60	 	 	 	 	 
	Bailey, Kristie	 	Account Representative	 	05/07/2012	 	City	 	$	31,595.20	 	 	 	 	 
	Baker, Benjamin	 	Mailroom Clerk	 	06/06/2017	 	Salem	 	$	29,120.00	 	 	 	 	 
	Baker, Raymond	 	Team Lead	 	11/27/2006	 	Salem	 	$	47,840.00	 	 	 	 	 
	Baker, Shelly	 	Director of Receivable Mgmt	 	12/11/1995	 	Salem	 	$	80,070.64	 	 	 	 	 
	Bard, Laurie	 	Billing Representative	 	01/09/2012	 	Chambersburg	 	$	29,016.00	 	 	 	 	 
	Bertuca, Nicole	 	Global Liaison	 	10/07/2008	 	Lombard	 	$	37,440.00	 	 	 	 	 
	Bezemes, Kaylee	 	Scanning Clerk	 	10/29/2018	 	Salem	 	$	23,566.40	 	 	 	 	 
	Bishop, Heather	 	Credentialing/Billing Rep	 	08/28/2012	 	Chambersburg	 	$	27,060.80	 	 	 	 	 
	Borah, Michele	 	Data  Operations Payments	 	03/02/2020	 	Lombard	 	$	28,288.00	 	 	 	 	 
	Borkovec, Mia	 	Clerical	 	11/20/2020	 	Lombard	 	$	26,000.00	 	 	 	 	 
	Bouley, Michele	 	A/R Representative	 	07/18/2005	 	Salem	 	$	39,041.60	 	 	 	 	 
	Bouzakine, Alexander	 	Sr. Report Specialist	 	06/01/2015	 	Salem	 	$	96,357.56	 	 	 	 	 
	Bowden, Janel	 	Operations Manager	 	06/14/2010	 	Salem	 	$	66,560.00	 	 	 	 	 
	Bowes, Deana	 	Client  Management Analyst	 	02/10/2020	 	Salem	 	$	42,577.60	 	 	 	 	 
	Boyce, Robert	 	Director, Application Support	 	11/22/2004	 	Chambersburg	 	$	82,750.20	 	 	 	 	 
	Brennan, Karen	 	A/R Representative	 	01/01/2009	 	Staten Island	 	$	50,752.00	 	 	 	 	 
	Brown, Kenya	 	Payment Poster	 	07/01/2013	 	Lombard	 	$	31,449.60	 	 	 	 	 
	Brozovic, Richard	 	Director, Interface	 	06/22/2009	 	Lombard	 	$	120,697.46	 	 	 	 	 
	Budgett-Stevenson, Alisha	 	Senior Accountant	 	03/06/2008	 	Salem	 	$	61,500.14	 	 	 	 	 
	Bueno, Heather	 	A/R Representative	 	07/19/2021	 	 	 	$	37,440.00	 	 	 	 	 
	Bullis, Jamie	 	Batching Representative	 	01/13/2020	 	Salem	 	$	26,000.00	 	 	 	 	 
	Burkhart, Tara	 	SR.  Operations Specialist	 	03/02/2020	 	Lombard	 	$	37,440.00	 	 	 	 	 
	Burris, Brenda	 	Reports Coordinator	 	06/27/1994	 	Salem	 	$	41,100.80	 	 	 	 	 
	Caine, Kristin	 	Team Lead - Charges	 	01/30/2018	 	Salem	 	$	39,520.00	 	 	 	 	 
	Callaway, Georgiann	 	Account Analyst	 	06/09/2014	 	Lombard	 	$	30,971.20	 	 	 	 	 
	Capozzi, Kimberly	 	Credit  Balance Representative	 	11/13/2018	 	Salem	 	$	33,217.60	 	 	 	 	 
	Carasoni, Susan	 	Treasury Analyst	 	05/03/2010	 	Warren	 	$	61,000.16	 	 	 	 	 
	Carl, Rebecca	 	Client Manager	 	02/07/2005	 	Moraine	 	$	63,000.08	 	 	 	 	 
	Carter, Michelle	 	Coder	 	10/17/2007	 	 	 	$	52,000.00	 	 	 	 	 
	Casagrande, Michelle	 	A/R Representative	 	07/06/2015	 	Salem	 	$	31,824.00	 	 	 	 	 
	Cassidy, Raymond	 	Regional VP, Mid-Atlantic Regi	 	12/04/2006	 	Warren	 	$	181,125.10	 	 	25	%	commission plan
	Chandragiri, Parul	 	Director of Operations	 	10/19/2020	 	 	 	$	110,000.02	 	 	 	 	 
	Charette, Karen	 	Coder	 	08/25/2008	 	Chambersburg	 	$	54,080.00	 	 	 	 	 
	Chaussey, Leslie	 	Client Manager	 	10/15/2013	 	Lombard	 	$	83,537.74	 	 	 	 	 
	Cherry, Nataya	 	A/R Representative	 	06/13/2011	 	Staten Island	 	$	45,240.00	 	 	 	 	 
	Choi, Henry	 	Senior Progammer Analyst	 	10/23/2000	 	Warren	 	$	118,766.44	 	 	 	 	 
	Ciarla, Filomena	 	Payment Representative	 	02/04/2002	 	Salem	 	$	32,760.00	 	 	 	 	 
	Cloutier, Jennifer	 	Provider Enrollment Rep	 	03/15/2021	 	Salem	 	$	31,200.00	 	 	 	 	 
	Coleman, Lindsey	 	Coder	 	03/02/2020	 	Lombard	 	$	28,662.40	 	 	 	 	 
	Collins, Jennifer	 	A/R Representative	 	11/01/2010	 	Salem	 	$	35,360.00	 	 	 	 	 
	Collins, Marissa	 	Global Liaison - Payments	 	03/02/2020	 	Lombard	 	$	37,440.00	 	 	 	 	 
	Collins, Veronica	 	IT Development Project Coordin	 	02/06/2012	 	Ravenna	 	$	57,398.38	 	 	 	 	 
	Comer, Emily	 	Client Manager Analyst	 	06/21/2021	 	 	 	$	31,200.00	 	 	 	 	 
	Concepcion, Yvonne	 	A/R Representative	 	09/10/2018	 	Staten Island	 	$	41,600.00	 	 	 	 	 
	Connolly, Gail	 	Client Liaison	 	11/07/2018	 	Baltimore	 	$	70,211.70	 	 	 	 	 
	Courtney, Mary	 	A/R Representative	 	11/27/2018	 	Crestview Hills	 	$	41,600.00	 	 	 	 	 
	Cox-Scharp, Taylor	 	Coder	 	03/01/2021	 	 	 	$	45,760.00	 	 	 	 	 
	Cruz, Crispin	 	Programmer	 	06/18/2012	 	Lombard	 	$	84,494.54	 	 	 	 	 
	Curtis, Nancy	 	Team Lead	 	09/19/2011	 	Salem	 	$	35,360.00	 	 	 	 	 
	Cutler, Tamara	 	Coder	 	03/02/2020	 	Lombard	 	$	56,721.60	 	 	 	 	 

 

    41 

     

    

 

	Cutrona, Kylie	 	Depositing Representative	 	03/02/2020	 	Salem	 	$	27,040.00	 	 	 	 	 
	Da Silva, Paulo	 	VP, Development	 	08/20/2001	 	Warren	 	$	120,062.54	 	 	 	 	 
	Daneault, Sandra	 	Customer Service Rep	 	03/06/2019	 	Salem	 	$	33,280.00	 	 	 	 	 
	Daniels, Shatita	 	Coding Manager	 	05/17/2021	 	 	 	$	84,000.02	 	 	 	 	 
	Danik, Heather	 	Customer Service Rep	 	07/19/2021	 	 	 	$	33,280.00	 	 	 	 	 
	Danjou, Daniel	 	CUSTOMER LEADER	 	04/09/2008	 	Salem	 	$	47,444.80	 	 	 	 	 
	DeBiasse, Erika	 	Office Manager	 	07/22/2019	 	Melbourne	 	$	41,600.00	 	 	 	 	 
	Del Valle, Jessica	 	Depositing Rep	 	06/04/2018	 	Salem	 	$	27,040.00	 	 	 	 	 
	Diaz, Amelia	 	Posting Clerk	 	07/06/2009	 	Lombard	 	$	28,100.80	 	 	 	 	 
	Dimaio, Loriann	 	Cash Depositor	 	01/01/2009	 	Staten Island	 	$	47,736.00	 	 	 	 	 
	DiMaio, Rosemarie	 	A/R Representative	 	01/01/2009	 	Staten Island	 	$	32,333.60	 	 	 	 	 
	DINNALL, ANDRENE	 	Customer Service Rep	 	07/19/2021	 	 	 	$	31,200.00	 	 	 	 	 
	Dippel, Patricia	 	Refund Rep	 	12/07/2018	 	Baltimore	 	$	45,864.00	 	 	 	 	 
	Dolan, Diane	 	A/R Representative	 	12/05/1995	 	Salem	 	$	52,000.00	 	 	 	 	 
	Dole-Crocker, Christina	 	Coder	 	07/29/2019	 	Salem	 	$	39,520.00	 	 	 	 	 
	Dolitskaya, Galina	 	Sr. iSeries RPGLE	 	06/05/2017	 	City	 	$	83,021.90	 	 	 	 	 
	Doyle, Kerri	 	Client Manager	 	08/31/2011	 	Freeport	 	$	84,460.22	 	 	 	 	 
	Duffy, Roxanne	 	A/R Representative	 	10/13/2009	 	Salem	 	$	28,158.00	 	 	 	 	 
	Dupont, Christine	 	A/R Representative	 	10/19/2009	 	Salem	 	$	37,960.00	 	 	 	 	 
	Durham, Jodi	 	Cash Control Rep	 	06/20/2016	 	Chambersburg	 	$	31,200.00	 	 	 	 	 
	Emeritz, Christine	 	Supervisor, Posting	 	03/28/1988	 	Lombard	 	$	45,718.40	 	 	 	 	 
	Engel, Maritza	 	Manager, Refunds and Client Re	 	09/06/1988	 	Lombard	 	$	77,891.06	 	 	 	 	 
	Epley, Rebecca	 	Team Lead Customer	 	03/02/2020	 	Lombard	 	$	51,022.40	 	 	 	 	 
	Estabrook, Annie	 	EDI Analyst / Supervisor	 	01/06/2014	 	Salem	 	$	41,600.00	 	 	 	 	 
	Fabian, Carol	 	Coder	 	01/15/1996	 	Lombard	 	$	44,844.80	 	 	 	 	 
	Fallon, Carol	 	A/R Representative	 	11/07/2018	 	Baltimore	 	$	37,366.16	 	 	 	 	 
	Finch, Karen	 	A/R Representative	 	06/16/2008	 	Salem	 	$	38,001.60	 	 	 	 	 
	Finson, Scott	 	Director of IT	 	11/07/2018	 	Baltimore	 	$	110,000.00	 	 	10	%	 
	Fortini, Donna	 	AR/CS Rep	 	11/07/2018	 	Baltimore	 	$	39,977.60	 	 	 	 	 
	Frand, Hichanell	 	Depositing Representative	 	04/14/2016	 	Salem	 	$	29,120.00	 	 	 	 	 
	Franklin, Marie	 	National Director of Coding,	 	04/12/2016	 	Lombard	 	$	125,000.20	 	 	20	%	 
	Fraser, Lauri	 	A/R Representative	 	03/18/2019	 	Salem	 	$	37,960.00	 	 	 	 	 
	Fray, Jenna	 	Batching Representative	 	11/30/2020	 	Salem	 	$	24,960.00	 	 	 	 	 
	Ganoe, Erika	 	ASC Manager	 	05/24/2010	 	Chambersburg	 	$	36,049.78	 	 	 	 	 
	Gantz, Sabrina	 	Refund Rep	 	01/30/2012	 	Chambersburg	 	$	27,601.60	 	 	 	 	 
	Garcia, Michelle	 	Clerical	 	12/28/2020	 	Lombard	 	$	26,520.00	 	 	 	 	 
	Garcia, Yvonne	 	Refund Rep	 	11/07/2018	 	Baltimore	 	$	51,854.40	 	 	 	 	 
	Gervasio, Cheryl	 	Coder	 	11/03/2003	 	City	 	$	56,659.20	 	 	 	 	 
	Gilardi, Sabrina	 	A/R Representative	 	07/10/2017	 	Salem	 	$	28,787.20	 	 	 	 	 
	Gilreath, Jeanne	 	Senior Vice President	 	03/13/2000	 	Warren	 	$	176,349.42	 	 	 	 	 
	Gomez, Evelyn	 	Depositing Rep	 	04/02/2013	 	Salem	 	$	29,120.00	 	 	 	 	 
	Gonzalez, Emily	 	A/R Representative	 	06/21/2021	 	 	 	$	37,440.00	 	 	 	 	 
	Grace, Brittany	 	Clerk	 	02/22/2021	 	Chambersburg	 	$	31,200.00	 	 	 	 	 
	Graichen, Maggie	 	Customer Service Rep	 	02/22/2017	 	Salem	 	$	34,964.80	 	 	 	 	 
	Green, Lynda	 	Vice Pres of Operation	 	11/23/1998	 	Salem	 	$	140,569.00	 	 	20	%	 
	Grenda, Kelly	 	Customer Service Rep	 	10/30/2018	 	Salem	 	$	33,280.00	 	 	 	 	 
	Haerinck, Bethany	 	A/R Representative	 	01/15/2007	 	Salem	 	$	43,680.00	 	 	 	 	 
	Haller, Stephen	 	Business Development Director	 	06/09/2014	 	City	 	$	110,000.02	 	 		 	commission plan
	Halloran, Terence	 	Chief Financial and Administrative	 	09/01/2015	 	Salem	 	$	254,514.00	 	 	 	 	 
	Hamilton, Amanda	 	Patients  Accounts Customer	 	03/02/2020	 	Lombard	 	$	29,244.80	 	 	 	 	 
	Hampleman, Robert	 	Patient  Accounts Customer	 	03/02/2020	 	Lombard	 	$	32,988.80	 	 	 	 	 
	Hampton, Angie	 	Coder	 	06/29/2015	 	Crestview Hills	 	$	46,987.20	 	 	 	 	 
	Harmon, Lacee	 	Customer Service Rep	 	04/05/2021	 	Lombard	 	$	32,240.00	 	 	 	 	 
	Hartling, Kacey	 	Billing Representative	 	01/25/2016	 	Salem	 	$	29,120.00	 	 	 	 	 
	Hatem, Karen	 	A/R Representative	 	03/02/1998	 	Salem	 	$	38,896.00	 	 	 	 	 
	Haubert, Marla	 	AR/CS Rep	 	09/30/2019	 	Chambersburg	 	$	27,560.00	 	 	 	 	 
	Hess, Maegen	 	Credentialing Specialist	 	10/21/2004	 	Chambersburg	 	$	37,960.00	 	 	 	 	 
	Hester, Jonell	 	A/R Representative	 	06/21/2021	 	 	 	$	37,440.00	 	 	 	 	 
	Hines, Dorothy	 	Billing Representative	 	09/02/2015	 	Salem	 	$	29,120.00	 	 	 	 	 
	Hinson, Joyce	 	Payment Representative	 	09/21/2012	 	Salem	 	$	29,120.00	 	 	 	 	 
	Hock, Deborah	 	A/R Representative	 	01/04/2016	 	Chambersburg	 	$	30,680.00	 	 	 	 	 
	Hofferbert, Jennifer	 	Customer Service Rep	 	11/07/2018	 	Baltimore	 	$	34,590.40	 	 	 	 	 
	Hopkins, Michael	 	Controller	 	04/20/2016	 	Salem	 	$	132,000.00	 	 	15	%	 
	Horine, Lorraine	 	Director of Project	 	02/04/2013	 	City	 	$	91,561.08	 	 	 	 	 
	Hudnall, Hannah	 	Clerk	 	06/10/2021	 	Lombard	 	$	29,120.00	 	 	 	 	 
	Hunsberger, Amy	 	Concurrency Specialist	 	03/21/1991	 	Chambersburg	 	$	21,580.00	 	 	 	 	 
	Ivanovitch, Lisa	 	Team Lead	 	11/11/1996	 	Salem	 	$	60,777.60	 	 	 	 	 
	Jackson, Natasha	 	Data  Entry Representative	 	07/19/2017	 	Lombard	 	$	28,620.80	 	 	 	 	 
	Jacobson, Christine	 	A/R Coordinator	 	10/02/1997	 	City	 	$	38,292.80	 	 	 	 	 
	Jardin, Lynn	 	Sr. Client Manager	 	01/19/1998	 	Salem	 	$	95,481.10	 	 	 	 	 
	Johns, David	 	IT Support	 	07/24/2002	 	Moraine	 	$	58,739.20	 	 	 	 	 
	Johns, Ryan	 	Regional Accountant	 	02/10/2014	 	Lombard	 	$	57,963.62	 	 	 	 	 

 

    42 

     

    

 

	Johnson, Roberta	 	A/R Representative	 	01/11/2021	 	 	 	$	41,600.00	 	 	 	 	 
	Jones, Kandie	 	A/R Representative	 	12/01/2015	 	Chambersburg	 	$	30,680.00	 	 	 	 	 
	Jones, Mary	 	AR/CS Rep	 	11/14/2016	 	Chambersburg	 	$	30,680.00	 	 	 	 	 
	Kagebein, Patricia	 	SVP, Operations & Integrations	 	09/29/1986	 	Lombard	 	$	199,999.80	 	 	50	%	 
	Kelleher, Janice	 	Support Supervisor	 	10/08/1996	 	Salem	 	$	94,168.88	 	 	 	 	 
	Kemp, Barbara	 	Data Operations Charge Entry	 	03/02/2020	 	Lombard	 	$	34,444.80	 	 	 	 	 
	Kemper, Donna	 	A/R Representative	 	06/29/2015	 	Crestview Hills	 	$	48,490.22	 	 	 	 	 
	Kennedy, Sarah	 	Charge Entry Specialist	 	08/09/2010	 	Chambersburg	 	$	31,536.13	 	 	 	 	 
	Kern, Victoria	 	Manager of Scan/Facility Ops	 	03/01/2005	 	Chambersburg	 	$	53,263.34	 	 	 	 	 
	Kidd, Stephanie	 	Specialist, IT & QA Testing	 	04/01/2001	 	Warren	 	$	75,176.40	 	 	 	 	 
	Kimball, Jennifer	 	Enrollment Manager	 	07/22/2019	 	Salem	 	$	65,000.00	 	 	 	 	 
	Kinder, Carmen	 	Clerical Representative	 	03/02/2020	 	Lombard	 	$	41,454.40	 	 	 	 	 
	Koltas, Monika	 	Global Liaison - AR	 	09/22/2014	 	Lombard	 	$	37,440.00	 	 	 	 	 
	Konieczna, Anna	 	EDI Manager	 	03/28/2005	 	Lombard	 	$	65,000.00	 	 	 	 	 
	Krachenfels, Laurie	 	Regional Director of Operations	 	03/25/1991	 	Lombard	 	$	124,000.24	 	 	20	%	 
	Kraus, Iris	 	Billing/Data Entry Rep	 	09/03/2002	 	Staten Island	 	$	47,444.80	 	 	 	 	 
	Kreps, Diana	 	A/R Representative	 	12/01/2010	 	Chambersburg	 	$	30,680.00	 	 	 	 	 
	Laden, Joe	 	VP Client Management	 	04/03/2017	 	City	 	$	117,500.00	 	 	10	%	 
	LaFazia, Christine	 	Account Representative	 	09/30/2013	 	City	 	$	32,926.40	 	 	 	 	 
	Lajoie, Andrea	 	A/R  Representative II	 	11/25/2002	 	Salem	 	$	47,756.80	 	 	 	 	 
	Lance, Cassandra	 	A/R Representative	 	06/03/2019	 	Salem	 	$	36,400.00	 	 	 	 	 
	Langsam, David	 	Chief Executive Officer	 	09/06/2007	 	Charlotte	 	$	404,999.92	 	 	 	 	 
	LaPine, Krista	 	A/R Representative	 	01/27/2020	 	Salem	 	$	33,280.00	 	 	 	 	 
	Larochelle, Robyn	 	Operations Manager	 	08/06/2001	 	Salem	 	$	58,264.96	 	 	 	 	 
	Larochelle, Rylee	 	A/R  Support Representative	 	06/20/2016	 	Salem	 	$	27,040.00	 	 	 	 	 
	Laughlin, Jessica	 	Operations and System Trainer	 	12/20/2004	 	Lombard	 	$	63,000.08	 	 	 	 	 
	Lawler, Matthew	 	Customer Service Rep	 	10/05/2020	 	Lombard	 	$	28,080.00	 	 	 	 	 
	LeBlanc, Anne	 	A/R Representative	 	03/25/2013	 	Salem	 	$	35,360.00	 	 	 	 	 
	Lenhardt, Anne	 	Clerk	 	01/22/2007	 	Lombard	 	$	33,488.00	 	 	 	 	 
	Lennens, Tina	 	A/R Representative	 	08/02/2021	 	 	 	$	37,440.00	 	 	 	 	 
	Lewis, Barbara	 	Director, People Services	 	12/14/2009	 	Lombard	 	$	115,000.08	 	 	20	%	 
	Lopez, Maria	 	Team Lead	 	01/27/2020	 	Lombard	 	$	37,440.00	 	 	 	 	 
	Lopez, Mary	 	Credentialing Specialist	 	04/15/2019	 	Lombard	 	$	52,000.00	 	 	 	 	 
	Lowenstein, Cindy	 	Batcher	 	07/14/2014	 	Salem	 	$	25,480.00	 	 	 	 	 
	Lyell, Stephanee	 	Coder	 	11/07/2018	 	Baltimore	 	$	44,740.80	 	 	 	 	 
	Lynk, Patti	 	A/R Representative	 	06/21/2021	 	 	 	$	35,360.00	 	 	 	 	 
	Maccrea, Stephen	 	Director Client Management	 	01/05/2004	 	City	 	$	120,000.14	 	 	10	%	 
	Madore, Christine	 	Billing Representative	 	08/23/2017	 	Salem	 	$	35,297.60	 	 	 	 	 
	Mahoney, Bridget	 	A/R Representative	 	06/09/2014	 	Staten Island	 	$	47,132.80	 	 	 	 	 
	Main, Carolyn	 	Billing/Data Entry Rep	 	06/29/2015	 	Crestview Hills	 	$	34,089.30	 	 	 	 	 
	Maines, Carla	 	A/R Representative	 	02/06/2017	 	Crestview Hills	 	$	34,798.40	 	 	 	 	 
	Maldonado, Maria	 	Operations Specialist	 	05/10/2021	 	Lombard	 	$	37,440.00	 	 	 	 	 
	Malozi, Patricia	 	A/R Representative	 	11/07/2018	 	Baltimore	 	$	44,740.80	 	 	 	 	 
	Maxwell, Lynne	 	Receptionist	 	08/28/1995	 	Salem	 	$	45,011.20	 	 	 	 	 
	McCarthy, Karin	 	Client Manager Analyst	 	06/18/2007	 	Salem	 	$	43,492.80	 	 	 	 	 
	McCulloh, Deborah	 	Payor Liasion	 	01/31/1991	 	Chambersburg	 	$	25,568.40	 	 	 	 	 

 

    43 

     

    

 

	McDougall, Blaise	 	Helpdesk Analyst	 	01/16/2006	 	Salem	 	$	59,766.72	 	 	 	 	 
	McGowan, Kimberly	 	A/R Representative	 	06/21/2021	 	 	 	$	37,440.00	 	 	 	 	 
	McGuire, Charitie	 	Patient Accounts Follow Up	 	03/02/2020	 	Lombard	 	 	 	 	 	 	 	 
	McIntosh, Karen	 	Finance  Representative	 	08/12/2011	 	Moraine	 	$	53,560.00	 	 	 	 	 
	McKallagat,  Shelagh	 	Manager, People Services	 	05/10/1995	 	Salem	 	$	79,897.22	 	 	 	 	 
	McKoy, Claudene	 	Billing  Representative	 	12/18/2006	 	Salem	 	$	31,200.00	 	 	 	 	 
	Menario, Laura	 	Refund Rep	 	03/29/1993	 	Salem	 	$	38,667.20	 	 	 	 	 
	Meuse, Kaitlyn	 	Team Lead - Payments	 	05/01/2017	 	Salem	 	$	39,520.00	 	 	 	 	 
	Miller, Jennifer	 	Associate Client Manager	 	07/12/2021	 	 	 	$	62,000.12	 	 	 	 	 
	Miller, Katrina	 	A/R Representative	 	05/06/2019	 	Chambersburg	 	$	27,560.00	 	 	 	 	 
	Montalvo, Cecilia	 	Sr. Operations Manager	 	06/20/2016	 	Lombard	 	$	84,000.02	 	 	 	 	 
	Moon, Linda	 	A/R Representative	 	06/21/2021	 	 	 	$	35,360.00	 	 	 	 	 
	Moore, Valerie	 	HRCOOR	 	02/11/2019	 	Lombard	 	$	58,850.00	 	 	 	 	 
	Moran, Aimee	 	Provider  Enrollment Coordinator	 	10/07/2019	 	Salem	 	$	43,680.00	 	 	 	 	 
	Morawski, Mary	 	Manager	 	11/07/2018	 	Baltimore	 	$	80,151.50	 	 	 	 	 
	Mortell-Gurley,  Cheyenne	 	Depositing Rep	 	12/07/2020	 	Salem	 	$	29,120.00	 	 	 	 	 
	Munster, Sean	 	VP, Behavioral Health Division	 	07/05/2000	 	Salem	 	$	122,500.04	 	 	25	%	commission plan
	Neer, Carleen	 	A/R Representative	 	09/28/2020	 	 	 	$	37,440.00	 	 	 	 	 
	Negron, Noraima	 	Billing  Representative	 	03/27/2017	 	City	 	$	40,726.40	 	 	 	 	 
	Nelson, Pamela	 	Charge Entry Specialist	 	10/20/2010	 	Chambersburg	 	$	27,476.80	 	 	 	 	 
	Newburry, Keisa	 	Coding Auditing and Training	 	05/29/2001	 	Lombard	 	$	68,000.14	 	 	 	 	 
	Nicholson, David	 	Legislative and Regulatory Affairs	 	11/07/2018	 	Baltimore	 	$	12,000.04	 	 	 	 	 
	Nolan, Alexandria	 	Customer Service Rep	 	01/11/2021	 	Lombard	 	$	27,040.00	 	 	 	 	 
	Norman, Lisa	 	Sr. Operations Specialist	 	06/30/2003	 	Lombard	 	$	50,024.00	 	 	 	 	 
	O'Haro, James Paul	 	Chief Operating Officer	 	01/17/2011	 	Charlotte	 	$	274,508.00	 	 	 	 	 
	Oliveira, Jodey	 	Client  Management Coordinator	 	10/02/2000	 	Salem	 	$	53,185.60	 	 	 	 	 
	Orienti, Patti	 	Manager, Posting	 	03/01/1977	 	Lombard	 	$	75,274.94	 	 	 	 	 
	Ortiz, Danielle	 	A/R Representative	 	11/16/2020	 	Salem	 	$	36,400.00	 	 	 	 	 
	Outland, Angela	 	A/R Representative	 	06/21/2021	 	 	 	$	34,320.00	 	 	 	 	 
	PAGE, JAZMIN	 	Coder	 	04/12/2021	 	 	 	$	48,880.00	 	 	 	 	 
	Parag, Danielle	 	A/R Manager	 	05/07/2012	 	Wilmington	 	$	48,900.28	 	 	 	 	 
	Parris, Joyce	 	Customer Service Rep	 	06/21/2021	 	 	 	$	31,200.00	 	 	 	 	 
	Parry, Donna	 	A/R Representative	 	06/01/2021	 	Salem	 	$	37,440.00	 	 	 	 	 
	Patel, Honey	 	Customer Service Rep	 	07/23/2018	 	Salem	 	$	37,440.00	 	 	 	 	 
	Patnaude, Renee	 	Payment  Representative	 	11/10/2014	 	Salem	 	$	32,760.00	 	 	 	 	 
	Payton, Chelce	 	Customer Service Rep II	 	10/05/2020	 	Lombard	 	$	29,120.00	 	 	 	 	 
	Pelletier, Tina	 	Director of Operations	 	01/03/2005	 	Freeport	 	$	95,000.10	 	 	 	 	 
	Perez, Loyra	 	CUSTOMER LEADER	 	08/16/2016	 	Salem	 	$	42,640.00	 	 	 	 	 
	Perry, Eva	 	Team Lead	 	12/22/2016	 	Salem	 	$	43,680.00	 	 	 	 	 
	Perry, Jennifer	 	Operations  Systems Coordinator	 	12/02/2002	 	Lombard	 	$	33,217.60	 	 	 	 	 
	Phillips, Beverley	 	Team Lead	 	02/22/2016	 	Salem	 	$	43,680.00	 	 	 	 	 
	Phipps, Abigail	 	Customer Service Rep	 	12/09/2019	 	Lombard	 	$	24,960.00	 	 	 	 	 
	Pietrowski, Denise	 	A/R Representative	 	07/09/2012	 	Salem	 	$	35,817.60	 	 	 	 	 
	Pinard, Amanda	 	Customer Care Representative	 	09/09/2019	 	Salem	 	$	31,200.00	 	 	 	 	 
	Plank, April	 	Customer  Service/Cash Receipts	 	10/26/2006	 	Chambersburg	 	$	39,520.00	 	 	 	 	 
	Plante, Deborah	 	Tester	 	06/25/2002	 	Salem	 	$	73,851.70	 	 	 	 	 
	Porter, Jamie	 	A/R Representative II	 	03/29/2021	 	 	 	$	45,760.00	 	 	 	 	 
	Poulin, Denise	 	AR Team Lead	 	07/31/2017	 	Salem	 	$	41,600.00	 	 	 	 	 
	Presa, Jennifer	 	A/R Representative	 	03/22/2021	 	 	 	$	37,440.00	 	 	 	 	 
	Price, Ciara	 	Provider  Enrollment Coordinator	 	01/27/2020	 	Salem	 	$	33,280.00	 	 	 	 	 
	RAIFORD-HOGAN,  KARISSA	 	Customer Service Rep	 	07/19/2021	 	 	 	$	31,200.00	 	 	 	 	 
	Rasely Bull, Charlotte	 	Sr. Client Manager Analyst	 	12/28/2010	 	Freeport	 	$	45,011.20	 	 	 	 	 
	Raycraft, Saida	 	Team Lead	 	11/02/2015	 	Salem	 	$	41,600.00	 	 	 	 	 
	Raynowska,  MarkieRose	 	Depositing Rep	 	03/15/2021	 	Salem	 	$	24,960.00	 	 	 	 	 
	Razza, Angela	 	Depositing Team Leader	 	07/13/2016	 	Salem	 	$	39,520.00	 	 	 	 	 
	Rector, Angela	 	Customer Service Rep	 	06/21/2021	 	Lombard	 	$	31,200.00	 	 	 	 	 
	Reed, Barbara	 	Corp EDI Transmissions	 	05/14/2007	 	Chambersburg	 	$	33,467.20	 	 	 	 	 
	Reed, Deidre L	 	Support Rep II	 	01/25/1997	 	Salem	 	$	61,755.20	 	 	 	 	 
	Reed, Tammy	 	AR/CS Rep	 	04/26/2021	 	Chambersburg	 	$	24,960.00	 	 	 	 	 
	Reifon, April	 	Customer Service Rep III/Team	 	12/16/2019	 	Lombard	 	$	34,320.00	 	 	 	 	 
	Reynolds, Stephanie	 	Manager	 	11/07/2018	 	Baltimore	 	$	90,000.04	 	 	10	%	 
	Ritter, Sherry	 	Invoicing  Representative	 	09/30/2013	 	Salem	 	$	38,480.00	 	 	 	 	 
	Robertson, Joyann	 	Billing  Representative	 	04/19/2021	 	Salem	 	$	22,880.00	 	 	 	 	 
	Roda-Sheldon, Lana	 	Customer Service Rep	 	11/28/2005	 	Lombard	 	$	35,817.60	 	 	 	 	 

 

    44 

     

    

 

	Rodgers, Tina	 	Administrative  Assistant	 	09/13/2013	 	Lombard	 	$	44,720.00	 	 	 	 	 
	Rodriguez, Santia	 	Scanning  Representative	 	11/23/2020	 	Salem	 	$	22,880.00	 	 	 	 	 
	Rowe, Nicole	 	Accounts Payable Accountant	 	08/29/2016	 	Salem	 	$	27,950.00	 	 	 	 	 
	Sanchez-Davila, Silvia	 	Junior Client Manager	 	07/13/2020	 	Lombard	 	$	67,500.16	 	 	 	 	 
	Scherer, Margaret	 	Charge Entry Specialist	 	10/19/2015	 	Crestview Hills	 	$	34,569.60	 	 	 	 	 
	Schulze, Tara	 	IT Support	 	11/07/2018	 	Baltimore	 	$	36,337.60	 	 	 	 	 
	Schuman, Alisha	 	Clerical	 	11/07/2018	 	Baltimore	 	$	32,801.60	 	 	 	 	 
	Scoleri, Catherine	 	Refund Analyst	 	03/02/2009	 	Lombard	 	$	31,179.20	 	 	 	 	 
	Seeley, Lisa	 	Customer Service Rep	 	11/07/2018	 	Baltimore	 	$	49,920.00	 	 	 	 	 
	Shashaty, Donna	 	Global Coordinator	 	01/01/2009	 	Staten Island	 	$	44,720.00	 	 	 	 	 
	Sheldon, Patricia	 	Depositing Rep	 	09/23/2019	 	Salem	 	$	27,040.00	 	 	 	 	 
	Shingaki, Miho	 	Clerical	 	10/16/2017	 	Melbourne	 	$	10,483.20	 	 	 	 	 
	Shriver, Daniel	 	Interface Project Manager	 	05/16/2011	 	Chambersburg	 	$	57,500.04	 	 	 	 	 
	Sierak, Dorota	 	Programmer	 	09/11/2001	 	Lombard	 	$	23,929.36	 	 	 	 	 
	Simpson, Justine	 	Director of Client Management	 	08/20/2018	 	Salem	 	$	108,000.10	 	 	 	 	 
	Small, Zulmira	 	Claims Processing Specialist	 	05/17/2021	 	Salem	 	$	33,280.00	 	 	 	 	 
	Smith, Randi	 	Scanning Clerk	 	11/28/2017	 	Chambersburg	 	$	31,720.00	 	 	 	 	 
	Smolke, Matthew	 	Clerk	 	06/10/2021	 	Lombard	 	 	 	 	 	 	 	 
	Souther, Catherine G	 	A/R Representative II	 	04/11/1994	 	Salem	 	$	51,230.40	 	 	 	 	 
	Spero, Dorothy	 	Reimbursement  Analyst	 	06/18/2012	 	Lombard	 	$	35,360.00	 	 	 	 	 
	St. Germain, Patricia	 	Client Analyst/Enrollment	 	12/08/2014	 	Salem	 	$	44,179.20	 	 	 	 	 
	Staley, Kimberly	 	Customer Service Rep	 	07/06/2021	 	Lombard	 	$	24,960.00	 	 	 	 	 
	Staley, Lacey	 	Customer Service Rep	 	07/12/2021	 	Lombard	 	$	29,120.00	 	 	 	 	 
	Starr, Crystal	 	System Liaison/Data Entry	 	04/16/2001	 	Chambersburg	 	$	50,318.32	 	 	 	 	 
	Stavinski, Corrine	 	Coder	 	01/24/2005	 	Chambersburg	 	$	45,240.00	 	 	 	 	 
	Stenbeck, Patricia	 	Batching  Representative	 	01/13/2020	 	Salem	 	$	23,920.00	 	 	 	 	 
	Stephenson, Tashai	 	Director of Operations	 	01/01/2015	 	Crestview Hills	 	$	95,000.10	 	 	 	 	 
	Stewart, Heather	 	Customer Service Rep	 	06/18/2001	 	Salem	 	$	37,481.60	 	 	 	 	 
	Stine, Dennis	 	RPA Developer	 	07/25/2007	 	Chambersburg	 	$	61,500.14	 	 	 	 	 
	Stitely, Gloria	 	Director of Operations	 	08/21/2001	 	Chambersburg	 	$	80,850.12	 	 	 	 	 
	Stotts, Louise	 	Refund Analyst	 	06/09/2014	 	Lombard	 	$	27,268.80	 	 	 	 	 
	Stubbs, Kalisha	 	CLERK	 	10/16/2017	 	Lombard	 	$	26,520.00	 	 	 	 	 
	Stundze, Laura	 	AR Epic Team Leader	 	07/07/2001	 	Salem	 	$	43,804.80	 	 	 	 	 
	Sullivan, Kathleen	 	Clerical  Representative	 	03/02/2020	 	Lombard	 	$	32,468.80	 	 	 	 	 
	Sumara, Marek	 	Network Admin	 	08/29/2011	 	Lombard	 	$	55,328.00	 	 	 	 	 
	Swan, Kimberly	 	Data Operations Charge Entry	 	03/02/2020	 	Lombard	 	$	38,584.00	 	 	 	 	 
	Swiercinski, Kimberly	 	A/R Representative	 	05/22/2006	 	Lombard	 	$	40,185.60	 	 	 	 	 
	Tackett, Aisha	 	Client Manager	 	08/01/2016	 	City	 	$	82,000.00	 	 	 	 	 
	Tapia, Carmen	 	Batcher	 	11/27/2017	 	Melbourne	 	$	22,880.00	 	 	 	 	 
	Thomas, Pamela	 	A/R Representative	 	03/14/2005	 	Chambersburg	 	$	26,915.20	 	 	 	 	 
	Thompson, Melissa	 	Operations  Manager	 	06/29/2015	 	Crestview Hills	 	$	47,631.73	 	 	 	 	 
	Thornell, Karen-Ann	 	Coder	 	04/24/1998	 	Salem	 	$	54,808.00	 	 	 	 	 
	Tilmes, Wendy	 	Coder	 	11/07/2018	 	Baltimore	 	$	57,761.60	 	 	 	 	 
	Toler, Stephanie	 	Coder	 	04/05/2021	 	 	 	$	47,840.00	 	 	 	 	 
	Trela, Gail	 	Operations Analyst	 	08/17/2020	 	Staten Island	 	$	55,000.14	 	 	 	 	 
	Turner, Shelly	 	Coding Specialist	 	06/21/2005	 	Moraine	 	$	41,516.80	 	 	 	 	 
	Vagle, Jennifer	 	SR. Global Liaison	 	09/20/1993	 	Lombard	 	$	49,920.00	 	 	 	 	 
	Valente, Jeanne	 	A/R Representative	 	08/02/2007	 	Salem	 	$	42,328.00	 	 	 	 	 
	Vassallo, Ashley	 	AR/CS Rep	 	06/14/2021	 	Chambersburg	 	$	27,040.00	 	 	 	 	 
	Vega, Vanessa	 	A/R Representative	 	06/29/2021	 	 	 	$	38,480.00	 	 	 	 	 
	Virola, Casandra	 	Clerk	 	11/25/2020	 	Lombard	 	 	 	 	 	 	 	 
	Vitale, Linda	 	Payment Poster	 	08/21/2006	 	Lombard	 	$	33,009.60	 	 	 	 	 
	Vogel, Richard	 	Director Client Management	 	06/11/2018	 	City	 	$	98,000.00	 	 	 	 	 
	Voithofer, Brice	 	SVP of Anesthesia Services &	 	07/23/2007	 	Charlotte	 	$	160,000.10	 	 	25	%	commission plan
	Voorhees, Jennifer	 	Operations  Specialist	 	03/02/2020	 	Lombard	 	$	34,840.00	 	 	 	 	 
	Wadleigh, Shawna	 	Billing  Representative	 	11/07/2018	 	Salem	 	$	29,120.00	 	 	 	 	 
	Wagner, Rochelle	 	Scanning Clerk	 	03/05/2018	 	Chambersburg	 	$	25,521.60	 	 	 	 	 
	Walsh, Wendy	 	A/R Representative	 	06/21/2021	 	 	 	$	39,520.00	 	 	 	 	 
	Warden, Deborah	 	Clerical  Representative	 	03/02/2020	 	Lombard	 	$	30,763.20	 	 	 	 	 
	Weeks, Dreama	 	Poster	 	11/07/2018	 	Baltimore	 	$	40,934.40	 	 	 	 	 
	Whitfield, Keita	 	Clerical Rep	 	03/02/2020	 	Lombard	 	$	28,641.60	 	 	 	 	 
	Whitlock, Krista	 	Customer Service Rep	 	10/05/2020	 	Lombard	 	$	32,240.00	 	 	 	 	 
	Wilkerson, Korina	 	Healthcare  Administrator	 	10/13/2009	 	Lima	 	$	43,950.40	 	 	 	 	 
	William, Cheryl	 	A/R Representative	 	07/29/2019	 	Salem	 	$	39,520.00	 	 	 	 	 
	Wilson, Alexander	 	Provider Enrollment Assistant II	 	11/30/2020	 	Salem	 	$	40,560.00	 	 	 	 	 
	Wilson, Elizabeth	 	VP Client Management	 	09/01/2011	 	Salem	 	$	165,000.16	 	 	25	%	 
	Wilson, Shana	 	Customer Service Rep	 	07/19/2021	 	 	 	$	31,200.00	 	 	 	 	 
	Winters, Christina	 	Coder	 	11/07/2018	 	Baltimore	 	$	48,048.00	 	 	 	 	 
	Wonning, Angela	 	Coder	 	11/12/2018	 	City	 	$	47,840.00	 	 	 	 	 
	Young, Deborah	 	Coder	 	12/22/2015	 	Salem	 	$	56,160.00	 	 	 	 	 
	Young, Eva	 	Poster	 	05/09/2016	 	Lombard	 	$	31,200.00	 	 	 	 	 
	Zeis, Brenda	 	A/R Representative	 	10/17/1994	 	Chambersburg	 	$	36,483.20	 	 	 	 	 
	Ziegler, Tara	 	Customer Service Rep	 	04/12/2021	 	Lombard	 	$	32,240.00	 	 	 	 	 
	Christopher, Sunil	 	 	 	 	 	 	 	 	 	 	 	25	%	 

 

    45 

     

    

 

Schedule
3.15

Insurance

 

	Coverage/Policy	Carrier	General Limits	Policy Period	Agency	Policy #
	Property	 C.N.A.	$6.4MM Prop/$7.2MM Income	12/01/2020 - 12/01/2021	Eastern Insurance Grp	6079964653
	General
Liability	$1M Occurrence/$2M Aggregate
	Umbrella	$5MM	CUE 6079964684
	Automobile Liability: Hired & Non-Owned	$1MM	BUA 6079964667
	Employers Liability (Workman's Comp)	$1MM	WC 6079964670
	Foreign General Liability	C.N.A.	$2MM	12/01/2020
- 12/01/2021	Eastern
Insurance Grp	PST
67 3227624
	Foreign Automobile Liability	$1MM
	Foreign Employers Liability	$1MM
	Directors & Officers Liability	Zurich American Insurance Company	$5M Occurrence	1/31/2021
- 1/31/2022	B&B	MPL0646020-
03
	Employment Practice	$5M Occurrence
	Fiduciary Liability	$1M Occurrence
	Crime
Bond	National Union Fire Ins Co of Pittsburgh	  $1M	1/31/2021
- 1/31/2021	B&B	03-880-20-19
	Specialty Professional Liability	
National Union Fire Ins Co of Pittsburgh	 	7/26/20 - 8/28/21	B&B	01-590-56-48
	Media Content Insurance	$6M
	Security & Privacy Liability	$3M sublimit
	Network Interruption	 
	Event Management	 
	Cyber Extortion	 
	Professional
and Cyber Liability	Admiral Insurance Group	Combination limit of $1.5M total and $1.5M per occurrence	8/28/21-
8/28/22	B&B	EO000055243
-01
	Professional
and Cyber Liability	Hudson Insurance Group	$2M	8/28/21-
8/28/22	Marsh & McLennan Agency	EEU13744
01

 

    46 

     

    

 

Schedule
3.16

Tax Matters

 

(a)

 

None.

 

(b)

 

None. 

 

(c)

 

None. 

 

(d)

 

None.

 

(e)

 

The
New York State Department of Taxation and Finance has filed Tax Liens against the Company related to the failure to file franchise Tax
Returns and to pay franchise Taxes for the tax periods ending December 31, 2011, and December 31, 2013. The Company has a record of these
taxes being paid and the New York State Department of Taxation and Finance has confirmed that there are no outstanding taxes owed. In
order to update their records, the New York State Department of Taxation and Finance requested copies of the Company’s franchise
tax filings for 2011 and 2013, which copies the Company sent by certified mail on September 27, 2021.

 

(f)

 

None.

 

(g)

 

None.

 

    47 

     

    

 

(h)

 

In
2018, the Company responded to a nexus questionnaire from the State of Texas. The Company has two employees in Texas working from their
homes. Following the response, the State of Texas requested that the Company file certain franchise tax returns. The Company has complied
and is, as of the date of the Agreement, is in good standing with the State of Texas.

 

(i)

 

None.

 

(j)

 

None.

 

(k)

 

None.

 

(l)

 

None.

 

(m)

 

None.

 

(n)

 

None.

 

(o)

 

None.

 

    48 

     

    

 

(p)

 

None.

 

(q)

 

None.

 

(r)

 

None.

 

(r)

 

None.

 

(r)

 

None.

 

(s)

 

None.

 

(t)

 

None.

 

(u)

 

None.

 

    49 

     

    

 

(v)

 

None.

 

(w)

 

None.

 

(x)

 

None.

  

(y)

 

None.

 

(z)

 

None.

 

    50 

     

    

 

Schedule
3.17

Material
Permits; Healthcare Matters; Billing

 

(a)

 

		1.	Delaware

		2.	New
                                            York

		3.	New
                                            Jersey

		4.	Ohio

		5.	Pennsylvania

		6.	New
                                            Hampshire

		7.	Kentucky

		8.	Maryland

		9.	Massachusetts

		10.	New
                                            Hampshire

		11.	Connecticut

		12.	Illinois

		13.	Maine

 

(b)

 

None.

 

(c)

 

None.

 

    51 

     

    

 

Schedule
3.18

Real Property

 

(a)

 

	9
Northeastern Blvd, Salem NH 03079	EIP
Northeastern Boulevard, LLC	c/o
Equity Industrial Partners Corp, 20 Pickering Street, Second Flr, Needam, MA 02492 Attn:  Donald A. Levine
	30
Technology Dr., Ste. 1B, Warren NJ 07059	30
Technology PP, LLC	102
Chestnut Ridge Road, Suite 204, Montvale, NJ 07645.
	3181
Black Gap Rd, Chambersburg PA 17202	Ground
Spring, LLC	3431
Maclays Mill Rd, Shippensburg, PA 17257
	520
East 22nd St, Lombard IL 60148	Increase
Your Profit, LLC	56
Hillburn Lane, North Barrington, IL 60010
	Unit
530, 530 East 22nd St, Lombard IL 60148	530
22nd Street, LLC	360
W. Butterfield Rd, Ste 310 Elmhurst, IL 60126
	Chapel
Place Bldg B, Thomas More Pwky, Crestview Hills, KY 41017	Thomas
More/Hemmer IV, Ltd.	Attn:
John Hemmer, 250 Grandview Dr., Ste 100, Ft. Mitchell KY 41017
	3333
Madison Pike, Fort Wayne, KY 41011 Storage Unit #05127	Highland
LLC dba 3LSelf Storage	3333
Madison Pike, Fort Wayne, KY 41011
	20
Independence Dr, Ste 2B, Freeport ME 04032	FNT,
LLC	20
Independence Dr, Ste 1B, Freeport ME 04032
	3131
S Dixie Dr, Ste 535, Dayton OH 45439	3131
Dixie Drive, LLC	c/o
Farbman Group, 28400 Northwestern Hwy, 4th Flr, Southfield, MI 48034
	5550
Glades Road, Ste 500, Boca Raton FL 33431	Town
Center Executive Suites	5550
Glades Rd, Ste 500 Boca Raton, FL 33431
	4TH
FLOOR - #99/100, 2nd Flr Prestige Towers, Residency Rd, Bangalore, Karnataka INDIA 560025	Multiple
LL's - Refer to Lease	Multiple
Addresses - Refer to Lease
	2ND
FLOOR - #99/100, 2nd Flr Prestige Towers, Residency Rd, Bangalore, Karnataka INDIA 560025	Multiple
LL's - Refer to Lease	Multiple
Addresses - Refer to Lease
	1775
W Hibiscus Blvd, Ste 215, Melbourne FL 32901	Brevard
Physician Associates, PLLC	1775
W Hibicus Blvd., Ste 215, Melbourne, FL 32901
	9920
Franklin Square Dr, Ste 120 White Marsh MD 21236	FDS
FRANKLIN 9920, LLC	FDS
FRANKLIN 9920, LLC, c/o Jones Lang LaSalle, 8601 Robert Fulton Drive, Suite 220, Columbia MD 21046 Attn: Property Management
	4133
Old Jacksonville Rd, Suites A, B & C, Springfield, IL 62711	Meadowbrook
Holdings LLC	2714
Johnathan PL, Springfield, IL 62711

 

    52 

     

    

 

Schedule
3.19(a)

Material Clients

 

		 	Revenue
    FY19	 	 	Revenue
    FY20	 	 	Totals	 
	Client	 	 	$	 	 	 	$	 	 	 	$	 
	1.	 	Brevard Physician
    Associates	 	 	3,488,165	 	 	 	3,360,988	 	 	 	6,849,153	 
	2.	 	Anesthesia Group Practice, Inc.	 	 	2,407,282	 	 	 	2,326,407	 	 	 	4,733,689	 
	3.	 	Midwest Diagnostic Pathology,
    S.C.	 	 	1,980,323	 	 	 	1,842,881	 	 	 	3,823,204	 
	4.	 	Emerson Practice Associates	 	 	1,600,250	 	 	 	1,312,647	 	 	 	2,912,897	 
	5.	 	SIUH Regency	 	 	2,812,123	 	 	 	-	 	 	 	2,812,123	 
	6.	 	HRI Clinics, Inc.	 	 	1,375,683	 	 	 	1,333,122	 	 	 	2,708,805	 
	7.	 	Doctors Emergency Practice, P.A.	 	 	1,332,871	 	 	 	948,232	 	 	 	2,281,103	 
	8.	 	Clinical Radiologists SC	 	 	-	 	 	 	2,209,753	 	 	 	2,209,753	 
	9.	 	Northeast Behavioral Health Corporation	 	 	1,168,233	 	 	 	1,017,039	 	 	 	2,185,272	 
	10.	 	Clinical Colleagues, Inc.	 	 	1,146,505	 	 	 	971,032	 	 	 	2,117,537	 
	11.	 	Anesthesiology Service Network,
    LLC	 	 	1,095,313	 	 	 	1,015,625	 	 	 	2,110,938	 
	12.	 	Northwest Radiology Associates,
    SC	 	 	950,350	 	 	 	807,682	 	 	 	1,758,032	 
	13.	 	Oak Street Health LLC	 	 	854,723	 	 	 	903,070	 	 	 	1,757,793	 
	14.	 	Hospital for Special Surgery	 	 	906,985	 	 	 	748,523	 	 	 	1,655,508	 
	15.	 	Linn County Anesthesiologists,
    P.C	 	 	856,623	 	 	 	755,184	 	 	 	1,611,807	 
	16.	 	Bronx Lebanon Hospital Center	 	 	793,590	 	 	 	760,147	 	 	 	1,553,737	 
	17.	 	CHESAPEAKE MEDICAL IMAGING	 	 	953,759	 	 	 	393,531	 	 	 	1,347,290	 
	18.	 	Eliot Community Human Services	 	 	651,319	 	 	 	623,436	 	 	 	1,274,755	 
	19.	 	BIH Neurology Associates, Inc.	 	 	582,987	 	 	 	516,344	 	 	 	1,099,331	 
	20.	 	Respiratory Specialists LTD	 	 	565,208	 	 	 	526,390	 	 	 	1,091,598	 
	21.	 	Consolidated Pathology Consultants	 	 	393,625	 	 	 	623,131	 	 	 	1,016,756	 
	22.	 	Livingston Pathology Associates,
    LLC	 	 	502,940	 	 	 	436,585	 	 	 	939,525	 
	23.	 	Johnson County Anesthesia	 	 	466,315	 	 	 	411,630	 	 	 	877,945	 
	24.	 	Mercy Hospital, Inc.	 	 	439,580	 	 	 	385,287	 	 	 	824,867	 
	25.	 	DuPage Pathology Associates,
    S.C.	 	 	420,444	 	 	 	400,127	 	 	 	820,571	 
	26.	 	Arlington Ridge Pathology	 	 	434,628	 	 	 	371,501	 	 	 	806,129	 
	27.	 	HCT PATHOLOGY SERVICES, LLC	 	 	410,190	 	 	 	366,486	 	 	 	776,676	 
	28.	 	SPN - Steward Medical Group	 	 	388,680	 	 	 	336,470	 	 	 	725,150	 
	29.	 	Eclipsys (SUNY Downstate)	 	 	347,964	 	 	 	369,368	 	 	 	717,332	 
	30.	 	Diagnostic Pathology Consultants,
    PA	 	 	313,826	 	 	 	381,440	 	 	 	695,266	 
	31.	 	DRS. HICKEN, CRANLEY, & TAYLOR,
    PA	 	 	370,690	 	 	 	306,421	 	 	 	677,111	 
	32.	 	NBM - New England Baptists Medical
    Assoc	 	 	352,055	 	 	 	307,726	 	 	 	659,781	 
	33.	 	TILL Inc.	 	 	343,701	 	 	 	284,301	 	 	 	628,002	 

  

    53 

     

    

 

	 	 	Revenue
    FY19	 	 	Revenue
    FY20	 	 	Totals	 
	Client	 	$	 	 	$	 	 	$	 
	34.	 	Anes. Assoc. of Lima	 	 	342,907	 	 	 	284,006	 	 	 	626,913	 
	35.	 	Addison Central Pathology, S.C.	 	 	321,361	 	 	 	302,786	 	 	 	624,147	 
	36.	 	Associated Pathologists	 	 	265,425	 	 	 	338,433	 	 	 	603,858	 
	37.	 	CRF - Children’s Hospital
    Coding 2019	 	 	328,499	 	 	 	275,206	 	 	 	603,705	 
	38.	 	Pathology Services of Springfield	 	 	296,481	 	 	 	302,703	 	 	 	599,184	 
	39.	 	University Physicians of Brooklyn,
    Inc.	 	 	323,936	 	 	 	266,400	 	 	 	590,336	 
	40.	 	McHenry Pathology Associates,
    SC	 	 	232,142	 	 	 	227,995	 	 	 	460,137	 

  

(i)

 

None.

 

(ii)

 

		1.	Items
                                            1 through 5 of Schedule 3.7(h) of this Disclosure Schedule are incorporated by reference
                                            herein.

 

		2.	In
                                            January 2021, the Service Agreement with Anesthesia Associates of Lima renewed for a three-year
                                            period. On July 19, 2021, Anesthesia Associates of Lima notified the Company that it intends
                                            to terminate the service agreement with the Company effective October 1, 2021. The Company
                                            has informed the customer that they remain under contract through the term, as agreed. The
                                            Company did provide the customer with an opportunity to terminate the agreement upon 90 days’
                                            notice on September 2022, fifteen months before the expiration of the contract.

 

		3.	On
                                            September 1, 2021, Brevard Physician Associates provided notice of its intent to terminate
                                            the BPA Services Agreement, effective January 1, 2022.

 

(iii)

 

		1.	The
                                            Company amended its July 17, 2018 Services Agreement with Johnson County Anesthesiologists
                                            Chartered effective as of October 1, 2021.

 

    54 

     

    

 

Schedule
3.19(b) 

Material Suppliers

 

	 	 	FY 19	 	 	FY 20	 	 	Totals	 
	Vendor/Supplier	 	$	 	 	$	 	 	$	 
	1.	 	Centron Data Services,
    Inc.	 	 	1,640,432	 	 	 	1,300,796	 	 	 	2,941,228	 
	2.	 	United Healthcare	 	 	-	 	 	 	2,075,917	 	 	 	2,075,917	 
	3.	 	GeBBS Healthcare Solutions	 	 	1,022,025	 	 	 	876,371	 	 	 	1,898,396	 
	4.	 	Cigna	 	 	914,508	 	 	 	-	 	 	 	914,508	 
	5.	 	American Express	 	 	618,673	 	 	 	289,268	 	 	 	907,941	 
	6.	 	Connectria, LLC	 	 	311,756	 	 	 	339,292	 	 	 	651,048	 
	7.	 	Change Healthcare	 	 	320,842	 	 	 	329,522	 	 	 	650,364	 
	8.	 	Hexplora LLC	 	 	248,340	 	 	 	352,180	 	 	 	600,520	 
	9.	 	Optum	 	 	292,048	 	 	 	287,216	 	 	 	579,264	 
	10.	 	UHY LLP	 	 	263,528	 	 	 	264,648	 	 	 	528,176	 
	11.	 	Accur8 Software	 	 	290,894	 	 	 	236,500	 	 	 	527,394	 
	12.	 	Reliance Standard	 	 	174,751	 	 	 	167,981	 	 	 	342,732	 
	13.	 	AETNA	 	 	166,971	 	 	 	153,546	 	 	 	320,517	 
	14.	 	Duane Morris LLP	 	 	100,000	 	 	 	204,586	 	 	 	304,586	 
	15.	 	BA Securities, LLC	 	 	180,000	 	 	 	108,000	 	 	 	288,000	 
	16.	 	W. B. Mason Co., Inc	 	 	124,910	 	 	 	116,712	 	 	 	241,622	 
	17.	 	Comcast	 	 	112,967	 	 	 	128,204	 	 	 	241,171	 
	18.	 	Certify	 	 	139,472	 	 	 	82,502	 	 	 	221,974	 
	19.	 	IPFS Corporation	 	 	91,622	 	 	 	104,684	 	 	 	196,306	 
	20.	 	ITSavvy LLC	 	 	110,673	 	 	 	74,709	 	 	 	185,382	 

 

(i)

 

None.

 

(ii)

 

None.

 

(iii)

 

None.

 

    55 

     

    

 

Schedule
3.20

Foreign
Corrupt Practices Act

 

None.

 

    56 

     

    

 

Schedule
3.21

Brokers

 

None.

 

    57 

     

    

 

EXHIBIT
B

 

FORM
OF ESCROW AGREEMENT

 

(see
attached)

 

    

     

    

 

Execution
Version

 

ESCROW
AGREEMENT

 

This
Escrow Agreement, dated this 30th day of September, 2021 (this “Escrow Agreement”), is entered into
by and among HPI Holdings, LLC, a Delaware limited liability company (“Parent”), Shareholder Representative
Services LLC, a Colorado limited liability company, solely in its capacity as the representative of the Company Stockholders (“Stockholders’
Representative,” and together with Parent, the “Parties,” and each individually, a “Party”),
and WILMINGTON TRUST, N.A., as escrow agent (“Escrow Agent”).

 

RECITALS

 

A.            Pursuant
to an Agreement and Plan of Merger, dated as of the date hereof (the “Merger Agreement”), by and among Parent,
Stockholders’ Representative, AdvantEdge Healthcare Holdings, Inc., a Delaware corporation (the “Company”),
and the other parties thereto, Parent agreed to acquire (indirectly through its wholly owned subsidiary) the Company from the Company
Stockholders in exchange for the Merger Consideration. Capitalized terms used but not defined herein shall have the meanings ascribed
to them in the Merger Agreement.

 

B.             The
Parties acknowledge that the Escrow Agent is not a party to, is not bound by, and has no duties or obligations under, the Merger Agreement,
that all references in this Escrow Agreement to the Merger Agreement are for convenience, and that the Escrow Agent shall have no implied
duties beyond the express duties set forth in this Escrow Agreement.

 

C.             The
Parties agree to place in escrow certain funds and the Escrow Agent agrees to hold and distribute such funds in accordance with the terms
of this Escrow Agreement.

 

D.             Pursuant
to Section 2.9(a) of the Merger Agreement, Parent is obligated at the Closing to deposit or cause to be deposited with the Escrow Agent,
(x) an amount of cash equal to $800,000 (the “Indemnity Escrow Amount”) into a separate escrow account (the
 “Indemnity Escrow Account”) for the purpose of securing the Company Stockholders’ indemnification obligations
set forth in Article VIII of the Merger Agreement, (y) an amount of cash equal to $375,000 (the “Adjustment Escrow Amount”)
into a separate account (the “Adjustment Escrow Account”) for the purpose of securing the purchase price obligations
set forth in Section 2.9(c) of the Merger Agreement and (z) an amount of cash equal to $16,800,000 (the “Earnout Escrow Amount”)
into a separate escrow account (the “Earnout Escrow Account,” and together with the Indemnity Escrow Account
and the Adjustment Escrow Account, collectively, the “Escrow Accounts”) for the purpose of securing the Earnout
Payment to the Company Stockholders in accordance with Section 2.10 and Exhibit D of the Merger Agreement.

 

E.             The
parties to the Merger Agreement have engaged Acquiom Financial LLC, a Colorado limited liability company (the “Payments Administrator”),
to act as payments administrator in connection with certain payments made pursuant to the Merger Agreement and this Escrow Agreement.

 

    1 

     

    

 

In
consideration of the promises and agreements of the Parties and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged, the Parties and the Escrow Agent agree as follows:

 

ARTICLE
1

 ESCROW DEPOSIT

 

Section
1.1            Receipt of Escrow Property.

 

(a)            Receipt
of Escrow Property. Pursuant to the terms of the Merger Agreement, upon execution hereof, (A) Parent shall deliver to the Escrow
Agent (i) the Indemnity Escrow Amount in immediately available funds, and the Escrow Agent shall thereafter deposit the Indemnity Escrow
Amount into the Indemnity Escrow Account (the “Indemnity Escrow Property”), (ii) the Adjustment Escrow Amount
in immediately available funds, and the Escrow Agent shall thereafter deposit the Adjustment Escrow Amount into the Adjustment Escrow
Account (the “Adjustment Escrow Property”) and (iii) the Earnout Escrow Amount in immediately available funds,
and the Escrow Agent shall thereafter deposit the Earnout Escrow Amount into the Earnout Escrow Account (the “Earnout Escrow
Property,” and together with the Indemnity Escrow Property and the Adjustment Escrow Property, collectively, the “Escrow
Property”). The Escrow Agent agrees to acknowledge receipt of the Escrow Property upon receipt thereof. The Escrow Property
deposited in the Indemnity Escrow Account, the Adjustment Escrow Account and the Earnout Escrow Account shall remain un-invested during
the term of the Escrow Agreement.

 

(b)           Separate
Accounts. All amounts held in the Escrow Accounts shall be held and managed in separate accounts or sub-accounts established by the
Escrow Agent and shall not be commingled. The Escrow Agent will hold the Indemnity Escrow Property, the Adjustment Escrow Property and
the Earnout Escrow Property in separate escrow accounts, not subject to any voluntary lien, attachment, trustee process or any other
judicial process of any creditor of any Company Stockholder or any creditor of a party hereto. The Escrow Property shall be held and
distributed pursuant to the terms and conditions of this Escrow Agreement. Except as Parent and Stockholders’ Representative may
otherwise agree in writing, no part of the Escrow Property may be withdrawn except as expressly provided in this Escrow Agreement. The
Escrow Agent shall keep an accurate record of all transactions with respect to the Escrow Account.

 

Section
1.2            Disbursements.

 

(a)            Disposition
and Termination of the Indemnity Escrow Property. The Parties shall act in accordance with, and the Escrow Agent shall hold and release
the Indemnity Escrow Property as provided in, this Section 1.2(a) as follows:

 

(i)            If,
at any time and from time to time prior to 11:59 p.m., Eastern time, on the date that is fourteen (14) months following the date of this
Escrow Agreement (the “Indemnity Escrow Termination Date”), Parent of any Parent Indemnitee (as defined in
the Merger Agreement) makes a claim in accordance with the terms of Article VIII of the Merger Agreement (each, an “Indemnification
Claim”), then Parent shall be entitled to deliver to the Escrow Agent, with a copy to the Stockholders’ Representative,
a written notice of such Indemnification Claim (an “Indemnification Claim Notice”), which Indemnification Claim
Notice shall set forth the specific amount of Losses subject to the applicable Indemnification Claim (the “Claimed Amount”),
which Claimed Amount cannot exceed the balance of the Indemnity Escrow Property. For the avoidance of doubt, any such written notice
shall include a copy of the Claim Notice previously delivered to Stockholders’ Representative seeking indemnification with respect
to such Indemnification Claim pursuant to Article VIII of the Merger Agreement. The Escrow Agent shall not release the Claimed Amount
set forth in an Indemnification Claim Notice received in accordance with this Section 1.2(a)(i) unless and until instructed to
do so pursuant to and in accordance with Sections 1.2(a)(ii)-(iii).

 

    2 

     

    

 

 

(ii)          This
Escrow Agreement shall not limit or otherwise modify in any way the events or circumstances which give rise to the obligation of any
Company Stockholder to make any payments pursuant to the Merger Agreement, or limit or otherwise modify in any way the procedures and
other provisions applicable to such obligations of the Company Stockholders, but shall solely provide Parent security therefor. The Escrow
Agent shall disburse all or any portion of the Indemnity Escrow Property as follows:

 

(A)       At
any time, within three (3) Business Days following receipt by the Escrow Agent of a Joint Direction or a Final Order with respect to
all or any portion of the Indemnity Escrow Property, the Escrow Agent shall disburse the Indemnity Escrow Property or applicable portion
thereof in accordance with such Joint Direction or Final Order.

 

(B)       Promptly
following the Indemnity Escrow Termination Date, upon receipt of a Joint Direction, the Escrow Agent shall release the remaining Indemnity
Escrow Property in the Indemnity Escrow Account then held by the Escrow Agent to the Payments Administrator (for further payment to the
Company Stockholders in accordance with the terms of the Merger Agreement), less the aggregate amount of the Reserve. For
purposes of this Agreement, the “Reserve” shall mean, as of the Indemnity Escrow Termination Date, the aggregate
amount of all then pending bona fide Indemnification Claims made in good faith as set forth in the Indemnification Claim Notices relating
thereto.

 

(iii)          The
Escrow Agent shall be entitled to assume conclusively and without independent investigation that evidence of a Final Order is sufficient
and shall have no duty to determine whether any such Final Order complies with the Merger Agreement. Any Party that delivers a Final
Order to the Escrow Agent shall concurrently deliver a copy of such Final Order to the other Party.

 

(iv)          All
payments of any part of the Indemnity Escrow Property shall be made by wire transfer of immediately available funds as set forth in the
Joint Direction or Final Order, as applicable.

 

(b)          Disposition
and Termination of the Adjustment Escrow Property. The Parties shall act in accordance with, and the Escrow Agent shall hold and
release the Adjustment Escrow Property as provided in, this Section 1.2(b) as follows:

 

(i)             If
the Actual Adjustment is a positive amount, then within three (3) Business Days after the final determination of such amount becomes
final in accordance with Section 2.9(b) of the Merger Agreement, Parent and Stockholders’ Representative will deliver a Joint Direction
to the Escrow Agent to release any remaining Adjustment Escrow Property to the Payments Administrator for further distribution to the
Company Stockholders in accordance with Section 2.9(c)(i) of the Merger Agreement. The Escrow Agent shall promptly, but in any event
within three (3) Business Days after receipt of such Joint Direction, disburse as directed, part or all, as the case may be, of the Adjustment
Escrow Property (but only to the extent funds are available in the Adjustment Escrow Account) in accordance with such Joint Direction.

 

(ii)           If
the Actual Adjustment is a negative amount, then within three (3) Business Days after the final determination of such amount becomes
final in accordance with Section 2.9(b) of the Merger Agreement, Parent and Stockholders’ Representative will deliver a Joint Direction
to the Escrow Agent to (A) release an amount equal to the absolute value of such negative amount from the Adjustment Escrow Property
to Parent and (B) release the funds remaining (if any) in the Adjustment Escrow Account after giving effect to clause (A), to the Payments
Administrator for further distribution to the Company Stockholders in accordance with Section 2.9(c)(ii) of the Merger Agreement. The
Escrow Agent shall promptly, but in any event within three (3) Business Days after receipt of such Joint Direction, disburse as directed,
part or all, as the case may be, of the Adjustment Escrow Property (but only to the extent funds are available in the Adjustment Escrow
Account) in accordance with such Joint Direction.

 

(iii)          Upon
receipt by the Escrow Agent of a copy of a Final Order from any Party, with respect to the Adjustment Escrow Property, the Escrow Agent
shall promptly, but in any event within three (3) Business Days after receipt of such Final Order, disburse as directed, part or all,
as the case may be, of the Adjustment Escrow Property (but only to the extent funds are available in the Adjustment Escrow Account) in
accordance with such Final Order. The Escrow Agent will act on such Final Order without further inquiry. Any Party that delivers a Final
Order to the Escrow Agent shall concurrently deliver a copy of such Final Order to the other Party.

 

(iv)          All
payments of any part of the Adjustment Escrow Property shall be made by wire transfer of immediately available funds or check as set
forth in the Joint Direction or Final Order, as applicable.

 

    3 

     

    

 

(c)          Disposition
and Termination of the Earnout Escrow Property. The Parties shall act in accordance with, and the Escrow Agent shall hold and release
the Earnout Escrow Property as provided in, this Section 1.2(c) as follows:

 

(i)            If
the Earnout Payment is more than the Earnout Escrow Property, then within three (3) Business Days after the final determination of such
amount becomes final in accordance with Exhibit D of the Merger Agreement, Parent and Stockholders’ Representative will deliver
a Joint Direction to the Escrow Agent to release the Earnout Escrow Property in full from the Earnout Escrow Account to the Surviving
Corporation, for further distribution to the Program Participants as set forth in the Consideration Spreadsheet in accordance with the
Management Carve-out Program, and the Payments Administrator, for further distribution to the Company Stockholders in accordance with
Section 2.10(b) of the Merger Agreement. The Escrow Agent shall promptly, but in any event within three (3) Business Days after receipt
of such Joint Direction, disburse as directed, part or all, as the case may be, of the Earnout Escrow Property (but only to the extent
funds are available in the Earnout Escrow Account) in accordance with such Joint Direction.

 

(ii)           If
the Earnout Payment is less than the Earnout Escrow Property, then within three (3) Business Days after the final determination of such
amount becomes final in accordance with Exhibit D of the Merger Agreement, Parent and Stockholders’ Representative will deliver
a Joint Direction to the Escrow Agent to deliver (A) an amount equal to the Earnout Payment to the Surviving Corporation, for further
distribution to the Program Participants as set forth in the Consideration Spreadsheet in accordance with the Management Carve-out Program,
and/or the Payments Administrator, for further distribution to the Company Stockholders in accordance with Section 2.10(c) of the Merger
Agreement, and (B) to Parent the amount of Earnout Escrow Property remaining in the Earnout Escrow Account following the payment of the
Earnout Payment contemplated in clause (A) of this Section 1.2(c)(ii). The Escrow Agent shall promptly, but in any event within
three (3) Business Days after receipt of such Joint Direction, disburse as directed, part or all, as the case may be, of the Earnout
Escrow Property (but only to the extent funds are available in the Earnout Escrow Account) in accordance with such Joint Direction.

 

(iii)          Upon
receipt by the Escrow Agent of a copy of a Final Order from any Party, with respect to the Earnout Escrow Property, the Escrow Agent
shall promptly, but in any event within three (3) Business Days after receipt of such Final Order, disburse as directed, part or all,
as the case may be, of the Earnout Escrow Property (but only to the extent funds are available in the Earnout Escrow Account) in accordance
with such Final Order. The Escrow Agent will act on such Final Order without further inquiry. Any Party that delivers a Final Order to
the Escrow Agent shall concurrently deliver a copy of such Final Order to the other Party.

 

(iv)          Promptly
following the Earnout Period, upon receipt of a Joint Direction, the Escrow Agent shall release the remaining Earnout Escrow Property
in the Earnout Escrow Account then held by the Escrow Agent to Parent.

 

    4 

     

    

 

(v)          All
payments of any part of the Earnout Escrow Property shall be made by wire transfer of immediately available funds or check as set forth
in the Joint Direction or Final Order, as applicable.

 

(d)          In
the event that the Escrow Agent makes any payment to any other party pursuant to this Escrow Agreement and for any reason such payment
(or any portion thereof) is required to be returned to an Escrow Account or another party or is subsequently invalidated, declared to
be fraudulent or preferential, set aside and/or required to be repaid to a receiver, trustee or other party under any bankruptcy or insolvency
law, other federal or state law, common law or equitable doctrine, then the recipient shall repay to the Escrow Agent upon written request
the amount so paid to it.

 

(e)          The
Escrow Agent will furnish monthly statements to the Parties setting forth the activity in the Escrow Accounts.

 

(f)           The
Parties acknowledge that, pursuant to Section 2.8(g) of the Merger Agreement, Parent, the Surviving Corporation, Merger Sub and any authorized
agent of the foregoing (including, the Payments Administrator) have the right to deduct and withhold any required Taxes (including any
Employment Taxes) from any payments to be made under the Merger Agreement and this Escrow Agreement. Notwithstanding anything in this
Escrow Agreement to the contrary, if Parent, the Surviving Corporation, Merger Sub and any authorized agent of the foregoing (including,
the Payments Administrator) is required to deduct or withhold any Taxes (including any Employment Taxes) under applicable Law from any
disbursements made pursuant to Section 1.2(a), Section 1.2(b) or Section 1.2(c), (i) the
Parties shall instruct the Escrow Agent to transfer to Parent, the Surviving Corporation, Merger Sub and any authorized agent of the
foregoing (including, the Payments Administrator), as the case may be, the amount of such Taxes prior to any such disbursement and (ii)
Parent, Surviving Corporation, Merger Sub and any authorized agent of the foregoing (including, the Payments Administrator) shall timely
pay such Taxes to the appropriate Governmental Entity.

 

Section
1.3 Security Procedure for Funds Transfer. Concurrent with the execution of this Escrow Agreement, the Parties shall deliver to the
Escrow Agent authorized signers’ forms in the form of Exhibit A-1 and Exhibit A-2 to this Escrow Agreement listing
individuals of such Party who are authorized to provide the Escrow Agent with a Joint Direction and any other written instruction permitted
pursuant to the terms of this Escrow Agreement (each an “Authorized Representative”). Each Party understands
and agrees that the Escrow Agent shall have no obligation or duty to act upon a written instruction for the disbursement of Escrow Property
under this Escrow Agreement if such written instruction is not signed by an Authorized Representative of such Party and such written
instruction is not delivered to, and able to be authenticated by, the Escrow Agent in accordance with this Escrow Agreement. The Escrow
Agent shall follow internal policies and procedures when confirming the validity or authenticity of funds transfer instructions received
in the name of the Parties, which may include a callback to one or more of the authorized individuals evidenced in Exhibit A-1
and Exhibit A-2. Once delivered to the Escrow Agent, Exhibit A-1 or Exhibit A-2 may be revised or rescinded only
in writing signed by an authorized representative of the applicable Party. Such revisions or rescissions shall be effective only after
actual receipt and following such period of time as may be necessary to afford the Escrow Agent a reasonable opportunity to act on it.
If a revised Exhibit A-1 or Exhibit A-2 or a rescission of an existing Exhibit A-1 or Exhibit A-2 is delivered
to the Escrow Agent by an entity that is a successor-in-interest to either Party, such document shall be accompanied by additional documentation
satisfactory to the Escrow Agent showing that such entity has succeeded to the rights and responsibilities of the applicable Party. The
Parties understand that the Escrow Agent’s inability to receive or confirm funds transfer instructions may result in a delay in
accomplishing such funds transfer, and agree that the Escrow Agent shall not be liable for any loss caused by any such delay.

 

    5 

     

    

 

Section
1.4        Income Tax Reporting.

 

(a)       The
Parties shall, upon the execution of this Agreement, provide the Escrow Agent with their duly completed and properly executed IRS Forms
W-9, together with any other documentation and information requested by the Escrow Agent in connection with the Escrow Agent’s
tax reporting obligations under the Internal Revenue Code of 1986, as amended (the “Code”), and the regulations
thereunder. The Parties agree that Parent shall be treated as the owner of the Escrow Property for U.S. federal income tax purposes until
such property is released pursuant to Section 1.2.

 

(b)       The
Escrow Agent shall comply with any reporting with respect to imputed interest income arising pursuant to Sections 483 and 1274 of the
Code (or any similar provision of foreign, state or local law) with respect to the release of any Indemnity Escrow Property pursuant
to Section 1.2(a) or any Earnout Escrow Property pursuant to Section 1.2(c), which amount shall be calculated by Parent
and provided to the Escrow Agent; provided, that the Escrow Agent shall not be obligated to verify such calculation. Parent shall
provide the Escrow Agent at the time of disbursement a detailed schedule indicating the allocation of the disbursement amount from the
Indemnity Escrow Property and the Earnout Escrow Property between (i) principal and (ii) imputed interest to be reported as income of
each Company Stockholder on an IRS Form 1099-INT.

 

(c)       Should
the Escrow Agent become liable for the payment of taxes, including withholding taxes relating to any funds, including interest and penalties
thereon, held by it pursuant to this Agreement or any payment made hereunder, the Escrow Agent shall satisfy such liability to the extent
possible from the Escrow Property. Parent and the Stockholders’ Representative agree, jointly and severally, to indemnify and hold
the Escrow Agent harmless pursuant to and in accordance with Section 3.1 hereof from any liability or obligation on account of taxes,
assessments, interest, penalties, expenses and other governmental charges that may be assessed or asserted against the Escrow Agent,
absent the Escrow Agent’s fraud, gross negligence or willful misconduct (as finally adjudicated by a court of competent jurisdiction).

 

(d)       The
Escrow Agent’s rights under this Section 1.4 shall survive the termination of this Agreement or the resignation or removal
of the Escrow Agent.

 

Section
1.5 Termination. Upon the disbursement of all of the Escrow Property, this Escrow Agreement shall terminate and be of no further
force and effect.

 

ARTICLE
2

DUTIES
OF THE ESCROW AGENT

 

Section
2.1 Scope of Responsibility. Notwithstanding any provision to the contrary, the Escrow Agent is obligated only to perform the duties
specifically set forth in this Escrow Agreement, which shall be deemed purely ministerial in nature. Under no circumstances will the
Escrow Agent be deemed to be a fiduciary to any Party or any other Person under this Escrow Agreement. The Escrow Agent will not be responsible
or liable for the failure of any Party to perform in accordance with this Escrow Agreement. The Escrow Agent shall neither be responsible
for, nor chargeable with, knowledge of the terms and conditions of any other agreement, including but not limited to the Merger Agreement,
instrument, or document other than this Escrow Agreement, whether or not a copy of such agreement has been provided to the Escrow Agent;
and the Escrow Agent shall have no duty to know or inquire as to the performance or nonperformance of any provision of any such agreement,
instrument, or document. References in this Escrow Agreement to any other agreement, instrument, or document are for the convenience
of the Parties, and the Escrow Agent has no duties or obligations with respect thereto. This Escrow Agreement sets forth all matters
pertinent to the escrow contemplated hereunder, and no additional obligations of the Escrow Agent shall be inferred or implied from the
terms of this Escrow Agreement or any other agreement.

 

    6 

     

    

 

Section
2.2 Attorneys and Agents. The Escrow Agent shall be entitled to rely on and shall not be liable for any action taken or omitted
to be taken by the Escrow Agent in accordance with the advice of counsel or other professionals retained or consulted by the Escrow Agent.
The Escrow Agent shall be reimbursed as set forth in Section 3.1 for any and all compensation (fees, expenses and other costs)
paid and/or reimbursed to such counsel and/or professionals. The Escrow Agent may perform any and all of its duties through its agents,
representatives, attorneys, custodians, and/or nominees.

 

Section
2.3 Reliance. The Escrow Agent shall not be liable for any action taken or not taken by it in accordance with the direction
or consent of the Parties or their respective agents, representatives, successors, or assigns, other than in the event of the Escrow
Agent’s fraud, gross negligence or willful misconduct. The Escrow Agent shall not be liable for acting or refraining from acting
upon any notice, request, consent, direction, requisition, certificate, order, affidavit, letter, or other paper or document believed
by it to be genuine and correct and to have been signed or sent by an Authorized Representative, without further inquiry into the person’s
or persons’ authority, other than in the event of the Escrow Agent’s fraud, gross negligence or willful misconduct. The Escrow
Agent shall be entitled to request and receive written instructions from the Parties and shall have no responsibility or liability for
any losses or damages of any nature that may arise from any action taken or not taken by the Escrow Agent in accordance with the written
direction of the Parties, other than in the event of the Escrow Agent’s fraud, gross negligence or willful misconduct. The Escrow
Agent shall have no responsibilities (except as expressly set forth herein) as to the validity, sufficiency, value, genuineness, ownership
or transferability of the Escrow Property, written instructions, or any other documents in connection therewith, and will not be regarded
as making nor be required to make, any representations thereto.

 

Section
2.4 Right Not Duty Undertaken. The permissive rights of the Escrow Agent to do things enumerated in this Escrow Agreement
shall not be construed as duties.

 

ARTICLE
3

PROVISIONS
CONCERNING THE ESCROW AGENT

 

Section
3.1 Indemnification. The Parties hereby agree, jointly and severally, to indemnify Escrow Agent, its directors, officers,
employees and agents (collectively, the “Indemnified Parties”), and hold the Indemnified Parties harmless from
any and against all liabilities, losses, actions, suits or proceedings at law or in equity, and any other reasonable expenses, fees or
charges of any character or nature, including, without limitation, reasonable and documented attorney’s fees and expenses of one
outside counsel, which an Indemnified Party may incur or with which it may be threatened by reason of acting as or on behalf of Escrow
Agent under this Agreement or arising out of the existence of the Escrow Accounts, except to the extent the same shall have been caused
by the Escrow Agent’s fraud, gross negligence or willful misconduct; provided that solely between the Parties, Parent, on
the one hand, and Stockholders’ Representative (on behalf of the Company Stockholders), on the other hand, (without limitation
to any indemnification obligations under the Merger Agreement) shall each only be liable for fifty percent (50%) of any amounts owed
to the Escrow Agent under this Section 3.1. The Escrow Agent shall have a first lien against the Escrow Accounts to secure the
obligations of the Parties hereunder. The terms of this Section 3.1 shall survive the termination of this Escrow Agreement and
the resignation or removal of the Escrow Agent.

 

Section
3.2 Limitation of Liability. THE ESCROW AGENT SHALL NOT BE LIABLE, DIRECTLY OR INDIRECTLY, FOR ANY (I) DAMAGES, LOSSES OR
EXPENSES ARISING OUT OF THE SERVICES PROVIDED HEREUNDER, OTHER THAN DAMAGES, LOSSES OR EXPENSES WHICH HAVE BEEN FINALLY ADJUDICATED TO
HAVE DIRECTLY RESULTED FROM THE ESCROW AGENT’S FRAUD, GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR (II) SPECIAL,
INDIRECT PUNITIVE OR CONSEQUENTIAL DAMAGES OR LOSSES OF ANY KIND WHATSOEVER (INCLUDING WITHOUT LIMITATION LOST PROFITS), EVEN IF THE
ESCROW AGENT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES AND REGARDLESS OF THE FORM OF ACTION.

 

    7 

     

    

 

Section
3.3 Resignation or Removal. The Escrow Agent may resign by furnishing written notice of its resignation to the Parties, and
the Parties may remove the Escrow Agent by furnishing to the Escrow Agent a Joint Direction of its removal along with payment of all
fees and expenses to which it is entitled through the date of termination, which shall be borne fifty percent (50%) by Parent and fifty
percent (50%) by the Stockholders’ Representative (on behalf of the Company Stockholders). Such resignation or removal, as the
case may be, shall be effective thirty (30) calendar days after the delivery of such notice or upon the earlier appointment of a successor,
and the Escrow Agent’s sole responsibility thereafter shall be to safely keep the Escrow Property and to deliver the same to a
successor escrow agent as shall be appointed by the Parties, as evidenced by a Joint Direction filed with the Escrow Agent or in accordance
with a court order. If the Parties have failed to appoint a successor escrow agent prior to the expiration of thirty (30) calendar days
following the delivery of such notice of resignation or removal, the Escrow Agent may petition any court of competent jurisdiction for
the appointment of a successor escrow agent or for other appropriate relief, and any such resulting appointment shall be binding upon
the Parties.

 

Section
3.4 Compensation. The Escrow Agent shall be entitled to compensation for its services as stated in the fee schedule attached
hereto as Exhibit B, which compensation shall be paid fifty percent (50%) by Parent and fifty percent (50%) by Stockholders’
Representative (on behalf of the Company Stockholders). The fee agreed upon for the services rendered hereunder is intended as compensation
for the Escrow Agent’s services as contemplated by this Escrow Agreement; provided, however, that in the event that
the conditions for the disbursement of funds under this Escrow Agreement are not fulfilled, or the Escrow Agent renders any service not
contemplated in this Escrow Agreement, or there is any assignment of interest in the subject matter of this Escrow Agreement, or any
material modification hereof, or if any material controversy arises hereunder, or the Escrow Agent is made a party to any litigation
pertaining to this Escrow Agreement or the subject matter hereof, then the Escrow Agent shall be compensated for such extraordinary services
and reimbursed for all reasonable and documented out-of-pocket costs and expenses, including reasonable and documented attorneys’
fees and expenses of one outside counsel, occasioned by any such delay, controversy, litigation or event, other than in the event that
the Escrow Agent’s fraud, gross negligence or willful misconduct is at issue in any such litigation; provided that solely
between the Parties, Parent, on the one hand, and Stockholders’ Representative (on behalf of the Stockholders), on the other hand,
shall each only be liable for fifty percent (50%) of such fees and expenses. The terms of this Section 3.4 shall survive the termination
of this Escrow Agreement and the resignation or removal of the Escrow Agent.

 

Section
3.5 Disagreements. If any conflict, disagreement or dispute arises between, among, or involving any of the parties hereto
concerning the meaning or validity of any provision hereunder or concerning any other matter relating to this Escrow Agreement, or the
Escrow Agent is in doubt as to the action to be taken hereunder, the Escrow Agent shall be fully protected and may, at its option, retain
the Escrow Property until the Escrow Agent (i) receives a Final Order directing delivery of the Escrow Property, in which event the Escrow
Agent shall be authorized to disburse the Escrow Property in accordance with such Final Order, (ii) receives Joint Direction directing
delivery of the Escrow Property, in which event the Escrow Agent shall be authorized to disburse the Escrow Property in accordance with
such Joint Direction, or (iii) files an interpleader action in any court of competent jurisdiction, and upon the filing thereof, the
Escrow Agent shall be relieved of all liability as to the Escrow Property and shall be entitled to recover reasonable and documented
attorneys’ fees of one outside counsel, expenses and other reasonable and documented out-of-pocket costs incurred in commencing
and maintaining any such interpleader action; provided that solely between the Parties, Parent, on the one hand, and Stockholders’
Representative (on behalf of the Stockholders), on the other hand, shall each only be liable for fifty percent (50%) of such fees and
expenses. The Escrow Agent shall be entitled to act on any such agreement, court order, or arbitration decision without further question,
inquiry, or consent.

 

    8 

     

    

 

Section
3.6 Merger or Consolidation. Any corporation or association into which the Escrow Agent may be converted or merged, or with
which it may be consolidated, or to which it may sell or transfer all or substantially all of its corporate trust business and assets
as a whole or substantially as a whole, or any corporation or association resulting from any such conversion, sale, merger, consolidation
or transfer to which the Escrow Agent is a party, shall be and become the successor escrow agent under this Escrow Agreement and shall
have and succeed to the rights, powers, duties, immunities and privileges as its predecessor, without the execution or filing of any
instrument or paper or the performance of any further act. The Escrow Agent shall provide prior written notice to the Parties in the
event of such conversion, sale, merger, consolidation or transfer.

 

Section
3.7 Attachment of Escrow Property; Compliance with Legal Orders. In the event that any Escrow Property shall be attached,
garnished or levied upon by any court order, or the delivery thereof shall be stayed or enjoined by an order of a court, or any order,
judgment or decree shall be made or entered by any court order affecting the Escrow Property, the Escrow Agent is hereby expressly authorized,
in its sole discretion, to respond as it deems appropriate or to comply with all writs, orders or decrees so entered or issued, or which
it is advised by legal counsel of its own choosing is binding upon it, whether with or without jurisdiction; provided, however, that
the Escrow Agent shall provide the Parties with written notice of such response or compliance, as applicable. In the event that the Escrow
Agent obeys or complies with any such writ, order or decree it shall not be liable to any of the Parties or to any other person, firm
or corporation, should, by reason of such compliance notwithstanding, such writ, order or decree be subsequently reversed, modified,
annulled, set aside or vacated. Escrow Agent shall receive and may conclusively rely upon an opinion of counsel to the effect that such
order is final, non-appealable and from a court of competent jurisdiction.

 

Section
3.8 Force Majeure. The Escrow Agent shall not be responsible or liable for any failure or delay in the performance of its obligation
under this Escrow Agreement arising out of or caused, directly or indirectly, by circumstances beyond its reasonable control, including,
without limitation, acts of God; earthquakes; fire; flood; wars; acts of terrorism; civil or military disturbances; sabotage; epidemic;
pandemic; riots; interruptions, loss or malfunctions of utilities, computer (hardware or software) or communications services; accidents;
labor disputes; acts of civil or military authority or governmental action; it being understood that the Escrow Agent shall use commercially
reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as reasonably practicable
under the circumstances.

 

Section
3.9 No Financial Obligation. The Escrow Agent shall not be required to use its own funds in the performance of any of its
obligations or duties or the exercise of any of its rights or powers, and shall not be required to take any action which, in the Escrow
Agent’s sole and absolute judgment, could involve it in expense or liability unless furnished with security and indemnity which
it deems, in its sole and absolute discretion, to be satisfactory.

 

ARTICLE
4

MISCELLANEOUS

 

Section
4.1 Successors and Assigns. This Escrow Agreement shall be binding on and inure to the benefit of the Parties and the Escrow
Agent and their respective successors and permitted assigns. No other Persons shall have any rights under this Escrow Agreement. No assignment
of the interest of any of the Parties shall be binding unless and until written notice of such assignment shall be delivered to the other
Party and the Escrow Agent and shall require the prior written consent of the other Party and the Escrow Agent (such consent not to be
unreasonably withheld).

 

    9 

     

    

 

Section
4.2        Definitions.

 

(a)       “Business
Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by law to be
closed in New York, New York.

 

(b)       “Final
Order” means a written, final and non-appealable judgment, order or decree of a court, arbitrator or other judicial body
of competent jurisdiction that decided the applicable matter, together with (i) a certificate executed by an Authorized Representative
of the prevailing Party, to the effect that such order is final and non-appealable and from a court, arbitrator or other judicial body
of competent jurisdiction having proper authority and (ii) the written payment instructions executed by an Authorized Representative
of the prevailing Party, to effectuate such order.

 

(c)       “Joint
Direction” means the joint written instruction executed by each Party as evidenced by the signatures of an Authorized Representative
of each of Parent and Stockholders’ Representative, directing the Escrow Agent, and setting forth instructions as to the manner
in which the Escrow Agent is, to disburse all or a portion of the Indemnity Escrow Property, the Adjustment Escrow Property or the Earnout
Escrow Property, as the case may be, or to take or refrain from taking any other action pursuant to this Escrow Agreement.

 

Section
4.3 Escheat. The Parties are aware that under applicable state law, property which is presumed abandoned may under certain
circumstances escheat to the applicable state. The Escrow Agent shall have no liability to the Parties, their respective heirs, legal
representatives, successors and assigns, or any other party, should any or all of the Escrow Property escheat by operation of law.

 

Section
4.4 Notices. All notices, requests, consents, claims, demands, waivers and other communications under this Escrow Agreement
shall be in writing and shall be deemed to have been given (a) when delivered by hand (with
written confirmation of receipt); (b) when received by the addressee if sent by a nationally recognized overnight courier (receipt requested);
(c) on the date sent by facsimile or e- mail of a PDF document (with confirmation of transmission) if sent during normal business hours
of the recipient, and on the next Business Day if sent after normal business hours of the recipient or (d) on the third (3rd) day after
the date mailed, by certified or registered mail, return receipt requested, postage prepaid. Such communications must be sent to the
respective parties hereto at the following addresses (or at such other address for such party as shall be specified in a notice given
in accordance with this Section 4.4):

 

If to Parent,
to:

 

HPI Holdings,
LLC

174 Waterfront,
Suite 330

National Harbor,
MD 20745

ATTN Pranil Vadgama

Pranil.Vadgama@hpiinc.com

 

with a copy
(which shall not constitute notice) to:

 

Shearman &
Sterling LLP

300
West 6th Street, Suite 2250

 

Austin, TX 78701

Attention: Carmelo
Gordian

Email:         Carmelo.Gordian@Shearman.com

 

    10 

     

    

 

If
to Stockholders’ Representative:

 

Shareholder Representative
Services LLC

950
17th Street, Suite 1400

Denver, CO 80202

Attention: Managing
Director

E-mail:       deals@srsacquiom.com

with a copy
(which shall not constitute notice) to:

 

AdvantEdge Healthcare
Holdings, Inc.

9 Northeastern
Blvd, Suite 400

Salem, NH 03079

Attention: David
Langsam

Chief
Executive Officer

Facsimile:  (908)
791-3330

E-mail:       dlangsam@ahsrcm.com

 

with a copy
(which shall not constitute notice) to:

 

Duane Morris LLP

30
South 17th Street

Philadelphia,
PA 19103-4196

Attention:Michael
P. Gallagher

Facsimile: (215)
689-4931

E-mail:       
MPGallagher@duanemorris.com

 

with a copy
(which shall not constitute notice) to:

 

Founders Equity,
Inc.

545 Fifth Avenue,
Suite 401

New York, NY 10017

Attention: John
White

Facsimile: (212)
829-0901

E-mail:       jdwhite@fequity.com

 

If to the Escrow
Agent:

 

Wilmington Trust,
National Association

50 South Sixth
Street, Suite 1290 Minneapolis, MN 55402Attn: Adam Meyers

Telephone: (302)
-357-6598

Email: ameyers@wilmingtontrust.com

 

Section
4.5 Governing Law. This Escrow Agreement and any claim, controversy or dispute arising under or related to this Escrow Agreement
shall be governed by and construed in accordance with the Laws of the State of Delaware, without giving effect to any choice of law or
conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of the
Law of any jurisdiction other than the State of Delaware.

 

    11 

     

    

 

Section
4.6 Jurisdiction and Venue. Each of the parties hereto (a) submits to the exclusive jurisdiction of the Chancery Court of the State
of Delaware (or, if the Chancery Court of the State of Delaware declines to accept jurisdiction over a particular matter, any state or
federal court sitting in Delaware) in any claim, complaint, action, cause of action, demand, inquiry, notice of violation, litigation,
citation, summons, subpoena, investigation, audit, suit, assessment, arbitration, or any proceeding or investigation of any nature, civil,
criminal, administrative, regulatory or otherwise, whether at law or in equity (“Action”) arising out of or
relating to this Escrow Agreement, (b) agrees that all claims in respect of such Action may be heard and determined in any such court
and (c) agrees not to bring any Action arising out of or relating to this Escrow Agreement in any other court. Each of the parties hereto
waives any defense of inconvenient forum to the maintenance of any Action so brought and waives any bond, surety or other security that
might be required of any other party hereto with respect thereto. Each party hereto agrees that service of summons and complaint or any
other process that might be served in any Action may be made on such party hereto by sending or delivering a copy of the process to any
other party hereto to be served at the address of such party and in the manner provided for the giving of notices in Section 4.4.
Nothing in this Section 4.6, however, shall affect the right of any party hereto to serve legal process in any other manner permitted
by law. Each party hereto agrees that a final, non-appealable judgment in any Action so brought shall be conclusive and may be enforced
by suit on the judgment or in any other manner provided by applicable Law.

 

Section
4.7 Entire Agreement. This Escrow Agreement and the Merger Agreement, together with all exhibits and attachments hereto, sets
forth the entire agreement and understanding of the parties related to the Escrow Property.

 

Section
4.8 Amendment. This Escrow Agreement may be amended, modified, superseded, rescinded, or canceled only by a written instrument
executed by the Parties and the Escrow Agent. All fees, costs and expenses (including reasonable attorney’s fees, costs and expenses)
incurred in connection with any amendment, modification or supplement shall be payable by the Parties.

 

Section
4.9 Waivers. The failure of any party to this Escrow Agreement at any time or times to require performance of any provision
under this Escrow Agreement shall in no manner affect the right at a later time to enforce the same performance. A waiver by any party
to this Escrow Agreement of any such condition or breach of any term, covenant, representation, or warranty contained in this Escrow
Agreement, in any one or more instances, shall neither be construed as a further or continuing waiver of any such condition or breach
nor a waiver of any other condition or breach of any other term, covenant, representation, or warranty contained in this Escrow Agreement.

 

Section
4.10 Severability. If a court of competent jurisdiction declares any provision hereof invalid, it will be ineffective only
to the extent of such invalidity, so that the remainder of the provision and this Escrow Agreement will continue in full force and effect.

 

Section
4.11 Headings. Section headings of this Escrow Agreement have been inserted for convenience of reference only and shall in
no way restrict or otherwise modify any of the terms or provisions of this Escrow Agreement.

 

Section
4.12 Counterparts; Facsimile Signatures. This Escrow Agreement may be executed in one or more counterparts (including by electronic
means), each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. Delivery of an
executed counterpart of a signature page to this Escrow Agreement by facsimile or .pdf shall be as effective as delivery of a manually
executed and delivered counterpart to this Escrow Agreement.

 

    12 

     

    

 

Section
4.13 Waiver of Jury Trial. THE PARTIES TO THIS AGREEMENT EACH HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY RIGHT TO
TRIAL BY JURY OF ANY CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION (A) ARISING UNDER THIS ESCROW AGREEMENT OR (B) IN ANY WAY CONNECTED WITH
OR RELATED OR INCIDENTAL TO THE DEALINGS OF THE PARTIES HERETO IN RESPECT OF THIS ESCROW AGREEMENT OR ANY OF THE TRANSACTIONS RELATED
HERETO, IN EACH CASE WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER IN CONTRACT, TORT, EQUITY, OR OTHERWISE. THE PARTIES TO THIS
ESCROW AGREEMENT EACH HEREBY AGREES AND CONSENTS THAT ANY SUCH CLAIM, DEMAND, ACTION, OR CAUSE OF ACTION SHALL BE DECIDED BY COURT TRIAL
WITHOUT A JURY AND THAT THE PARTIES TO THIS ESCROW AGREEMENT MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS ESCROW AGREEMENT WITH
ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE WAIVER OF THEIR RIGHT TO TRIAL BY JURY.

 

Section
4.14 Merger Agreement. The Parties acknowledge that, solely as between the Parties, if there is any conflict between the terms and
provisions of the Merger Agreement and this Escrow Agreement, the terms and provisions of the Merger Agreement will govern and control.

 

Section
4.15 Confidentiality. Except as required by Law, the Escrow Agent agrees to keep confidential, and to cause any of its Affiliates
or agents to keep confidential and not disclose any and all documents, materials, and any other non-public information which it shall
have obtained regarding the Parties in connection with the execution and delivery of this Escrow Agreement and its performance of its
duties and obligations hereunder. This Section 4.15 shall survive termination of this Escrow Agreement for a period of 12 months
after such termination.

 

[The
remainder of this page left intentionally blank.]

 

    13 

     

    

 

IN
WITNESS WHEREOF, this Escrow Agreement has been duly executed as of the date first written above.

 

	 	PARENT:
	 	 
	 	HPI HOLDINGS, LLC
	 	 
	 	By:	 
	 	Name:	Pranil Vadgama
	 	Title: 	Treasurer
	 	 
	 	 
	 	STOCKHOLDERS’ REPRESENTATIVE:
	 	 
	 	SHAREHOLDER REPRESENTATIVE
	 	SERVICES LLC, solely in its
    capacity as the Stockholders’ Representative
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	 	 
	 	ESCROW AGENT:
	 	 
	 	WILMINGTON TRUST, NATIONAL ASSOCIATION
	 	 
	 	By:	 
	 	Name:	Adam Meyers
	 	Title:	Officer

 

[Signature
Page to Escrow Agreement]

 

     

     

    

 

 

EXHIBIT
A-1

 

CERTIFICATE
AS TO AUTHORIZED REPRESENTATIVES OF PARENT

 

HPI
Holdings, LLC, a Delaware limited liability company (“Parent”) hereby designates each of the following persons as
its Authorized Representatives for purposes of this Escrow Agreement, and confirms that the title, contact information and specimen signature
of each such person as set forth below is true and correct. Each such Authorized Representative is authorized to initiate and approve
transactions of all types for the Escrow Accounts established under the Escrow Agreement to which this Exhibit A-1 is attached,
on behalf of Parent.

 

	Name
    (print):	Pranil
    Vadgama
	Specimen
    Signature:	 
	Title:	Treasurer
	Telephone
    Number	Office:
    (301) 990-3995
	(required):	Cell:  (770)
    547-5827
	If
    more than one, list all	 
	applicable
    telephone	 
	numbers.	 
	E-mail
    (required):	Email
    1: Pranil.Vadgama@hpiinc.com
	If
    more than one, list all	Email
    2:
	applicable
    email	 
	addresses.	 

 

	Name
    (print):	Akshay
    Shah
	Specimen
    Signature:	 
	Title:	Secretary
	Telephone
    Number	Office:
    (301) 990-3995
	(required):	Cell:  (240)
    298-7580
	If
    more than one, list all	 
	applicable
    telephone	 
	numbers.	 
	E-mail
    (required):	Email
    1: akshay.shah@hpiinc.com
	If
    more than one, list all	Email
    2:
	applicable
    email	 
	addresses.	 

 

[Exhibit
A-1 to Escrow Agreement]

 

     

     

    

 

 

COMPLETE
BELOW TO UPDATE EXHIBIT A-1

 

If
Parent wishes to update this Exhibit A-1, Parent must complete, sign and send to the Escrow Agent an updated copy of this Exhibit
A-1 with such changes. Any updated Exhibit A-1 shall be effective once signed by Parent and the Escrow Agent and shall entirely
supersede and replace any prior Exhibit A-1 to this Escrow Agreement.

 

	HPI HOLDINGS, LLC	 
	 	 
	By:	             	 
	Name:	 
	Title:	 
	Date:	 
	 	 
	 	 
	WILMINGTON TRUST, NATIONAL ASSOCIATION
    (as Escrow Agent)	 
	 	 
	By:	 	 
	Name:	 
	Title:	 
	Date:	 

 

[Exhibit
A-1 to Escrow Agreement]

 

     

     

    

 

  

EXHIBIT
A-2

 

CERTIFICATE
AS TO AUTHORIZED REPRESENTATIVES OF STOCKHOLDERS’ REPRESENTATIVE

 

Shareholder
Representative Services LLC, solely in its capacity as Stockholders’ Representative (the “Stockholders’ Representative”),
designates each of the following persons as its Authorized Representatives for purposes of this Escrow Agreement, and confirms that the
title, contact information and specimen signature of each such person as set forth below is true and correct. Each such Authorized Representative
is authorized to initiate and approve transactions of all types for the Escrow Accounts established under the Agreement to which this
Exhibit A-2 is attached, on behalf of Stockholders’ Representative.

 

	Name
    (print):	Casey
    McTigue
	Specimen
    Signature:	 
	Title:	Executive
    Director
	Telephone Number

    (required):
	Office:
    (415) 363-6081
	E-mail
    (required):	Email:
    cmctigue@srsacquiom.com

 

	Name
    (print):	Michelle
    Kirkpatrick
	Specimen
    Signature:	 
	Title:	Senior
    Director
	Telephone Number

    (required):
	Office:
    (720) 799-8614
	E-mail
    (required):	Email:
    mkirkpatrick@srsacquiom.com

 

	Name
    (print):	Lon
    LeClair
	Specimen
    Signature:	 
	Title:	President
	Telephone Number

    (required):
	Office:
    (303) 222-2078
	E-mail
    (required):	Email:
    lleclair@srsacquiom.com

 

	Name
    (print):	Paul
    Koenig
	Specimen
    Signature:	 
	Title:	Managing
    Director
	Telephone Number

    (required):
	Office:
    (303) 957-2850
	E-mail
    (required):	Email:
    pkoenig@srsacquiom.com

 

 

[Exhibit
A-2 to Escrow Agreement]

 

     

     

    

 

  

COMPLETE
BELOW TO UPDATE EXHIBIT A-2

 

If
Stockholders’ Representative wishes to update this Exhibit A-2, Stockholders’ Representative must complete, sign and
send to the Escrow Agent an updated copy of this Exhibit A-2 with such changes. Any updated Exhibit A-2 shall be effective
once signed by Stockholders’ Representative and the Escrow Agent and shall entirely supersede and replace any prior Exhibit
A-2 to this Escrow Agreement.

 

	SHAREHOLDER REPRESENTATIVE SERVICES
    LLC (as Stockholders’ Representative)	 
	 	 
	By:	                            	 
	Name:	 
	Title:	 
	Date:	 
	 	 
	WILMINGTON TRUST, NATIONAL ASSOCIATION
    (as Escrow Agent)	 
	 	 
	By:	 	 
	Name:	 
	Title:	 
	Date:	 

 

[Exhibit
A-2 to Escrow Agreement]

 

     

     

    

 

Exhibit
B

 

Fees
of Escrow Agent

 
	Acceptance Fee:	WAIVED

 

Initial
Fees as they relate to Wilmington Trust acting in the capacity of Escrow Agent – includes review of the Escrow Agreement; acceptance
of the Escrow appointment; setting up of Escrow Account(s) and accounting records; and coordination of receipt of funds for deposit to
the Escrow Account(s).

Acceptance
Fee payable at time of Escrow Agreement execution

  
	Escrow Agent Administration Fee (One-time):	$2,500

 

For
ordinary administrative services by Escrow Agent – includes daily routine account management; investment transactions; cash transaction
processing (including wire and check processing); monitoring claim notices pursuant to the agreement; disbursement of funds in accordance
with the agreement; and mailing of trust account statements to all applicable parties. Tax reporting is included. One-time Administration
Fee payable at time of Escrow Agreement execution

 

Wilmington
Trust’s fee is based on the following assumptions:

 

		●	Number
                                            of Escrow Accounts to be established: Three (3)

		●	Duration
                                            of Escrow: approximately 14 months, not including any unresolved claims;

		●	Number
                                            of Deposits to Escrow Account(s): One initial deposit (Cash)-Indemnity ($800,000); Adjustment
                                            ($375,000); and Earnout ($16,800,000)

		●	Escrow
                                            Property shall remain un-invested.

 
	Out-of-Pocket Expenses:	Billed At Cost

 

[Exhibit
B to Escrow Agreement]

 

     

     

    

 

EXHIBIT
C

 

FORM
OF LETTER OF TRANSMITTAL

 

(see
attached)

 

     

     

    

  

 

LETTER
OF TRANSMITTAL

 

SUBMITTED
IN CONNECTION WITH PAYMENT FOR SECURITIES OF

 

ADVANTEDGE
HEALTHCARE HOLDINGS, INC.

 

This
Letter of Transmittal is being delivered to you in connection with the acquisition of AdvantEdge Healthcare Holdings, Inc. (the “Company”)
by HPI Holdings, LLC (“Parent”) (the “Merger”), pursuant to the Agreement and Plan of Merger dated September
30, 2021 (the “Merger Agreement”), by and among Parent, the Company, AHS Granite Merger Sub, Inc., a Delaware corporation
(“Merger Sub”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity
as the representative, agent and attorney-in-fact of the Company Stockholders (as defined in the Merger Agreement) (the “Stockholders’
Representative”). Capitalized terms not defined herein are defined in the Merger Agreement.

 

As
a result of the Merger (a) the Company has become a wholly owned subsidiary of Parent, and (b) the outstanding securities of the Company
(the “Securities”), have been canceled and converted into the right to receive the consideration specified in the Merger
Agreement. To receive payment of the consideration (“Consideration”) represented by your Securities, you (the “Undersigned”)
must complete and sign this Letter of Transmittal, including the applicable exhibits, and deliver this Letter of Transmittal to Acquiom
Financial LLC (the “Payment Administrator”).

 

In
accordance with the Merger Agreement, except as otherwise provided below, the certificates representing your former Securities listed
on Form 3 are hereby surrendered to be exchanged for the Consideration on the terms set forth in the Merger Agreement and this Letter
of Transmittal. By signing and submitting this Letter of Transmittal, you also hereby represent, warrant, covenant and agree as follows:

 

1.       The
Undersigned is the sole legal and beneficial owner of the Securities set forth on Form 3 as of Closing, with good title to the Securities
and full power and authority to sell, assign, transfer and surrender the Securities, free and clear of all Liens and restrictions on
transfer (other than restrictions under applicable federal, state and other securities Laws and to the extent provided in the Stockholders’
Agreement). The Undersigned owns no additional Securities other than the Securities described in Form 3. The Undersigned has not transferred,
assigned or otherwise disposed of such Securities, or entered into any agreement to transfer, assign or otherwise dispose of such Securities.
All authority conferred or agreed to be conferred in this Letter of Transmittal shall be binding upon the successors, assigns, heirs,
executors, administrators and legal representatives of the Undersigned and shall not be affected by, and shall survive, the death or
incapacity of the Undersigned. The surrender of the Securities described on Form
3 hereby is irrevocable.

 

     

     

    

 

 

 

2.       The
Undersigned, upon request, will execute and deliver any additional documents reasonably necessary or desirable to complete the payment
of the Consideration. In such case, the Undersigned acknowledges that the delivery will be effected, and the risk of loss and title to
any such items will pass, only upon receipt thereof by the Payment Administrator. All authority conferred or agreed to be conferred in
this Letter of Transmittal shall be binding upon the successors, assigns, heirs, executors, administrators and legal representatives
of the Undersigned and shall not be affected by, and shall survive, the death or incapacity of the Undersigned.

 

3.       The
Undersigned hereby waives any appraisal rights or dissenter’s rights which the Undersigned might otherwise have in connection with
the Undersigned’s ownership of the Securities under applicable Law in connection with the transactions contemplated by the Merger
Agreement.

 

4.       The
Undersigned understands that (i) unless and until the Undersigned submits a properly completed Letter of Transmittal according to the
terms herein, no cash payments of Consideration pursuant to the Merger Agreement shall be made to the Undersigned or its designee, and
(ii) no interest will accrue on any cash payment due.

 

5.       The
Undersigned has had an opportunity to review the Merger Agreement and shall be bound by the provisions of the Merger Agreement, including
the indemnification and release provisions set forth therein.

 

6.       The
Undersigned hereby irrevocably (i) appoints the Stockholders’ Representative as its exclusive representative, agent and attorney-in-fact
on the Undersigned’s behalf for the purposes set forth in the Merger Agreement and (ii) acknowledges and agrees to the exculpation
and indemnification provisions in favor of the Stockholders’ Representative set forth in the Merger Agreement. Without limiting
the foregoing, the Undersigned (a) agrees that the information contained in this Letter of Transmittal may be shared with the Parent
and Stockholders’ Representative in connection with this transaction and (b) understands that Parent, the Company, the Surviving
Corporation and any related entity may rely upon the representations, warranties, covenants and agreements contained herein as if each
such Person was a party to this Letter of Transmittal and each shall have the rights, remedies and benefits under this Letter of Transmittal
as if such Person was a party hereto.

 

7.       The
Undersigned understands and agrees that (i) a portion of the consideration to which it may be entitled under the Merger Agreement will
be placed in escrow to be held pursuant to the terms of the Merger Agreement and the escrow agreement referred to in the Merger Agreement
and (ii) the Undersigned shall only be entitled to a portion of such amount (if any) as and when such amount is payable in accordance
with the provisions of the Merger Agreement and the escrow agreement referred to in the Merger Agreement, as applicable.

 

     

     

    

 

 

 

8.       If
the Undersigned is an entity, the Undersigned is duly organized, validly existing and in good standing under the Laws of the jurisdiction
of its organization, except where the failure to be so qualified or in such good standing would not, individually or in the aggregate,
prevent, impair or delay the ability of the Undersigned to fulfill its obligations hereunder. The Undersigned has all requisite power
and authority (if the Undersigned is an entity) or legal capacity (if the Undersigned is a natural person) to execute and deliver this
Letter of Transmittal and to perform his, her or its obligations under this Letter of Transmittal. The execution and delivery of this
Letter of Transmittal by the Undersigned, and the consummation by the Undersigned of the transactions contemplated hereby, have been
duly authorized by all necessary action, if any, on the part of the Undersigned. This Letter of Transmittal has been duly executed and
delivered by the Undersigned and constitutes a valid and binding obligation of the Undersigned, enforceable against the Undersigned in
accordance with its terms, subject to the effect of (i) applicable bankruptcy, insolvency, reorganization, moratorium and other similar
Laws now and hereunder in effect relating to the rights of creditors generally and (ii) rules of law and equity governing specific performance,
injunctive relief and other equitable remedies.

 

9.       This
Letter of Transmittal will be governed by and construed in accordance with the Laws of the State of Delaware without giving effect to
any choice of law or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause
the application of the Law of any jurisdiction other than the State of Delaware.

 

     

     

    

     

     

    

     

     

    

 

     

     

    

 

     

     

    

     

     

    

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

 

 

     

     

    

  

EXHIBIT
D

 

EARNOUT
PAYMENT CALCULATION

 

1.
              Definitions. Capitalized terms not otherwise
defined in this Section 1 shall have the meanings set forth in the Agreement.

 

“Baseline
Amount” means $16,800,000 for Section 2(a) below and $6,000,000 for Section 2(b) below.

 

“Bookings”
means the annual run rate of revenue expected to be earned from the new clients that have entered into new customer contracts with the
applicable Group Company or any Affiliate of Parent within the AdvantEdge platform with economic terms consistent with the Ordinary Course
of the Business during the Earnout Period.

 

“Churn”
means the annual run rate of revenue previously expected to be earned from clients that during the Earnout Period have (i) had an adverse
change in the business relationship, or any material dispute, with the applicable Group Company, (ii) terminated, cancelled or failed
to renew, or given any notice that references their intention to terminate, cancel or fail to renew their business relationship with
the applicable Group Company or (iii) ceased or materially reduced, or given any notice that references their intention to cease or materially
reduce, their business dealings with the applicable Group Company. Notwithstanding anything to the contrary herein, the Company’s
historic run rate of revenue with BPA shall not be considered in calculating Churn.

 

“Earnout
Percentage” means the percentage obtained by dividing Net New Revenue by Lost BPA Revenue, which shall not exceed 100%.

 

“Earnout
Period” means the period from August 31, 2021 to December 31, 2021.

 

“Lost
BPA Revenue” means $3,700,000 for Section 2(a) below and $1,350,000 for Section 2(b)) below.

 

“Net
New Revenue” means Bookings less Churn.

 

2.             Earnout
Conditions.

 

a.       No
BPA and No Indiana Agreement. If (i) BPA has not (A) signed a new agreement with any Group Company or an Affiliate of Parent with
substantially the same economic terms as the Company’s existing agreement with BPA but without the early termination clause contained
therein prior to the Closing or during the Earnout Period, (B) signed an amendment to the Company’s existing agreement with BPA
that removes the early termination clause contained therein prior to the Closing or during the Earnout Period, or (C) otherwise confirmed
in writing that BPA intends to remain a customer of any Group Company or an Affiliate of Parent following the Closing and the Earnout
Period to Parent’s satisfaction in its sole discretion prior to the Closing or during the Earnout Period, and (ii) Indiana has
not signed the Indiana Agreement prior to the Closing or during the Earnout Period, Parent will pay an Earnout Payment equal to the following
formula:

 

Earnout
Payment = Baseline Amount x Earnout Percentage

 

By
way of illustration only, if, as of the end of the Earnout Period, Churn = $2,000,000 and Bookings = $5,000,000, the Earnout Payment
would be equal to $16,800,000 x 81.0811%, or $13,621,621.62.

 

By
way of illustration only, if, as of the end of the Earnout Period, Churn = 0 and Bookings = $5,000,000, the Earnout Payment would be
equal to $16,800,000 x 100%, or $16,800,000.00.

 

     

     

    

 

b.       No
BPA but Signed Indiana Agreement. If (i) BPA has not (A) signed a new agreement with any Group Company or an Affiliate of Parent
with substantially the same pricing terms as the Company’s existing agreement with BPA but without the early termination clause
contained therein prior to the Closing or during the Earnout Period, (B) signed an amendment to the Company’s existing agreement
with BPA that removes the early termination clause contained therein prior to the Closing or during the Earnout Period, or (C) otherwise
confirmed in writing that BPA intends to remain a customer of any Group Company or an Affiliate of Parent following the Closing and the
Earnout Period to Parent’s satisfaction in its sole discretion prior to the Closing or during the Earnout Period, and (ii) Indiana
did not sign the Indiana Agreement prior to Closing but entered into the Indiana Agreement following the Closing during the Earnout Period
(such date, the “Indiana Signing Date”), within 30 days of the Indiana Signing Date, $10,800,000 shall be paid
to the Payments Administrator, for further distribution to the Company Stockholders (pro rata based upon such Person’s Pro Rata
Share), other than the Dissenting Stockholders. The remaining $6,000,000 will be paid based on the following formula:

 

Earnout
Payment = Baseline Amount x Earnout Percentage

 

By
way of illustration only, if, as of the end of the Earnout Period, Churn = $4,000,000 and Bookings = $5,000,000, the Earnout Payment
would be equal to $6,000,000 x 74.0741%, or $4,444,444.44.

 

By
way of illustration only, if, as of the end of the Earnout Period, Churn = $3,000,000 and Bookings = $5,000,000, the Earnout Payment
would be equal to $6,000,000 x 100%, or $6,000,000.00.

 

c.       BPA
Signs. If BPA (A) signs a new agreement with any Group Company or an Affiliate of Parent with substantially the same economic terms
as the Company’s existing agreement with BPA but without the early termination clause contained therein, (B) signs an amendment
to the Company’s existing agreement with BPA that removes the early termination clause contained therein or (C) signs a new agreement
with any Group Company or an Affiliate of Parent satisfactory to Parent in its sole discretion after the Closing during the Earnout Period
(such date, the “BPA Signing Date”), within 30 days of the BPA Signing Date, $16,800,000, if Indiana has not
signed the Indiana Agreement prior to the BPA Signing Date, or $6,000,000, if Indiana has signed the Indiana Agreement prior to the BPA
Signing Date, shall be paid to the Payments Administrator, for further distribution to the Company Stockholders (pro rata based upon
such Person’s Pro Rata Share), other than the Dissenting Stockholders. Upon such payment, no further Earnout Payments shall be
payable by Parent to the Company Stockholders.

 

     

     

    

 

3.             Earnout
Upside. If the Company achieves an additional $1,650,000 of Net New Revenue (i.e., Net New Revenue is at least $5,350,000 pursuant
to Section 2(a) above or Net New Revenue is at least $3,000,000 pursuant to Section 2(b) above), Parent will pay $6,000,000 in addition
to the payments contemplated by Section 2(a) or Section 2(b) above, as applicable.

 

4.             Earnout
Limitations. The maximum that Parent shall be required to pay under this Agreement including the Earnout Payments pursuant to Sections
2 and 3 hereof shall be

$86,000,000.

 

5.             Earnout
Statement.

 

a.       Proposed
Earnout Calculations. Unless a final Earnout Payment was already made pursuant to Section 2(c) above, as soon as practicable, but
no later than thirty (30) days after December 31, 2021, Parent shall prepare and deliver to the Stockholders’ Representative Parent’s
good faith proposed calculation of each of (a) Bookings, (b) Churn, (c) New Net Revenue, and (d) the Earnout Payment (which calculations
shall collectively be referred to herein as the “Proposed Earnout Calculations”), in each case, including reasonably
detailed calculations of the components thereof and in a manner consistent with the definitions thereof set forth in this Agreement.

 

     

     

    

 

b.       Dispute
Mechanism. If the Stockholders’ Representative does not deliver written notice of any dispute (an “Earnout Dispute
Notice”) to Parent within thirty (30) days after receiving the Proposed Earnout Calculations, the Proposed Earnout Calculations
shall be deemed to set forth the final Earnout Payment, and shall be final and binding upon the Parties. Prior to the end of such thirty
(30)-day period, the Stockholders’ Representative may accept the Proposed Earnout Calculations by delivering written notice to
that effect to Parent, in which case the Proposed Earnout Calculations shall be deemed to set forth the final Earnout Payment and shall
be final and binding upon the Parties when such notice is given. If the Stockholders’ Representative delivers an Earnout Dispute
Notice to Parent within such thirty (30)-day period, Parent and the Stockholders’ Representative shall use good faith efforts to
resolve the dispute during the thirty (30)-day period commencing on the date Parent receives the Earnout Dispute Notice from the Stockholders’
Representative. Any Earnout Dispute Notice shall include the Stockholders’ Representative’s alternative calculations with
respect to each component of the Proposed Earnout Calculations, along with the basis for and amount of each disputed item, together with
supporting documentation. If the Stockholders’ Representative and Parent do not agree upon a final resolution with respect to any
disputed items within such thirty (30)-day period, then the remaining items in dispute shall be submitted promptly to the Accounting
Firm. Any item not specifically submitted to the Accounting Firm for evaluation shall be deemed final and binding on the Parties (as
set forth in the Proposed Earnout Calculations, the Earnout Dispute Notice or as otherwise resolved in writing by Parent and the Stockholders’
Representative). The Accounting Firm shall be requested to render a determination of each disputed item within forty-five (45) days after
referral of the matter to the Accounting Firm, which determination must be in writing and must set forth, in reasonable detail, the basis
therefor and must be based solely on (A) the definitions and other applicable provisions of this Agreement, (B) a single presentation
(which presentations shall be limited to the remaining items in dispute set forth in the Proposed Earnout Calculations and the Earnout
Dispute Notice) submitted by each of Parent and the Stockholders’ Representative to the Accounting Firm within fifteen (15) days
after the engagement thereof (which the Accounting Firm shall forward to Parent or the Stockholders’ Representative, as applicable),
(C) one (1) written response to the Stockholders’ Representative’s initial presentation, which response may be submitted
to the Accounting Firm by Parent within five (5) Business Days after receipt of the Stockholders’ Representative’s initial
presentation (which the Accounting Firm shall forward to the Stockholders’ Representative), and (D) one (1) written response to
Parent’s initial presentation, which response may be submitted to the Accounting Firm by the Stockholders’ Representative
within five (5) Business Days after receipt of Parent’s initial presentation (which the Accounting Firm shall forward to Parent),
and not on independent review, which such determination shall be conclusive and binding on each Party. Ex parte communications
by the Accounting Firm with Parent or Stockholders’ Representative regarding substantive matters in connection herewith shall be
prohibited. The terms of appointment and engagement of the Accounting Firm shall be as reasonably agreed upon between the Stockholders’
Representative and Parent, and any associated engagement fees shall be initially borne 50% by the Stockholders’ Representative
(solely on behalf of the Company Stockholders) and 50% by Parent; provided, however, that such fees shall ultimately be
borne by Parent and the Stockholders’ Representative (solely on behalf of the Company Stockholders) in the same proportion as the
aggregate amount of the disputed items that is unsuccessfully disputed by each such Party (as determined by the Accounting Firm) bears
to the total amount of the disputed items submitted to the Accounting Firm. Except as provided in the preceding sentence, all other costs
and expenses incurred by the Parties in connection with resolving any dispute hereunder before the Accounting Firm shall be borne by
the Party incurring such cost and expense. The Accounting Firm shall resolve each disputed item by choosing a value not in excess of,
nor less than, the greatest or lowest value, respectively, set forth in the presentations (and, if applicable, the responses) delivered
to the Accounting Firm pursuant to this Section 5. The Proposed Earnout Calculations shall be revised as appropriate to reflect the resolution
of any objections thereto pursuant to this Section 5 and, as so revised, such Proposed Earnout Calculations shall be deemed to set forth
the final Earnout Payment, for all purposes hereunder and shall be final and binding upon the Parties.

 

c.       Access.
Parent shall, and shall cause each of the Group Companies to, promptly make its relevant financial records and personnel available to
the Stockholders’ Representative and its accountants and other representatives at reasonable times at any time during the review
by the Stockholders’ Representative of, and the resolution of any objections with respect to, the Proposed Earnout Calculations.

 

d.       Dispute
Resolution Procedures. The Parties agree that the procedures set forth in this Section 5 for resolving disputes with respect to the
Proposed Earnout Calculations shall be the sole and exclusive method for resolving any such disputes; provided, however,
that this provision shall not prohibit Parent or the Stockholders’ Representative from instituting litigation to enforce any final
determination of the Earnout Payment by the Accounting Firm in any court or other tribunal of competent jurisdiction in accordance with
Section 11.15 of the Agreement. The substance of the Accounting Firm’s determination shall not be subject to review or appeal,
absent a showing of fraud or manifest error. It is the intent of the Parties to have any final determination of the Earnout Payment by
the Accounting Firm proceed in an expeditious manner; provided, however, that any deadline or time period contained herein
may be extended or modified by the written agreement of Parent and the Stockholders’ Representative and the Parties agree that
the failure of the Accounting Firm to strictly conform to any deadline or time period contained herein shall not be a basis for seeking
to overturn any determination rendered by the Accounting Firm which otherwise conforms to the terms of this Section 5.Exhibit 10.5

 

EXECUTION VERSION

 

  

MEMBERSHIP INTEREST PURCHASE AGREEMENT

 

by and among

 

ALLIANCE INTERMEDIATE HOLDCO, LLC,

 

ALLIANCE PHYSICAL THERAPY PARTNERS, LLC,

 

HIGHLINE MANAGEMENT INC.,

 

and

 

ALLIANCE PT BUYER, INC.

 

Dated as of November 15, 2021

 

 

    

     

    

 

TABLE OF CONTENTS

 

Page

 

	ARTICLE I PURCHASE AND SALE OF INTERESTS	5
	 	1.1	Purchase and Sale of Interests	5
	 	1.2	Calculation of Closing and Final Consideration	5
	 	1.3	The Closing	8
	 	1.4	Closing Date Payments by Buyer	8
	 	1.5	Escrow Amount	9
	 	 	 	 
	ARTICLE II CONDITIONS TO CLOSING	     9
	 	2.1	Conditions to All Parties’ Obligations	9
	 	2.2	Conditions to Buyer’s Obligations	9
	 	2.3	Conditions to Seller’s and the Company’s Obligations	11
	 	2.4	Waiver of Conditions	12
	 	 	 	 
	ARTICLE III REPRESENTATIONS AND WARRANTIES OF SELLER	     12
	 	3.1	Organization and Power	12
	 	3.2	Authorization; Valid and Binding Agreement	12
	 	3.3	No Breach	12
	 	3.4	Ownership	13
	 	3.5	Brokers	13
	 	3.6	Litigation	13
	 	3.7	No Other Representations and Warranties	13
	 	 	 	 
	ARTICLE IV REPRESENTATIONS
AND WARRANTIES OF THE COMPANY      	14
	 	4.1	Organization and Power	14
	 	4.2	Capitalization	14
	 	4.3	Authorization; Valid and Binding Agreement	15
	 	4.4	No Breach	15
	 	4.5	Financial Statements	15
	 	4.6	Absence of Certain Developments	16
	 	4.7	Title to Properties	18
	 	4.8	Tax Matters	19
	 	4.9	Contracts and Commitments	21
	 	4.10	Intellectual Property	24
	 	4.11	Information Technology and Data Matters	26
	 	4.12	Litigation	27
	 	4.13	Employee Benefit Plans	27
	 	4.14	Insurance	30
	 	4.15	Compliance with Laws	30
	 	4.16	Environmental Compliance and Conditions	31
	 	4.17	Affiliated Transactions	32
	 	4.18	Employment and Labor Matters	32
	 	4.19	No Brokers	34
	 	4.20	Regulatory Compliance	34
	 	4.21	Undisclosed Liabilities	34
	 	4.22	No Other Representations and Warranties	38

  

    i

     

    

  

TABLE OF CONTENTS
(CONT'D)

 

Page 

 

	ARTICLE V REPRESENTATIONS
    AND WARRANTIES OF BUYER	     38
	 	5.1	Organization and Power	38
	 	5.2	Authorization; Valid and Binding Agreement	39
	 	5.3	No Breach	39
	 	5.4	Litigation	39
	 	5.5	No Brokers	39
	 	5.6	Investment Representation	39
	 	5.7	Financing	40
	 	5.8	Solvency	40
	 	5.9	No Other Information	40
	 	 	 	 
	ARTICLE VI CERTAIN
    PRE-CLOSING COVENANTS OF THE PARTIES	     41
	 	6.1	Conduct of the Business	41
	 	6.2	Conditions	42
	 	6.3	Consents and Notices	42
	 	6.4	Access to Information	42
	 	6.5	Financing	43
	 	6.6	Financing Cooperation	45
	 	 	 	 
	ARTICLE VII ADDITIONAL
    COVENANTS OF BUYER	     47
	 	7.1	Access to Books and Records	47
	 	7.2	Director and Officer Liability and Indemnification	47
	 	7.3	Conditions	50
	 	7.4	Contact with Clients and Other Business Relations	50
	 	7.5	Payment of Indebtedness and Seller Transaction Expenses	50
	 	7.6	Employee Matters	51
	 	 	 	 
	ARTICLE VIII TERMINATION	     52
	 	8.1	Termination	52
	 	8.2	Effect of Termination	54
	 	 	 	 
	ARTICLE IX REMEDIES
    FOR BREACHES OF THIS AGREEMENT	     55
	 	9.1	Indemnification by Seller	55
	 	9.2	Indemnification by Buyer	55
	 	9.3	Indemnity Escrow Fund	55
	 	9.4	Survival and Time Limitations	56
		9.05            	 	56
	 	9.6	Limitations on Indemnification by Seller	56
	 	9.7	Limitations on Indemnification by Buyer	57
	 	9.8	Third Party Claims	57
	 	9.9	Determination of Indemnification Amounts	59
	 	9.10	Other Indemnification Matters	59

 

    ii

     

    

 

TABLE OF CONTENTS
(CONT'D)

 

Page

 

	ARTICLE X ADDITIONAL
    COVENANTS AND AGREEMENTS	     60
	 	10.1	Tax Matters	60
	 	10.2	Further Assurances	63
	 	 	 	 
	ARTICLE XI DEFINITIONS	     63
	 	11.1	Definitions	63
	 	11.2	Other Definitional Provisions	80
	 	 	 	 
	ARTICLE XII MISCELLANEOUS	     81
	 	12.1	Press Releases and Communications; Use of Company Name	81
	 	12.2	Expenses	81
	 	12.3	Notices	82
		12.04	Assignment	83
	 	12.5	Severability	83
	 	12.6	No Strict Construction; Disclosure Schedules; Headings	83
	 	12.7	Amendment and Waiver	84
	 	12.8	Complete Agreement	84
	 	12.9	Counterparts	84
	 	12.10	Governing Law; Consent to Jurisdiction	85
	 	12.11	WAIVER OF JURY TRIAL	85
	 	12.12	No Third Party Beneficiaries	85
	 	12.13	No Additional Representations; Disclaimer; Non-Recourse	86
	 	12.14	Specific Performance; Other Remedies	86
	 	12.15	Consents	87
	 	12.16	Electronic Delivery	87
	 	12.17	Deliveries	87
	 	12.18	Seller’s Representative	87

 

    iii

     

    

 

MEMBERSHIP INTEREST
PURCHASE AGREEMENT

 

This MEMBERSHIP INTEREST PURCHASE
AGREEMENT (this “Agreement”) is made as of November 15, 2021, by and among Alliance Intermediate Holdco, LLC,
a Delaware limited liability company (the “Company”), Alliance Physical Therapy Partners, LLC, a Delaware limited
liability company (“Seller”), Alliance PT Buyer, Inc., a Delaware corporation (“Buyer”), and
Highline Management Inc., a Delaware corporation, in its capacity as the Seller’s Representative (the “Seller’s
Representative”) (the foregoing parties, collectively, the “Parties” and each a “Party”).
Capitalized terms used and not otherwise defined herein have the meanings set forth in Article XI below.

 

WHEREAS, Seller owns all of
the issued and outstanding membership interests of the Company (collectively, the “Interests”);

 

WHEREAS, the Company owns all
of the issued and outstanding membership interests of Alliance Physical Therapy Group, LLC, a Michigan limited liability company (“APTG”,
and together with the Company and APTG's direct and indirect wholly owned Subsidiaries, the “Acquired Companies”);

 

WHEREAS, APTG provides management
services to related physical therapy providers at one or more healthcare facilities (each, a “Managed Practice”, and
collectively, the “Managed Practices”) pursuant to Management Services Agreements (the Managed Practices together
with the Company and the Acquired Companies, collectively, the “Relevant Entities”);

 

WHEREAS, on the terms and subject
to the conditions set forth in this Agreement, Buyer desires to purchase from Seller, and Seller desires to sell to Buyer, all of the
Interests;

 

WHEREAS, concurrently with
the execution and delivery of this Agreement BPOC V Aggregator A, L.P. (the “Equity Investor”) has delivered to Seller
(1) an equity commitment letter dated the date hereof, attached hereto as Exhibit A (together with all amendments, exhibits,
attachments, appendices and schedules thereto as of the date hereof, the “Equity Commitment Letter”), relating to
the commitment of the Equity Investor, upon the terms and subject to the conditions set forth therein, to provide Buyer with equity financing
in the amount set forth therein (such financing, the “Equity Financing”) for the purpose of investing in Buyer, directly
or indirectly, the cash amounts set forth therein (the “Equity Financing”) for the purposes of funding the transactions
contemplated hereby and (2) a limited guaranty dated as of the date hereof (together with all amendments, exhibits, attachments,
appendices and schedules thereto as of the date hereof, the “Guaranty”) attached hereto as Exhibit B in
favor of Seller for the purpose of guaranteeing the obligations of the Buyer to pay the Termination Fee on the terms and conditions set
forth in Section 8.02(b) of this Agreement;

 

WHEREAS, as of the date hereof,
the (A) Institutional Holders have entered into restrictive covenant agreements substantially in the form attached hereto as Exhibit C
(the “Institutional Holder Restrictive Covenant Agreements”), pursuant to which the Institutional Holders have
agreed (effective as of and contingent upon the Closing) to certain confidentiality, non-disparagement, non-solicitation and no-hire
covenants and (B) certain members of the Company’s management have entered into restrictive covenant agreements in substantially
as Exhibit D (the “Management Restrictive Covenant
Agreements” and, together with the Institutional Holder Restrictive Covenant Agreements, the “Restrictive Covenant
Agreements”), pursuant to which such Persons have agreed (effective as of and contingent upon the Closing) to certain confidentiality,
non-competition, non-disparagement, non-solicitation and no-hire covenants; and

 

    

     

    

 

WHEREAS, the respective board
of managers or directors or other governing bodies, as applicable, of Seller, the Company and Buyer have approved this Agreement and
the transactions contemplated hereby, upon the terms and subject to the conditions set forth herein.

 

NOW, THEREFORE, in consideration
of the mutual covenants, representations, warranties, conditions and agreements contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

 

ARTICLE I

 

PURCHASE AND SALE OF INTERESTS

 

1.1            Purchase
and Sale of Interests. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing, Seller will sell,
assign, transfer and convey to Buyer, and Buyer will purchase and acquire from Seller, all of the Interests, free and clear of all Liens,
in exchange for the Estimated Purchase Price.

 

1.2            Calculation
of Closing and Final Consideration.

 

(a)            For
purposes of this Agreement, the “Estimated Purchase Price” means an amount equal to the Enterprise Value, plus
the total amount of Estimated Cash, minus the outstanding amount of Estimated Indebtedness, minus the unpaid Estimated
Seller Transaction Expenses, plus the amount, if any, of the Estimated Net Working Capital Excess, minus the amount, if
any, of the Estimated Net Working Capital Deficit, minus the amount of the Escrow Amount, and minus the Expense Fund Amount.

 

(b)            At
least three (3) Business Days prior to the Closing Date, the Company will deliver to Buyer a statement, executed by the chief financial
officer of the Company or other similar officer (the “Estimated Closing Statement”), which (i) sets forth the
Company’s good faith estimate of (A) the aggregate amount of Cash as of the Closing Effective Time (the “Estimated
Cash”); (B) the aggregate amount of the Indebtedness as of the Closing (the “Estimated Indebtedness”);
(C) the aggregate amount of Seller Transaction Expenses as of the Closing (the “Estimated Seller Transaction Expenses”);
(D) the Net Working Capital (the “Estimated Net Working Capital”), including the amount of any Estimated Net
Working Capital Excess or Estimated Net Working Capital Deficit; and (ii) includes reasonably detailed calculations, data,
and schedules supporting the computation of the amounts contained therein and is prepared and calculated in accordance with Section 1.02(g).
During the period from the Seller’s delivery of the Estimated Closing Statement until the Closing, Seller will, and will cause
the Company to use commercially reasonable efforts to (i) assist Buyer and its representatives in the review of the Estimated Closing
Statement and provide Buyer and its representatives with reasonable access during normal business hours to the books, records (including
work papers, schedules, memoranda and other documents), supporting data, facilities, representatives and employees of the Relevant Entities
for purposes of their review of the Estimated Closing Statement, and (ii) cooperate with Buyer and its representatives in connection
with such review, including providing on a reasonably timely basis all other information necessary in connection with the review of the
Estimated Closing Statement as is reasonably requested by Buyer or its representatives. Buyer shall have the right to suggest changes
to the Estimated Closing Statement and Seller shall in good faith consider and reflect any such changes.

  

(c)            No
later than ninety (90) days after the Closing Date, Buyer will deliver to Seller a statement, executed by the chief financial officer
or other similar officer of Buyer or an Affiliate thereof (together, the “Closing Statement”), which (i) sets
forth Buyer’s good faith estimate of (A) the aggregate amount of Cash as of immediately prior to the Closing (the “Final
Cash”); (B) the aggregate amount of the Indebtedness as of immediately prior to the Closing (the “Final Indebtedness”);
(C) the aggregate amount of Seller Transaction Expenses as of immediately prior to the Closing (the “Final Seller Transaction
Expenses”); and (D) the Net Working Capital (the “Final Net Working Capital”), including the amount
of any Final Net Working Capital Excess or Final Net Working Capital Deficit; and (ii) includes reasonably detailed calculations,
data, and schedules supporting the computation of the amounts contained therein and is prepared and calculated in accordance with Section 1.02(g).
In the event Buyer fails to deliver a Closing Statement in accordance with this Section 1.02(c), the Estimated Closing Statement
will be deemed to be the Closing Statement for the purposes of this Section 1.02.

 

    5 

     

    

 

(d)            During
the period from Buyer’s delivery of the Closing Statement until final determination of the Final Cash, Final Indebtedness, Final
Seller Transaction Expenses, and Final Net Working Capital (including any Final Net Working Capital Excess or Final Net Working Capital
Deficit), Buyer will, and will cause the Relevant Entities to, (i) assist Seller and its representatives in the review of the Closing
Statement and provide Seller and its representatives with reasonable access during normal business hours to the relevant books, records,
supporting data, representatives and relevant employees of the Relevant Entities for purposes of their review of the Closing Statement,
and (ii) cooperate in good faith with Seller and its representatives in connection with such review, including providing on a timely
basis all the information and materials necessary or otherwise reasonably requested by Seller or its representatives in connection with
the review of the Closing Statement. If Seller has any objections to the Closing Statement, Seller will deliver to Buyer a statement
setting forth its objections thereto (an “Objections Statement”), which statement will identify in reasonable detail
those items and amounts to which Seller objects and the rationale for such objections (the “Disputed Items”). If an
Objections Statement is not delivered to Buyer within sixty (60) days after delivery of the Closing Statement or the Seller accepts the
Closing Statement in writing, the Closing Statement, including the calculations of Final Cash, Final Indebtedness, Final Seller Transaction
Expenses, and Final Net Working Capital (including any Final Net Working Capital Excess or Final Net Working Capital Deficit) determined
pursuant to Section 1.02(c), will be final, binding and non-appealable by the Parties; provided, that, in the event
Buyer or any Relevant Entity does not provide any reasonably requested papers or documents necessary for Seller’s review of the
Closing Statement within ten (10) days of the request therefor, so long as such request was made within fifty (50) days of
the delivery of the Closing Statement, such sixty (60)-day period will be extended by the greater of (A) one (1) day for each
additional day required for Buyer or any Relevant Entity to respond to such request in all material respects and (B) 10 calendar
days. Seller and Buyer will negotiate in good faith to resolve the Disputed Items, and all such discussions related thereto will (unless
otherwise agreed by Buyer and Seller) be governed by Rule 408 of the Federal Rules of Evidence and any applicable similar state
statute. If they resolve their differences over the Disputed Items, Final Cash, Final Indebtedness, Final Seller Transaction Expenses,
and Final Net Working Capital (including any Final Net Working Capital Excess or Final Net Working Capital Deficit) shall be the amounts
agreed upon by them. If they do not reach a final resolution within thirty (30) days after the delivery of the Objections Statement to
Buyer, Seller and Buyer will submit any unresolved Disputed Items to Riveron Consulting, LP, or if such firm is unwilling or unable to
serve, such other independent national accounting, consulting or valuation firm mutually agreeable to Buyer and Seller (the “Accounting
Expert”). In the event the parties submit any unresolved Disputed Items to the Accounting Expert, each party may submit its
final position in writing with respect to each of the Disputed Items (which in the case of each party may be a position that, with respect
to the unresolved Disputed Items (but not, for the avoidance of doubt, with respect to any other items), is different than (but not more
favorable to the submitting party than) the Closing Statement initially submitted to Seller or the Objections Statement delivered to
Buyer, as applicable) together with such supporting documentation as it deems appropriate, to the Accounting Expert within thirty (30)
days after the date on which such unresolved Disputed Items were submitted to the Accounting Expert for resolution, it being agreed that
the parties will make their respective submission contemporaneously, and with a copy to the other party. Seller and Buyer will use their
respective commercially reasonable efforts to cause the Accounting Expert to resolve such Disputed Items as soon as practicable, but
in any event within thirty (30) days after the date on which the Accounting Expert receives the submissions prepared by Seller and Buyer.
Seller and Buyer will not engage in any ex parte communications with the Accounting Expert. Buyer and Seller shall instruct the
Accounting Expert to review only those unresolved Disputed Items. The Accounting Expert will resolve such disputes; provided,
however, that Accounting Expert shall act solely as an expert, and not as an arbitrator, and shall not determine an amount of
any item of any party’s submission greater than the highest amount or less than the lowest amount of such item claimed by the parties.
Each of Buyer and Seller agree that it shall not have any right to, and shall not, institute any Action of any kind challenging such
determination or with respect to the matters that are the subject of this Section 1.02, except that the foregoing shall not
preclude an Action to enforce such determination. In the event any dispute is submitted to the Accounting Expert for resolution as provided
in Section 1.02, the fees, charges and expenses of the Accounting Expert shall be allocated and be paid by Buyer, on the
one hand, and/or Seller, on the other hand, based upon the percentage which the portion of the disputes not awarded to each party bears
to the amount actually contested by such party. For example, if Seller claims that the appropriate adjustments are $1,000 greater than
the amount determined by Buyer and if the Accounting Expert ultimately resolves the dispute by awarding to Seller $300 of the $1,000
contested, then the fees, costs and expenses of the Accounting Expert will be allocated 30% (i.e., 300 ÷ 1,000) to Buyer and 70%
(i.e., 700 ÷ 1,000) to Seller. The Accounting Expert’s final calculations of (i) Final Cash shall be deemed the Final Cash,
(ii) Final Indebtedness shall be deemed the Final Indebtedness, (iii) Final Seller Transaction Expenses shall be deemed the
Final Seller Transaction Expenses, and (iv) Final Net Working Capital shall be deemed the Final Net Working Capital (including any
Final Net Working Capital Excess or Final Net Working Capital Deficit).

 

    6 

     

    

 

(e)            Within
five (5) Business Days following the final determination of the Final Cash, Final Indebtedness, Final Seller Transaction Expenses,
and Final Net Working Capital (including any Final Net Working Capital Excess or Final Net Working Capital Deficit):

 

(i)            if
the Net Adjustment Amount is positive, then (A) Buyer will pay an amount equal to such excess to Seller, by wire transfer of immediately
available funds up to the amount of the Adjustment Escrow Funds to an account or accounts designated by Seller, and (B) Buyer and
Seller will jointly instruct the Escrow Agent to pay to Seller, by wire transfer of immediately available funds, the remainder, if any,
of the Adjustment Escrow Funds, to an account or accounts designated by Seller;

 

(ii)            if
the Net Adjustment Amount is negative, then Buyer and Seller will jointly instruct the Escrow Agent to pay (A) to Buyer, by wire
transfer of immediately available funds, an amount equal to such shortfall from (and up to the amount of) the Adjustment Escrow Funds
to an account or accounts designated by Buyer, and (B) to Seller, by wire transfer of immediately available funds, the remainder,
if any, of the Adjustment Escrow Funds, to an account or accounts designated by Seller; and

 

(iii)            if
the Net Adjustment Amount is zero, then Buyer and Seller will jointly instruct the Escrow Agent to pay to Seller, by wire transfer of
immediately available funds, the Adjustment Escrow Funds to an account or accounts designated by Seller. For the avoidance of doubt,
Seller shall have no liability under this Section 1.02(e) in excess of the Adjustment Escrow Funds.

 

(f)            All
payments required pursuant to Section 1.02(d) and Section 1.02(e) will be deemed to be adjustments
for Tax purposes to the Estimated Purchase Price to the extent permitted by applicable Law.

 

(g)            The
Estimated Closing Statement and the Closing Statement shall be prepared in a manner consistent with the definitions of the terms Cash, Indebtedness,
Seller Transaction Expenses, and Net Working Capital, and, in respect of Net Working Capital, calculated in a manner consistent with
the Agreed Accounting Principles. The Estimated Closing Statement and the Closing Statement will entirely disregard any and all effects
on the assets or Liabilities of the Company as a result of the transactions contemplated hereby or of any financing or refinancing arrangements
entered into at any time by Buyer or any other transaction entered into by Buyer in connection with the consummation of the transactions
contemplated hereby. The Closing Statement will be based solely on facts and circumstances as they exist as of the Closing and will exclude
the effect of any fact, event, change, circumstance, act, development or decision occurring after the Closing. The parties agree
that the purpose of preparing and calculating the Net Working Capital hereunder is to measure changes in Net Working Capital without
the introduction of new or different accounting methods, policies, practices, procedures, classifications, judgments or estimation methodologies
except as specifically set forth in the Agreed Accounting Principles.

 

    7 

     

    

 

(h)            The
process set forth in this Section 1.02 shall be the exclusive remedy of the parties for any disputes related to items to
the extent reflected on the Closing Statement; provided, however, in no event shall any party be entitled to any duplicative
recovery as a result of the rights and remedies afforded herein.

 

1.3            The
Closing. The closing of the transactions contemplated by this Agreement (the “Closing”) will take place at the
offices of McGuireWoods LLP, located at 77 W. Wacker Drive, Suite 3100, Chicago, Illinois 60601, or remotely via electronic
exchange of documents and signatures, on the third (3rd) Business Day following satisfaction or waiver of the conditions to the Closing
set forth in Article II (other than those conditions that by their nature are to be satisfied at the Closing, but subject
to the satisfaction or waiver of such conditions at the Closing) or such other date and place as Buyer and Seller may mutually agree;
provided, however, that the Closing shall not occur before the day that is thirty-five (35) days from the
date hereof unless Buyer provides notice in writing to Seller of the waiver of such thirty-five day period. The date of the Closing is
herein referred to as the “Closing Date.” The Closing will be deemed to occur at 12:01 a.m. central time on the
Closing Date (the “Closing Effective Time”).

 

1.4            Closing
Date Payments by Buyer. Subject to the satisfaction of the conditions set forth in Sections 2.01, 2.02 and 2.03 (other than those
to be satisfied at the Closing), at the Closing, Buyer will:

 

(a)            Pay,
or cause to be paid, to Seller, the Estimated Purchase Price;

 

(b)            Pay,
or cause to be paid, on behalf of the Relevant Entities, the outstanding amount of Estimated Indebtedness of the type set forth on Schedule
1.04(b)), by wire transfer of immediately available funds, to the Persons or bank accounts specified in the payoff letters delivered
in accordance with Section 2.02(d)(iii);

 

(c)            Pay,
or cause to be paid, on behalf of the Relevant Entities, the outstanding amount of Estimated Seller Transaction Expenses, to the applicable
recipients, by wire transfer of immediately available funds, to the Persons or bank accounts specified in written invoices delivered
to Buyer at least two (2) Business Days prior to the Closing Date;

 

(d)            Pay,
or cause to be paid, to the account directed by the Seller’s Representative, the Expense Fund Amount; and

 

(e)            Pay,
or cause to be paid, to the Escrow Agent, by wire transfer of immediately available funds, the Escrow Amount, with such amount to be
deposited in separate non-interest bearing accounts established and designated by the Escrow Agent and held by Escrow Agent in accordance
with this Agreement and the Escrow Agreement.

 

    8 

     

    

  

1.5            Escrow
Amount. The Escrow Amount will not be used for any purpose except as expressly provided in this Agreement or in the Escrow Agreement.

 

1.6            Withholding.
Notwithstanding anything in this Agreement to the contrary, Buyer, the Company, and the Company’s Subsidiaries shall be entitled
to deduct and withhold from any payments made pursuant to this Agreement such amounts as such Person reasonably and in good faith determines
it is required to deduct and withhold with respect to such payments under the Code or any provision of state, local or non-U.S. Law.
The Person making the deduction and withholding shall give the Person subject to deduction and withholding a reasonable opportunity to
mitigate or avoid such deduction in withholding. To the extent that amounts are so withheld, such withheld amounts will be treated for
all purposes of this Agreement as having been paid to the Person in respect of which such deduction and withholding was made.

 

ARTICLE II

 

CONDITIONS TO CLOSING

 

2.1            Conditions
to All Parties’ Obligations. The obligations of the Parties to consummate the Closing are subject to the satisfaction
(or, if permitted by applicable Law, waiver by the party for whose benefit such condition exists) of the following conditions as of or
prior to the Closing Date:

 

(a)            The
applicable waiting periods (and any extensions thereof), if any, under the HSR Act will have expired or been terminated;

 

(b)            No
temporary restraining order, preliminary or permanent injunction, Order, judgment or ruling enacted, promulgated, issued, entered, amended
or enforced by any Governmental Body will be in effect enjoining, restraining, preventing or prohibiting consummation of the Closing
or making the consummation of the Closing illegal; and

 

(c)            This
Agreement will not have been terminated in accordance with Section 8.01.

 

2.2            Conditions
to Buyer’s Obligations. The obligation of Buyer to consummate the Closing is subject to the satisfaction of the following conditions
as of the Closing Date, any of which may be waived in writing by Buyer:

 

(a)            Each
of (i) the representations and warranties in Sections 3.01, 3.02, 3.03(a), 3.05, 4.01, 4.02,
4.04, 4.05, and 4.19 shall be true and correct in all respects (subject to de minimis inaccuracies) as of the Closing
Date as if made anew as of such date (except to the extent any such representation and warranty expressly relates to an earlier date
(in which case as of such earlier date)), (ii) the representations and warranties in Section 3.04 and the first sentence
of Section 4.06 shall be true and correct in all respects as of the date hereof, and (iii) the remaining representations
and warranties of Seller and the Company contained in Article III and Article IV, respectively, (A) that
is qualified as to or by Material Adverse Effect will be true and correct as of the Closing Date as if made anew as of such date (except
to the extent any such representation and warranty expressly relates to an earlier date (in which case as of such earlier date)), except
to the extent of changes or developments contemplated by the terms of this Agreement or caused by the transactions contemplated
hereby and (B) that is not qualified as to or by Material Adverse Effect will be true and correct as of the Closing Date as if made
anew as of such date (except to the extent any such representation and warranty expressly relates to an earlier date (in which case as
of such earlier date)), except to the extent of changes or developments contemplated by the terms of this Agreement or caused by the
transactions contemplated hereby and except for any failure of any such representation and warranty referred to in this clause (iii) to
be true and correct that has not had a Material Adverse Effect;

 

    9 

     

    

 

(b)            The
Company and Seller will have performed in all material respects all of the covenants and agreements required to be performed by them
under this Agreement at or prior to the Closing contemplated by this Agreement or caused by the transactions contemplated hereby;

 

		(c)	The
                                            Pre-Closing Restructuring shall have been consummated;

 

(d)            The
Company and Seller, as applicable, will have delivered to Buyer each of the following:

 

(i)            a
certificate of the Company executed by a duly authorized officer thereof, dated the Closing Date, stating that the preconditions specified
in Section 2.02(a) and Section 2.02(b), have been satisfied;

 

(ii)            a
copy of the Escrow Agreement, duly executed by Seller’s Representative and the Escrow Agent;

 

(iii)            payoff
letters, in form and substance reasonably satisfactory to the Company and Buyer, with respect to the payoff amounts of the Indebtedness
identified on Schedule 2.02(c)(iii);

 

(iv)            an
assignment of the Interests of Seller, duly executed by Seller;

 

(v)            an
Internal Revenue Service Form W-9, duly completed and executed by Seller;

 

(vi)            a
certificate, in form and substance reasonably acceptable to Buyer, of an authorized officer of the Company, dated as of the Closing Date,
certifying to the accuracy of, and attaching, (A) a copy of the Company’s Organizational Documents, (B) a copy of the
resolutions of the Company’s board of managers authorizing the execution and delivery of this Agreement and the consummation of
the transactions contemplated hereby, and (C) good standing certificate of the Company from its jurisdiction of formation and of
foreign qualification as of a date not more than 10 Business Days prior to the Closing Date);

 

(vii)            written
resignations or other evidence of removal of each of the directors, managers, and officers of the Company as requested by Buyer at least
five (5) Business Days prior to the Closing Date;

 

    10 

     

    

  

(viii)            to
the extent certificated, certificates evidencing all of the issued and outstanding Interests;

 

(ix)            all
of the consents, notices, approvals, and Permits set forth on Schedule 2.02(d)(ix);

 

(x)            evidence
of the termination of the contracts and agreements set forth on Schedule 2.02(d)(x) as of the Closing such that no Person
shall have any right or obligation thereunder from and after the Closing in form and substance satisfactory to the Buyer;

 

(xi)            a
release from each of the D&O Indemnity Excluded Persons set forth on Schedule 2.02(d)(xi) in substantially the form attached
hereto as Exhibit D;

 

(xii)            all
other documents required to be delivered by Seller or the Company on or prior to the Closing Date pursuant to this Agreement.

 

2.3            Conditions
to Seller’s and the Company’s Obligations. The obligations of Seller and the Company to consummate the Closing are subject
to the satisfaction of the following conditions as of the Closing Date, any of which may be waived in writing by Seller:

 

(a)            Each
of (i) the representations and warranties in Sections 5.01, 5.02, and 5.05
shall be true and correct in all respects (subject to de minimis inaccuracies) as of the Closing Date as if made anew as of
such date (except to the extent such representation and warranty expressly relates to an earlier date in which case as of such earlier
date)), and (ii) the remaining representations and warranties set forth in Article V hereof will be true and correct
as of Closing Date as if made anew as of such date (except to the extent any such representation and warranty expressly relates to an
earlier date (in which case as of such earlier date)), except for any failure of such representations and warranties referred to in this
clause (ii) to be true and correct that has not had a material adverse effect on the financial condition or operating results of
Buyer or on the ability of Buyer to consummate the transactions contemplated hereby;

 

(b)            Buyer
will have performed in all material respects all of the covenants and agreements required to be performed by it under this Agreement
at or prior to the Closing, except for actions contemplated by this Agreement or caused by the transactions contemplated hereby; and

 

(c)            Buyer
will have delivered to Seller each of the following:

 

(i)            a
certificate of Buyer executed by a duly authorized officer thereof, dated the Closing Date, stating that the preconditions specified
in Section 2.03(a) and Section 2.03(b) have been satisfied;

 

(ii)            a
copy of the Escrow Agreement, duly executed by Buyer and the Escrow Agent; and

 

    11 

     

    

  

(iii)            all
other documents required to be delivered by Buyer on or prior to the Closing Date pursuant to this Agreement.

 

2.04        
Waiver of Conditions. All conditions to the Closing will be deemed to have been satisfied or waived from and after the Closing.

 

ARTICLE III

 

REPRESENTATIONS AND WARRANTIES
OF SELLER

 

Seller represents and warrants to Buyer that the
statements of Seller contained in this Article III are true and correct as of the date hereof and as of the Closing Date
(except to the extent any such representation and warranty expressly relates to an earlier date (in which case, as of such earlier date)),
as follows:

 

3.1            Organization
and Power. Seller is a duly organized limited liability company, validly existing and in good standing under the Laws of the state
of its organization, with full organizational power and authority to enter into this Agreement, perform its obligations hereunder and
under each Transaction Document to which Seller is a party and to consummate the transactions contemplated hereby and thereby.

 

3.2            Authorization;
Valid and Binding Agreement. The execution, delivery and performance of this Agreement and each other Transaction Document to which
Seller is a party by Seller and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized
by all requisite action on the part of Seller, and no other proceedings on Seller’s part are necessary to authorize the execution,
delivery or performance of this Agreement or any other Transaction Document to which Seller is a party. This Agreement constitutes a
valid and binding obligation of Seller, enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy,
insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar Laws affecting creditors’ rights and general
principles of equity affecting the availability of specific performance and other equitable remedies.

 

3.3            No
Breach. Except as set forth on Schedule 3.03, the execution, delivery and performance of this Agreement or any Transaction
Document to which Seller is a party by Seller and the consummation of the transactions contemplated hereby and thereby do not (a) violate
any provision of the Organizational Documents of Seller or any Relevant Entity, (b) conflict with or result in any breach of any
Law, statute, rule or regulation or Order, judgment or decree to which Seller is subject, or require any authorization, filing,
consent, approval, exemption or other action by or written notice to any Governmental Body, in each case other than as required under
the HSR Act, (c) violate, result in a breach of, or constitute a default under, give rise to any right of termination, cancelation,
acceleration under loss of any benefit under, or require the consent of or any notice to any third party that has not been obtained,
whether under any Contract, license, Permit, or other agreement, instrument, or commitment to which Seller is bound, or (d) result
in the creation or imposition of a Lien on any of the Relevant Entities or on Seller that affects any of the Relevant Entities.

 

    12 

     

    

 

3.4            Ownership.
Seller is the record and beneficial owner of the Interests set forth opposite Seller’s name on Schedule 3.04(a). Seller
holds good and valid title to all of its Interests, free and clear of any Liens, other than transfer restrictions imposed by the Organizational
Documents of the Company, federal and state securities Laws, and Permitted Liens. Except as set forth on Schedule 3.04(b), Seller
is not a party to any option, warrant, purchase right or other Contract or commitment (other than this Agreement) that could require
Seller to sell, transfer or otherwise dispose of any Interest of the Company. Seller is not a party to any voting trust, proxy or other
contract with respect to the voting of any Interest or the Equity Securities of any Relevant Entity.

 

3.5            Brokers.
Except for amounts owed by Seller to Cain Brothers that constitute Seller Transaction Expenses, Seller has not incurred any obligation
for any finder’s or broker’s fees, commissions or similar compensation payable to a broker, finder, investment banking firm,
financial advisor, or other similar Person in connection with the transactions contemplated by this Agreement.

 

3.6            Litigation.
Except as set forth on Schedule 3.06, there are no Actions pending or, to Seller’s knowledge, threatened in writing
against Seller with respect to any of its businesses, properties or assets, in any such case that (a) challenges or seeks to enjoin,
delay, or obtain damages in respect of this Agreement, the Transaction Documents to which Seller is a party, or any of the transactions
contemplated hereby or thereby or (b) would reasonably be expected to materially affect the legality, validity or enforceability
of this Agreement or any other Transaction Document to which Seller is a party or the consummation of the transactions contemplated hereby
or thereby.

 

3.7            No
Other Representations and Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS ARTICLE III AND ARTICLE IV,
SELLER MAKES NO EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, AND SELLER HEREBY DISCLAIMS ANY SUCH REPRESENTATION OR WARRANTY WITH RESPECT
TO THE EXECUTION AND DELIVERY OF THIS AGREEMENT, ITS SUBJECT MATTER, AND THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS
AGREEMENT. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, BUYER WILL ACQUIRE THE INTERESTS WITHOUT ANY REPRESENTATION OR WARRANTY
AS TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, IN AN “AS IS” CONDITION AND ON A “WHERE IS”
BASIS, EXCEPT AS OTHERWISE EXPRESSLY REPRESENTED OR WARRANTED BY SELLER IN THIS ARTICLE III OR THE COMPANY AND SELLER IN ARTICLE IV.

 

    13 

     

    

 

ARTICLE IV

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company and the Seller
represent and warrant to Buyer, as of the date hereof and as of the Closing Date (except to the extent any such representation and warranty
expressly relates to an earlier date (in which case, as of such earlier date)), as follows:

  

4.1            Organization
and Power. The Relevant Entities are duly organized, validly existing and in good standing under the Laws of the jurisdiction of
its organization, have all requisite corporate or other legal entity power and authority and all Permits, authorizations and licenses
necessary to own their properties and to carry on their businesses as now conducted and are qualified to do business in every jurisdiction
in which their ownership of property or the conduct of businesses as now conducted requires them to qualify, except in each such case
where the failure to hold such Permits, authorizations and licenses or to be so qualified would not reasonably be expected to materially
impair the ability of any Relevant Entity to conduct its business in the ordinary course of business consistent with past practice. The
Company has full limited liability company power and authority to enter into this Agreement, perform its obligations hereunder and under
each Transaction Document to which it is a party, and to consummate the transactions contemplated hereby and thereby. The Relevant Entities
have the full power and authority to enter into and perform their obligations, as applicable, under each Transaction Document to which
they are party and to consummate the transactions contemplated thereby.

 

4.2            Capitalization.
The Interests constitute all the Equity Securities of the Company. Except as set forth on Schedule 4.02(a), no Relevant Entity
owns or holds the right to acquire any stock, partnership interest, joint venture interest or other equity ownership interest in any
other Person. Except as set forth on Schedule 4.02(b), there are no outstanding (a) limited liability company interests or
other Equity Securities or voting securities of any Relevant Entity, (b) securities convertible or exchangeable into capital stock
of any Relevant Entity, (c) options, warrants, purchase rights, subscription rights, preemptive rights, conversion rights, exchange
rights, calls, puts, rights of first refusal or other contracts that require any Relevant Entity to issue, sell or otherwise cause to
become outstanding or to acquire, repurchase or redeem the Equity Securities of any Relevant Entity, or (d) stock appreciation,
restricted units, restricted stock units, phantom stock, profit participation or similar rights with respect to any Relevant Entity.
Schedule 4.02(b) sets forth the number and type of issued and outstanding Equity Securities of each Relevant Entity, and
the identity of each owner (beneficially and of record) of all such Equity Securities and the number of Equity Securities held by each
holder. To the Company’s Knowledge, there are no conditions or circumstances that may give rise to or provide the basis for the
assertion of a claim by any Person to the effect that such Person is entitled to repurchase, redeem or otherwise acquire or retire or
to receive any Equity Securities of any Relevant Entity. All of the Equity Securities of each Relevant Entity are authorized, validly
issued, fully paid (to the extent applicable), and non- assessable (to the extent applicable) and have not been issued in violation of,
and, except as set forth on Schedule 4.02(c), are not subject to, any preemptive or subscription rights, rights of first refusal
or similar rights. Except as set forth on Schedule 4.02(d), no Relevant Entity is required to make or pay any dividends or distributions
in respect of its Equity Securities. The Company has made available to Buyer copies of each Relevant Entity’s Organizational Documents
as in effect on the date hereof and no Relevant Entity is in default or violation of any provision of such Organizational Documents.
The books of account, stock records, minute books and other records of the Company, the Acquired Companies, the Managed Practices, are
accurate and complete in all material respects.

 

    14 

     

    

 

4.3            Authorization;
Valid and Binding Agreement. The execution, delivery and performance of this Agreement and each Transaction Document by the Company
and each Relevant Entity, as applicable, and the consummation of the transactions contemplated hereby and thereby have been duly and
validly authorized by all requisite action on the part of the Company, each Relevant Entity, as applicable, and the Monitor pursuant
to the terms of the Monitor Order and no other proceedings on the Company’s or any Relevant Entity’s part are necessary to
authorize the execution, delivery or performance of this Agreement. Mike Frost, Manuel Vianna, Dotty Bollinger, Abhaya Shrestha, Joe
Laporta and Michael Wiggin have been the only current or former employee, independent contractor, consultant, officer, director, or other
service provider of the Institutional Holders or their respective Affiliates that is or has been a director, officer, manager, independent
contractor, consultant or other service provider of the Company. This Agreement and each Transaction Document constitutes a valid and
binding obligation of the Company or any Relevant Entity, as applicable, enforceable in accordance with its terms, except as enforceability
may be limited by bankruptcy, insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar laws affecting creditors’
rights and general principles of equity affecting the availability of specific performance and other equitable remedies.

 

4.4            No
Breach. Except as set forth on Schedule 4.04, the execution, delivery and performance of this Agreement and any Transaction
Document by the Company, or any Relevant Entity to which it is a party, and the consummation of the transactions contemplated hereby
and thereby do not and will not, (a) violate any provision of the Organizational Documents of any Relevant Entity, (b) conflict
with or result in any breach of any Law, statute, rule or regulation or Order, judgment or decree to which any Relevant Entity is
subject, or require any authorization, filing, consent, approval, exemption or other action by or written notice to any Governmental
Body, in each case other than as required under the HSR Act, (c) violate, result in a breach of, or constitute a default under,
give rise to any right (concurrently or with the passage of time and/or upon the occurrence of one or more events or conditions) of termination,
cancelation, acceleration under loss of any benefit under, or require the consent of or any notice to any third party that has not been
obtained, whether under any Contract, license, Permit, or other agreement, instrument, or commitment to which any Relevant Entity is
bound, or (d) result in the creation or imposition of a Lien (other than a Permitted Lien) on any assets or property of any Relevant
Entity.

 

4.5            Financial
Statements. The Company has made available to Buyer true and correct copies of (a) the Relevant Entities’ unaudited consolidated
balance sheets as of September 30, 2021 (the “Latest Balance Sheet”) and the related statements of income and
cash flows for the nine-month period then ended and (b) the Relevant Entities’ audited consolidated balance sheet, consolidated
statements of operations, and consolidated statements cash flows for the fiscal years ended December 31, 2020 and December 31,
2019 (all such financial statements referred to in clauses (a) and (b), the “Financial Statements”). Except as
set forth on Schedule 4.05, the Financial Statements present fairly, in all material respects, the financial condition and consolidated
results of operations and cash flows of the Relevant Entities as of the times and for the periods referred to therein in accordance with
GAAP, consistently applied (subject in the case of the unaudited Financial Statements to (y) the absence of footnote disclosures
and other presentation items and (z) changes resulting from year-end adjustments).

 

    15 

     

    

 

4.6            Absence
of Certain Developments. Since the date of the Latest Balance Sheet through the date hereof, there has not been any event, change,
occurrence, or circumstance that has had, or would reasonably be expected to have, individually or in the aggregate, a Material Adverse
Effect. Except as set forth on Schedule 4.06, as required by applicable Law (including as required in directly connection with
COVID-19 or the Coronavirus Pandemic pursuant to applicable Law or Order by Governmental Body), or as expressly contemplated by this
Agreement, since the Latest Balance Sheet through the date hereof, the Relevant Entities have been operated in the ordinary course
of business, and no Relevant Entity has:

 

(a)            amended
or modified its Organizational Documents;

 

(b)            issued,
reissued or sold, or authorized the issuance, reissuance or sale of, any of its Equity Securities (including, for the avoidance of doubt,
incentive equity);

 

(c)            declared,
set aside or paid any dividend or other distribution of assets in respect of any of its Equity Securities;

 

(d)            adjusted,
split, combined, recapitalized, subdivided or reclassified any of its Equity Securities;

 

(e)            subjected
any portion of its properties or assets that are material to the Relevant Entities, taken as a whole, to any Lien, except for Permitted
Liens;

 

(f)            sold,
assigned, leased, subleased, sublicensed, covenanted not to assert with respect to, transferred or otherwise disposed of any portion
of its assets (except for Owned Intellectual Property), tangible or intangible, owned, leased, or licensed that are material to the Relevant
Entities, taken as a whole;

 

(g)            sold,
assigned, transferred, leased, licensed, abandoned, disposed of, or permitted to lapse (other than patents expiring at the end of their
statutory term and not as a result of any act or omission by the Relevant Entity, including failure by the Relevant Entity to pay any
required maintenance fees) any Owned Intellectual Property;

 

(h)            (i) made
or granted any bonus or any compensation or salary increase or decrease to any current (or former) employee or individual service provider
whose annual base salary or fees was (or was at the time of his or her termination) in excess of $125,000, (ii)  made
or granted any increase or decrease in any current (or former) employee benefit plan or arrangement, or amended or terminated any existing
employee benefit plan or arrangement or made, modified, or terminated any employment, consulting, change in control, retention, termination,
deferred compensation, severance or similar agreement, (iii) accelerated
or committed to accelerate the funding, payment or vesting of any compensation (including any equity or equity-based compensation), severance,
or benefits, or (iv) hired engaged, furloughed, temporarily laid off or terminated (other than for “cause”) any employee,
officer, or independent contractor of any Relevant Entity with annual base compensation in excess of $125,000, except, in the case of
the foregoing clauses (i), (ii) or (iii), (A) as may be required under applicable Law or any applicable Contract in effect,
or (B) otherwise involving any employee or independent contractor of any Relevant Entity whose annual base compensation does not
exceed $125,000;

 

(i)            acquired
(including by merger) the Equity Securities, capital stock, assets or any division of any other Person;

 

(j)            made
any loans or advances to, investment in, or guarantees for the benefit of, any Persons (except to employees in the ordinary course of
business);

 

    16 

     

    

 

(k)          
initiated, canceled, compromised or settled any Action;

 

(l)            (i) amended
any Tax Return or filed any Tax Return in a manner inconsistent with the past practices of the Relevant Entities, (ii) made or changed
any election in respect of Taxes, (iii) adopted or changed any method of accounting or annual reporting, (iv) settled or compromised
any Tax claim or assessment, (v) entered into any closing agreement relating to any Tax, (vi) agreed to an extension or waiver
of a statute of limitations period applicable to any Tax claim or assessment, (vii) failed to pay any Tax when due and payable (including
estimated Taxes), (viii) surrendered any right to claim a Tax refund, (ix) adopted or change any method of accounting (including
with respect to Taxes) or (x) taken any other similar action relating to the filing of any Tax Return or the payment of any Tax;

 

(m)            negotiated,
modified, extended or entered into any Labor Agreement (as hereinafter defined) or recognized or certified any labor union, labor organization,
works council or group of employees of any Relevant Entity as the bargaining representative for such employees;

 

(n)            implemented
or announced any employee layoffs, plant closings, reductions in force, furloughs, temporary layoffs, salary or wage reductions, work
schedule changes or other such actions that could implicate the WARN Act;

 

(o)            waived
or released any noncompetition, nonsolicitation, nondisclosure, noninterference, nondisparagement, or other restrictive covenant obligation
of any current or former employee or independent contractor;

 

(p)            adopted
a plan or agreement of complete or partial liquidation, dissolution, merger consolidation, restructuring, recapitalization or other reorganization
of the Company or any Relevant Entity;

 

(q)            made
any assignment for the benefit of creditors, or taken any action to commence voluntary proceedings under any federal or state bankruptcy
code or Law, or taken any action in respect of any bankruptcy proceeding filed against any Relevant Entity, or sought, consented to,
or acquiesced in the appointment of any custodian, receiver, liquidator, trustee or assignee in bankruptcy or similar insolvency proceeding
related to any Relevant Entity;

 

(r)            entered
into, amended, renewed, waived, or terminated any Contract with a Related Party;

 

(s)          
acquired any real property;

 

(t)            incurred
or discharged any material liabilities or obligations, except current liabilities incurred in the ordinary course of business, or incurred,
created, paid or repaid any Indebtedness;

 

    17 

     

    

 

(u)            declared,
set aside or made any payment, dividend or distribution of cash or other property to any of such Relevant Entity’s equity holders
with respect to such equity holder’s Equity Securities or otherwise (including any so-called “tax distributions”),
or purchased, redeemed or otherwise acquired any Equity Securities of such Relevant Entity;

 

(v)            made
any change in any annual accounting period, method of accounting or accounting policies or practices, estimation techniques, assumptions,
policies or principles theretofore adopted or followed, except as required by GAAP and reflected in a note to the Financial Statements
or made any write down in the value of its accounts receivable or reversed any accruals or reserves;

 

(w)            incurred
any damage, destruction or loss, whether or not covered by insurance, with respect to the Assets of the Relevant Entities having a replacement
cost of more than $50,000 in any single occurrence or $250,000 in the aggregate;

 

(x)            changed
in any material respect any business or operational practice (except in anticipation of the transactions contemplated by this Agreement);
or

 

(y)            agreed
or committed to do any of the foregoing.

 

4.7
          Title to Properties.

 

(a)            Except
as set forth on Schedule 4.07(a), the Relevant Entities own good, valid, and marketable title to, or hold pursuant to valid and
enforceable leases, all of the assets, machines, equipment, properties and interests in the real and personal property, shown to be owned
or leased by the Relevant Entities on the Latest Balance Sheet or acquired after the date of the Latest Balance Sheet, free and clear
of all Liens, except for Permitted Liens. Each of the foregoing properties, assets and rights (whether owned, leased or licensed) of
the Relevant Entities, are sufficient in all material respects to enable Buyer to conduct the business of the Relevant Entities following
the Closing in substantially the same manner in which such business is currently conducted.

 

(b)            The
Relevant Entities do not own any real property. Schedule 4.07(b) sets forth a complete list of all of the real property leased,
subleased, licensed or otherwise occupied by the Relevant Entities and used in the business of the Relevant Entities (the “Leased
Real Property” and such leases, subleases, licenses and other agreements, the “Leases”). The Leases of the
Relevant Entities made available to Buyer are materially true, correct and complete copies of all of the Leases. All of the Leases are
valid, binding and in full force and effect, except as otherwise noted on Schedule 4.07(b). Except as set forth on Schedule
4.07(b): (i) a Relevant Entity holds a valid and existing leasehold interest under each such Lease, free and clear of all Liens,
except for Permitted Liens, subject to proper authorization and execution of such Lease by the other party and the application of any
bankruptcy or creditor’s rights Laws; (ii) the Relevant Entities’ possession and quiet enjoyment of the Leased Real
Property under each Lease has not been disturbed and there are no disputes as to occupancy with respect to any Lease; and (iii) the
Relevant Entities are currently in possession of and have not subleased, licensed or otherwise granted any Person the right to use or
occupy any of the Leased Real Property or portion thereof. The Relevant Entities have not received any notice of any breach of or default
under any of the Leases that has not been cured, and the Relevant Entities and, to the Company’s Knowledge, each other party
thereto, is in compliance with all obligations of such party thereunder. To the Company’s Knowledge, the Relevant Entities have
not received any written decree, Order, writ or Action pending, or to the Company’s Knowledge, has any been threatened in writing,
relating to the ownership, lease, use or occupancy of the Leased Real Property or any portion thereof. Neither the Company nor any Subsidiary
owes, or is reasonably expected to owe in the future, any brokerage commissions or finder’s fees with respect to any Lease.

 

    18 

     

    

 

4.8          
Tax Matters.

 

Except as set forth on Schedule
4.08:

 

(a)            The
Relevant Entities have filed income and other material Tax Returns required to be filed by it for taxable periods ending after the Reference
Date and all such Tax Returns were true, correct and complete in all material respects. The Relevant Entities have timely paid all income
and other material Taxes (whether or not such Taxes are shown or required to be shown on a Tax Return).

 

(b)            All
material Taxes that the Relevant Entities are obligated to withhold from amounts owing to any employee, creditor or other third party
have been withheld and timely paid. The Relevant Entities have properly collected and remitted all sales, use, ad valorem, and value
added and other similar taxes with respect to sales or leases made or services provided to its customers and has properly received and
retained any appropriate tax exemption certificates and other documentation for all sales or leases made or services without charging
or remitting sales, use, ad valorem, value added and other similar taxes that qualify such sales as exempt from sales , use, ad valorem,
value added and other similar taxes.

 

(c)            There
are no Liens for Taxes on any assets of the Relevant Entities, other than Liens for Taxes not yet due and payable.

 

(d)            The
Relevant Entities have not waived any statute of limitations in respect of Taxes (or any Tax assessment or deficiency) or agreed to any
extension of time with respect to a Tax assessment or deficiency, which waiver or extension is still in effect.

 

(e)            There
is no Action concerning any Tax Liability or Tax Return of any Relevant Entity claimed or raised by any taxing authority that is in progress
or, to the Knowledge of the Company, threatened. No deficiency or proposed adjustment which has not been settled or otherwise resolved
for any amount of Tax has been proposed, asserted or assessed by any taxing authority against any Relevant Entity. None of the Relevant
Entities has received from any Governmental Body (including jurisdictions where the Relevant Entities do not file Tax Returns) any (i) notice
indicating an intent to open an audit or other review with respect to Taxes, (ii) request for information related to Tax matters
or (iii) notice of deficiency or proposed adjustment for any amount of Tax (or Tax attributes) proposed, asserted or assessed by
any Governmental Body. Neither Seller nor any Relevant Entity has received a written notice from any Governmental Body that it is required
to pay Taxes or file Tax Returns in a jurisdiction in which the Relevant Entity does not file Tax Returns or pay Taxes.

 

    19 

     

    

 

(f)             None
of the Relevant Entities has participated in or is participating in any “reportable transaction” within the meaning of Section 6707A(1) of
the Code and Treasury Regulation Section 1.6011-4(b).

 

(g)             None
of the Relevant Entities has been a member of any affiliated group filing a consolidated Tax Return or of any affiliated, consolidated,
combined, or unitary group, as defined under applicable state, local or non-U.S. Law (other than any such group of which the Company
is the common parent). None of the Relevant Entities has any liability for Taxes of any Person under Treasury Regulation Section 1.1502-6
or any similar provision of state, local or non-U.S. law as a transferee or successor, by contract or otherwise.

 

(h)            None
of the Relevant Entities is party or bound by any Tax allocation or Tax sharing or similar agreement with respect to Taxes.

 

(i)             None
of the Relevant Entities nor the Buyer by virtue of its ownership in the Company will be required to include any item of income in, or
exclude any item of deduction from, taxable income for any taxable period (or portion thereof) beginning after the Closing Date as a
result of any (i) change in method of accounting for a taxable period ending on or prior to the Closing Date, (ii) “closing
agreement” as described in Section 7121 of the Code (or any corresponding or similar provision of state, local or non-U.S.
Tax law) executed on or prior to the Closing Date, (iii) intercompany transaction or excess loss account described in Treasury Regulations
under Section 1502 of the Code (or any corresponding or similar provision of state, local, or non-U.S. Tax law), (iv) any use
of an improper method of accounting for a taxable period ending on or prior to the Closing Date, (v) installment sale or
open transaction disposition made on or prior to the Closing Date, or (vi) prepaid amount received or deferred revenue accrued on
or prior to the Closing Date.

 

(j)             None
of the Relevant Entities is subject to Tax in any jurisdiction outside the United States by virtue of (i) having a permanent establishment
or other place of business or (ii) having a source of income in that jurisdiction.

 

(k)            None
of the Relevant Entities has adopted as a method of accounting, or otherwise accounted for any advance payment or prepaid amount under,
(i) the “deferral method” of accounting described in Rev. Proc. 2004-34, 2004-22 IRB 991, and Section 451(c) of
the Code (or any similar method under state, local or non-U.S. Law) or (ii) the method described in Treasury Regulation Section 1.451-5(b)(1)(ii) (or
any similar method under state, local or non-U.S. Law).

 

(l)             The
Relevant Entities have (i) to the extent applicable, properly complied with all requirements of applicable Tax Law in order to defer
the amount of the employer’s share of any “applicable employment taxes” under Section 2302 of the CARES Act, (ii) not
deferred any payroll tax obligations pursuant to Payroll Tax Executive Order, (iii) to the extent applicable, properly complied
with all requirements of applicable Tax Law and duly accounted for any available Tax credits under Sections 7001 through 7005 of the
Families First Act and Section 2301 of the CARES Act, and (iv) properly complied with all requirements of applicable Tax Law
with respect to the receipt of Provider Relief Fund payments.

 

    20 

     

    

 

(m)            The
unpaid Taxes of the Relevant Entities (i) did not, as of the date of the Last Balance Sheet, exceed the reserve for Tax Liability
(rather than any reserve for deferred Taxes established to reflect timing differences between book and Tax income) set forth on the face
of the Last Balance Sheet (rather than in any notes thereto), and (ii) do not exceed that reserve as adjusted for the passage of
time through the Closing Date in accordance with the past custom and practice of the Relevant Entities in filing their Tax Returns.

 

(n)            None
of the Relevant Entities is a partner or a member of any partnership, limited liability company, joint venture or any other entity, in
each case, that is classified as a partnership for federal income tax purposes.

 

(o)            Each
of the Acquired Companies is properly treated for U.S. federal and applicable state and local income Tax purposes as a disregarded entity.

 

(p)            None
of the Acquired Companies has made any election or otherwise taken any action to cause the Partnership Tax Audit Rules to apply
at any earlier date than is required by Law.

 

(q)            Each
of the Acquired Companies has complied in all material respects with respect to any “escheat,” “abandoned property,”
 ”unclaimed property,” or other similar Laws.

 

		4.9	Contracts
                                            and Commitments.

 

(a)            Except
as set forth on Schedule 4.09(a), neither the Company nor any Relevant Entity is a party to any:

 

(i)            Contract
for (A) the sale of any of the assets of any Relevant Entity (whether by merger, sale of Equity Securities, sale of assets or otherwise)
other than the sale or disposition of obsolete equipment in the ordinary course of business or (B) the acquisition of all,
substantially all, or any material portion of the assets or properties of another Person (whether by merger, purchase of Equity Securities,
purchase of assets or otherwise);

 

(ii)            Contract
that is a settlement, conciliation or similar agreement with any Governmental Body or pursuant to which any Relevant Entity will have
any material outstanding obligation after the date of this Agreement;

 

(iii)            collective
bargaining agreement or Contract with any labor union, labor organization, or works council (each, a “Labor Agreement”);

 

    21 

     

    

 

(iv)            Contract
for the employment or engagement of any officer, employee, independent contractor, or other person or entity on a part-time, full- time,
consulting or other basis (including Licensed Personnel) providing for base compensation in excess of $125,000 per annum and all Contracts
providing for severance or loans to officers, directors, employees or Affiliates, other than advances in the ordinary course of business;

 

(v)            Contracts
that contain any change in control provisions (A) that would require consent of a third party, (B) create a right of termination
of a third party, or (C) which would otherwise result in any payments or benefits to any Person upon consummation of, or as a result
of, the transactions contemplated hereby;

 

(vi)            Contracts
that contain obligations to pay or provide severance, retention and/or transaction bonus payments to any current or former employee,
director, officer or independent contractor or any other Person;

 

(vii)            Contract
or indenture relating to Indebtedness of any Relevant Entity, including the borrowing of money or mortgaging, pledging or otherwise placing
a Lien on any Relevant Entity’s assets or any guaranty of any obligation for borrowed money in excess of $100,000;

 

(viii)            Contract
for capital expenditures in excess of $100,000 in the aggregate that have yet to be performed, other than capital expenditures related
either to new clinics in development in the ordinary course of business or to existing clinics in lease renewal in the ordinary course
of business;

 

(ix)            Contract
that creates, governs or controls any joint venture, partnership or similar arrangement or the sharing of revenues, profits or losses;

 

(x)            Lease
or other Contract under which it is lessee of, or holds or operates any tangible personal property owned by any other party, for which
the annual rental exceeds $150,000;

 

(xi)            (A) Leases
or (B) other Contracts under which it leases or subleases real property to or from any third party for which the annual rent payable
by or to such Relevant Entity exceeds $150,000;

 

(xii)            Contract
between any Relevant Entity, on the one hand, and any other Relevant Entity or equity holder, director, limited liability company manager,
or officer of an Affiliate of any Relevant Entity or any of their Affiliates, or any of their “associates” or members of
their “immediate family” (as defined in Rule 12b- 2 and 16a-1 of the Securities Exchange Act of 1934), on the other;

 

(xiii)            Contract
or agreement relating to the development, ownership, use, registration, or enforcement of, or exercise of rights under, any Company Intellectual
Property (except for non-exclusive, commercially available off-the- shelf Software costing of less than $50,000 annually that
are subject to “shrink- wrap” or “click-wrap” license agreements);

 

    22 

     

    

 

(xiv)            Contract
under which the Company or any Relevant Entity has loaned to, or made an investment in, or guaranteed the obligations of, any Person;

 

(xv)            Contract
pursuant to which any Person provides management or administrative support services to the Company or any Relevant Entity or pursuant
to which any Relevant Entity provides management or administrative support services to any other Person;

 

(xvi)            settlement,
corporate integrity agreement, non-prosecution agreement, conciliation or similar Contract, in each case, with any Governmental Body
during the prior three (3) years or pursuant to which any Relevant Entity will have any outstanding monetary obligations or any
non-monetary obligations after the date hereof;

 

(xvii)            all
Contracts with any Referral Source or Referral Recipient, excluding all employment agreements and offer letters with any Relevant Entity’s
employees;

 

(xviii)            all
Contracts with any Governmental Body;

 

(xix)            all
Contracts for sales and marketing services and Contracts with Referral Recipients for which the annual fees or compensation payable thereunder
by any Relevant Entity exceeds $125,000;

 

(xx)            Organizational
Documents in respect of the Equity Securities of any Person (other than the Company or any Relevant Entity);

 

(xxi)            Contract
that provides for any continuing “earn out,” “performance guarantee” or other similar contingent payments or
payments of deferred purchase price of property or services that may be payable following the date of this Agreement;

 

(xxii)            Contract
that requires the indemnification of any Person (excluding indemnities contained in the Organizational Documents of the Company or any
Relevant Entity, Leases, agreements for the purchase, sale or license of products or services entered into in the ordinary course of
business and agreements in connection with the Contracts set forth on Schedule 4.09(a)(i));

 

(xxiii)            Contract
that restricts the Company or any Relevant Entity from engaging in any line of business or geographic area or from competing with any
Person;

 

(xxiv)            Contract
that contains any (A) exclusivity provision, stand-still provision, non-solicitation or non-hire provision; (B) ”most
favored nation” provision; (C)  right of first refusal, right of first offer, right of first negotiation or other preferential
right to purchase any material assets of the Company or any Relevant Entity; or

 

    23 

     

    

 

(xxv)            without
duplication of the foregoing, Contracts that resulted in payments during the fiscal year ended December 31, 2020, by or to the Company
or any Relevant Entity of more than $250,000 in the aggregate for any individual Contract.

 

(b)            The
Relevant Entities have made available to Buyer true and correct copies of all written Contracts, together with all amendments, waivers
or other changes thereto, that are referred to on Schedule 4.09(a) (each, a “Material Contract” and, collectively,
the “Material Contracts”).

 

(c)            (i) No
Relevant Entity is in breach of, or in default under, any Material Contract, (ii) to the Knowledge of the Company, each other party
to each of the Material Contracts is not in breach of, or in default thereunder, (iii) there has not occurred any event that with
or without the lapse of time or the giving of notice or both would constitute a default under, result in the acceleration, cancellation
or termination of or the right of any Person to declare a default or exercise any remedy under, or accelerate the maturity or performance
of or payment under, or cancel, terminate, amend or modify, any Material Contract, and (iv) each Material Contract is valid, binding,
enforceable and in full force and effect, except for such failures to be valid, binding or in full force and effect that would not reasonably
be expected to be material to the Relevant Entities, taken as a whole.

 

4.10         
Intellectual Property.

 

(a)            All
Registered Intellectual Property and material unregistered Owned Intellectual Property are set forth on Schedule 4.10(a). All
Registered Intellectual Property has been maintained in the ordinary course of business by the Relevant Entity by the filing of all necessary
filings, maintenance, and renewals, and timely payment of requisite fees. No loss or expiration of any Registered Intellectual Property
is threatened, pending, or reasonably foreseeable, except in the ordinary course of business, including patents expiring at the end of
their statutory terms, and not as a result of any act or omission by any Relevant Entity. Except as set forth on Schedule 4.10(a),
(i) the Relevant Entities exclusively own and possess all right, title and interest in and to, or have a valid and enforceable license
or other right to use, all Company Intellectual Property, (ii) the Relevant Entities are not currently violating, infringing, or
misappropriating the Intellectual Property rights of any Person, and (iii) to the Company’s Knowledge, no Person is currently
violating, infringing, or misappropriating the Owned Intellectual Property.

 

(b)            All
Owned Intellectual Property and Intellectual Property that is exclusively licensed to a Relevant Entity is valid, subsisting, and enforceable.
Except as disclosed in Schedule 4.10(b), there are no claims, proceedings, investigations or Orders by any Governmental Body pending
or, to the Knowledge of the Company, threatened against a Relevant Entity which challenge the validity or ownership of or right to use
any Owned Intellectual Property.

 

    24 

     

    

 

(c)            The
Relevant Entities have taken commercially reasonable measures to maintain and protect their rights in and to Company Intellectual Property,
and as a matter of course enters into customary nondisclosure and confidentiality agreements generally as and when necessary or appropriate
under the circumstances. Except as set forth in Schedule 4.10(c), all Intellectual Property developed by or on behalf of a Relevant
Entity related to its business was (i) developed by Relevant Entity employees working within the scope of their employment at the
time of such development, all of whom are and were obligated to assign and did assign all such Intellectual Property rights to the Relevant
Entity, or (ii) developed by independent contractors or other Persons who have executed appropriate instruments of assignment in
favor of the Relevant Entity as assignee or assignees that have conveyed to the Relevant Entity ownership of all of their rights in and
to Company Intellectual Property. No funding, facilities, or personnel of any Governmental Body or any university or research organization
has been used in connection with the development of any Owned Intellectual Property. No Governmental Body, university, research organization
or standards setting organization has any right, title or interest in or to any Owned Intellectual Property. No Relevant Entity has disclosed
the source code of any Owned Software to any Person other than to employees or independent contractors pursuant to a written non-disclosure
agreement.

 

(d)            All
Owned Software (i) materially conforms to all specifications, representations, warranties, and other documentation provided by the
Relevant Entities or conveyed thereby to their customers or other transferees, (ii) is operative for its intended purpose, free
of any Malicious Code, and (iii) has been maintained by the Relevant Entities on their own behalf or on behalf of their customers
and other transferees to its reasonable satisfaction and in accordance with its contractual obligations to customers and industry standards.
There are no programming defects, errors or bugs in such Owned Software that are outside the scope of programming defects, errors and
bugs typically corrected in the ordinary course of Software maintenance procedures and programs or that, if such defects, errors or bugs
were not corrected, would materially and adversely affect the business.

 

(e)            The
Relevant Entities are in material compliance with the terms and conditions of all licenses for the Open Source Materials contained in
or distributed with the Owned Software or Owned Intellectual Property. No Open Source Materials are contained in, distributed or made
available with, or used in the development of the Owned Software in a manner that (A) requires the Relevant Entities to license,
redistribute, disclose or otherwise make generally available any material portion of Software (apart from such Open Source Materials
in their unmodified form); (B) creates obligations for the Relevant Entities to grant, or purport to grant, to any third party any
rights or immunities under any Intellectual Property (including any patent non-asserts or patent licenses and apart from such Open Source
Materials in their unmodified form); (C) imposes any material present economic limitations on the commercial exploitation of any
Owned Software; (D) imposes a requirement that any other licensee of any Owned Software be permitted to modify, make derivative
works of, or reverse-engineer any material part of any Owned Software (apart from such Open Source Materials in their unmodified form);
or (E) creates or imposes a material restriction or restraint on the Relevant Entities’ ability to use, distribute, or make
available any of the Owned Software (apart from such Open Source Materials in their unmodified form).

 

    25 

     

    

 

(f)            The
operation of the business of the Relevant Entities, including the processing of data, operation of the Business Systems and the provision
of services, does not violate, infringe or misappropriate, and since the Reference Date has not violated, infringed, or misappropriated,
the Intellectual Property rights of any Person, and the Relevant Entities have not received any written notice, request for indemnification
or threat from any Person related to the foregoing (including any unsolicited offer to license Intellectual Property), nor have the Relevant
Entities requested or received any opinions of counsel related to the same.

 

(g)            The
consummation of the transactions contemplated hereby will not result in the loss or impairment of any Relevant Entity’s right to
own or use the Company Intellectual Property. As of the time immediately following the Closing, the Company Intellectual Property will
be owned or available for use by the Relevant Entities on terms and conditions identical to those under which the Relevant Entities own
or use the Company Intellectual Property immediately prior to the Closing, without payment of additional fees.

 

		4.11	Information
                                            Technology and Data Matters.

 

(a)            The
Relevant Entities own, lease, license, or otherwise have the legal right to use all Business Systems. The Business Systems owned or controlled
by the Relevant Entities are in all material respects operational, fulfill the purposes for which they were acquired or developed, and
have security, back-up, and disaster recovery arrangements in place and hardware and software capacity, support and maintenance that
are sufficient in all material respects for the business of the Relevant Entities as it is currently conducted. Since the Reference Date,
the Relevant Entities have maintained in the ordinary course of business all required licenses and service Contracts, including the purchase
of a sufficient number of license seats for all Software, with respect to the Business Systems owned or controlled by the Relevant Entities.
Since the Reference Date, there has not been any material failure or outage with respect to any of the Business Systems owned or controlled
by the Relevant Entities that has not been remedied or replaced, as appropriate, in all material respects.

 

(b)            Except
as set forth on Schedule 4.11(b), each of the Relevant Entities is, and has been since the Reference Date, in compliance in all
material respects with all Data Security Requirements. Since the Reference Date, the Relevant Entities have not, and, to the Company’s
Knowledge, no third party that Processes Protected Data for or on behalf of the Relevant Entities has, experienced any material Security
Breaches or any other Security Breaches that required any notification to any affected individual, Governmental Body, or other party
pursuant to any Data Security Requirement (regardless of materiality). The Relevant Entities have not, and, to the Company’s Knowledge,
no third party that Processes Protected Data for or on behalf of any Relevant Entity has, received any written notices or complaints
from any Person (including any Governmental Body) regarding a Security Breach (regardless of materiality) or noncompliance with Data
Security Requirements. The Relevant Entities maintain systems and procedures designed to receive and effectively respond to written complaints
and, to the extent required by applicable Law, individual rights requests, in connection with the Relevant Entity’s Processing
of Personal Information, and, to the extent required by applicable Law, the Relevant Entities have complied in all material respects
with all such individual rights requests.

 

    26 

     

    

 

(c)            The
Relevant Entities have provided to the Buyer complete and accurate copies of all privacy and security policies, HIPAA implementation
procedures and HIPAA security risk analyses prepared by the Relevant Entities, or a third party on the Relevant Entities’ behalf,
for purposes of compliance with the Privacy Laws. Each Relevant Entity has a written and signed business associate agreement with each
Person who is a “business associate” (as defined in 45 C.F.R. § 160.103) of such Relevant Entity.

 

(d)            The
Relevant Entities have all valid and legal rights necessary under applicable Law to take all actions comprising or relating to their
Processing of Protected Data in connection with the business of the Relevant Entities as currently conducted, and the execution, delivery,
or performance of this Agreement will not affect these rights or violate any Data Security Requirements. The Relevant Entities have implemented,
and have required by contract all third parties that receive Protected Data from or on behalf of the Relevant Entities, to implement,
reasonable physical, technical and administrative safeguards that are designed to protect Protected Data from unauthorized access by
any Person, and to ensure compliance in all material respects with all Data Security Requirements.

 

4.12         Litigation.
Except as set forth on Schedule 4.12, there are no, and since the Reference Date, have been no claims, actions, complaints,
disputes, charges, suits, hearings, subpoenas, investigations, audits, inquiries, petitions, arbitrations, or other proceedings (whether
federal, state, local or foreign and whether at Law or in equity) (each an “Action”) pending or, to the Company’s
Knowledge, threatened by or against any Relevant Entity, or by, against or involving the equity holders, directors, limited liability
company managers, officers, employees or agents of any Relevant Entity (in their capacity as such) or before or by any Governmental Body,
and no Relevant Entity is subject to any outstanding Order. To the Company’s Knowledge, there are no facts that exist that are
reasonably expected to give rise to an Action against or affecting the Relevant Entities or any of their assets, at Law or in equity,
by or before any Governmental Body, or by or on behalf of any third party.

 

4.13         Employee
Benefit Plans.

 

(a)            Schedule
4.13(a) sets forth any “pension plans” (as defined under Section 3(2) of the Employee Retirement Income
Security Act of 1974, as amended (“ERISA”)) (the “Pension Plans”), “welfare plans”
(as defined under Section 3(1) of ERISA) (the “Welfare Plans”) or any other “employee benefit plan”
(as such term is defined in Section 3(3) of ERISA), whether or not subject to ERISA, and any other employee benefit plan, program,
policy, agreement or arrangement of any kind, including any stock option or ownership plan; stock appreciation rights plan; stock purchase
plan; phantom stock plan; equity plan; executive compensation plan; bonus, retention, compensation, incentive compensation, change in
control, deferred compensation, retirement, welfare, post- employment welfare employment, severance, paid leave, profit sharing, vacation,
health, welfare, material fringe benefit, or supplemental insurance plan, program, policy, agreement or arrangement maintained or contributed
to or by any Relevant Entity or with respect to which any Relevant Entity has any Liability (collectively, the “Plans”).
Each of the Pension Plans that is intended to be qualified under Section 401(a) of the Code has received a favorable determination
letter or, with respect to a prototype or volume submitter plan, can rely on an opinion letter from the Internal Revenue Service and,
to the Company’s Knowledge, no event has occurred and no condition exists with respect to the form or operation of such Plan that
would reasonably be expected to cause the loss of such qualification or exemption or the imposition of any material Liability, penalty
or tax under ERISA or the Code. The Plans comply in form and in operation, in all material respects with the requirements of all applicable
Law, including the Code and ERISA.

 

    27 

     

    

 

(b)            With
respect to each Plan, Seller has made available to Buyer true, complete, and correct copies of, as applicable, (i) the plan document,
adoption agreement, and all amendments related thereto, and, with respect to any unwritten Plans, a written summary of the key terms
of such Plan; (ii) the most recent summary plan description and any summaries of material modification; (iii) the latest determination
or opinion letter from the Internal Revenue Service; (iv) the three most recently filed Forms 5500 and the three most recent compliance
testing results; (v) all trusts, insurance policies and other funding documents; and (vi) any material notices, letters or
other correspondence from the Internal Revenue Services, the Department of Labor, or any similar Governmental Body regarding the operation
and administration of the Plans.

 

(c)            With
respect to the Plans, all required contributions, distributions and payments due on behalf of any current or former employee, independent
contractor, consultant, or other service provider, that are due before the Closing Date have been or will be made or timely properly
accrued on the books and records of Seller or the Relevant Entity, as applicable.

 

(d)            None
of the Plans are subject to Title IV of ERISA, including any multiemployer plan, nor provide for medical or life insurance benefits to
retired or former employees, officers, directors or other individual service providers of any Relevant Entity (other than as required
under Code Section 4980B, or similar state Law). Neither Seller, nor any Relevant Entity is a participating or contributing employer
in, or has any Liability under, any (i) “multiemployer plan” (as defined in Section 3(37) of ERISA) with respect
to employees of any Relevant Entity nor has any Relevant Entity incurred any withdrawal Liability with respect to any multiemployer plan
or any Liability in connection with the termination or reorganization of any multiemployer plan that has not been satisfied in full;
(ii) any “multiple employer plan” (as defined in Section of
413(c) of the Code or Section 210 of ERISA); or (iii) any “multiple employer welfare arrangement” (as defined
in Section 3(40) of ERISA). No Relevant Entity has any unsatisfied Liability solely as a result of being treated as a single employer
with any other Person for the purposes of Section 414 of the Code.

 

(e)            Except
as set forth on Schedule 4.13(e), neither the execution or delivery of this Agreement nor the consummation of the transactions
contemplated hereby, either alone or in conjunction with any other event, could reasonably be expected to (i) result in any payment
or penalty becoming due to any current or former employee, officer, or other service provider of any Relevant Entity, (ii) increase
any compensation, severance, or benefits otherwise payable under any Plan or otherwise, (iii) entitle any current or former
employee, officer or other service provider of any Relevant Entity to payment, or accelerate the time of payment, funding, or vesting,
or increase the amount of compensation, severance, or benefits due to any current or former employee, officer, or other service provider
of the Relevant Entity under any Plan or otherwise, (iv) result in the forgiveness of any indebtedness owed to any Relevant Entity
by any current or former employee, officer or other service provider of any Relevant Entity, or (v) restrict the ability of a Relevant
Entity to modify or terminate any Plan. No payment or series of payments that would constitute a “parachute payment” (within
the meaning of Section 280G of the Code and determined without regard to the exceptions set forth in Section 280G(b)(5)) has
been made or will be made by Seller or any Relevant Entity, directly or indirectly, to any employee, officer, director or independent
contractor in connection with the execution of this Agreement or as a result of the consummation of the transactions contemplated hereby.

 

    28 

     

    

 

(f)            There
has been no non-exempt “prohibited transaction” within the meaning of Section 4975 of the Code or Section 406 of
ERISA, and, to the Company’s Knowledge, no breach of fiduciary duty (as determined under ERISA) has occurred with respect to any
Plan, which, in either case, would reasonably be expected to result in material liability to the Relevant Entities.

 

(g)            The
Relevant Entities have materially complied and are in material compliance with the requirements of COBRA as well as the Patient Protection
and Affordable Care Act, including the Health Care and Education Reconciliation Act of 2010, as amended and including any guidance issued
thereunder (“PPACA”). No Relevant Company has incurred (whether or not assessed), or is reasonably expected to incur
or to be subject to, any material Tax or other penalty under PPACA (including with respect to the reporting requirements under Sections
6055 and 6056 of the Code, as applicable) or under Section 4980B, 4980D or 4980H of the Code.

 

(h)            With
respect to the Plans, no Actions or other claims (other than routine claims for benefits in the ordinary course) are pending or, to the
knowledge of the Relevant Entities, threatened, and there is no fact or circumstance that would reasonably be expected to give rise to
any such Action or claim that could result in a material liability to the Relevant Entities.

 

(i)            None
of the Relevant Entities is not party to, nor has any obligation under, any contract or Plan to indemnify or gross-up any Person for
any Tax, including under Section 4999 of the Code and Section 409A of the Code (or any corresponding provisions of state, local
or non-U.S. Tax Laws).

 

(j)            Each
Contract, arrangement, or plan of Seller or any Relevant Entity that is a “nonqualified deferred compensation plan” (as defined
for purposes of Code Section 409A(d)(1)) is in documentary and operational compliance with Code Section 409A and the applicable
guidance issued thereunder in all material respects. The Relevant Entities do not have any actual or potential obligation to reimburse
or otherwise ‘‘gross-up’’ any Person for the interest or additional Tax set forth under Section 409A(a)(1)(B) or
Section 4999 of the Code.

 

    29 

     

    

 

(k)            No
Plan is sponsored, maintained, or contributed to for the benefit of any employees, independent contractors, or other service providers
located outside of the United States.

 

4.14         
Insurance.

 

(a)            Schedule
4.14 contains a true, correct, and complete list of each insurance policy maintained by the Relevant Entities. The Company has made
available to Buyer true and correct copies of each insurance policy maintained by the Relevant Entities. Each such insurance policy is
in full force and effect as of the date hereof and will continue in effect until the Closing (or if such policies are canceled or lapse
prior to the Closing, renewal or replacements thereof will be entered into in the ordinary course of business to the extent available
on commercially reasonable terms). No Relevant Entity is in material default with respect to its obligations under any such insurance
policies, no written notice or, to the Knowledge of the Company, other notice of default or termination has been received by any Relevant
Entity, all premiums due have been paid, and no claims are pending, or to the Knowledge of the Company, threatened that would reasonably
be expected to exceed the policy limits of any insurance policy. No Relevant Entity has received any written notice of any proposed increases
in the premiums or any other adverse change in the terms of any insurance policy to take effect after the date hereof. Such insurance
policies provide all coverage required by applicable Law and by any Material Contracts.

 

(b)            Each
Licensed Personnel providing services on behalf of any Relevant Entity currently maintains and historically has maintained (during all
periods that such Person provided services to or on behalf of any Relevant Entity since the Reference Date) valid professional liability
insurance policies, with liability limits no less than those required by applicable Law. There are no Actions pending or, to the Knowledge
of the Company, threatened against any such Licensed Personnel for which claims have been made against any such insurance policy. To
the Knowledge of the Company, since the Reference Date, no Licensed Personnel providing services on behalf of any Relevant Entity has
received written or, to the Knowledge of the Company, other notice from any insurance carrier denying or disputing any claim, the amount
of any claim or the coverage of any claim made on any such insurance policy or similarly reserving rights in connection therewith.

 

4.15        
Compliance with Laws.

 

(a)            Except
as set forth on Schedule 4.15(a), each of the Relevant Entities is, and since the Reference Date has been, in material compliance
with all applicable Laws. Since the Reference Date, no Relevant Entity has been cited by, fined by or otherwise received written notice
or, to the Knowledge of the Company, other notice from any Governmental Body of any material failure to comply with any Laws that has
not been paid or cured in full.

 

(b)            Schedule
4.15(b)(i) sets forth an accurate and complete listing of all material Permits held by the Relevant Entities in the conduct
of their businesses (other than Permits granted by a Governmental Body for the use or occupancy of a specific location such as
a certificate of occupancy or business license). The Relevant Entities have made available to Buyer true and correct copies of all such
material Permits held by the Relevant Entities in the conduct of its business. Except as set forth on Schedule 4.14(b)(ii), each
of the Relevant Entities holds all Permits that are necessary or required by applicable Law to own and conduct their businesses, except
for such failures that would not reasonably be expected to result in a material Liability to any Relevant Entity or impair the ability
of any Relevant Entity to conduct its business in the ordinary course consistent with past practice. Such material Permits are valid
and in full force and effect and no Relevant Entity is or, since the Reference Date has been in violation of any term of any such Permits.
No condition exists or event has occurred that, in itself or with the giving of notice or lapse of time or both, has resulted or to the
Knowledge of the Company, would reasonably be expected to result in the suspension, revocation, termination, restriction, limitation,
modification or non-renewal of any material Permit. Since the Reference Date, no Relevant Entity has received written notice or, to the
Knowledge of the Company, other notice from any Governmental Body that it has taken or intends to take, action to suspend, revoke, terminate,
place on probation, restrict, limit, modify or not renew any such material Permit. Immediately after the Closing, all material Permits
held by the Relevant Entities will be available for use by the applicable Relevant Entity on the same terms as they are now used.

 

    30 

     

    

 

4.16        
Environmental Compliance and Conditions. Except as set forth on Schedule 4.16:

 

(a)            Each
of the Relevant Entities is, and since the Reference Date has been, in compliance in all material respects with all applicable Environmental
Laws;

 

(b)            The
Relevant Entities have, and since the Reference Date have held, all Permits required under applicable Environmental Laws to operate at
the Leased Real Property and to carry on their respective businesses as currently conducted (the “Environmental Permits”);

 

(c)            Since
the Reference Date, or earlier to the extent unresolved, the Relevant Entities have not, received any written notice, report, Order or
other information from any Governmental Body or other Person regarding any actual or alleged violation of Environmental Laws, or any
liabilities or potential liabilities for investigation costs, cleanup costs, response costs, corrective action costs, personal injury,
property damage, natural resources damages or attorney fees under Environmental Laws; and

 

(d)            No
Relevant Entity, nor any Person whose liability has been assumed or undertaken by any Relevant Entity, has disposed of, arranged for
or permitted the disposal of, transported, handled, manufactured, distributed, exposed any Person to, or released any Hazardous Substance
at any Leased Real Property, or owned or operated any property or facility which is or has been contaminated by any Hazardous Substances,
in quantities or concentrations that require investigation or remediation by the Company or would otherwise give rise to current or future
material Liabilities for the Relevant Entities under Environmental Laws.

  

(e)            Seller
and the Relevant Entities have furnished to Buyer all material environmental reports relating to the Relevant Entities’ past or
current properties, facilities, or operations that are in their possession.

 

    31 

     

    

 

4.17          Affiliated
Transactions. Except as set forth on Schedule 4.17, no officer, director, employee, or any direct equity holder of any Relevant
Entity, or to the Knowledge of the Company any indirect equity holder of any Relevant Entity or, any Affiliates or immediate family members
of any of the foregoing (each of the foregoing, a “Related Party”) (a) is a party to any Contract or transaction
with any Relevant Entity (other than (i) any agreement, Contract, lease commitment or transaction that relates solely to the employment
of such Person, or (ii) in the case of Seller and its Affiliates, arms-length commercial Contracts entered into in the ordinary
course of business with portfolio companies of the Institutional Holders), (b) has any interest in any material property (real,
personal or mixed and whether tangible or intangible), used in or pertaining to the Relevant Entities or their businesses, or (c) is
the direct or indirect owner of any Equity Securities or other financial or profit interest in a Person that (i) has business dealings
(whether as a customer, supplier, or otherwise) or a financial interest in any transaction with the Relevant Entities or (ii) competes
with a Relevant Entity.

 

4.18          Employment
and Labor Matters

 

(a)            Except
as set forth on Schedule 4.18(a), (i) no Relevant Entity is a party to or bound by any Labor Agreement and no employees of
any Relevant Entity are represented by any labor union, works council, or other labor organization with respect to their employment with
any Relevant Entity, (ii) no Relevant Entity has experienced any actual or, to the Knowledge of the Company, threatened material
labor grievance, labor arbitration, strike, walkout, lockout, work stoppage or slowdown, picketing, handbilling or other material
labor dispute, or any claim or charge of unfair labor practices or other material collective bargaining dispute since the Reference Date,
(iii) there are no Actions or similar matters pending or, to the Knowledge of the Company, threatened between Seller or any Relevant
Entity, on the one hand, and any employees, independent contractors, or other individual, non-employee service providers, on the other
hand (in each case, in their capacities as such), or that otherwise relate to any alleged violation of any Employment Laws (as hereinafter
defined), and there have been no such Actions or matters since the Reference Date (iv) there are no union representation questions,
union representation campaigns, or representation or certification efforts, demands or proceedings by any labor union, works council,
other labor organization or group of employees of any Relevant Entity pending or, to the Knowledge of the Company, threatened, and there
have been no such actions since the Reference Date, and (v) to the Knowledge of the Company, there have been no labor organizing
activities with respect to any employees of any Relevant Entity since the Reference Date. There are no material labor grievances, labor
arbitrations, unfair labor practice charges or claims, strikes, slowdowns, work stoppages, picketing or handbilling campaigns, lockouts
or other material labor disputes that are pending or, to the Knowledge of the Company, threatened against or affecting Seller or any
Relevant Entity.

 

(b)            Neither
Seller nor any Relevant Entity has any outstanding obligation or Liability under the WARN Act. No employee layoff, facility closure or
shutdown, reduction-in-force, furlough, temporary layoff, material work schedule change or reduction in hours, or reduction in
salary or wages, of any Relevant Entity has occurred since March 1, 2020 or is currently contemplated, announced or planned, including
as a result of COVID-19 or any Law, directive, guidelines or recommendations by any Governmental Body in connection with or in response
to COVID-19.

 

    32 

     

    

 

(c)            The
Relevant Entities are, and since the Reference Date have been in material compliance with all applicable Laws regarding labor, employment
and employment practices, including those relating to terms and conditions of employment, wages, hours, immigration (including the completion
of Forms I-9 for all employees and the proper confirmation of employee visas), discrimination, harassment, retaliation, whistleblowing,
classification of exempt and non-exempt employees and independent contractors, layoffs and plant closures (including the WARN Act), equal
opportunity, disability rights or benefits, the payment and withholding of Taxes, the maintenance and handling of personnel records,
COVID-19, employee trainings and notices, workers’ compensation, labor relations, employee leave issues, affirmative action, unemployment
insurance and occupational health and safety (collectively, the “Employment Laws”). Since the Reference Date, each
Relevant Entity: (A) has properly classified and treated each Person who has performed services for such Relevant Entity as an independent
contractor, consultant, leased employee, or other non-employee service provider or as an exempt or non-exempt employee, as applicable,
for all applicable purposes (including under the Fair Labor Standards Act and similar state Laws); and (B) has fully and timely
paid all wages, salaries, wage premiums, commissions, bonuses, severance payments, expense reimbursements, fees, termination pay, vacation,
and other compensation that has come due and payable to its employees, independent contractors, temporary employees, and other service
providers as required under applicable Law, Contract or company policy. No Relevant Entity has any Liability as a joint employer with
respect to any temporary employees leased or staffed through a third-party entity.

 

(d)            Schedule
4.18(d) sets forth a complete list of all independent contractors and consultants that provide services to the Relevant Entities
(whether in the Person’s own right or through an entity owned by the individual), including (i) the name of the individual
(and their entity, if applicable), (ii) a description of the services provided, including engagement date, (iii) compensation
rate, and (iv) work location.

 

    33 

     

    

 

(e)            Schedule
4.18(e) sets forth a complete list of all employees, independent contractors, consultants, and temporary employees who have
executed a confidentiality, intellectual property assignment, non-competition, non-solicitation, non-disparagement agreement and/or other
restrictive covenant agreement with any Relevant Entity, copies of which have been provided to Buyer. To the Knowledge of the Company,
no current or former employee, independent contractor, or consultant is precluded from performing services for any Relevant Entity due
to restrictive covenant obligations that are owed by such individual to a third-party and, to the Knowledge of the Company, no such individual
is in breach of any restrictive covenant obligations by virtue of performing services to the Relevant Entity.

 

(f)            To
the Knowledge of the Company, no current employee of any Relevant Entity with annualized compensation at or above $100,000, intends to
terminate his or her employment prior to the one (1) year anniversary of the Closing.

 

(g)            The
Relevant Entities have promptly and reasonably investigated all sexual harassment, or other discrimination, retaliation or allegations
of which any of them is aware. With respect to each such allegation with potential merit, the Relevant Entities have taken prompt corrective
action that is reasonably calculated to prevent further improper action. The Relevant Entities do not reasonably expect any material
Liability with respect to any such allegations.

 

4.19          No
Brokers. The Relevant Entities have no Liability for any brokerage commissions, finders’ fees or similar compensation in connection
with the transactions contemplated by this Agreement.

 

		4.20	Regulatory
                                            Compliance.

 

(a)            Compliance
with Healthcare Laws. Except as set forth in Schedule 4.20(a): (i) each Relevant Entity and such Relevant Entity’s
equity holders, directors, limited liability company managers, and officers are, at all times since the Reference Date, has been, in
compliance in all material respects with all Healthcare Laws applicable to it or its business, properties or assets; (ii) since
the Reference Date, no Relevant Entity has received any written notice or, to the Company’s Knowledge, other notice from any Governmental
Body or Third Party Payor Program or other Person that asserts any material noncompliance with any Healthcare Laws that has not been
corrected; (iii) to the Company’s Knowledge, no condition or state of facts exists that would provide a valid basis for any
such assertion of material noncompliance with any Healthcare Laws, and (iv) none of the Relevant Entities or such Relevant Entity’s
equity holders, directors, limited liability company managers or officers, nor to the Knowledge of the Company, employees, Licensed Personnel,
consultants, agents or other Persons associated with a Relevant Entity are, or since the Reference Date have been, the subject of an
investigation or Action by any Governmental Body for material violation of, or failure to comply in any material respect with, any Healthcare
Laws. There are no material restrictions imposed by any Governmental Body upon the business, activities or services of the Relevant Entities,
other than those generally applicable to companies that provide services similar to those provided by the Relevant Entities.

 

(b)            Exclusions.
None of the Relevant Entities, nor any of their directors, officers, members, managers, managing employees, employees, or Licensed Personnel,
nor any other Person with an “ownership interest” or “indirect ownership interest” (as those terms are defined
in 42 C.F.R. § 420.201) in any Relevant Entity, nor, to the Company’s Knowledge, any of their agents or subcontractors, is
or since the Reference Date has been (or, to the Company’s Knowledge, has been threatened to be): (i) excluded from any Government
Healthcare Program pursuant to 42 U.S.C. § 1320a-7 and its implementing regulations or engaged in any activities that are prohibited
by or are cause for mandatory or permissive exclusion or civil or criminal penalties under any Healthcare Laws; (ii) “suspended”
or “debarred” from selling products to the United States government or its agencies pursuant to the Federal Acquisition
Regulation, relating to debarment and suspension applicable to federal government agencies generally (42 C.F.R. Subpart 9.4), or pursuant
to any other applicable Law; (iii) debarred, disqualified, suspended or excluded from participation in any Government Healthcare
Program or is listed on the list of excluded parties maintained by the United States General Services Administration or the Office of
the Inspector General of the United States Department of Health and Human Services, or a comparable state healthcare exclusion listing,
nor is any such debarment, disqualification, suspension or exclusion threatened or pending; (iv) subject to a civil monetary penalty
assessed under Section 1128A of the Social Security Act, sanctioned, indicted or convicted of a crime, or pled nolo contendere
or to sufficient facts, in connection with any allegation of violation of any Government Healthcare Program requirement or Healthcare
Laws or (v) made a party to any other Action by or on behalf of any Governmental Body that may prohibit her, him or it from selling
products or providing services to any governmental or other purchase pursuant to applicable Law.

 

    34 

     

    

 

(c)            Participation
in Third Party Payor Programs. Schedule 4.20(c)(i) lists all National Provider Identifiers and provider numbers for each Relevant
Entity that participates in any Government Healthcare Program. Each of the Relevant Entities and their Licensed Personnel that participates
in any Third Party Payor Program is, and since the Reference Date, has been qualified to participate in such Third Party Payor Program
and is and has been duly enrolled and certified therein, and has and has had the requisite provider and supplier numbers to bill the
Third Party Payor Program in the state or states in which such entity operates. The Relevant Entities and their equity holders, directors,
limited liability company managers, officers, Licensed Personnel, employees and, to the Knowledge of the Company, independent contractors
are operating and, since the Reference Date have operated, in compliance in all material respects with all Government Healthcare Program
statutes and regulations and all provisions of each Third Party Payor Program Contract to which it is party or by which it is bound.
There is no Action pending or, to the Knowledge of the Company, threatened, which has resulted in or, to the Company’s Knowledge,
would reasonably be expected to result in any revocation, suspension, termination, probation, restriction, limitation, non-renewal or
other adverse modification of the participation by any Relevant Entity in any Third Party Payor Program or of any supplier or provider
number, or result in any Relevant Entity’s exclusion from any Third Party Payor Program.

 

(d)            Reporting
and Billing. The Relevant Entities have (i) timely filed all material reports and billings required to be filed with respect
to each Third Party Payor Program and have billing practices that are in material compliance with all applicable Laws governing reimbursement
and claims, (ii) paid all known and undisputed refunds, overpayments, discounts and adjustments due with respect to any such report
or billing. There is no pending or, to the Knowledge of the Company, threatened appeal, adjustment, challenge, audit (including written
or, to the Company’s Knowledge, other notice of an intent to audit), inquiry (excluding routine billing reconciliations and reviews
in the ordinary course of business) or Action by any Third Party Payor Program with respect any Relevant Entity’s billing practices
and reimbursement claims, other than those refunds, overpayments, discounts and adjustments reflected, accrued, or reserved in the Latest
Balance Sheet (including as disclosed as footnotes thereto), and (iii) never since the Reference Date been audited or otherwise
examined by any Third Party Payor Program other than in the ordinary course of business. All reports, billings and claims submitted by
the Acquired Companies to a Third Party Payor Program since the Reference Date were submitted in material compliance with all applicable
Healthcare Laws governing reimbursement and claims and the payment policies and manuals of the applicable Third Party Payor Program,
were for goods actually sold and services actually performed by the billing Relevant Entity to eligible patients in accordance with the
applicable Third Party Payor Program Contracts, policies, manuals and payment rates, and the Relevant Entities have sufficient documentation
supporting such billings and claims. The Relevant Entities collect copayments, deductibles and other patient financial responsibilities
in compliance in all material respects with applicable Healthcare Laws. The Relevant Entities have not been the subject of any Recovery
Audit Contractor audits, Medicaid Integrity Program audits, Zone Program Integrity Contractor audits, or other reviews or audits with
respect to any Government Healthcare Program since the Reference Date.

 

    35 

     

    

 

(e)            Corporate
Integrity Agreements. None of the Relevant Entities, nor any of their directors, officers, members, managers, managing employees,
employees or Licensed Personnel, nor any other Person with an “ownership interest” or “indirect ownership interest”
(as those terms are defined in 42 C.F.R. § 420.201) in any Relevant Entity is or, since the Reference Date, has been a party to,
or bound by, any Order, individual integrity agreement, corporate integrity agreement, corporate compliance agreement, deferred prosecution
agreement, or other formal or informal agreement with any Governmental Body regarding material non-compliance with Healthcare Laws. Since
the Reference Date, no Relevant Entity or, and to the Knowledge of the Company, no Relevant Entity’s directors, officers, or employees,
has made, with respect to the business and operations of such Person a voluntary disclosure pursuant to the OIG’s self-disclosure
protocol or CMS’s Self-Referral Disclosure Protocol, or has been subject to any reporting obligations pursuant to any settlement
agreement, or similar arrangement, with the OIG or any other Governmental Body

 

(f)            Licensed
Personnel. While performing services on behalf of the Relevant Entities, the Licensed Personnel are, and at all times since the Reference
Date have been, in compliance in all material respects with applicable Healthcare Laws, and hold and, at all times since the Reference
Date that such Persons have been Licensed Personnel and performing services for or on behalf of any of the Relevant Entities, all Healthcare
Licenses required in the performance of their respective duties for the applicable Relevant Entity and such Licensed Personnel is duly
enrolled and credentialed with each Third Party Payor Program that requires such enrollment or credentialing for reimbursements or payments
submitted by any Relevant Entity. Each Healthcare License held by the Licensed Personnel is in full force and effect and no suspension,
revocation, termination, impairment, limitation, modification or non-renewal of any such Healthcare License is pending or, to the Knowledge
of the Company, threatened.

 

(g)            Fraud
and Abuse. None of the Relevant Entities’ independent contractors currently provides or has provided since the Reference Date,
directly or indirectly, sales representative or marketing services to the Relevant Entities or, to the Company’s Knowledge, the
Companies’ Referral Recipients. No Relevant Entity, nor any of their respective officers, managers, employees or Licensed
Personnel, has, at any time since the Reference Date, knowingly and willfully, offered, paid, solicited or received anything of value,
paid directly or indirectly, overtly or covertly, in cash or in kind, in violation of any applicable Healthcare Law, to or from (i) any
physician, family member (as defined by the Stark Law) of a physician or an entity in which a physician or such physician family member
has an ownership or investment interest, (ii) any healthcare provider, pharmacy, drug or equipment supplier, distributor, manufacturer,
Third Party Payor Program or other third-party provider (in each case, including any of their respective officers, directors, or employees)
or (iii) any Person (including any patient, supplier, medical staff member, Licensed Personnel, contractor, Referral Source, Referral
Recipient or Third Party Payor Program), in each case of clauses (i) through (iii), in order to illegally induce business or otherwise
illegally obtain business or payments.

 

    36 

     

    

 

		(h)	Material
                                            Third-Party Payors and Suppliers.

 

(i)            Schedule
4.20(h)(i) contains a correct and complete list of the identity of the ten (10) largest Third Party Payor Programs of the
Relevant Entities, as measured by actual payments received by the Relevant Entities from such payors during the twelve (12)-month period
ended December 31, 2020 (each, a “Material Payor”). No Material Payor has indicated that it intends to terminate,
limit or negatively alter its business relationship with the Relevant Entities or their businesses or reduce the reimbursement rates
for claims submitted to such Material Payor.

 

(ii)            Schedule
4.20(h)(ii) contains a correct and complete list of the identity of the ten (10) largest suppliers of the Relevant Entities
as measured by the Relevant Entities’ purchases of goods and services from such suppliers during the twelve (12)-month period ended
December 31, 2020 (each, a “Material Supplier”). No Material Supplier has indicated that it intends to terminate,
limit or negatively alter its business relationship with the Relevant Entities or their businesses.

 

(i)            Compliance
Program. The Relevant Entities have, and since the Reference Date have maintained an effective compliance program. The Relevant Entities
have provided to Buyer complete and accurate copies of all compliance program materials. Provider Relief Funds. Schedule 4.20(j) sets
forth all grants and the amounts of funds received and/or requested by the Relevant Entities from the U.S. Department of Health and Human
Services under the CARES Act Provider Relief Fund (the “PRF Payments”). Other than the PRF Payments that have already
been received by the Relevant Entities, no Relevant Entity has applied for any additional payments from the CARES Act Provider Relief
Fund. Each Relevant Entity has maintained accounting records associated with the PRF Payments in material compliance with the Relief
Fund Payment Terms and Conditions and related guidance available as of the date hereof. Each Relevant Entity utilized all such PRF Payments
pursuant to the Public Health and Social Services Emergency Fund in material compliance with all applicable Laws and the applicable Relief
Fund Payment Terms and Conditions. Other than the PRF Payments, no Relevant Entity has applied for or received any loan, exclusion, forgiveness
or other item under the CARES Act or otherwise in connection with the Coronavirus Pandemic, including any “Payment Protection
Program” loan, “Economic Stabilization Fund” loan or other United States Small Business Administration loan. Undisclosed
Liabilities. There is no Liability, debt or obligation or claim against any Relevant Entity, except for Liabilities and obligations
(a) reflected, accrued, and reserved for in the Latest Balance Sheet (including as disclosed in the footnotes thereto), (b) that
have arisen after the date of the Latest Balance Sheet in the ordinary course of business of the Relevant Entities (which Liabilities
are not material, individually or in the aggregate, and none of which is a Liability for breach of Contract, tort, or infringement or
an Action or an environmental Liability), (c) would not have a Material Adverse Effect, (d) that are Seller Transaction Expenses,
or (e) that are set forth on Schedule 4.21.

 

    37 

     

    

 

4.22          No
Other Representations and Warranties. EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES CONTAINED IN THIS ARTICLE IV, NEITHER
THE COMPANY NOR ANY OTHER RELEVANT ENTITY MAKES ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY, AND THE COMPANY, ON BEHALF OF ITSELF
AND EACH RELEVANT ENTITY, HEREBY DISCLAIMS ANY SUCH REPRESENTATION OR WARRANTY WITH RESPECT TO THE EXECUTION AND DELIVERY OF THIS AGREEMENT, ITS
SUBJECT MATTER, AND THE CONSUMMATION OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING,
BUYER WILL ACQUIRE THE INTERESTS WITHOUT ANY REPRESENTATION OR WARRANTY AS TO MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, IN
AN “AS IS” CONDITION AND ON A “WHERE IS” BASIS, EXCEPT AS OTHERWISE EXPRESSLY REPRESENTED OR WARRANTED BY SELLER
IN ARTICLE III OR THE COMPANY IN ARTICLE IV.

 

ARTICLE V

 

REPRESENTATIONS AND WARRANTIES
OF BUYER

 

Buyer represents and warrants
to the Company and Seller that the representations and warranties contained in this Article V are true and correct as of
the date hereof and as of the Closing Date (except to the extent any such representation and warranty expressly relates to an earlier
date (in which case, as of such earlier date)), as follows:

 

5.1            Organization
and Power. Buyer is a Delaware corporation duly organized, validly existing and in good standing under the Laws of the state of its
organization, with full organizational power and authority to enter into this Agreement and perform its obligations hereunder and to
consummate the transactions contemplated hereby.

 

5.2            Authorization;
Valid and Binding Agreement. The execution, delivery and performance of this Agreement and each other Transaction Document
to which Buyer is a party by Buyer and the consummation of the transactions contemplated hereby and thereby have been duly and validly
authorized by all requisite action on the part of Buyer, and no other proceedings on Buyer’s part are necessary to authorize the
execution, delivery or performance of this Agreement or any other Transaction Document to which Buyer is now a party. This Agreement
constitutes a valid and binding obligation of Buyer, enforceable in accordance with its terms, except as enforceability may be limited
by bankruptcy, insolvency, fraudulent conveyance, reorganization or moratorium Laws, other similar laws affecting creditors’ rights
and general principles of equity affecting the availability of specific performance and other equitable remedies.

 

    38 

     

    

 

5.3            No
Breach. Except as set forth on Schedule 5.03, the execution, delivery and performance of this Agreement or any Transaction
Document to which Buyer is a party by Buyer and the consummation of the transactions contemplated hereby and thereby do not (a) violate
any provision of the Organizational Documents of Buyer, (b) conflict with or result in any breach of any Law, statute, rule or
regulation or Order, judgment or decree to which Buyer is subject, or require any authorization, filing, consent, approval, exemption
or other action by or written notice to any Governmental Body, in each case other than as required under the HSR Act, (c) violate,
result in a breach of, or constitute a default under, give rise to any right of termination, cancelation, acceleration under loss of
any benefit under, or require the consent of or any notice to any third party that has not been obtained, whether under any Contract,
license, Permit, or other agreement, instrument, or commitment to which Buyer is bound, or (d) result in the creation or imposition
of a Lien on assets or property of Buyer.

 

5.4            Litigation.
There are no material Actions pending or, to Buyer’s knowledge, threatened in writing against or involving Buyer, at Law or
in equity, or before or by any Governmental Body, which would reasonably be expected to materially affect the legality, validity or enforceability
of, or adversely affect Buyer’s performance under, this Agreement or the Transaction Documents or the consummation of the transactions
contemplated hereby or thereby.

 

5.5            No
Brokers. Except as set forth on Schedule 5.05, there are no claims for brokerage commissions, finders’ fees or similar
compensation payable by Buyer in connection with the transactions contemplated by this Agreement.

 

5.6            Investment
Representation. Buyer is acquiring the Interests for its own account with the present intention of holding such securities for investment
purposes and not with a view to, or for sale in connection with, any distribution (as such term is used in Section 2(a)(11) of the
Securities Act) of such securities in violation of any federal or state securities laws. Buyer is an “accredited investor”
as defined in Regulation D promulgated by the Securities and Exchange Commission under the Securities Act. Buyer acknowledges that it
is informed as to the risks of the transactions contemplated hereby and of ownership of the Interests. Buyer acknowledges that the Interests
have not been registered under the Securities Act, or any state or foreign securities laws and that the Interests may not be sold, transferred,
offered for sale, assigned, pledged, hypothecated or otherwise disposed of unless such transfer, sale, assignment, pledge, hypothecation
or other disposition is pursuant to the terms of an effective registration statement under the Securities Act, and the Interests are
registered under any applicable state or foreign securities laws or sold pursuant to an exemption from registration under the Securities
Act, and any applicable state or foreign securities laws.

 

    39 

     

    

 

5.7            Financing.

 

(a)            Buyer
has delivered to Seller a true, accurate and complete copy of a fully executed Equity Commitment Letter, relating to the Equity Financing
for the purposes of funding the transactions contemplated hereby.

 

(b)            Buyer
has delivered to Seller true, accurate and complete copies of fully executed debt commitment letters dated the date hereof, including
all amendments, exhibits, attachments, appendices and schedules thereto as of the date hereof attached hereto as Exhibit E
(collectively, the “Debt Commitment Letters” and, together with the Equity Commitment Letter, the “Commitment
Letters”) from the lenders named therein (the “Lenders”), relating to the commitments of the Lenders, upon
the respective terms and subject to the respective conditions set forth therein, to lend to Buyer the respective amounts set forth therein
(collectively, the “Debt Financing” and, together with the Equity Financing, the “Financings”)
for the purpose of funding the transactions contemplated hereby (the “Required Amount”).

 

(c)            Buyer
has delivered to Seller a true, accurate and complete copy of a fully executed guaranty, of the Equity Investor in favor of Seller for
the purpose of guaranteeing the obligations of the Buyer to pay the Termination Fee on the terms and conditions set forth in Section 8.01(f) of
this Agreement, in each case upon the terms and subject to the conditions set forth therein. The Guaranty is in full force and effect
and is a legal, valid, binding and enforceable obligation of the Equity Investor except as enforcement may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium and other Laws affecting creditors’ rights generally and except insofar as the availability
of equitable remedies may be limited by applicable Law.

 

5.8
           Solvency. Buyer is not entering into the transactions contemplated
hereby with the actual intent to hinder, delay or defraud either present or future creditors of Buyer, Seller or the Company. Buyer is
currently Solvent and, assuming the accuracy of the representations and warranties of the Company and Seller set forth herein, upon consummation
of the transaction contemplated hereby, Buyer and the Relevant Entities will remain Solvent. As used in this paragraph, the term “Solvent”
means, with respect to a particular time, that at such time (i) the sum of the assets of such Person will exceed its debts, (ii) such
Person has not incurred debts beyond its ability to pay such debts as such debts mature, and (iii) such Person has sufficient capital
with which to conduct its business.

 

5.9
          No Other Information.

 

(a)            Buyer
acknowledges and agrees that, (i) except for the representations and warranties contained in Article III and Article IV
of this Agreement, as qualified by the Disclosure Schedules, none of Seller, the Relevant Entities, or any other Person on behalf
of Seller or the Relevant Entities makes any express or implied representation or warranty with respect to Seller or any Relevant Entity
or with respect to any other information provided to Buyer or its representatives in connection with the transactions contemplated hereby,
and (ii) none of Seller, the Relevant Entities, or any other Person will have or be subject to any liability or indemnification
obligation to Buyer or any other Person resulting from the distribution to Buyer or its representatives, or Buyer’s use of, or
reliance on, any such information, including any information, documents, projections, forecasts or other material made available to Buyer
or its representatives in an electronic “dataroom,” management presentations, or offering memoranda in expectation of the
transactions contemplated hereby, unless and to the extent any such information is covered by a representation or warranty contained
in Article III or Article IV of this Agreement.

 

    40 

     

    

 

(b)            Buyer
acknowledges and agrees that it (i) has had an opportunity to discuss the business and affairs of the Relevant Entities with the
management of the Company, (ii) has had reasonable access to (A) the books and records of the Relevant Entities and (B) the
electronic dataroom maintained in connection with the transactions contemplated hereby, (iii)
has been afforded the opportunity to ask questions of and receive answers from officers of the Company, (iv) is a sophisticated
purchaser, and (v) has conducted to its satisfaction an independent investigation review and analysis of the Relevant Entities,
the business and the transactions contemplated hereby with the assistance of its expert advisors, including legal counsel, and has relied
solely on the results of its own independent investigation and has not relied on any representation, warranty or other statement of Seller,
any Relevant Entity, or by any Person on behalf of Seller or any Relevant Entity other than the representations and warranties of Seller
or the Company expressly contained in Article III and Article IV of this Agreement and that all other representations
and warranties are expressly and specifically disclaimed.

 

ARTICLE VI

 

CERTAIN PRE-CLOSING COVENANTS OF THE PARTIES

 

6.1            Conduct
of the Business.

 

(a)            From
the date hereof until the earlier of (x) the Closing Date and (y) the valid termination of this Agreement pursuant to Section 8.01
(such period, the “Interim Period”), except as set forth on Schedule 6.01, consented to in writing by Buyer
(which consent will not be unreasonably withheld, conditioned or delayed), reasonably required directly in connection with COVID-19 or
the Coronavirus Pandemic , or as contemplated or required by this Agreement or the transactions contemplated hereby, the Company will
use its commercially reasonable efforts to: (i) conduct its business in the ordinary course of business; and (ii) preserve
its present commercial relationships, in all material respects, with its vendors and other Persons with whom the Relevant Entities have
similar relationships, and to preserve the present operations, organization and goodwill of each of the foregoing; provided that
the foregoing notwithstanding, the Relevant Entities may use all available cash to pay any Seller Transaction Expenses or Indebtedness,
for distributions or dividends, or for any other purpose prior to the Closing Effective Time.

 

(b)            During
the Interim Period, except as otherwise set forth on Schedule 6.01, consented to in writing by Buyer (which consent will not be
unreasonably withheld, conditioned or delayed), reasonably required in connection with COVID-19 or the Coronavirus Pandemic, or as contemplated
or required by this Agreement or the transactions contemplated hereby, the Company will not take any action that, if taken prior
to the date hereof, would be required to be disclosed pursuant to Section 4.06; provided that the foregoing notwithstanding,
the Relevant Entities may use all available cash to pay any Seller Transaction Expenses or Indebtedness, for distributions or dividends,
or for any other purpose prior to the Closing Effective Time.

 

    41 

     

    

 

(c)            From
the Closing Effective Time until the Closing, the Company agrees not to and shall cause the Relevant Entities not to (i) withdraw,
remove or otherwise make any payments to third parties of Cash, other than in the ordinary course of business consistent with past practice
of the Company and the Relevant Entities, and (ii) enter into any Contracts obligating the Company or the Relevant Entities to take
any of the actions described in the foregoing clause (i).

 

(d)            During
the Interim Period, Seller shall, and shall cause the Acquired Companies to, take any actions necessary to ensure that any employee of
a Managed Practice, as of the date hereof, becomes an employee of an Acquired Company on or before December 31, 2021.

 

(e)            Prior
to the Closing Date, Seller shall transfer all of its equity interests in each of Border Therapy Services, LLC, a Texas limited liability
company (“Border”) and Lorenz Management, LLC, a Michigan limited liability company (“Lorenz”)
to Agility Health Rehabilitation, LLC, a Michigan limited liability company (“Agility”) such that, at the Closing,
each of Border and Lorenz is a wholly owned Subsidiary of Agility (the “Pre- Closing Restructuring”).

 

6.2            Conditions.
During the Interim Period, the Company and Seller will use commercially reasonable efforts to take or cause to be taken all actions
to do or cause to be done and assist and cooperate with the Buyer in doing all things reasonably necessary, proper, or advisable, to
consummate the transactions contemplated hereby as soon as reasonably possible after the satisfaction of the conditions set forth in
Sections 2.01, 2.02 and 2.03 (other than those to be satisfied at the Closing).

 

6.3            Consents
and Notices. During the Interim Period, the Company and Seller shall, and shall cause the applicable Relevant Entity to, give notices
to the applicable third parties and will use commercially reasonable efforts (which shall not include the payment of a consent or similar
fee) to cause the applicable Relevant Entity to obtain any applicable third party consents requested by Buyer that are required of such
Relevant Entity in connection with the transactions contemplated herein.

 

6.4            Access
to Information. Unless this Agreement is terminated in accordance with Article VIII and unless prohibited by Law, the
Company shall permit Buyer and its representatives access, upon reasonable prior written notice to the Company and during normal business
hours throughout the Interim Period, to the properties, books and records of the Relevant Entities (except as restricted by any applicable
confidentiality obligations of Seller and/or the Relevant Entities entered into prior to the date hereof) under the supervision of the
Company’s personnel and in such a manner as not to interfere with the normal operations of the Relevant Entities. Any access under
this Section 6.04 shall be subject to such reasonable additional limitations as the Relevant Entities may reasonably
require to prevent disclosure of the transactions contemplated hereby and/or the material disruption of the business of the Relevant
Entities. Notwithstanding anything to the contrary in this Agreement, Seller and the Relevant Entities shall not be required to disclose
any information to Buyer or its representatives if such disclosure would, in Seller’s reasonable judgment: (a) cause significant
competitive harm to the Relevant Entities or their business if the transactions contemplated hereby are not consummated; (b) jeopardize
any attorney-client or other privilege; or (c) contravene any Law or Order of any Governmental Body, fiduciary duty or contract.

 

    42 

     

    

 

		6.5	Financing.

 

(a)            Buyer
shall use reasonable best efforts to take, or cause to be taken, all actions and do, or cause to be done, all things necessary, proper
or advisable (in its reasonable judgement) to arrange and consummate the Debt Financing at the Closing on the terms and conditions set
forth in the Debt Commitment Letters, including using reasonable best efforts to: (i) comply with and maintain the Debt Commitment
Letters in effect; (ii) negotiate and enter into definitive agreements with respect to the Debt Financing on conditions described
in the Debt Commitment Letters or on conditions no less favorable (taken as a whole) to Buyer (in the reasonable judgment of the Buyer);
(iii) comply with and perform the obligations applicable to it pursuant to such Debt Commitment Letters; (iv)
to the extent the conditions in Article II have been satisfied or waived, consummate the Debt Financing on the terms
and conditions set forth in the Debt Commitment Letters; and (v) satisfy (or obtain wavier thereof) on a timely basis all conditions
applicable to it to obtain the Debt Financing that are within its control. If any portion of the Debt Financing expires or terminates
or otherwise becomes unavailable, Buyer shall use reasonable best efforts to arrange for and obtain as promptly as reasonably practicable
following the occurrence of any such event alternative debt financing (the “Alternative Financing”) in an amount sufficient
to consummate the transactions contemplated hereby and perform all of its obligations hereunder on terms and conditions that are not
materially less favorable or more onerous (including imposition of new conditions or expansion of existing conditions), in the aggregate,
than those set forth in the Debt Commitment Letters, it being understood that if Buyer proceeds with any Alternative Financing, Buyer
shall be subject to the same obligations with respect to such Alternative Financing as set forth in this Agreement with respect to the
Debt Financing. Nothing contained in this Section 6.05 or elsewhere in this Agreement shall require, and in no event shall
the “best efforts”, “commercially best efforts” or “reasonable best efforts” of the Buyer be deemed
or construed to require, the Buyer to (i) seek or obtain equity financing other than the Equity Financing, (ii) pay any fees
in excess of those contemplated by any Debt Commitment Letters or the fee letters associated therewith (including the “flex”
terms), (iii) agree to any other terms that are materially less favorable to the Buyer or the Acquired Companies than such corresponding
material terms contained in or contemplated by the Debt Commitment Letters or the fee letters associated therewith (in either case, whether
to secure waiver of any conditions contained therein or otherwise), including any “flex” provision therein, or (iv) bring
suit or any other type of legal action against any Lender or other financing source with respect to any obligation under the Debt Commitment
Letters or the fee letters associated therewith.

 

    43 

     

    

 

(b)            Buyer
shall take (or cause to be taken) all actions and do (or cause to be done) all things necessary, proper or advisable (in its reasonable
judgment) to obtain the Equity Financing on the terms and conditions set forth in the Equity Commitment Letter, including to: (i) maintain
the Equity Commitment Letter in effect, (ii) negotiate and enter into definitive agreements with respect to the Equity Financing
on conditions described in the Equity Commitment Letters or on conditions no less favorable (taken as a whole) to Buyer (in the reasonable
judgment of the Buyer), (iii) comply with and perform the obligations applicable to it pursuant to such Equity Commitment Letter,
(iv) to the extent the conditions in Sections 2.01 and 2.02 have been satisfied or waived, consummate the Equity Financing,
including enforcing its rights under the Equity Commitment Letter and causing the Equity Investors to fund the Equity Financing at the
Closing, and (v) satisfy on a timely basis all conditions applicable to it in such definitive agreements that are within its control.

 

(c)            Buyer
shall not replace, amend or waive any Commitment Letter or any provision thereof (it being agreed that any Alternative Financing complying
with the provisions hereof shall not be deemed an amendment, modification, waiver or replacement) without the Seller’s prior written
consent (which consent shall not be unreasonably withheld, conditioned or delayed) if such replacement, amendment or waiver would, or
would reasonably be expected to, when taken together with any other amendments, modifications, or waivers: (i) delay or prevent
the Closing, (ii) make the funding of any of the Financings (or satisfaction of the conditions to obtaining any of the Financings)
less likely to occur, (iii) adversely impact the ability of Buyer to enforce its rights against the other parties to the Commitment
Letters or the definitive agreements with respect thereto, the ability of Buyer to consummate the transactions contemplated by this Agreement
to be consummated at the Closing or the likelihood of the consummation of such transactions to be consummated at the Closing, (iv) reduce
(or would reasonably be expected to have the effect of reducing) the aggregate amount of any of the Financings (including by changing
the amount of fees to be paid or original issue discount of the Debt Financing unless the Equity Financing is increased by a corresponding
amount) to an amount below what is necessary to pay the Required Amount (after giving effect to other available financing), or (v)
impose new conditions or adversely expand, amend or modify any of the existing conditions to the receipt of any of the Financings,
or otherwise add, expand, amend or modify any other provision of the Commitment Letters, in a manner that would reasonably be expected
to delay or prevent the funding of any of the Financings (or satisfaction of the conditions to any of the Financings) at the Closing.
Upon any permitted amendment, supplement, modification or replacement of any Commitment Letter (including with respect to any Alternative
Financing) in accordance with this Section 6.05, the term “Commitment Letters” shall mean the Commitment Letters
as so amended, supplemented, modified or replaced, and references to “Financings”, “Equity Financing”, “Debt
Financing” and/or “Alternative Financing” shall including the financing contemplated by the Commitment Letters as so
amended, supplemented, modified or replaced.

 

    44 

     

    

 

(d)            Buyer
shall provide the Seller prompt notice (i) upon becoming aware of any material breach, default, written repudiation, cancellation
or termination by any party of any Commitment Letter or any termination of any Commitment Letters and (ii) upon receipt by Buyer
or any of its Affiliates or Representatives of any written notice or other written communication of any such material breach,
default, written repudiation, cancellation or termination. As soon as reasonably practicable, the Buyer shall provide any information
reasonably requested by the Seller relating to any circumstance referred to in clause (i) or (ii) of the immediately preceding
sentence. In addition, Buyer shall, upon reasonable written request of the Seller, keep the Seller informed on a reasonably current basis
and in reasonable detail of the status of its efforts to finalize the Financings and provide to the Seller copies of all definitive documents
related to the Financings; provided that, the fee amounts and percentages, pricing caps, market flex and other commercially sensitive
terms in a copy of any fee letter delivered pursuant hereto may be redacted.

 

6.6            Financing
Cooperation.

 

(a)            Prior
to the Closing, the Seller, the Company and the Relevant Entities shall, and shall use reasonable best efforts to cause the appropriate
officers and employees of the Company and the Relevant Entities to provide reasonable cooperation as is reasonably requested by Buyer,
at Buyer’s sole cost and expense, upon reasonable prior notice in connection with the Debt Financing, including (without limitation):
(i) participating in a reasonable number of meetings (including customary one-on-one meetings between the Lenders and/or rating
agencies and appropriate senior management of the Company or the Relevant Entities), presentations, due diligence sessions, and other
marketing efforts, so long as any such meetings, presentations or sessions may be attended virtually, (ii) reasonably assisting
Buyer in the preparation and execution (subject, other than with respect to customary authorization letters, to the occurrence of the
Closing) of management representation letters and other materials reasonably and customarily requested and delivering any possessory
collateral within its possession to the Lenders (subject to the occurrence of the Closing); (ii) providing reasonably promptly to
Buyer and its financing sources such financial and other information regarding the Company or any Relevant Entity as is reasonably requested
in connection with the Debt Financing, and assisting with the preparation of materials for rating agency presentations and similar documents
required in connection with the Debt Financing; (iii) reasonably cooperating in satisfying the conditions precedent set forth in
any definitive documentation relating the Debt Financing;(iv) taking all reasonably requested formal corporate actions, subject
to the occurrence of the Closing; and (v) delivering to Buyer at least three (3) Business Days prior to the Closing Date all
documentation and information as is reasonably requested in writing by the Lenders at least five (5) Business Days prior to the
Closing Date about the Company or any Relevant Entity required by U.S. regulatory authorities under applicable “know your customer”
and anti-money laundering rules and regulations, including without limitation the PATRIOT Act; and (vii) (1) delivering
to Buyer and the Lenders the historical financial statements regarding the Acquired Companies identified in the Debt Commitment Letters
and (2) reasonably assisting Buyer in its preparation of the pro forma financial statements.

 

    45 

     

    

 

(b)            Notwithstanding
anything to the contrary in this Agreement, none of the Seller or its Affiliates or any Acquired Company or any of their respective officers,
directors or employees shall be required to (i) pay any commitment or other similar fee prior to the Closing, (ii) approve
any document or other matter related to the financing or incur any liability of any kind (or cause their Representatives to incur any
liability of any kind) prior to the Closing, (iii) enter into any agreement or commitment in connection with the Debt Financing
(or any Alternative Financing) which would be effective prior to the Closing or provide any certification or opinion of any Acquired
Company which would be effective prior to the Closing, (iv) provide any resolution, certificate, consent, comfort letter or opinion,
other than customary authorization letters, (v) provide access to or disclose any information to Buyer or its Representatives to
the extent such disclosure would jeopardize the attorney-client privilege or attorney work product protections or violate any applicable
Law or Material Contract, or (vi) take any action that could (A) unreasonably interfere with the day-to-day operations of such
Person, (B) cause any representation, warranty, covenant or agreement in this Agreement or any Transaction Document to be breached,
(C) cause any director, manager, officer or employee of Seller, its Affiliates or any Acquired Company to incur any personal liability,
(D) conflict with the Organizational Documents of the Company or any Relevant Entity or any Law, (E) result in the contravention
of, or that could reasonably be expected to result in a violation or breach of, or a default under, any material Contract, (F) change
any fiscal period, or (G) authorize any corporate action prior to the Closing (it being agreed that directors and officers of the
Acquired Companies may sign resolutions or consents that do not become effective until the Closing to the extent that they shall remain
directors and/or officers after giving effect to the Closing).

 

(c)            The
Seller, on behalf of the Company and the Relevant Entities, hereby consents to the use of the Relevant Entities’ logos in connection
with the Debt Financing; provided, that such logos are used solely in a manner that is not intended to nor reasonably likely to
harm or disparage the Company or any Relevant Entity or the Reputation or goodwill of the Company or any Relevant Entity and their marks.

 

(d)            The
Seller and the Seller’s Representative, on behalf of itself and its respective equity holders, Affiliates, directors, managers,
officers, employees, agents and representatives, each hereby (x) waives any rights or claims against any Lender in connection with
this Agreement or any agreements to which any Lender has loaned or committed to loan any money or extended any financing to Buyer or
any of its Affiliates (collectively, the “Loan Documents”) or any of the transactions contemplated hereby or thereby,
whether at law or in equity, in contract or in tort or otherwise, and agree not to commence any claim, action, suit or other legal proceeding
against any Lender in connection with this Agreement, the Loan Documents or the transactions contemplated hereby or thereby, and (y) agrees
not to commence (and if commenced, agrees to dismiss or otherwise terminate) any claim, action, suit or other legal proceeding against
any Lender in connection with this Agreement, the Loan Documents or the transactions contemplated hereby or thereby. In furtherance and
not in limitation of the foregoing waiver, the Parties hereby agree that no Lender shall have any liability for any claims, losses, settlements,
damages, costs, expenses, fines, penalties or interest to the Seller and the Seller’s Representative (or any of their respective
equity holders, Affiliates, directors, managers, officers, employees, agents or representatives) in connection with this Agreement, the
Loan Documents or any transaction contemplated hereby or thereby.

 

    46 

     

    

 

ARTICLE VII

 

ADDITIONAL COVENANTS OF
BUYER

 

7.1            Access
to Books and Records. For a period of seven (7) years after the Closing, Buyer will cause the Relevant Entities to provide
Seller and its authorized representatives with reasonable access (for the purpose of examining and copying), during normal business hours
and upon reasonable prior written notice, to the personnel, books and records of the Relevant Entities with respect to periods or occurrences
prior to or on the Closing Date, but only to the extent relating to (a) the preparation and filing of any Tax return or the defense
of any Tax claim or assessment or (b) any Action involving Seller or the Acquired Companies (other than such Actions relating to
the transactions contemplated hereby). For a period of seven (7) years after the Closing, Buyer will not, and will not permit any
Relevant Entity to, destroy, alter or otherwise dispose of any books and records of any Relevant Entity, or any portions thereof, relating
to periods prior to the Closing Date without first offering to surrender to Seller such books and records or such portions thereof and
giving Seller a reasonable amount of time to accept such offer.

 

7.2            Director
and Officer Liability and Indemnification.

 

(a)            For
a period of six (6) years after the Closing, the Organizational Documents of the Relevant Entities shall contain provisions no less
favorable than those existing as of the date hereof with respect to the exculpation, indemnification or advancement of expenses of any
current and former officers, directors, managers or direct or indirect equity holders of any Relevant Entity (each, a “D&O
Indemnified Person”) (unless required by Law), it being the intent of the Parties that the D&O Indemnified Persons will
continue to be entitled to such exculpation, indemnification and advancement of expenses to the full extent of the Law; provided,
that D&O Indemnified Persons shall not include the D&O Indemnity Excluded Persons.

 

(b)            Buyer
will, or will cause the Relevant Entities to, at Buyer’s expense, at the Closing, obtain and fully pay for, and following the Closing
maintain in effect, irrevocable “tail” insurance policies naming the D&O Indemnified Persons as direct beneficiaries
(with respect to matters existing or occurring at or prior to the Closing) with a coverage period of at least six (6) years from
the Closing Date from an insurance carrier with the same or better credit rating as the Relevant Entities’ current insurance carrier
with respect to directors’ and officers’ liability insurance in an amount and scope of coverage at least as favorable as
the Relevant Entities’ existing policies (the “Tail Policy”); provided, however, that Buyer shall
not be obligated to pay for the excess, if any, of the cost of such Tail Policy and $165,000 (the “D&O Premium Cap”);
provided, further, that, to the extent Buyer is unable to procure a Tail Policy at a price below the D&O Premium Cap,
Buyer shall not be obligated to obtain such Tail Policy unless Seller pays for the cost thereof in excess of the D&O Premium Cap.
Buyer will not, and will cause the Relevant Entities not to, cancel or change such insurance policies in any respect. Buyer will
make available to Seller and any D&O Indemnified Person, upon request, proof of compliance with this Section 7.02(b).

 

    47 

     

    

 

(c)            Buyer
hereby acknowledges (on behalf of itself and its Affiliates, including the Relevant Entities from and after the Closing) that the D&O
Indemnified Persons may have certain rights to indemnification, advancement of expenses and/or insurance provided by current direct or
indirect equity holders, members or other Affiliates of Seller or its respective direct or indirect equity holders (“Indemnitee
Affiliates”) separate from the obligations of Buyer, the Relevant Entities hereunder. The Parties agree that, from and after
the Closing, (i) Buyer and the Relevant Entities are the indemnitors of first resort (i.e., their obligations to the D&O Indemnified
Persons are primary and any obligation of any Indemnitee Affiliate to advance expenses or to provide indemnification or insurance for
the same expenses or liabilities incurred by the D&O Indemnified Persons are secondary), (ii) Buyer and the Relevant
Entities will be required to advance the full amount of expenses incurred by the D&O Indemnified Persons and will be liable for the
full amount of all fees, costs, expenses, judgments, penalties, interest, fines and amounts paid in settlement to the extent legally
permitted, without regard to any rights the D&O Indemnified Persons may have against any Indemnitee Affiliate, and (iii) the
Parties (on behalf of themselves and their respective Subsidiaries) irrevocably waive, relinquish and release the Indemnitee Affiliates
from any and all claims against the Indemnitee Affiliates for contribution, subrogation or any other recovery of any kind in respect
thereof.

 

(d)            In
the event that all or substantially all of the equity or assets of any Relevant Entity are sold, or any Relevant Entity merges or otherwise
combines with another Person, in each case whether in one transaction or a series of transactions, then Buyer and the Relevant Entity
will, in each such case, ensure that the successors and assigns of the Relevant Entity, as applicable, assume the obligations set forth
in this Section 7.02. The provisions of this Section 7.02(d) will apply to all of the successors and assigns
of the Relevant Entities.

 

(e)            Notwithstanding
anything to the contrary, no D&O Indemnified Person shall have rights with respect to advancement, indemnification, contribution
or other recovery of any kind from the Buyer, the Company or any Relevant Entity for any matter which (i) is a claim in connection
with or arising under this Agreement or (ii) such D&O Indemnified Person has committed fraud with respect to the representations
and warranties contained in this Agreement (including, without limitation, the costs and expenses of defending any claims with respect
to such matter).

 

		(f)	Regulatory
                                            Filings.

 

(i)            Buyer
will, within five (5) Business Days after the date hereof, make or cause to be made all filings and submissions under any Laws or
regulations applicable to Buyer and its Affiliates, including under the HSR Act (if applicable), for the consummation of the transactions
contemplated hereby and, at Seller’s request, include in each such filing or submission a request for early termination or acceleration
of any applicable waiting or review periods, to the extent available under applicable laws or regulations. Buyer will pay all
fees associated with all filings and submissions referred to in this Section 7.02(f).

 

    48 

     

    

 

 

(ii)            Buyer
will comply with any additional requests for information, including requests for production of documents and production of witnesses
for interviews or depositions by any Governmental Body. Without limiting any other provision hereof, in furtherance of the foregoing,
Buyer agrees (on behalf of itself and each of its Affiliates) to use its reasonable best efforts to take or cause to be taken any and
all actions reasonably necessary, proper or advisable to avoid, eliminate and resolve any and all impediments under the HSR Act or trade
regulation Law that may be asserted by any Governmental Body (including the Federal Trade Commission or the Antitrust Division of the
U.S. Department of Justice or state attorney general) or any other Person with respect to the transactions contemplated by this Agreement
so as to enable the consummation of the transactions contemplated by this Agreement to occur as expeditiously as possible (and in any
event no later than the End Date (as hereinafter defined)) and to obtain all consents, approvals and waivers under the HSR Act and other
trade regulation Laws that may be required by any Governmental Body, including any such actions necessary, proper or advisable to avoid
the entry of, or to have vacated or terminated, any decree, decision, Order or judgment that would restrain, prevent or delay the consummation
of the transactions contemplated hereby, on or before the End Date, including by contesting, administratively or in court, any ruling,
Order, or other action of any Governmental Body or any other Person respecting the transactions contemplated by this Agreement; provided,
however, Buyer’s shall have no obligation to make or consent to any divestiture.

 

(iii)            Except
as specifically required by this Agreement, during the Interim Period, Buyer will not take any action, or refrain from taking any action,
that would reasonably be expected to delay or impede the obtaining of clearance or the expiration of the required waiting periods under
the HSR Act or any other trade regulation Laws or the obtaining of any consents from any applicable Governmental Body. Without limiting
the generality of the foregoing, Buyer will not, and will not permit any of its Affiliates to, acquire or agree to acquire (by merging
or consolidating with, or by purchasing a substantial portion of the assets of or equity in, or by any other manner), any Person or portion
thereof, or otherwise acquire or agree to acquire any assets at any time during the Interim Period, if the entering into a definitive
agreement relating to, or the consummation of, such acquisition, merger or consolidation could reasonably be expected to (A) impose
any delay in the obtaining of, or increase the risk of not obtaining, any Permits or other approvals of any Governmental Body necessary
to consummate the transactions contemplated hereby or the expiration or termination of any applicable waiting period, (B) increase
the risk of any Governmental Body entering an Order prohibiting the consummation of the transactions contemplated hereby, (C) increase
the risk of not being able to remove any such Order on appeal or otherwise, or (D) delay or prevent the consummation of the transactions
contemplated hereby.

 

    49 

     

    

 

(iv)            Buyer
will keep the Company reasonably apprised of the status of all filings and submissions referred to in this Section 7.02(f),
including promptly furnishing the Company with copies of notices or other communications received by Buyer in connection therewith to
the extent not prohibited by applicable law; provided that Buyer may designate any competitively sensitive materials provided under this
Section 7.02(f) as for the review of the Company’s legal counsel only, in which case such materials shall only
be given to the Company’s legal counsel and shall not be disclosed to any Affiliates, employees, officers or directors of the Company
or Seller without Buyer’s prior written consent. Buyer will provide the Company with copies of draft filings or submissions to
any Governmental Body referred to in Section 7.02(f), with the exception of HSR filings, and allow time for Company to provide
comment prior to submission. Buyer will not permit any of its officers, employees or other representatives or agents to participate in
any meeting with any Governmental Body in respect of such filings and submissions unless it consults with the Company in advance and,
to the extent permitted by such Governmental Body, gives the Company the opportunity to attend and participate thereat.

 

7.3            Conditions. During
the Interim Period, Buyer will use commercially reasonable efforts to take or cause to be taken all actions to do or cause to be done
and assist and cooperate with the other Parties in doing all things reasonably necessary, proper, or advisable, to consummate the transactions
contemplated hereby as soon as reasonably possible after the satisfaction of the conditions set forth in Sections 2.01, 2.02
and 2.03 (other than those to be satisfied at the Closing).

 

7.4            Contact
with Clients and Other Business Relations Prior to the Closing, except as otherwise expressly authorized pursuant to the terms of
this Agreement, Buyer will not contact and/or communicate with the employees, clients, suppliers, payors or other business relations
of the Relevant Entities with respect to the Company, the Relevant Entities or the transactions contemplated hereby, without prior consultation
with and written approval of the Seller’s Representative (which approval shall not be unreasonably withheld, conditioned, or delayed);
provided that the foregoing shall not prohibit Buyer from contacting, in the ordinary course of business, any client of the Relevant
Entities, in each case, not in connection with the transactions contemplated by this Agreement.

 

7.5            Payment
of Indebtedness and Seller Transaction Expenses Buyer will repay, or cause to be repaid, all amounts necessary to discharge fully
the then outstanding balance of all Indebtedness identified on Schedule 2.02(c)(iii) and the Seller Transaction Expenses,
to the account(s) designated by each Person to whom such amounts are to be paid.

 

    50 

     

    

 

		7.6	Employee
                                            Matters

 

(a)            For
at least one (1) year following the Closing Date (or until the date of termination of the relevant employee, if earlier), Buyer
shall, or shall cause its Subsidiaries to, provide to the employees of any Relevant Entity, including employees not actively at work
due to injury, vacation, military duty, disability or other leave of absence, who are employed by a Relevant Entity immediately prior
to the Closing and who continue to be so employed immediately following the Closing (“Company Employees”) with (i) at
least the same level of base salary or hourly wage rate, as the case may be, that was provided to such Company Employee immediately
prior to the Closing, (ii) target annual cash performance bonus opportunities (but not change in control, severance, deferred compensation,
retention, long-term incentive compensation, or equity or equity-based incentive opportunities) that are not materially less than the
target annual cash performance bonus opportunities (but not change in control, severance, deferred compensation, retention, long-term
incentive compensation, or equity or equity-based incentive opportunities) in effect with respect to the Company Employee immediately
prior to the Closing, (iii) severance pay to Company Employees who incur a “qualifying termination” at any time during
the one (1) year period following the Closing at levels that are not materially less favorable in the aggregate than the levels
of such severance pay as in effect under the applicable Plans immediately prior to the Closing (where, for such purpose, “qualifying
termination” shall mean any termination of employment that would have resulted in severance pay under such Plan if such termination
has occurred immediately prior to the Closing) and (iv) other employee benefits (other than any equity or equity- based, defined
benefit pension, post-termination welfare, change in control, severance, deferred compensation, retention, long-term incentive compensation,
or equity or equity- based incentive opportunities) that are substantially comparable in the aggregate to those provided to such Company
Employees immediately prior to the Closing.

 

(b)            For
at least one (1) year following the Closing Date (or until the date of termination of the relevant employee, if earlier), Buyer
shall, or shall cause its Affiliates to, honor all vacation, sick pay and other paid time off for Company Employees accrued but unused
as of the Closing Date, on terms and conditions consistent with the terms and conditions in effect immediately prior to the Closing Date.

 

(c)            Buyer
shall use commercially reasonable efforts to credit periods of employment with the Relevant Entities and any of their respective predecessors
for purposes of determining eligibility, vesting, and (solely for paid time off and severance) level of benefits for the Company Employee
under all employee benefit plans, programs, policies or arrangements of Buyer or its Subsidiaries in which such Company Employee is eligible
to participate on or following the Closing Date (other than any defined benefit pension, post-termination welfare, change in control,
deferred compensation, retention, equity or equity-based incentive opportunities) (each, a “Buyer Benefit Plan”),
in each case, to the same extent such service was recognized under a comparable Plan for the same purpose prior to the Closing; provided,
however, that no such crediting of service shall result in duplication of benefits or compensation for the same period of service.

 

(d)            With
respect to each Buyer Benefit Plan that is a group health plan that in the plan year in which the Closing occurs replaces coverage under
a comparable Plan in which the Company Employee participated immediately prior to the Closing Date, Buyer shall, or shall cause its Subsidiaries
to use commercially reasonable efforts to (i) waive all preexisting condition exclusions, evidence of insurability or good health,
waiting periods, actively-at-work exclusions or other limitations with respect to participation and coverage requirements applicable
to the Company Employee to the extent waived or satisfied under the comparable Plan in which such Company Employee participated immediately
prior to the Closing Date, and (ii) credit the Company Employee for any applicable amounts paid or eligible expenses incurred
(whether in the nature of co-payments or coinsurance amounts, amounts applied toward deductibles or other out-of-pocket expenses) by
such Company Employee (and any covered spouses, dependents or beneficiaries) under the terms of the Plan toward satisfying any applicable
deductible, co-payment, coinsurance, maximum out-of-pocket requirements and like adjustments or limitations under the applicable Buyer
Benefit Plan that replaces such Company Employee for the plan year in which the Closing Date occurs.

 

    51 

     

    

 

(e)            Nothing
contained in this Section 7.06 or any other provision of this Agreement, expressed or implied, shall give any Person, other
than the Parties any rights or remedies of any nature whatsoever, including but not limited to any right to employment or service or
continued employment or service for any period or any particular term or condition of employment or service with the Company or Buyer
or any of its Affiliates, under or by reason of this Section 7.06 and no provision of this Section 7.06 shall
create any third party beneficiary rights in any other Person, including any current or former employee, director, consultant or other
individual service provider of the Company, to enforce the provisions of this Section 7.06 or any other matter related thereto
or shall be construed to establish, amend or modify any Plan or any compensation or benefit plan, program, policy or arrangement or to
limit the ability of Buyer or any of its Affiliates (including following the Closing the Company to amend, modify or terminate any benefit
or compensation plan, program, policy, agreement, contract or arrangement. Nothing in this Section 7.06 shall be construed
to limit the ability of Buyer or any of its Affiliates (including following the Closing the Company) to terminate the employment or service
of any Person at any time and for any or no reason.

 

ARTICLE VIII

 

TERMINATION

 

8.1           Termination.

 

This Agreement may be terminated at any time
prior to the Closing:

 

(a)           by
the mutual written consent of Buyer and Seller;

 

(b)          by
Buyer, by giving written notice to Seller, if there has been a material violation or breach by the Company or Seller of any covenant,
agreement, representation or warranty contained in this Agreement that has prevented the satisfaction of any condition to the obligations
of Buyer at the Closing set forth in Section 2.02(a) or Section 2.02(b) and such violation or breach
has not been waived by Buyer or, in the case of a covenant or agreement breach, cured by the Company or Seller, as applicable, by the
earlier of (x) thirty (30) days following Buyer’s written notice to the Company and Seller of such breach and (y)
the End Date; provided that Buyer shall not have the right to terminate this Agreement pursuant
to this Section 8.01(b) if Buyer is then in material breach of any of its covenants, obligations, representations or
warranties set forth in this Agreement such that a condition to the obligations of Seller and the Company at the Closing set forth in
Section 2.03(a) or Section 2.03(b) would not be satisfied;

 

    52 

     

    

 

(c)          by
Seller, by giving written notice to Buyer, if there has been a material violation or breach by Buyer of any covenant, agreement, representation
or warranty contained in this Agreement that has prevented the satisfaction of any condition to the obligations of the Company and Seller
at the Closing set forth in Section 2.03(a) or Section 2.03(b) and such violation or breach has not
been waived by Seller or, in the case of a covenant or agreement breach, cured by Buyer by the earlier of (x) thirty (30) days following
Seller’s written notice to Buyer of such breach and (y) the End Date; provided (A) the failure to deliver the full
consideration payable pursuant to Article I under this Agreement at the Closing as required hereunder (each of which shall
be deemed a Willful Breach by Buyer) will be subject to cure hereunder and (B) that Seller shall not have the right to terminate
this Agreement pursuant to this Section 8.01(c) if the Company or Seller is then in material breach of any of its covenants,
obligations, representations or warranties set forth in this Agreement such that a condition to the obligations of Buyer at the Closing
set forth in Section 2.02(a) or Section 2.02(b) would not be satisfied;

 

(d)          by
either Buyer or Seller if the transactions contemplated hereby have not been consummated by 5:00 p.m. central time on January 31,
2022 (the “End Date”); provided that if on the End Date the conditions to Closing set forth in Section 2.01(a) or
2.01(b) shall not have been satisfied but all other conditions to Closing shall be satisfied or shall be capable of being
satisfied upon satisfaction of the conditions to Closing set forth in such section, then Seller shall have the right to extend the End
Date an additional fifteen (15) days by notifying Buyer in writing of such election before the End Date; provided further that
neither Buyer nor Seller will be entitled to terminate this Agreement pursuant to this Section 8.01(d) if the failure
to consummate the Closing results primarily from such Person’s Willful Breach (or, in the case of the Seller, a Willful Breach
by the Company) of any representation, warranty, covenant or agreement contained in this Agreement;

 

(e)          by
either Buyer or Seller, effective upon written notice to the other party, if there shall be in effect a final, non-appealable Order or
Law of a Governmental Body of competent jurisdiction permanently enjoining, restraining, preventing, or prohibiting the consummation
of the transactions contemplated hereby, or making the consummation of the Closing illegal; or

 

(f)           by
the Seller if (A) the conditions in Sections 2.01 and 2.02 have been satisfied or have been waived (other than those
conditions that by their nature only can be satisfied by actions taken at the Closing provided, that each such condition is then capable
of and would be satisfied assuming a Closing would occur at such time), (B) the Company and the Seller have satisfied all of their
obligations under Section 6.06 and shall not have caused the failure of the condition set forth in Section 2.02(d),
and (C) the Company has delivered to Buyer, at least two (2) Business Days prior to such termination, a certificate irrevocably
certifying that it is ready, willing and able to consummate the Closing on the date required by Section 1.03 and stands so
ready, willing and able at the time of termination.

 

    53 

     

    

 

		8.2	Effect
                                            of Termination.

 

(a)            In
the event of the termination of this Agreement by either Buyer or Seller as provided in Section 8.01, the provisions of this
Agreement will immediately become void and of no further force or effect (other than this Section 8.02 and Article XII
(solely applicable to those obligations that survive termination)), and the definitions related thereto that will survive the termination
of this Agreement in accordance with their terms; provided, however, that the Confidentiality and Non-Disclosure Agreement,
dated July 5, 2021, between Beecken Petty O’Keefe & Company, LLC and Alliance Physical Therapy Partners, LLC (the
 “Confidentiality Agreement”) will survive the termination of this Agreement in accordance with its terms); provided,
however, that nothing herein shall relieve Seller or the Company from Liability for losses incurred by the other Parties resulting
from Seller’s and/or the Company’s Willful Breach of this Agreement.

 

(b)            In
the event that this Agreement is validly terminated by Seller pursuant to Section 8.01(f) solely because the Lenders
(including in connection with any Alternative Financing) are unwilling or unable to consummate the Debt Financing or Alternative Financing
(as applicable), then Buyer shall pay, or cause to be paid, to the Seller a termination fee in an aggregate amount equal to 5% of the
Enterprise Value (the “Termination Fee”), without offset or deduction of any kind, within five (5) Business Days
following such termination by wire transfer of immediately available funds to accounts specified by the Company in writing to Buyer.
Solely for purposes of establishing the basis for the amount thereof, it is agreed that the Termination Fee is liquidated damages, and
not a penalty, and the payment of the Termination Fee in the circumstances specified herein is supported by due and sufficient consideration
(including the fact that the Seller would not be entitled to receive the Final Purchase Price and would suffer other losses of an incalculable
nature and amount).

 

(c)            In
the event of a valid termination of this Agreement pursuant to Section 8.01(f), the rights, if applicable, of the Seller
to receive (i) the Termination Fee and (ii) any indemnification or expense reimbursement obligations under this Agreement (collectively,
the “Obligations”), including from Equity Investors pursuant to the Guaranty, if such Obligations are payable pursuant
to Section 8.02(b) and are actually indefeasibly paid in full, shall be the sole and exclusive remedy of the Company,
the Seller, the Relevant Entities and any of their respective, shareholders, equity holders, partners, directors, managers, officers,
employees and Affiliates against Buyer, its shareholders, and any current, former or future director, officer, employee, incorporator,
member, partner, manager, stockholder, equity holder, controlling Person, Affiliate, agent, attorney, representative or assignee of,
and any financial advisor or lender to, Buyer, including the Lenders, or any current, former or future director, officer, employee, incorporator,
member, partner, manager, stockholder, equity holder, controlling Person, Affiliate, agent, attorney, representative or assignee of,
and any financial advisor or lender to, any of the foregoing (the “Buyer Related Parties”) for any and all losses
suffered or as a result of or arising out of this Agreement (including the failure to consummate the transactions contemplated hereby)
or any Ancillary Document. Except to enforce the provisions of this Section 8.02(c) or specifically set forth herein,
upon the termination of this Agreement pursuant to Section 8.01(f) and, if payable pursuant to Section 8.02(b),
payment in full of the Obligations, neither the Company, the Seller, nor any of their respective Affiliates shall be entitled to bring
or maintain any other claim action or proceeding against Buyer and/or any of the Buyer Related Parties arising out of or in connection
with any of the transactions contemplated by this Agreement.

 

    54 

     

    

 

ARTICLE IX

 

REMEDIES FOR BREACHES OF THIS AGREEMENT

 

9.1            Indemnification
by Seller. Subject to the terms and conditions of this Article IX, Seller shall indemnify and hold harmless Buyer and
its Affiliates and their respective successors and assigns (the “Buyer Indemnitees”) from and against any Adverse
Consequences that any Buyer Indemnitee may suffer or incur (including any Adverse Consequences they may suffer or incur after the end
of any applicable Limitation Date, provided an indemnification claim with respect to such Adverse Consequence is made pursuant to this
Article IX prior to the end of any applicable Limitation Date) resulting from, arising out of, or caused by (i) any
breach or inaccuracy of any representation or warranty made by Seller in Article III of this Agreement, (ii) any breach
or inaccuracy of any representation or warranty made by Seller and the Company in Article IV of this Agreement, (iii) any
breach of any covenant or agreement of Seller or the Company (prior to Closing) in this Agreement or (iv) any multiple employer
welfare arrangement Losses related to the Managed Practices for the 2020 and 2021 calendar years (the “MEWA Indemnity”).

 

9.2            Indemnification
by Buyer. Subject to the terms and conditions of this Article IX, Buyer shall indemnify and hold harmless Seller, its
Affiliates, and their successors and assigns (the “Seller Indemnitees”) from and against the entirety of any Adverse
Consequences they may suffer or incur (including any Adverse Consequences they may suffer or incur after the end of any applicable Limitation
Date, provided, that an indemnification claim with respect to such Adverse Consequence is made pursuant to this Article IX
prior to the end of any applicable Limitation Date) resulting from, arising out of, relating to, in the nature of, or caused by (a) any
breach or inaccuracy of any representation or warranty made by the Buyer in Article V of this Agreement, or (b) any
breach of any covenant or agreement of the Buyer in this Agreement.

 

9.3            Indemnity
Escrow Fund.

 

(a)            At
the Closing, the Buyer shall deposit, or cause to be deposited, the Indemnity Escrow Amount with the Escrow Agent pursuant to Section 1.04(e) (the
aggregate amount of cash held by the Escrow Agent pursuant to this Section 9.03 and the Escrow Agreement, from time to time,
the “Indemnity Escrow Fund”), which Indemnity Escrow Fund shall be held by the Escrow Agent pursuant to this Agreement
and the Escrow Agreement. Subject to Section 9.04, the Indemnity Escrow Fund shall constitute partial security for the benefit
of the Buyer (on behalf of itself or any other Buyer Indemnitee) with respect to any Adverse Consequences pursuant to the indemnification
obligations of the Seller under this Article IX.

 

    55 

     

    

 

(b)            Within
five (5) Business Days after the Non-Fundamental Limitation Date, the Escrow Agent shall, pursuant to the terms of the Escrow Agreement,
release to the Seller (i) all Indemnity Escrow Funds in the Indemnity Escrow Account minus (ii) the aggregate amount for which
claims for indemnification were made by Buyer against the Indemnity Escrow Funds in connection with this ARTICLE  IX prior
to the Non-Fundamental Limitation Date and not yet resolved (the “Pending Claim Amount”). Furthermore, following
the Non-Fundamental Limitation Date, within two (2) Business Days after final determination (in accordance with this Agreement)
that all or any portion of the Pending Claim Amount is not owed to Buyer hereunder, the Escrow Agent shall, pursuant to the terms of
the Escrow Agreement, release to Seller, such portion of the Pending Claim Amounts.

 

9.4            Survival
and Time Limitations. All representations, warranties, covenants and agreements of the Parties in this Agreement or any other certificate
or document delivered pursuant to this Agreement will survive the Closing as follows: (a) all representations and warranties of
Seller or the Company other than Seller Fundamental Representations shall survive until eighteen (18) months following the Closing
Date (the “Non-Fundamental Limitation Date”), (b) all Seller Fundamental Representations shall survive until
thirty six (36) months following the Closing Date (the “Fundamental Limitation Date”, and the Fundamental Limitation
Date and the Non- Fundamental Limitation Date, may each be referred to herein as a “Limitation Date”), provided, that
any claim related to a Willful Breach or fraudulent breaches of the representations and warranties of Seller or the Company may be made
at any time without limitation, (c) all representations and warranties of Buyer other than Buyer Fundamental Representations shall
survive until the Non-Fundamental Limitation Date, (d) all Buyer Fundamental Representations shall survive the Closing without limitation,
(e) the MEWA Indemnity shall survive until the Non- Fundamental Limitation Date and (f) the covenants and agreements of the
Parties contained in this Agreement that are to be performed at or after the Closing shall survive the Closing in accordance with their
respective terms for the time period contemplated for performance or, if no time period for performance is contemplated, until the one
(1) year anniversary of the Closing Date.

 

		9.6	Limitations
                                            on Indemnification by Seller.

 

(a)            With
respect to the matters described in Section 9.01, Seller will have no liability with respect to such matters until Buyer
Indemnitees have suffered aggregate Adverse Consequences by reason of all such breaches in excess of .75% of the Enterprise Value (the
 “Threshold Amount”), after which point (subject to the limitations set forth herein) Seller will be obligated to indemnify
Buyer Indemnitees from and against all Adverse Consequences in excess of the Threshold Amount; provided, that the foregoing limitations
shall not apply in respect of any Adverse Consequences relating to (i) breaches of the Seller Fundamental Representations, (ii) the
MEWA Indemnity or (iii) any Willful Breach or fraudulent breach of a representation or warranty.

 

(b)            With
respect to the matters described in Section 9.01, the aggregate maximum liability of Seller shall be an amount equal to the
Indemnity Escrow Amount (the “Cap”); provided, that the foregoing limitation shall not apply in respect of
any Adverse Consequences relating to breaches of the Seller Fundamental Representations, or any Willful Breach or fraudulent breach of
a representation or warranty, for which the Seller’s maximum liability will be the Enterprise Value.

 

    56 

     

    

 

(c)            With
respect to the matters described in Section 9.01, the Seller’s liability with respect to such matters shall first be
claimed and recovered against the Indemnity Escrow Account, to the extent such funds are available, in accordance with the terms and
conditions of the Escrow Agreement; it being agreed and understood that the Indemnity Escrow Account shall be the sole source
of recovery by the Buyer Indemnitees with respect to all such matters; provided, that the foregoing sole recourse limitation shall
not apply in respect of any Adverse Consequences relating to (i) breaches of the Seller Fundamental Representations, or (ii) any
Willful Breach or fraudulent breach of a representation or warranty, for which the Seller’s maximum liability will be the Enterprise
Value.

 

(d)            Buyer
acknowledges and agrees that the limitation on and waivers of liability in this Section 9.05 may not be avoided or restricted
by (i) seeking damages or any other relief for breach of contract, in tort, under statute, or pursuant to any other theory of liability,
all of which are hereby irrevocably waived, or (ii) asserting or threatening any claim against any Person that is not a party hereto
(or a successor to a Party) for breaches of the representations, warranties, covenants or agreements contained in this Agreement; provided,
that the foregoing clause (ii) shall not apply in the case of claims for fraud against any such Person.

 

		9.7	Limitations
                                            on Indemnification by Buyer.

 

(a)            With
respect to the matters described in Section 9.02(a), Buyer will have no liability with respect to such matters until Seller
Indemnitees have suffered Adverse Consequences by reason of all such breaches in excess of the Threshold Amount, after which point (subject
to the limitations set forth herein) Buyer will be obligated to indemnify Seller Indemnitees from and against all Adverse Consequences
in excess of such Threshold Amount; provided, that the foregoing limitations shall not apply in respect of any Adverse Consequences
relating to (i) breaches of any Buyer Fundamental Representation or (ii) any Willful Breach or fraudulent breach of a representation
or warranty.

 

(b)            With
respect to the matters described in Section 9.02(a), the aggregate maximum liability of Buyer shall be the Cap; provided,
that the foregoing limitation shall not apply in respect of any Adverse Consequences relating to (i) breaches of any Buyer Fundamental
Representation or (ii) any Willful Breach or a fraudulent breach of a representation or warranty, in which case the aggregate maximum
liability of Buyer shall be the Enterprise Value. With respect to the matters described in Section 9.02(b), the aggregate
maximum liability of Buyer shall be the Enterprise Value.

 

		9.8	Third
                                            Party Claims.

 

(a)            If
a third party initiates a claim, demand, dispute, lawsuit or arbitration (a “Third-Party Claim”) against any Person
(the “Indemnified Party”) with respect to any matter that the Indemnified Party may make a claim for indemnification
against any Party (the “Indemnifying Party”) under this Article IX, then the Indemnified Party must promptly
notify the Indemnifying Party in writing of the existence of such Third-Party Claim and must deliver copies of any documents served on
the Indemnified Party with respect to the Third-Party Claim; provided, however, that any failure on the part of an Indemnified Party
to so notify an Indemnifying Party shall not limit any of the obligations of the Indemnifying Party under this Article IX
(except to the extent such failure prejudices the defense of such proceeding).

 

    57 

     

    

 

(b)            Upon
receipt of the notice described in Section 9.08(a), the Indemnifying Party will have the right to defend the Indemnified
Party against the Third-Party Claim with counsel reasonably satisfactory to the Indemnified Party, provided, that (i) the
Indemnifying Party notifies the Indemnified Party in writing within fifteen (15) days after the Indemnified Party has given notice of
the Third-Party Claim that the Indemnifying Party will indemnify the Indemnified Party from and against the entirety of any Adverse Consequences
the Indemnified Party may suffer with respect to such Third-Party Claim (subject to any applicable limitations set forth herein), (ii) the
Indemnifying Party provides the Indemnified Party with evidence reasonably acceptable to the Indemnified Party that the Indemnifying
Party will have the financial resources to defend against the Third-Party Claim and fulfill its indemnification obligations hereunder,
(iii) the Third-Party Claim involves only money damages and does not seek an injunction or other equitable relief and (iv) the
Indemnifying Party conducts the defense of the Third-Party Claim actively and diligently. The Indemnifying Party will keep the Indemnified
Party apprised of all material developments, including settlement offers, with respect to the Third-Party Claim and permit the Indemnified
Party to participate in the defense of the Third-Party Claim. So long as the Indemnifying Party is conducting the defense of the Third-Party
Claim in accordance with this Section 9.08(a)(b), the Indemnifying Party will not be responsible for any attorneys’
fees or other expenses incurred by the Indemnified Party regarding the Third-Party Claim.

 

(c)            In
the event that the Indemnifying Party assumes the defense of a Third- Party Claim in accordance with Section 9.07(b) above,
the Indemnified Party may retain separate counsel and participate in the defense of the Third-Party Claim, but the fees and expenses
of such counsel shall be at the expense of the Indemnified Party, unless the Indemnified Party shall reasonably determine that there
is a material conflict of interest between or among the Indemnified Party and the Indemnifying Party with respect to such Third-Party
Claim, in which case the reasonable fees and expenses of such counsel will be borne by the Indemnifying Party.

 

(d)            In
the event that the Indemnifying Party fails or elects not to assume the defense of a Third-Party Claim that the Indemnifying Party had
the right to assume under Section 9.07(b) above, the Indemnified Party shall have the right to undertake and control
the defense of such Third-Party Claim subject to Section 9.08(a); provided, however, that in the event the
Indemnifying Party fails to consent to the entry of any judgment or enter into any settlement with respect to such Third-Party Claim,
the Indemnifying Party shall be obligated to further indemnify the Indemnified Party for the incremental fees and expenses in excess
of those related to the compromise or settlement amount incurred by the Indemnified Party.

 

(e)            Neither
the Indemnified Party nor the Indemnifying Party will consent to the entry of any judgment or enter into any settlement with respect
to the Third-Party Claim without the prior written consent of the other party, which consent will not be unreasonably withheld or delayed.

 

    58 

     

    

 

(f)            Except
as otherwise provided herein or with respect to fraud or for specific performance, Buyer, for itself and on behalf of the other Buyer
Related Parties (including, after the Closing, the Relevant Entities) hereby acknowledges and covenants and agrees that, from and after
the Closing, the Buyer Related Parties’ sole and exclusive remedy with respect to any and all claims arising under or relating
(directly or indirectly) to this Agreement, the subject matter of this Agreement, any Exhibit or Disclosure Schedule hereto, or
any ancillary agreement, certificate or other document entered into, made, delivered or made available in connection herewith, or the
transactions contemplated hereby or thereby (the “Potential Claim Matters”), regardless of the legal theory under
which any liability or obligation may be sought to be imposed, whether sounding in contract, tort, statute or otherwise, and whether
at Law, in equity or otherwise, will be as set forth in this Article IX.

 

9.9           Determination
of Indemnification Amounts. After the giving notice of any claim for indemnification, the amount of indemnification to which an Indemnified
Party shall be entitled under this Article IX shall be determined: (i) by the written agreement between the Indemnified
Party and the Indemnifying Party; (ii) by a final judgment or decree of the arbitrator or arbitration tribunal, or court of competent
jurisdiction, as applicable; or (iii) by any other means to which the Indemnified Party and the Indemnifying Party shall mutually
agree in writing. The judgment or decree of a court shall be deemed final when the time for appeal, if any, shall have expired and no
appeal shall have been taken or when all appeals taken shall have been finally determined.

 

9.10         Other
Indemnification Matters. All indemnification payments under this Article IX will, to the extent permitted by Law, be
deemed adjustments to the Final Purchase Price to the maximum extent permitted by applicable Law. Neither Buyer nor the Sellers shall
take any position on any Tax Return, or before any Governmental Body, that is inconsistent with such treatment unless otherwise required
by any Law. For purposes of determining whether there has been any misrepresentation or breach of a representation or warranty, and for
purposes of determining the amount of Adverse Consequences resulting therefrom, all qualifications or exceptions in any representation
or warranty relating to or referring to the terms “material”, “materiality”, “in all material respects”,
 “Material Adverse Effect” or any similar term or phrase shall be disregarded (other than with respect to Section 4.06)
or Section 4.09(c), it being the understanding of the Parties that for purposes of determining liability under this Article IX
the representations and warranties of the Parties contained in this Agreement shall be read as if such terms and phrases were not
included in them.

 

    59 

     

    

 

ARTICLE X

 

ADDITIONAL COVENANTS AND AGREEMENTS

 

10.1            Tax
Matters

 

(a)            Responsibility
for Filing Tax Returns. The Seller’s Representative shall, at its expense, prepare, or cause to be prepared, and file, or cause
to be filed, on a timely basis all Tax Returns due before the Closing Date and all Pass-Through Tax Returns with respect to the
Relevant Entities for taxable periods ending on or prior to the Closing Date which are first due (taking into account any applicable
extensions) to be filed after the Closing Date (a “Seller Return”). Buyer shall prepare, or cause to be prepared,
and file, or cause to be filed, on a timely basis all Pass-Through Tax Returns required to be filed for the Relevant Entities for a Straddle
Period, (collectively the “Buyer Return”). The Seller Returns and Buyer Returns are hereinafter referred to as “Applicable
Tax Returns”. At least thirty (30) days prior to the date on which such Applicable Tax Return is required to be filed (taking into
consideration applicable extensions), the Party preparing such Applicable Tax Returns (the “Preparing Party”) shall
provide a copy of such Applicable Tax Return to the other Party (the “Reviewing Party”) for its review, comment and
approval (not to be unreasonably withheld, conditioned or delayed); provided, however, if such Applicable Tax Return is required to be
filed within ninety (90) days following the Closing Date or end of the relevant taxable period, the Preparing Party will provide a copy
of such Tax Applicable Tax Return to the Reviewing Party as soon as commercially reasonable. The Reviewing Party shall provide any comments
to such Applicable Tax Returns within fifteen (15) days after the delivery of such Applicable Tax Returns. In connection with the Reviewing
Party’s review, the Preparing Party will provide or cause to be provided promptly to the Reviewing Party any information reasonably
requested by the Reviewing Party. If the Reviewing Party submits comments to the Preparing Party within such review period, the Preparing
Party shall consider in good faith and incorporate any reasonable comments from the Reviewing Party. If the Reviewing Party does not
submit comments within such review period, then the Reviewing Party will be deemed to have approved such Tax Returns.

 

(b)            Straddle
Period Allocation. To the extent permitted by law, the Relevant Entities shall adopt the interim closing of the books method for
the taxable year including the Closing Date. To the extent it is necessary for purposes of this Agreement to determine the allocation
of Taxes among a Straddle Period, the amount of any Taxes based on or measured by income, receipts, payroll or sales of the Relevant
Entities for the portion of the Straddle Period ending on the Closing Date will be determined based on an interim closing of the books
as of the close of business on the Closing Date (and for such purpose, the taxable period of the Company and of any partnership or other
pass through entity in which the Company holds a beneficial interest will be deemed to terminate at such time) and the amount of other
Taxes of the Relevant Entities for the portion of the Straddle Period ending on the Closing Date will be deemed to be the amount of such
Tax for the entire taxable period multiplied by a fraction, the numerator of which is the number of days in the taxable period ending
on the Closing Date and the denominator of which is the number of days in such Straddle Period.

 

(c)            Transaction
Tax Deductions. For all Tax purposes (including for purposes of determining the amount of income Taxes taken into account in the
calculation of Indebtedness, as finally determined), any and all deductions for (i) expenses with respect to the Indebtedness being
paid by or on behalf of Seller or the Acquired Companies in connection with the Closing, and (ii) all Seller Transaction Expenses
being paid by or on behalf of Seller or the Relevant Entities prior to or in connection with the Closing (such deduction described in
clauses (i) and (ii), the “Transaction Tax Deductions”) shall, to the extent at least “more
likely than not” permitted by applicable Law to be deducted in the Pre-Closing Tax Period, be treated for income Tax purposes as
having been incurred by Seller or the Acquired Companies in, and reflected as a deduction on the income Tax Returns of Seller or the
Acquired Companies for, the Pre-Closing Tax Period. The Parties agree that, to the extent permitted by applicable Law, the Acquired Companies
shall elect to apply the safe harbor pursuant to Revenue Procedure 2011-29, 2011-18 IRB with respect to the deduction of any Seller Transaction
Expenses which constitute success-based fees and any such deductions shall be included in the calculation of Transaction Tax Deductions.

 

    60 

     

    

 

(d)            Books
and Records; Cooperation. Seller, the Relevant Entities and Buyer shall reasonably cooperate, and shall cause their respective representatives
to reasonably cooperate, in preparing and filing all Tax Returns, including maintaining and making available to each other all records
necessary in connection with Taxes and in resolving all audits, examinations or other disputes with Tax authorities for all Pre-Closing
Tax Periods. Buyer and Seller recognize that Seller may need access, from time to time, after the Closing Date, to certain Tax records
and information held by the Relevant Entities to the extent pertaining to events occurring prior to the Closing Date; therefore, Buyer
agrees that from and after the Closing Date, Buyer shall, and shall cause the Relevant Entities and their Affiliates and successors to,
(i) retain and maintain such Tax records and information for three (3) years and (ii) for purposes of permitting Seller
to prepare any Tax Return to prepare any Tax Return in accordance with Section 10.01(a) and allow Seller (upon its request
and its sole cost) to inspect, review and make copies of such Tax records and the Company’s information as Seller or its representatives
may deem necessary or appropriate from time to time consistent with such purpose.

 

(e)            Transfer
Taxes. Buyer will pay all of any real property transfer tax, stamp tax, stock transfer tax, or other similar Tax imposed on any Relevant
Entity or Seller as a result of the transactions contemplated by this Agreement (collectively, “Transfer Taxes”).
The party required by applicable Law will, at its own expense, file all Tax Returns and other documentation with respect to all such
Transfer Taxes, and the parties agree to cooperate in the filing of any returns with respect to the Transfer Taxes, including promptly
supplying any information in their possession that is reasonably necessary to complete such returns.

 

(f)            Amended
Tax Returns; Tax Elections. Without the prior written consent of Seller’s Representative, which shall not be unreasonably withheld,
delayed or conditioned, Buyer will not cause or permit any Relevant Entity to (i) except as required by applicable Law, file, amend
or otherwise modify any Tax Return that relates in whole or in part to any Pre-Closing Tax Period (other than to file Tax Returns in
accordance with Section 10.01(b)), (ii) make or change any election for, or that has retroactive effect to, any Pre-
Closing Tax Period, (iii) settle, voluntarily approach, enter into voluntary disclosure agreement with, or file any ruling request
with any Tax authority with respect to any Pre- Closing Tax Period or Taxes attributable to a Pre-Closing Tax Period or (iv) extend
or waive the statute of limitations with respect to any Pre-Closing Tax Period, in each case, solely to the extent such action could
reasonably be expected to adversely impact the Seller or its beneficial owners.

 

    61 

     

    

 

(g)            Tax
Refunds. Until the date that is three (3) years following the Closing Date, Seller shall be entitled to any Tax refunds plus
any interest that are received by Buyer or any Relevant Entity that relate to any Pre-Closing Tax Period (“Tax Refunds”).
Buyer will pay over to Seller any such Tax Refund (as determined pursuant to the last sentence hereof) within five (5) days after
actual receipt of such Tax Refund. If requested by Seller, Buyer will cause the Relevant Entity to request a refund (rather than a credit
in lieu of refund) with respect to all Pre-Closing Tax Periods, at Seller’s expense. Seller shall not be entitled to and Buyer
shall not be obligated pay over any such Tax Refund that relates to (A) the carryback of any deductions, losses, credits
or other items from any Tax period (or portion thereof) beginning after the Closing Date, or (B) with respect to Taxes paid after
the Closing, the amount of any Tax refunds payable to Seller under this Section 10.01(g) shall be net of (i) Taxes
attributable to such refund or credit (such as federal Taxes anticipated to be incurred with respect to refunds or credits of state Taxes),
(ii) reasonable third-party costs incurred after Closing in obtaining such refunds, including Tax Return preparation or filing costs,
to the extent such costs are not separately paid or reimbursed by Seller, and (iii) any Taxes required to be withheld on such payment
to Seller.

 

(h)            Tax
Sharing Agreements. Seller shall cause all Tax sharing and other similar agreements of the Relevant Entities to be terminated prior
to Closing such that after the Closing, none of the Relevant Entities shall be bound thereby or have any liability thereunder.

 

(i)             Intended
Tax Treatment; Allocation of Purchase Price. The Parties agree to treat the purchase, and sale of the Interests under this Agreement
for U.S. federal income Tax purposes (and applicable state and local income Tax purposes as a purchase of an undivided interests in assets
of the Acquired Companies from Seller (the “Intended Tax Treatment”). For applicable income Tax purposes, the Parties
shall allocate the Purchase Price, together with any assumed liabilities, costs, payments and other items required to be treated as “consideration”
or sale proceeds for income Tax purposes (the “Allocable Consideration”) among the assets of the Acquired Companies
in accordance with the provisions of Section 1060 of the Code, the Treasury Regulations promulgated thereunder, and the methodology
set forth on Exhibit F (the “Allocation Methodology”). Within ninety (90) days following the determination
of Final Net Working Capital, in accordance with Section 1.02, the Buyer shall deliver to the Seller’s Representative
a draft allocation schedule of the Allocable Consideration among the assets of the Acquired Companies (the “Allocation Schedule”)
for Seller’s Representative’s review and comment, which Allocation Schedule shall be prepared in accordance with the Allocation
Methodology. If Seller’s Representative does not provide Buyer with comments within thirty (30) days following receipt of such
Allocation Schedule (the “Allocation Review Period”), Seller’s Representative shall be deemed to have accepted
such Allocation Schedule as prepared by the Buyer. If Seller’s Representative raises any objection to such Allocation Schedule
within such Allocation Review Period, the Parties will negotiate in good faith to resolve such objection(s). The Parties agree to file
their respective Tax Returns in accordance with the Allocation Schedule and the Intended Tax Treatment. No Party shall take or permit
others to take on its behalf any position (whether in connection with a Tax audit, a Tax Return, Tax proceeding, or otherwise) that is
inconsistent with the Intended Tax Treatment or Allocation Schedule unless required to do so pursuant to a final “determination”
within the meaning of Section 1313(a) of the Code or other applicable Law.

 

    62 

     

    

 

(j)            Following
the Closing, Buyer and Seller and any of their respective Affiliate shall cooperate and use commercially reasonable efforts to take such
actions as are necessary or reasonably requested to cause Advent Rehabilitation, LLC (“Advent”) (i) to make a valid
 “push-out” election under Section 6226 of the Code and the Treasury Regulations promulgated thereunder (and applicable
state or local income Tax Law) to the extent such election is available with respect to any “imputed underpayment” (as defined
in the Partnership Tax Audit Rules) arising in connection with any Tax audit or other proceeding related to a Pre-Closing Tax Period
of Advent (and to make any similar elections under any provision of applicable state or local Law); and (ii) to make an election
under Section 754 of the Code that is effective for the taxable year including the Closing Date.

 

10.2         Further
Assurances From time to time and subject to the other terms of this Agreement, as and when requested by any Party and at such requesting
Party’s expense, any other Party will execute and deliver, or cause to be executed and delivered, all such documents and instruments
and will take, or cause to be taken, all such further or other actions as may be reasonably required to carry out the provisions hereof
and give effect to the transactions contemplated by this Agreement.

 

ARTICLE XI

 

DEFINITIONS

 

11.1         Definitions.
For purposes hereof, the following terms, when used herein with initial capital letters, will have the respective meanings set forth
below:

 

“Accounting Expert”
has the meaning set forth in Section 1.02(d).

 

“Acquired Companies”
has the meaning set forth in the Recitals. “Action” has the meaning set forth in Section 4.12.

 

“Adjustment Escrow
Account” means the account established by the Escrow Agent pursuant to the terms of the Escrow Agreement.

 

“Adjustment Escrow Amount”
means $1,000,000.

 

“Adjustment Escrow
Funds” means, as of any date of determination, the excess (if any) of the Adjustment Escrow Amount (disregarding any interest
accrued on the Escrow Amount), minus the sum of all distributions and other payments to any Person from the Adjustment Escrow Account
paid pursuant to the terms of the Escrow Agreement on or prior to such date of determination.

 

    63 

     

    

 

“Adverse Consequences”
means all actions, suits, proceedings, hearings, investigations, charges, complaints, claims, demands, Orders, dues, penalties, fines,
costs, amounts paid in settlement, liabilities, obligations, Taxes, Liens, losses, damages, deficiencies, costs of investigation, court
costs, and other expenses (including interest, penalties and reasonable attorneys’ fees and expenses).

 

“Affiliate”
of any particular Person means any other Person controlling, controlled by or under common control with such particular Person where
 “control” means the possession, directly or indirectly, of the power to direct the management and policies of a Person whether
through the ownership of voting securities, contract or otherwise.

 

“Agreed Accounting
Principles” means the accounting methods, policies, practices, procedures, classifications, judgments, assumptions and estimation
methodologies set forth on Schedule 10.01(a), in each case calculated in accordance with GAAP and applied in a manner consistent
with the methods used in preparing the Latest Balance Sheet.

 

“Agreement” has the meaning set forth in
the preamble to this Agreement.

 

“Allocable Consideration” has the meaning
set forth in Section 10.01(i).

 

“Allocation Methodology” has the meaning
set forth in Section 10.01(i).

 

“Allocation Review Period” has the meaning
set forth in Section 10.01(i).

 

“Allocation Schedule” has the meaning set
forth in Section 10.01(i).

 

“APTG” has the meaning set forth in the
Recitals.

 

“Beneficiary Inducement
Statute” means 42 U.S.C. § 1320a-7a(a)(5) and its respective implementing regulations.

 

“Business Day”
means any day other than a Saturday or a Sunday or a weekday on which banks in Chicago, Illinois, are authorized or required to
be closed.

 

“Business Systems”
means all Software, websites, applications (including mobile applications), computer hardware (whether general or special purpose), servers,
electronic data processing, networks, interfaces, platforms, peripherals and computer systems, and all other information technology equipment,
in each case, that are used, owned or controlled by the Relevant Entities in the conduct of their business.

 

“Buyer” has the meaning set forth in the
preamble to this Agreement.

 

“Buyer Benefit Plan” has the meaning set
forth in Section 7.06(b).

 

    64 

     

    

 

“Buyer Fundamental
Representations” means the representations and warranties set forth in Sections 5.01, 5.02, 5.03(a), 5.05
and 5.08.

 

“Buyer Related Parties” has the meaning
set forth in Section 8.02(c).

 

“CARES Act”
means the Coronavirus Aid, Relief, and Economic Security Act (H.R. 748), as amended, (or similar provision of U.S. state or local Law)
and the regulations promulgated thereunder.

 

“Cash” means,
as of the Closing (but before taking into account the consummation of the transactions contemplated hereby), all cash (including foreign
currencies), negotiable instruments, checks, money orders, marketable securities, short-term instruments and other cash equivalents,
but excluding any Restricted Cash. For the avoidance of doubt, Cash will be calculated net of issued but uncleared checks and
drafts and outbound wires, whether foreign or domestic, to the extent there has been a reduction of accounts receivable on account thereof
and in accordance with the Accounting Principles but will include checks, other wire transfers, and drafts deposited or available for
deposit for the account of the Company or any Relevant Entity, whether foreign or domestic.

 

“CHIP” means
the children’s health insurance program established under Title XXI of the Social Security Act of 1965, 42 U.S.C. § 1396,
et seq.

 

“Closing” has the meaning set forth in
Section 1.03.

 

“Closing Date” has the meaning set forth
in Section 1.03.

 

“Closing Effective Time” has the meaning
set forth in Section 1.03.

 

“Closing Statement” has the meaning set
forth in Section 1.02(c).

 

“CMS Advance Payments”
means those certain cash payments received by Relevant Entities in connection with the Medicare Accelerated and Advance Payment Program
implemented by The Centers for Medicare & Medicaid Services (CMS).

 

“Code” means the Internal Revenue Code
of 1986, as amended.

 

“Commitment Letters” has the meaning set
forth in Section 5.07(b).

 

“Company” has the meaning set forth in
the preamble to this Agreement.

 

“Company Employees” has the meaning set
forth in Section 7.06(a).

 

“Company Intellectual
Property” means all Owned Intellectual Property and all Intellectual Property used or held for use in connection with, or otherwise
necessary for, conducting the business of the Company.

 

    65 

     

    

 

“Company’s Knowledge”
or “Knowledge of the Company” means the current, actual knowledge of Jonathan Fennell, Richard Leaver, Daniel Shockley,
and Tiffany Warden after reasonable inquiry.

 

“Company Name” has the meaning set forth
in Section 12.01(b).

 

“Confidentiality Agreement” has the meaning
set forth in Section 8.02.

 

“Contract”
means any written or oral agreement, contract, indenture, deed of trust, note, bond, mortgage, lease, sublease, license, guarantee, commitment,
Permit, loan or credit agreement, indenture, purchase order, or other agreement, instrument, concession, franchise or license, including,
without limitation, employment agreements, independent contractor or consulting agreements, staffing company contracts, customer contracts
and customer orders, or other legally binding arrangement or understanding.

 

“Coronavirus Pandemic”
means, as declared by the World Health Organization on March 11, 2020, the 2020 Coronavirus Pandemic caused by COVID-19.

 

“Counsel” means McGuireWoods LLP.

 

“COVID-19”
means the severe acute respiratory syndrome coronavirus (SARS- CoV-2) also known as the novel coronavirus, and the disease caused thereby,
COVID-19, including any mutation or variation thereof.

 

“D&O Indemnified Person” has the meaning
set forth in Section 7.02(a).

 

“D&O Indemnity
Excluded Persons” means the Institutional Holders and any of their Affiliates, partners, employees, directors, officers or
service providers.

 

“D&O Premium Cap” has the meaning set
forth in Section 7.02(a).

 

“Data Security Requirements”
means, to the extent applicable to a Relevant Entity, (a) any Laws regulating the Processing of Personal Information, including,
without limitation, to the extent applicable to a Relevant Entity, HIPAA (as hereinafter defined), 42 C.F.R. Part 2, the California
Consumer Privacy Act and any implementing regulations therein, the Gramm-Leach- Bliley Act, the Fair Credit Reporting Act, the Controlling
the Assault of Non-Solicited Pornography And Marketing Act of 2003, all Laws related to online privacy policies, the Telephone Consumer
Protection Act, the Illinois Biometric Information Privacy Act, and all Laws related to data breach notification (collectively, the “Privacy
Laws”); (b) all industry standards relating to the Processing of Protected Data that are binding upon a Relevant Entity,
including, to the extent applicable to such Relevant Entity, the Payment Card Industry Data Security Standard issued by the PCI Security
Standards Council, as it may be amended from time to time, and the related payment card brand rules; (c) all Contracts between any
Relevant Entity and any Person that are applicable to the Processing of Protected Data; (d) all binding policies and procedures
relating to the Processing of Protected Data, including without limitation all website and mobile application privacy policies and internal
information security procedures; and (e) the Digital Advertising Alliance’s Self-Regulatory Principles for Online Behavioral
Advertising.

 

    66 

     

    

 

“Debt Commitment Letters” has the meaning
set forth in Section 5.07(b).

 

“Debt Financing” has the meaning set forth
in Section 5.07(b).

 

“Disclosure Schedules”
means the disclosure schedules delivered by the Parties on the date hereof.

 

“Disputed Items” has the meaning set forth
in Section 1.02(d).

 

“Electronic Delivery” has the meaning set
forth in Section 12.16.

 

“Employment Laws” has the meaning set forth
in Section 4.18(c).

 

“End Date” has the meaning set forth in
Section 8.01(d).

 

“Enterprise Value” means $135,000,000.

 

“Environmental Laws”
means all Laws concerning pollution, protection of the environment, or human health and safety (as it relates to Hazardous Substances),
including all those relating to the generation, handling, transportation, treatment, storage, disposal, distribution, labeling, discharge,
release, threatened release, control, or cleanup of, or exposure to, any Hazardous Substances, as such of the foregoing are promulgated
and in effect on or prior to the Closing Date.

 

“Environmental Permits”
has the meaning set forth in Section 4.16(b).

 

“Equity Commitment
Letter” has the meaning set forth in the recitals to this Agreement.

 

“Equity Financing”
has the meaning set forth in the recitals to this Agreement.

 

“Equity Securities”
means with respect to any Person, all (i) units, capital stock, partnership interests or other equity interests (including classes,
groups or series thereof having such relative rights, powers, and/or obligations as may from time to time be established by the issuer
thereof or the governing body of its Affiliate, as the case may be, including rights, powers, and/or duties different from, senior to
or more favorable than existing classes, groups and series of units, stock and other equity interests and including any so-called “profits
interests”) or securities or agreements providing for profit participation features, equity appreciation rights, phantom equity
or similar rights to participate in profits, (ii) warrants, options or other rights to purchase or otherwise acquire, or contracts
or commitments that contain requirements for the issuance of, securities described in the foregoing clauses of this definition, and (iii) other
securities or interests convertible or exchangeable into securities described in the foregoing clauses of this definition.

 

“ERISA” has the meaning set forth in Section 4.13(a).

 

“Escrow Agent” means Citibank, N.A.

 

    67 

     

    

 

“Escrow Agreement”
means an Escrow Agreement, in mutually agreeable form, to be entered into by Buyer, Seller, and the Escrow Agent.

 

“Escrow Amount”
means the sum of the Indemnity Escrow Amount and the Adjustment Escrow Amount.

 

“Estimated Cash” has
the meaning set forth in Section 1.02(b).

 

“Estimated Closing Statement”
has the meaning set forth in Section 1.02(b).

 

“Estimated Indebtedness”
has the meaning set forth in Section 1.02(b).

 

“Estimated Net Working Capital”
has the meaning set forth in Section 1.02(b).

 

“Estimated Net Working
Capital Deficit” means the amount of the excess of the Net Working Capital Target over Estimated Net Working Capital, if any.

 

“Estimated Net Working
Capital Excess” means the amount of the excess of Estimated Net Working Capital over the Net Working Capital Target, if any.

 

“Estimated Purchase
Price” has the meaning set forth in Section 1.02(a).

 

“Estimated Seller
Transaction Expenses” has the meaning set forth in Section 1.02(b).

 

“Expense Fund Amount”
means $200,000.

 

“Federal Anti-Kickback
Statute” means 42 U.S.C. § 1320a-7b(b) and its implementing regulations.

 

“Federal Civil Monetary
Penalty Provisions” means 42 U.S.C. § 1320a-7a, 31 U.S.C. § 3801 and their respective implementing regulations.

 

“Federal False Claims
Act” means 42 U.S.C. §§ 3729 et seq. and their implementing regulations.

 

“Federal Physician
Self-Referral Law” means 42 U.S.C. §§ 1395nn et seq. and their implementing regulations.

 

“Final Cash” has the
meaning set forth in Section 1.02(c).

 

“Final Indebtedness”
has the meaning set forth in Section 1.02(c).

 

“Final Net Working Capital”
has the meaning set forth in Section 1.02(c).

 

“Final Net Working
Capital Deficit” means the amount of the excess of the Net Working Capital Target over Final Net Working Capital, if any.

 

    68 

     

    

 

“Final Net Working
Capital Excess” means the amount of the excess of Final Net Working Capital over the Net Working Capital Target, if any.

 

“Final Purchase Price”
means an amount equal to (i) the Enterprise Value, plus (ii) the Final Cash, minus (iii) the Final Indebtedness,
minus (iv) the Final Seller Transaction Expenses, plus (v) the Final Net Working Capital Excess, if any, minus
(vi) the Final Net Working Capital Deficit, if any, minus (vii) the Escrow Amount, (viii) minus the
Expense Fund Amount.

 

“Final Seller Transaction
Expenses” has the meaning set forth in Section 1.02(c).

 

“Financial Statements”
has the meaning set forth in Section 4.05.

 

“Financings” has the meaning set forth
in Section 4.05.

 

“GAAP” means
United States generally accepted accounting principles as in effect on the date hereof.

 

“Government Healthcare
Program” means any “federal health care program” as defined in 42 U.S.C. §1320a-7b(f), including Medicare,
Medicaid, CHAMPUS, state CHIP programs, TriCare and all other similar or successor healthcare reimbursement programs with or for the
Company’s benefit of any Governmental Body of the United States or any state, territory or locality thereof.

 

“Governmental Body”
means any federal, state, local, municipal, foreign or other government or quasi-governmental authority or any department, agency, commission,
board, subdivision, bureau, agency, instrumentality, court or other tribunal of any of the foregoing.

 

“Hazardous Substance”
means any materials, substances or wastes for which liability or standards of conduct may be imposed pursuant to any Environmental Law,
including petroleum products or byproducts, per- and polyfluoroalkyl substances, asbestos, polychlorinated biphenyls, noise, odor, mold,
radiation or any hazardous substance as defined in CERCLA.

 

“Healthcare Laws”
means any Law or Order relating to the regulation of the healthcare industry, healthcare providers, healthcare facilities, participation
in Third Party Payor Programs, the practice of physical therapy, the practice of occupational therapy, the practice of speech therapy,
institutional and professional licensure, direct or one-on-one therapy compliance requirements, the securing, administering and dispensing
of devices and durable medical equipment, medical documentation, medical record retention, unprofessional conduct, fee- splitting, referrals,
patient brokering, kickbacks, billing and submission of false or fraudulent claims, “out of network” billing and “surprise”
medical bills, workers’ compensation, claims processing, quality, safety, medical necessity, medical privacy and security, patient
confidentiality and informed consent, the hiring of employees or acquisition of services or supplies from Persons excluded from participation
in Government Healthcare Programs, standards of care, quality assurance, risk management, utilization review, mandated reporting of incidents,
occurrences, diseases and events, advertising or marketing of healthcare services, and the enforceability of restrictive covenants on
healthcare providers, to the extent applicable to any Relevant Entity, including, without limitation: (a) any Law or regulations
relating to Government Healthcare Programs, or payments or reimbursement therefrom; (b) HIPAA; (c) all Laws or regulations
relating to health care fraud and abuse, including, but not limited to, the Federal Civil Monetary Penalty Provisions, the Federal False
Claims Act, the Federal Anti-Kickback Statute, the Program Fraud Civil Remedies Act of 1986, the Beneficiary Inducement Statute, the
Federal Physician Self- Referral Law and mail/wire fraud, and, to the extent applicable, their respective state Law counterparts; (d) quality,
safety and medical necessity Laws relating to the regulation, provision or administration of, or payment for, healthcare products or
services; (e) Laws relating to the regulation of the corporate practice of physical therapy or any other learned or licensed profession;
and (f) in respect of the Licensed Personnel, Laws or regulations relating to any Healthcare Licenses that are required to be obtained
or maintained by such Licensed Personnel in connection with the services provided by such Licensed Personnel on behalf of the Relevant
Entities.

 

    69 

     

    

 

“Healthcare Licenses”
means all Permits issued or granted by any healthcare regulatory agency or other Governmental Body to individuals in relation to the
provision of healthcare items or services.

 

“HIPAA”
means the Health Insurance Portability and Accountability Act of 1996, the health information privacy and security provisions of the
Health Information Technology for Economic and Clinical Health Act, and the regulations and other guidance issued thereunder, including
but not limited to the Privacy, Security, Breach Notification, and Enforcement Rules at 45 C.F.R. Parts 160 through 164.

 

“HSR Act”
means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

 

“Indebtedness”
means the principal amount, plus any related accrued and unpaid interest, fees, prepayment premiums or penalties of (i) all indebtedness
for borrowed money of or in respect of advances to any Relevant Entity; (ii) all obligations of the Company or the Relevant Entities
(including related party obligations) under any credit facility, or evidenced by any note, debenture or other debt security; (iii) all
indebtedness in respect of unpaid severance or deferred compensation obligations (in each case, to the extent such amounts are accrued
as of the Closing), together with the employer portion of any employment, payroll and other Taxes incurred in respect of such obligations;
(iv) all obligations owed under any capital leases; (v) any CMS Advance Payments; (vi) any outstanding commitment by which
the Company or any Relevant Entity has assured a creditor against a loss (including all outstanding reimbursement obligations as an account
party or applicant in respect of letters of credit, but without duplication of any such amount included in Restricted Cash); (vii) all
obligations arising from cash/book overdrafts; (viii) all guaranties, endorsements, assumptions and other contingent obligations
in respect of, or to purchase or to otherwise acquire, indebtedness for borrowed money of third parties the repayment of which is guaranteed
(directly or indirectly) by the Company or the Relevant Entities; (ix) all obligations in respect of deferred purchase price of
property, assets or services purchased (including earn-outs or seller notes for the maximum amount payable); (x) all guaranteed
payments, dividends or other distributions due or declared to the members or other holders of equity interests of the Company; (xi) the
employer’s share of payroll Taxes to the extent payable by any Relevant Entity and attributable to any payments made in connection,
in whole or in part, with the transactions contemplated by this Agreement and any amounts payable to gross-up or make whole any Person
for income or excise Taxes imposed with respect to such amounts; (xii) Pre-Closing Taxes; (xiii) refunds, overpayments or other
amounts owed to patients, customers, and Third Party Payor Programs outside of the ordinary course of business; and (xiv) all fees,
expenses, premiums, penalties, breakage costs, change of control payments or make-whole payments directly resulting from any of the foregoing.
Notwithstanding the foregoing, Indebtedness does not include Seller Transaction Expenses, or any current liabilities of the Relevant
Entities included in the definition of Net Working Capital, calculated in accordance with the Agreed Accounting Principles.

 

    70 

     

    

 

“Indemnified Party” has the meaning set
forth in Section 9.03(a).

 

“Indemnifying Party” has the meaning set
forth in Section 9.03(a).

 

“Indemnity Escrow Account” means Section 9.03.

 

“Indemnity Escrow Amount” means $10,125,000.

 

“Indemnity Escrow Funds” has the meaning
set forth in Section 9.03.

 

“Institutional Holders”
means GPB Capital Holdings, LLC and the investment funds and vehicles controlled thereby. The Institutional Holders are intended third
party beneficiaries of each and every provision of this Agreement that references them by name.

 

“Intellectual Property”
means all rights to any and all of the following in any jurisdiction throughout the world: (i) patents, industrial designs, and
utility models, and any applications for any of the foregoing; (ii) trademarks, service marks, certification marks, trade names,
trade dress, logos, slogans, tag lines, fictitious business names (d/b/a’s), internet domain names, social media accounts, websites,
and all other source or business identifiers or designators of origin (all whether registered or unregistered); all applications and
registrations for any of the foregoing; all renewals and extensions for any of the foregoing; and all common Law rights in and goodwill
associated with any of the foregoing (collectively, “Trademarks”); (iii) works of authorship, copyrights, mask
work rights, database rights, and design rights (all whether registered or unregistered); applications and registrations for any of the
foregoing; all renewals and extensions for any of the foregoing; all moral rights associated with any of the foregoing; and all economic
rights of authors and inventors, however denominated, associated with any of the foregoing; (iv) computer software, databases, source
code, object code, development tools, comments, user interfaces, menus, buttons, and icons; all files, data, scripts, application programming
interfaces, manuals, design notes, programmers’ notes, architecture, algorithms, and other items and documentation related to or
associated with any of the foregoing; any derivative works, foreign language versions, fixes, upgrades, updates, enhancements, new versions,
previous versions, new releases, and previous releases of any of the foregoing; and all media and other tangible property necessary for
the delivery or transfer of any of the foregoing (collectively, “Software”); (v) proprietary information, confidential
information, and trade secrets, including inventions (whether or not patentable), invention disclosures, ideas, developments, improvements,
know-how, designs, drawings, algorithms, source code, methods, processes, techniques, formulae, research and development, compilations,
compositions, manufacturing processes, production processes, devices, data, specifications, reports, analyses, data analytics, customer
lists, supplier lists, pricing information, cost information, business plans, business proposals, marketing plans, and marketing proposals;
(vi) any rights recognized under applicable Law in or that are equivalent or similar to any of the foregoing.

 

    71 

     

    

 

“Interests”
has the meaning set forth in the recitals to this Agreement.

 

“Interim Period”
has the meaning set forth in Section 6.01(a).

 

“Latest Balance Sheet”
has the meaning set forth in Section 4.05.

 

“Law” means
any federal, state, local, municipal, foreign, international, multinational or other constitution, statute, law, rule, regulation, legally-binding
policy or manual, ordinance, code, principle of common law or treaty.

 

“Leased Real Property” has the meaning
set forth in Section 4.07(b).

 

“Leases” has the meaning set forth in Section 4.07(b).

 

“Liability”
means any actual or potential liability or obligation (including as related to Taxes), whether known or unknown, asserted or unasserted,
foreseen or unforeseen, absolute or contingent, accrued or unaccrued, liquidated or unliquidated and whether due or to become due, regardless
of when asserted.

 

“Licensed Personnel”
means any individual Person who: (a) is employed by, or is an independent contract of, any Relevant Entity; and (b) is required
by applicable Laws or regulations to hold a Healthcare License in connection with her/his profession or the services she/he provides
to, for or on behalf of any Relevant Entity within the scope of her/his employment or engagement thereby.

 

“Liens”
means any lien, license, mortgage, security interest, pledge deposit or other encumbrance.

 

“Malicious Code”
means any (i) back door, time bomb, drop dead device, or other Software routine designed to disable a computer program automatically
with the passage of time or under the positive control of a Person other than the user of the program; (ii) virus, Trojan horse,
worm, or other Software routine or hardware component designed to permit unauthorized access, to disable, erase, or otherwise harm Software,
hardware, or data; and (iii) similar program.

 

“Managed Practice”
or “Managed Practices” has the meaning set forth in the recitals to this Agreement.

 

“Management Services
Agreement” means an agreement between a Managed Practice and APTG, pursuant to which APTG provides management services to the
Managed Practice for its operations at one or more healthcare facilities.

 

    72 

     

    

 

“Material Adverse
Effect” means any event, occurrence, or development that has a material adverse effect upon the financial condition or operating
results of the Relevant Entities taken as a whole, except any adverse effect related to or resulting from, in each case other than to
the extent disproportionately affecting the Relevant Entities taken as a whole when compared to other similarly situated businesses in
the industry in which the Company operates, (i) general business or economic conditions affecting the industry in which any Relevant
Entity operates or the economy of the United States generally, including changes in the credit, debt, capital or financial markets (including
changes in interest or exchange rates) or the economy of any region or country in which any Relevant Entity conducts business, (ii) national
or international political or social conditions, including the engagement by the United States in hostilities or the escalation thereof,
whether or not pursuant to the declaration of a national emergency or war, or the occurrence or the escalation of any military or terrorist
attack upon the United States, or any of its territories, possessions, or diplomatic or consular offices or upon any military installation,
equipment or personnel of the United States, (iii) an act of god, disaster, emergency, calamity, epidemic, pandemic (including the
Coronavirus Pandemic), disease outbreak (including COVID-19) or other health crisis, public health event or the worsening of any of the
foregoing or a party’s response thereto, including any Law, directive, pronouncement or guideline issued by a Governmental Body
providing for business closures, travel restrictions, “shelter in place” or other restrictions that relate to, or arise out
of an epidemic, pandemic or disease outbreak, or any loss of customers, suppliers, orders or contracts or other effect on the businesses
of the Relevant Entities in connection with an actual or threatened epidemics, pandemics or disease outbreaks, (iv) financial, banking,
or securities markets (including any disruption thereof and any decline in the price of any security or any market index), (v) changes
in GAAP or the interpretation thereof, (vi) changes in Laws, rules, regulations, Orders, or other binding directives issued by any
Governmental Body, (vii) the taking of any action requested by Buyer or otherwise contemplated by this Agreement or the other agreements
contemplated hereby or the identity of Buyer or the announcement of this Agreement, the other agreements contemplated hereby or the transactions
contemplated hereby or thereby, including the effects of the transactions contemplated hereby or thereby on relationships with customers,
suppliers, Governmental Bodies, employees, or other third-party relationships, (viii) any matter set forth in the Disclosure Schedules,
(ix) any adverse change in or effect on the business of the Relevant Entities that is cured by or on behalf of the Relevant Entities
before the earlier of the Closing Date and the date on which this Agreement is terminated pursuant to Section 8.01, (x) any
adverse change in or effect on the business of the Relevant Entities that is caused by any delay in consummating the Closing in accordance
with Section 1.03 as a result of any violation or breach by Buyer of any covenant, agreement, representation or warranty
contained in this Agreement that has prevented the satisfaction of any condition to the obligations of the Company at the Closing, or
(xi) any failure of the Relevant Entities to meet projections, forecasts or revenue or earning predictions for any period (provided
that the underlying causes of such failure may, to the extent applicable, be considered in determining whether there has been a Material
Adverse Effect).

 

“Material Contract” or “Material
Contracts” has the meaning set forth in Section 4.09(b).

 

“Material Payor” has the meaning set forth
in Section 4.20(h)(i).

 

“Material Supplier” has the meaning set
forth in Section 4.20(h)(ii).

 

“Medicaid” means the medical
assistance program established by Title XIX of the Social Security Act of 1965, 42 U.S.C. § 1396, et seq.

 

    73 

     

    

 

“Medicare”
means the health insurance program for the elderly and disabled established by Title XVIII of the Social Security Act of 1965, 42 U.S.C.
 § 1395, et seq.

 

“Monitor”
means Joseph T. Gardemal III, as independent monitor in that certain action referred to as Securities and Exchange Commission v. GPB
Capital Holdings, LLC, et al. filed in the Eastern District of New York on February 4, 2021 (“SEC v. GPB”).

 

“Monitor Order”
means that certain Order Appointing Monitor, dated February 23, 2021, as amended by that certain Amended Order Appointing Monitor,
dated April 14, 2021, in relation to SEC v. GPB.

 

“Net Adjustment Amount”
means an amount, which may be positive or negative, equal to the Final Purchase Price, as finally determined, minus the Estimated
Purchase Price.

 

“Net Working Capital”
means (i) all current assets (excluding Cash and any current or deferred Tax assets) of the Relevant Entities as of the Closing
Effective Time (but before taking into account the consummation of the transactions contemplated hereby except as set forth in the proviso
below), minus (ii) all current liabilities (excluding any items constituting Indebtedness or otherwise included in Seller
Transaction Expenses and any current or deferred Tax assets) of the Relevant Entities as of the Closing Effective Time (but before taking
into account the consummation of the transactions contemplated hereby except as set forth in the proviso below), in each case using the
same line items set forth on Schedule 10.01(a) and calculated in accordance with the Agreed Accounting Principles. For the
avoidance of doubt, the determination of Net Working Capital and the preparation of the Closing Statement will take into account only
those components (i.e., only those line items) and adjustments reflected on Schedule 10.01(a) and used in calculating the
Net Working Capital Target. Further to the preceding sentence, the determination of Estimated Purchase Price and Final Purchase Price
will be in accordance with the Agreed Accounting Principles (and without any change in or introduction of any new reserves), and without
duplication to any items counted in such determination.

 

“Net Working Capital Target” means $4,800,000.

 

“Objections Statement” has the meaning
set forth in Section 1.02(d).

 

“OIG” means
the Office of the Inspector General of the U.S. Department of Health and Human Services.

 

“Open Source Materials”
means all Software (in source or object code form) licensed under a license commonly referred to as an open source, free software, copyleft
or community source code license (including any library or code licensed under the GNU General Public License, GNU Lesser General Public
License, GNU Affero GPL (AGPL), Apache Software License, or any other public source code license arrangement).

 

“Order”
means any order, injunction, judgment, decree, writ, ruling, award, assessment or arbitration award of any Government Body.

 

“Organizational Documents”
means, with respect to any entity (as applicable), the certificate of incorporation, articles of incorporation, bylaws, partnership agreement,
limited liability company agreement, formation agreement, or other similar organizational documents of such entity (in each case, as
amended through the date of this Agreement).

 

    74 

     

    

 

“Owned Intellectual
Property” means all Intellectual Property owned or purported to be owned by any Relevant Entity.

 

“Owned Software” means all Software that
is Owned Intellectual Property.

 

“Pass-Through Tax
Returns” means any income Tax Return (such as IRS Form 1065 and associated Form K-1s and corresponding state and
local Tax Returns) for a Pre-Closing Tax Period for the Relevant Entities that allocate income, gains, losses, deductions or other Tax
attributes or Taxes to its beneficial owners and does not reflect or concern Taxes that are imposed on the entity itself for which the
Tax Return is filed.

 

“Payroll Tax Executive
Order” means the Presidential Memorandum on Deferring Payroll Tax Obligations in Light of the Ongoing COVID-19 Disaster, as
issued on August 8, 2020 and including any administrative or other guidance published with respect thereto by any Taxing Authority
(including IRS Notice 2020-65 and IRS Notice 2021-11).

 

“Partnership Tax Audit
Rules” means Sections 6221 through 6241 of the Code, together with any guidance issued thereunder or successor provisions and
any similar provision of state or local tax laws.

 

“Pension Plans” has the meaning set forth
in Section 4.13(a).

 

“Permits”
means all licenses, certificates, accreditations, clearances, permits, franchises, approvals, authorizations, registrations, enrollments,
certificates of need, provider or supplier numbers, national provider identifiers, provider agreements, certifications, accreditations,
waivers, consents or Orders of, or filings with, or notifications to, any Governmental Body.

 

“Permitted
Liens” means (i) Liens securing Liabilities that are reflected or reserved against in the consolidated balance sheet
of the Company prepared in accordance with GAAP to the extent so reflected or reserved, (ii) Liens for Taxes or other
governmental charges not yet due and payable by the Company or the amount or validity of which is being contested in good faith by
appropriate proceedings by any Relevant Entity, and, in the case of the foregoing clauses (i) and (ii) with respect to
which appropriate reserves have been established and maintained on the Financial Statements in accordance with GAAP
(iii) landlords’, mechanics’, carriers’, workers’, repairers’ and similar statutory Liens arising
or incurred in the ordinary course of business for amounts that are not yet due and payable and that are not, individually or in the
aggregate, material to the Relevant Entities taken as a whole, (iv) zoning, entitlement, building code and other land use or
regulations imposed by any Governmental Body having jurisdiction over the Leased Real Property, (v) covenants, conditions,
restrictions, easements and other similar matters of record affecting title to the Leased Real Property, (vi) Liens arising
under worker’s compensation, unemployment insurance, social security, retirement and similar legislation, (vii) purchase
money Liens and Liens securing rental payments under capital lease arrangements, (vii) non-exclusive licenses of Intellectual
Property granted by the Relevant Entities in the ordinary course of business,    , and (ix) Liens securing
Indebtedness for borrowed money to be paid off at the Closing.

 

    75 

     

    

 

“Person”
means an individual, a partnership, a corporation, a limited liability company, a trust, an association, a joint stock company, a trust,
a joint venture, an unincorporated organization, a Governmental Body, or other entity.

 

“Personal Information”
means, to the extent regulated by Contract, Law or privacy policy applicable to the Relevant Entities, any data that identifies, relates
to, describes, is reasonably capable of being associated with, or could reasonably be linked, directly or indirectly, with a particular
individual or household, including, to the extent regulated by Contract, Law or privacy policy applicable to the Relevant Entities: protected
health information as defined by HIPAA; patient identifying information as defined by 42 C.F.R. Part 2; name; Social Security number;
government-issued identification numbers; health or medical information, including health insurance information; financial account information;
passport numbers; user names/email addresses in combination with a password or security code that would allow access to an online account;
unique biometric identifiers (e.g., fingerprints, retinal scans, face scans, or DNA profile); employee ID number; date of birth; digital
signature; and Internet Protocol (IP) addresses.

 

“Plans” has the meaning set forth in Section 4.13(a).

 

“Potential Claim Matters” has the meaning
set forth in Section 9.06(b).

 

“Pre-Closing Taxes”
means (a) all unpaid income Taxes (whether or not such Taxes are due and payable as of the Closing Date) of the Relevant Entities
with respect to any Pre-Closing Tax Period (including any income Taxes that any Relevant Entity is required to pay of any equity holder
by means of withholding and filing composite returns), (i) which shall not be an amount less than zero in any jurisdiction or with
respect to any Tax period and (including non- resident withholding or other similar Taxes any Relevant Entity is liable for with respect
to income Taxes of any equity owner) and (ii) which shall not include any offsets or reductions with respect to Tax refunds or overpayments
of Tax, plus (b) any Taxes that any of the Relevant Entities relating to events, transactions or payments made prior to the Closing
Date has deferred under the CARES Act or the Payroll Tax Executive Order.

 

“Pre-Closing Tax Period”
means any taxable period ending on or before the Closing Date and the portion through the end of the Closing Date of any Straddle Period.

 

“PRF Payments” has the meaning set forth
in Section 4.20(j).

 

“Processing”
(including correlative term “Processes”) means the maintenance, transmission, collection, use (including, without
limitation, for the purpose of sending telephone calls, text messages and emails), disclosure, processing, retention, storage, protection,
transfer or disposal of data or information.

 

“Program Fraud Civil
Remedies Act of 1986” means 31 U.S.C. § 3801, et seq. and their implementing regulations.

 

“Projections” has the meaning set forth
in Section 12.13(b).

 

“Protected Data”
means (a) Personal Information, and (b) all data that a Relevant Entity is required by Contract to safeguard and/or keep confidential.

 

    76 

     

    

 

“Reference Date”
means the date that is three (3) years prior to the date hereof (provided such period is not intended to extend any applicable statute
of limitations); provided, however, that for purposes of Section 4.20, Reference Date means the date that is six (6) years
prior to the date hereof (provided such period is not intended to extend any applicable statute of limitations).

 

“Referral Recipient”
means any Person to whom the Relevant Entities or any of their Licensed Personnel refers, recommends or arranges for the referral of
patients or other health care business.

 

“Referral Source”
means any Person in a position to refer, recommend or arrange for the referral of patients or other health care business, including,
any physician, physician practice, surgery center, home health agency, hospital or other health care provider.

 

“Registered Intellectual
Property” means all of the Owned Intellectual Property that is the subject of an application, certificate, filing, registration,
or other document issued by, filed with, or recorded by any Governmental Body, quasi-governmental authority, or registrar.

 

“Related Party” has the meaning set forth
in Section 4.17.

 

“Relevant Entity”
or “Relevant Entities” has the meaning set forth in the Recitals.

 

“Relief Fund Payment
Terms and Conditions” means the Terms and Conditions and related guidance applicable to each PRF Payment received by the Relevant
Entities as of the date hereof.

 

“Required Amount” has the meaning set forth
in Section 5.07(b).

 

“Restricted Cash”
means all cash posted to support reimbursement obligations with respect to letters of credit, performance bonds or other similar obligations
or otherwise subject to any legal or contractual restriction on the ability to freely transfer or use such cash for any lawful purpose,
and cash, escrows, sureties and deposits with third parties (including landlords) of the Relevant Entities, in each case determined in
accordance with GAAP.

 

“Securities Act” means the Securities Act
of 1933, as amended.

 

“Security Breach”
means any (a) security breach of Protected Data under Data Security Requirements, including any unauthorized access, acquisition,
use, exfiltration, or disclosure of Protected Data; or (b) intentional unauthorized interference with system operations or security
safeguards of Business Systems, including any phishing incident or ransomware attack.

 

“Seller” has the meaning set forth in the
preamble to this Agreement.

 

“Seller Fundamental
Representations” means the representations and warranties set forth in Sections 3.01, 3.02, 3.03(a), 3.04,
3.05, 4.01, 4.02, 4.03, 4.04(a), and 4.19.

 

“Seller Return” has the meaning set forth
in Section 10.01(a).

 

    77 

     

    

 

“Seller Transaction
Expenses” means the aggregate fees and expenses of the Relevant Entities relating to the transactions contemplated hereby,
including amounts payable (i) to investment banking, accounting, attorney or other professional fees, including investment banking
services for the Company, (ii) to Counsel for legal services to the Company and Seller, in each case for clause (i) through
(ii) above to the extent unpaid at the time of determination (which, unless otherwise expressly indicated herein, will be the Closing)
and to the extent related to the transactions contemplated hereby, and (iii) in connection with any change in control, transaction
bonus, retention bonus, severance, or similar payments to be made by any Relevant Entity to any current or former employees, directors,
officers, independent contractors, other service providers or any other Person in connection with the transactions contemplated by this
Agreement, and the employer portion of any payroll or similar Taxes associated with the foregoing.

 

“Software” has the meaning set forth in
the definition of Intellectual Property.

 

“Solvent” has the meaning set forth in
Section 5.08.

 

“Straddle Period” means any taxable period
that includes (but does not end on) the Closing Date.

 

“Subsidiary”
means, with respect to any Person, any corporation, partnership, limited liability company, association or other business entity of which
(i) if a corporation, a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any
contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly,
by that Person or one or more of the other Subsidiaries of that Person or a combination thereof, or (ii) if a partnership, limited
liability company, association or other business entity, a majority of the partnership, limited liability company, or other similar ownership
interests thereof is at the time owned or controlled, directly or indirectly, by any Person or one or more Subsidiaries of that Person
or a combination thereof. For purposes hereof, a Person or Persons will be deemed to have a majority ownership interest in a partnership,
limited liability company, association or other business entity if such Person or Persons is allocated a majority of partnership, association
or other business entity gains or losses or otherwise control the managing director, managing member, general partner or other managing
Person of such partnership, limited liability company, association or other business entity. Unless the context requires otherwise, each
reference to a Subsidiary will be deemed to be a reference to a Subsidiary of the Company.

 

“Tail Policy” has the meaning set forth
in Section 12.02.

 

“Tax” or
 “Taxes” means any U.S. federal, state, local or foreign income, gross receipts, capital stock, franchise, profits,
withholding, social security, unemployment, disability, real property, ad valorem, alternative minimum, add-on minimum, personal property
(tangible or intangible), stamp, excise, occupation, sales, use, transfer, value added, alternative minimum, estimated or other tax,
including any interest, penalty or addition to tax or additional amounts thereto, whether disputed or not.

 

“Tax Refund” has the meaning set forth
in Section 10.01(f).

 

    78 

     

    

 

“Tax
Returns” means any declaration, estimate, return, report, information return or other document (including amendments,
schedules or any related or supporting information) filed or required to be filed with any Governmental Body or other authority in connection
with the determination, assessment or collection of any Tax or the administration of any Laws, regulations or administrative requirements
relating to any Tax.

 

“Third Party Payor
Programs” means all Government Healthcare Programs and all other state or local governmental insurance programs and private,
non-governmental medical insurance programs, managed care plans or organizations, health benefit plans, health maintenance organizations,
preferred provider organizations, employer-sponsored health plans, multi-employer welfare trusts, workers’ compensation programs,
third party payors or other payment programs for medical or health care expenses with which the Relevant Entities contract to provide
goods and services or through which the Relevant Entities receive reimbursements for goods and services provided.

 

“Trademarks” has the meaning set forth
in the definition of Intellectual Property.

 

“Transaction Document”
means each of the Escrow Agreement, the Disclosure Schedules, the Equity Commitment Letter, the Debt Commitment Letters, the Guaranty
and each of the other documents, certificates, and instruments to be delivered hereunder or thereunder (including the closing deliverables
contemplated by Sections 2.02 and 2.03).

 

“Transaction Tax Deductions” has the meaning
set forth in Section 10.01(c).

 

“Transfer Taxes” has the meaning set forth
in Section 10.01(d).

 

“Treasury Regulations”
means the regulations promulgated under the Code by the U.S. Department of the Treasury.

 

“TriCare”
means the health care insurance system for United States military service members and their dependents that covers care not available
through the usual United States military medical service or public health service facilities, formerly known as CHAMPUS.

 

“WARN Act”
means the United States Worker Adjustment and Retraining Notification Act and the regulations promulgated thereunder and any similar
state or local Law.

 

“Welfare Plans” has the meaning set forth
in Section 4.13(a).

 

“Willful Breach”
means (a) an action or failure to act by one of the Parties that constitutes a material breach of this Agreement, and such action
was taken or such failure occurred with such party’s knowledge or intention that such action or failure to act could be expected
to constitute a material breach of this Agreement, and such breach (i) resulted in, or contributed to, the failure of any of the
conditions set forth in Section 1.04 to be satisfied or (ii) resulted in, or contributed to, the Closing not being consummated
at the time the Closing would have occurred pursuant to Section 1.03, or (b) the failure of Buyer to deliver at the
Closing the full consideration payable pursuant to Article I under this Agreement.

 

    79 

     

    

 

		11.2	Other
                                            Definitional Provisions.

 

(a)            Accounting
terms that are not otherwise defined in this Agreement have the meanings given to them under GAAP. To the extent that the definition
of an accounting term defined in this Agreement is inconsistent with the meaning of such term under GAAP, the definition set forth in
this Agreement will control.

 

(b)            Any
reference to any particular Code Section or any other Law or regulation will be interpreted to include any revision of or successor
to that section, Law or regulation regardless of how it is named, numbered or classified.

 

(c)            All
references in this Agreement to Exhibits, Disclosure Schedules, Articles, Sections, subsections and other subdivisions refer to the corresponding
Exhibits, Disclosure Schedules, Articles, Sections, subsections and other subdivisions of or to this Agreement unless expressly provided
otherwise. The table of contents and the titles appearing at the beginning of any Articles, Sections, subsections or other subdivisions
of this Agreement and the Exhibits are for convenience only, do not constitute any part of this Agreement or such Exhibit, and will be
disregarded in construing the language hereof.

 

(d)            The
Exhibits and Disclosure Schedules to this Agreement are incorporated herein for all purposes.

 

(e)            The
words “this Agreement,” “herein,” “hereby,” “hereunder” and “hereof,” and
words of similar import, refer to this Agreement as a whole and not to any particular subdivision unless expressly so limited. The words
 “this Article,” “this Section” and “this subsection,” and words of similar import, refer only to
the Article, Section or subsection hereof in which such words occur. The word “or” is exclusive, and the word “including”
(in its various forms) means “including without limitation”.

 

(f)            All
references to “$” and dollars will be deemed to refer to United States currency unless otherwise specifically provided.

 

(g)            Pronouns
in masculine, feminine or neuter genders will be construed to state and include any other gender, and words, terms and titles (including
terms defined herein) in the singular form will be construed to include the plural and vice versa, unless the context otherwise requires.

 

(h)            All
references to days or months will be deemed references to calendar days or months unless otherwise expressly specified.

 

(i)            The
phrase “date hereof” means the date of this Agreement without giving effect to any amendments, modifications or supplements
hereto.

 

(j)            All
references to time will be deemed to be Chicago, Illinois, local time unless otherwise expressly specified.

 

(k)            As
used herein “ordinary course of business” with respect to any Person means the ordinary course of business of such Person
consistent with past practice and custom, as the same may have been adjusted in response to, or otherwise altered because of,
COVID-19 or the Coronavirus Pandemic to the extent required by applicable Law.

 

    80 

     

    

 

ARTICLE XII

 

MISCELLANEOUS

 

12.1         Press
Releases and Communications; Use of Company Name.

 

(a)            No
press release or other public announcement related to this Agreement or the transactions contemplated hereby shall be issued or made
by any Party (nor will any Party permit any of its advisors to do any thereof) without the prior approval of Seller’s Representative
and Buyer, unless required by Law (in the reasonable opinion of counsel) in which case Buyer and Seller will have the right to review
such press release, announcement or communication prior to its issuance, distribution or publication; provided, however,
that the foregoing will not restrict or prohibit Seller, Buyer, Buyer’s Affiliates or any Relevant Entity from making any announcement
to its employees, customers and other business relations to the extent Seller, Buyer or such Relevant Entity reasonably determines in
good faith that such announcement is necessary or advisable after consultation with and the prior written consent of Buyer or Seller,
as applicable, such consent not to be unreasonably withheld. For the avoidance of doubt, the Parties acknowledge and agree that the Institutional
Holders and their Affiliates (except for the Relevant Entities) may provide general information about the subject matter of this Agreement
and the Relevant Entities (including its and their performance and improvements) in connection with the Institutional Holders’
or their Affiliates’ fund raising, marketing, informational or reporting activities.

 

(b)            Effective
as of the Closing Date (and contingent on Closing), Seller shall cease use of, and shall cause its Affiliates and each of their respective
successors and assigns to cease use of the name and related marks and logos of the Relevant Entities (collectively, the “Company
Name”); provided, however, that nothing contained herein will waive or restrict or otherwise limit any rights that Seller or
any of its Affiliates may have under applicable Law to any use of the legal name of the Company that constitutes nominative fair use
or fair use under applicable Law.

 

12.2            Expenses.
Except as otherwise expressly provided herein, each Party will each pay its own expenses (including attorneys’ and accountants’
fees and expenses) in connection with the negotiation of this Agreement, the performance of its obligations hereunder and the consummation
of the transactions contemplated by this Agreement (whether consummated or not). For the avoidance of doubt, the following will be at
the sole cost and expense of Buyer, and neither Seller nor the Company will have any Liability with respect to the following costs: (a) the
costs of the filings of the notification and report forms under the HSR Act in connection with the transactions contemplated hereby (including,
but not limited to, costs incurred in respect of filing fees, diligence, legal fees and other fees, expenses and Taxes related thereto)
and (b) the costs of obtaining a Tail Policy, including the premium for such policy.

 

    81 

     

    

 

12.3         Notices.
All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement will be
in writing and will be deemed to have been given (a) when personally delivered, (b) when transmitted via e-mail to the e-mail
address set forth below if the sender on the same day sends a confirmatory email and/or if no failure message is received, or (c)
the day following the day (except if not a Business Day then the next Business Day) on which the same has been delivered prepaid to a
reputable national overnight air courier service. Notices, demands and communications, in each case to the respective parties, will be
sent to the applicable address set forth below, unless another address has been previously specified in writing:

 

Notices
to Buyer and, after the Closing, the Company:

 

Alliance PT Buyer, Inc.

c/o Beecken Petty O'Keefe and Company

131 South Dearborn Street

Suite 2800

Chicago, IL 60603

Attention: Troy Phillips, David Poss

E-mail:
tphillips@bpoc.com, dposs@bpoc.com

 

with
a copy to (which will not constitute notice):

 

Kirkland & Ellis LLP

300 North LaSalle Street

Chicago, Illinois 60654

Attention: Ryan D. Harris, P.C.

E-mail:
ryan.harris@kirkland.com

 

Notices
to Seller, and, prior to the Closing, the Company:

 

Seller’s
Representative:

Highline
Management Inc.

535
West 24th Street

New York, NY 10011

 

with
a copy to (which will not constitute notice):

 

McGuireWoods LLP

West Wacker Drive, Suite 4100

Chicago, Illinois 60601

Attention: Geoff Cockrell

E-mail:
gcockrell@mcguirewoods.com

 

    82 

     

    

 

12.4         Assignment.
This Agreement and all of the provisions hereof will be binding upon and inure to the benefit of the Parties and their respective successors
and permitted assigns, except that neither this Agreement nor any of the rights, interests or obligations hereunder may be assigned or
delegated by any Party, by operation of Law or otherwise, without the prior written consent of the other Parties, and any purported assignment
or delegation without such consent shall be null and void; provided that, after the Closing, (a) Seller may assign this Agreement
to any of its beneficial owners or successors, by operation of law or otherwise, and (b) Buyer may collaterally assign its rights
under this Agreement to any of its lenders or financing sources. Buyer and its Affiliates retain all risks and obligations if they enter
into any agreement with any Person that is broader than or inconsistent or conflicts with Buyer’s rights, interests or obligations
hereunder, and any such broader, inconsistent or conflicting right, obligation, covenant or agreement will not be effective or binding
against Seller or its Affiliates.

 

12.5         Severability.
Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable
Law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable Law, such provision will be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions
of this Agreement, and the Parties will amend or otherwise modify this Agreement to replace any prohibited or invalid provision with
an effective and valid provision that gives effect to the intent of the Parties to the maximum extent permitted by applicable Law.

 

12.6         No
Strict Construction; Disclosure Schedules; Headings. The language used in this Agreement will be deemed to be the language
chosen by the Parties to express their mutual intent, and no rule of strict construction will be applied against any Person. The
Disclosure Schedules have been arranged for purposes of convenience in separately numbered sections corresponding to sections of this
Agreement; provided, however, that each section of the Disclosure Schedules will be deemed to incorporate by reference
all information disclosed in any other section of the Disclosure Schedules to the extent that the relevance of such item to such other
section is reasonably apparent. Capitalized terms used in the Disclosure Schedules and not otherwise defined therein have the meanings
given to them in this Agreement. In the event a subject matter is addressed in more than one representation and warranty, Buyer will
be entitled to rely only on the most specific representation and warranty addressing such matter. The specification of any dollar amount
or the inclusion of any item in the representations and warranties contained in this Agreement or the Disclosure Schedules or Exhibits
is not intended to imply that the amounts, or higher or lower amounts, or the items so included, or other items, are or are not required
to be disclosed (including whether such amounts or items are required to be disclosed as material or threatened in writing) or are within
or outside of the ordinary course of business, and no Party will use the fact of the setting of the amounts or the fact of the inclusion
of any item in this Agreement or the Disclosure Schedules or Exhibits in any dispute or controversy between the Parties as to whether
any obligation, item or matter not described or included in this Agreement or in any Disclosure Schedule or Exhibit is or is not
required to be disclosed (including whether the amount or items are required to be disclosed as material or threatened in writing) or
is within or outside of the ordinary course of business for purposes of this Agreement. The information contained in this Agreement and
in the Disclosure Schedules and Exhibits hereto is disclosed solely for purposes of this Agreement, and no information contained herein
or therein will be deemed to be an admission by any Party to any third party of any matter whatsoever (including any violation of Law
or breach of contract). The descriptive headings contained in this Agreement are for convenience of reference only and shall not affect
in any way the meaning or interpretation of this Agreement.

 

    83 

     

    

 

12.7         Amendment
and Waiver. Any provision of this Agreement may be amended or waived only in a writing signed by Buyer, the Company and Seller’s
Representative, and may be waived only in a writing signed by the Party against whom such waiver is to be effective; provided that
(a) Section 7.02 will not be amended or waived without the consent of a majority of the D&O Indemnified Persons
and (b) Sections 6.06, 8.02(c), 12.04(b), 12.12, and this Section 12.07(b) (and any
provision of this Agreement, to the extent an amendment, waiver or termination of such provision would modify the substance of such referenced
Sections) will not be amended, waived or terminated without the consent of the Lenders. No waiver of any provision hereunder or any breach
or default thereof will extend to or affect in any way any other provision or prior or subsequent breach or default. The failure of any
Party to assert any of its rights hereunder shall not constitute a waiver of any of such rights.

 

12.8         Complete
Agreement. This Agreement, together with each Exhibit or Disclosure Schedule hereto, the other Transaction Documents, and each
ancillary agreement, certificate or other document entered into in connection herewith (including the Confidentiality Agreement), contains
the complete agreement by, between and among the Parties and supersede any prior understandings, agreements or representations by, between
or among the Parties, written or oral, which may have related to the subject matter hereof in any way. The Parties agree that prior drafts
of this Agreement and of any provision herein will be deemed to not provide any evidence as to the meaning of any provision hereof or
the intent of the Parties with respect hereto and that such drafts will be deemed joint work product of the Parties. The Parties have
voluntarily agreed to define their rights, Liabilities and obligations respecting the transactions contemplated by this Agreement exclusively
in contract pursuant to and subject to the express terms and provisions of this Agreement; and the Parties expressly disclaim that they
are owed any duties or are entitled to any remedies not expressly set forth in this Agreement (except as required by Law). Furthermore,
the Parties each hereby acknowledge that this Agreement embodies the justifiable expectations of sophisticated parties derived from arm’s
length negotiations; all Parties specifically acknowledge that no Party has any special relationship with another Party that would justify
any expectation beyond that of an ordinary buyer and an ordinary seller in an arm’s length transaction.

 

12.9         Counterparts.
This Agreement may be executed in multiple counterparts (including by means of telecopied signature pages or electronic transmission
in portable document format (pdf)), any one of which need not contain the signatures of more than one party, but all such counterparts
taken together will constitute one and the same instrument.

 

    84 

     

    

 

12.10       Governing
Law; Consent to Jurisdiction. This Agreement, and all claims or causes of action (whether in contract or tort or statute, whether
at Law or in equity) that may be based upon, arise out of or relate to this Agreement or the transactions contemplated hereby or the
negotiation, execution or performance of this Agreement or the transactions contemplated hereby will be governed by and construed
in accordance with the internal Laws of the State of Delaware without regard to its conflicts of Laws principles. SUBJECT TO SECTION 1.02,
SECTION 8.02, AND SECTION 9.07 (EACH OF WHICH WILL GOVERN ANY DISPUTE ARISING THEREUNDER), THE PARTIES TO THIS
AGREEMENT SUBMIT TO THE EXCLUSIVE JURISDICTION OF THE STATE COURTS LOCATED IN WILMINGTON, DELAWARE OR THE COURTS OF THE UNITED STATES
LOCATED IN WILMINGTON, DELAWARE IN RESPECT OF THE INTERPRETATION AND ENFORCEMENT OF THE PROVISIONS OF THIS AGREEMENT AND ANY RELATED
AGREEMENT, CERTIFICATE OR OTHER DOCUMENT DELIVERED IN CONNECTION HEREWITH AND BY THIS AGREEMENT WAIVE, AND AGREE NOT TO ASSERT, ANY DEFENSE
IN ANY ACTION FOR THE INTERPRETATION OR ENFORCEMENT OF THIS AGREEMENT AND ANY RELATED AGREEMENT, CERTIFICATE OR OTHER DOCUMENT DELIVERED
IN CONNECTION HEREWITH, THAT THEY ARE NOT SUBJECT THERETO OR THAT SUCH ACTION MAY NOT BE BROUGHT OR IS NOT MAINTAINABLE IN SUCH
COURTS OR THAT THIS AGREEMENT MAY NOT BE ENFORCED IN OR BY SUCH COURTS OR THAT THEIR PROPERTY IS EXEMPT OR IMMUNE FROM EXECUTION,
THAT THE ACTION IS BROUGHT IN AN INCONVENIENT FORUM, OR THAT THE VENUE OF THE ACTION IS IMPROPER. SERVICE OF PROCESS WITH RESPECT THERETO
MAY BE MADE UPON BUYER BY A REPUTABLE NATIONAL OVERNIGHT AIR COURIER SERVICE IN ADDITION TO ANY OTHER METHOD OF SERVICE AUTHORIZED
BY APPLICABLE LAW.

 

12.11       WAIVER
OF JURY TRIAL. EACH PARTY HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL
BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR THE CONFIDENTIALITY
AGREEMENT. EACH PARTY (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OF THE OTHER PARTIES HAS REPRESENTED, EXPRESSLY
OR OTHERWISE, THAT ANY OF THE OTHER PARTIES WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS
IN THIS SECTION 12.11.

 

12.12       No
Third Party Beneficiaries. Certain provisions of this Agreement are intended for the benefit of, and will be enforceable by, the
D&O Indemnified Persons, Counsel, and the Institutional Holders, as applicable. Except as otherwise expressly provided herein, nothing
expressed or referred to in this Agreement will be construed to give any Person, other than the Parties and the D&O Indemnified Persons,
Counsel, and the Institutional Holders, as applicable, any legal or equitable right, remedy or claim under or with respect to this Agreement
or any provision of this Agreement. Notwithstanding anything to the contrary contained herein, the Lenders will be third party beneficiaries
of Sections 6.06, 8.02(c), Error! Reference source not found.(b), 12.07(b), and this Section 12.12.

 

 

    85 

     

    

 

12.13       No
Additional Representations; Disclaimer; Non-Recourse

 

(a)            Buyer
acknowledges and agrees that it has conducted to its satisfaction, an independent investigation of the financial condition, results of
operations, assets, liabilities, and properties of the Relevant Entities, and, in making its determination to proceed with the transactions
contemplated by this Agreement, Buyer has relied solely on the results of such independent investigation and the representations and
warranties of Seller expressly set forth in Article III and of the Company expressly set forth in Article IV,
respectively, as qualified by the Disclosure Schedules. The representations and warranties of Seller expressly set forth in Article III
and of the Company expressly set forth in Article IV, respectively, as qualified by the Disclosure Schedules, constitute
the sole and exclusive representations, warranties and statements of any kind of any of Seller and the Relevant Entities to Buyer in
connection with the transactions contemplated hereby, and Buyer understands, acknowledges and agrees that all other representations,
warranties and statements in respect of any kind or nature of Seller and the Company, expressed or implied (including any relating to
the future or historical financial condition, results of operations, prospects, assets or liabilities of the Relevant Entities, or the
quality, quantity or condition of the Relevant Entities’ assets), are specifically disclaimed by the Company and Seller.

 

(b)            In
connection with the investigation by Buyer of the Relevant Entities, Buyer has received or may receive from the Relevant Entities certain
financial projections, forward-looking financial statements and other financial forecasts and certain business plan information (the
 “Projections”). Buyer acknowledges and agrees that there are uncertainties inherent in attempting to make such Projections
that Buyer is familiar with such uncertainties, that Buyer is taking full responsibility for making its own evaluation of the completeness,
adequacy and accuracy of the Projections so furnished to it (including the reasonableness of the assumptions underlying such estimates,
projections, forecasts or plans), and that Buyer will not have, and will not assert any, claim against anyone with respect thereto. Accordingly,
Buyer acknowledges that none of the Company, Seller, or any past, present or future direct or indirect member or equity holder, officer,
director, employee, agent or Affiliate of any of the foregoing, whether in an individual, corporate or any other capacity, makes any
representation, warranty or other statement with respect to, and Buyer is not relying on, the Projections, and Buyer agrees that it has
not relied thereon.

 

12.14       Specific
Performance; Other Remedies. The Parties agree that the Parties would suffer irreparable damage prior to a termination in the event
that the Closing is not consummated in accordance with the terms of this Agreement, and that money damages or other legal remedies would
not be an adequate remedy for any such damages. Accordingly, the Parties acknowledge and hereby agree that in the event of any breach
or threatened breach by a Party of its covenants or obligations set forth in this Agreement, the non- breaching Parties will be entitled
to an injunction or injunctions to prevent or restrain breaches or threatened breaches of this Agreement by the breaching Party, and
to specifically enforce the terms and provision of this Agreement to prevent breaches or threatened breaches of, or to enforce compliance
with, the covenants and obligations of the Parties under this Agreement, in addition to any other remedy to which the Parties are entitled
at Law or in equity, including right of the Parties to terminate this Agreement pursuant to Article VIII and to seek money
damages. Buyer the Parties agrees not to raise any objections to the availability of the equitable remedy of specific performance to
prevent or restrain breaches or threatened breaches of this Agreement by any Party.

 

    86 

     

    

 

Each Party hereby waives (a) any defenses
in any action for specific performance, including the defense that a remedy at Law would be adequate, and (b) any requirement under
any Law to post a bond or other security as a prerequisite to obtaining equitable relief.

 

12.15       Consents.
Buyer acknowledges that certain consents to the transactions contemplated by this Agreement may be required from parties to contracts,
leases, licenses or other agreements to which any Relevant Entity is a party (including the contracts set forth on Schedule 4.09(a))
and such consents have not been obtained. Buyer agrees and acknowledges that Seller will have no liability whatsoever to Buyer (and Buyer
will not be entitled to assert any claims) arising out of or relating to the failure to obtain any consents that may have been or may
be required in connection with the transactions contemplated by this Agreement or because of the default, acceleration or termination
of any such contract, lease, license or other agreement as a result thereof. Buyer further agrees that no representation, warranty, covenant
or agreement of the Company or Seller contained herein will be breached or deemed breached and no condition of Buyer will be deemed not
to be satisfied as a result of the failure to obtain any consent or as a result of any such default, acceleration or termination or any
lawsuit, action, claim, proceeding or investigation commenced or threatened by or on behalf of any Person arising out of or relating
to the failure to obtain any consent or any such default, acceleration or termination of such contracts.

 

12.16       Electronic
Delivery. This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments
hereto or thereto, to the extent delivered by means of electronic mail (any such delivery, an “Electronic Delivery”),
will be treated in all manner and respects as an original agreement or instrument and will be considered to have the same binding legal
effect as if it were the original signed version thereof delivered in person. At the request of any Party or to any such agreement or
instrument, each other Party or thereto will re execute original forms thereof and deliver them to all other Parties. No Party or to
any such agreement or instrument will raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement
or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and
each such Party forever waives any such defense, except to the extent such defense related to lack of authenticity.

 

12.17       Deliveries.
Any document or item will be deemed “delivered”, “provided” or “made available” within the meaning
of this Agreement if such document or item (i) is included in the electronic data room (ii) is actually delivered or provided
to Buyer or (iii) is made available upon request, including at any of the Relevant Entities’ offices.

 

		12.18	Seller’s
                                            Representative.

 

(a)            Designation
of the Seller’s Representative. The Seller’s Representative is hereby constituted and appointed as agent and attorney-in-fact
for and on behalf of the Company and each of the Seller with respect to the matters specifically delegated to Seller’s Representative
pursuant to this Agreement. The Seller’s Representative has full authority and power to fulfill the role of the Seller’s
Representative hereunder and under the Escrow Agreement, and to take all actions contemplated by this Agreement and the Escrow Agreement
to be taken by the Company and the Seller, with the ability to execute and deliver all instruments, certificates and other documents
of every kind incident to the foregoing to all intents and purposes and with the same effect as the Company or Seller could do
personally. The death, incapacity, dissolution, liquidation, insolvency or bankruptcy of the Company or Seller will not terminate the
authority and agency of the Seller’s Representative. The power-of-attorney granted in this Section is coupled with an interest
and is irrevocable. The Seller representing a majority or more of the aggregate Interests of the Company will be entitled, at any time
or from time to time, upon at least five (5) Business Days prior written notice to Buyer, to appoint a successor or replacement
Person to serve as the Seller’s Representative hereunder.

 

    87 

     

    

 

(b)            Authority
of the Seller’s Representative. Without limiting the generality of the foregoing appointment, the Seller’s Representative
is authorized and empowered to: (A) in connection with the Closing, execute
and receive all documents, instruments, certificates, statements and agreements on behalf of and in the name of the Company and Seller
necessary or desirable to effectuate the Closing and consummate the transactions contemplated herein; (B) execute and deliver, on
behalf of and in the name of the Company and Seller any amendment to this Agreement so long as the express terms of such amendment do
not both adversely and disproportionately affect the rights or obligations of any such Person as compared to any other of such Persons;
(C) engage and employ, on behalf of the Company and the Seller, any agents and representatives (including legal counsel and other
professionals) and incur such expenses as the Seller’s Representative may in its sole discretion determine necessary or appropriate
in connection with the administration of the foregoing, at the expense of the Company and/or the Seller; (D) pay or cause to be
paid all expenses incurred or to be incurred by or on behalf of the Company and the Seller in connection with this Agreement, or establish
such reserves as the Seller’s Representative may from time to time determine, in its sole discretion, to be necessary or desirable
in connection with the expenses and other costs to be borne by the Company or the Seller hereunder; (E) accept, deliver and receive
instructions and notices to the Company or the Seller required or permitted under this Agreement; (F) take all other actions to
be taken by or on behalf of the Company and Seller and exercise any and all rights that the Company or Seller is permitted or required
to do or exercise under this Agreement; and (G) take all other actions that are either necessary or appropriate in its judgment
for the accomplishment of the foregoing or contemplated by the terms of this Agreement. By his, her, or its execution of this Agreement,
the Company and Seller hereby ratifies and confirms any act of or action by the Seller’s Representative with respect to the subject
matter hereof during the time period prior to the Company’s and Seller’s execution of this Agreement.

 

(c)            Reliance
on Seller’s Representative. Buyer and Seller are entitled to rely exclusively upon any communication given or other action
taken by Seller’s Representative pursuant to this Agreement or the Escrow Agreement and will not be liable for any action taken
or not taken in good faith reliance on a written communication or other written instruction from Seller’s Representative.

 

    88 

     

    

 

(d)            Liability
of Seller’s Representative. Seller’s Representative will not have any Liability to the Company or Seller or any Person
claiming by, through or under the Company or Seller, for or in respect of any of its acts or omissions which are not contrary to the
provisions of this Section 12.18, except to the extent arising out of the Seller’s Representative’s willful misconduct
or gross negligence. Seller will indemnify Seller’s Representative from and against any and all loss, liability or expense
incurred on the part of Seller’s Representative and arising out of or in connection with its duties as Seller’s Representative
or the exercise or non-exercise of its approval rights, as the case may be, including the reasonable costs and expenses incurred by Seller’s
Representative in defending against any claim or liability in connection herewith, and its actual out-of-pocket expenses incurred in
performing its duties as such, so long as such performance of its duties or exercise or non-exercise of its approval rights did not involve
gross negligence or willful misconduct and it was not contrary to the provisions of this Section 12.18.

 

(e)            Expense
Fund Amount. The Seller’s Representative shall use the Expense Fund Amount to pay all costs and expenses incurred by or on
behalf of the Seller’s Representative, in his, her, or its capacity as such, including all costs and expenses incurred in connection
with any pending or threatened dispute or claim with respect to this Agreement or any agreement, document or instrument entered into
pursuant to this Agreement. If the Seller’s Representative determines to release all or a portion of the Expense Fund Amount to
the Company, which shall in no event be later than two (2) years after the Closing Date, such amounts will be distributed to Seller.

 

[Signature pages follow.]

 

    89 

     

    

 

IN WITNESS WHEREOF, the Parties
have executed this Membership Interest Purchase Agreement on the day and year first above written.

 

	 	COMPANY:
	 	 
	 	ALLIANCE INTERMEDIATE HOLDCO, LLC
	 	 
	 	By:	/s/ Richard Leaver
	 	 	Name:	Richard Leaver
	 	 	Title:	Authorized Signatory

 

Signature
Page To

Membership
Interest Purchase Agreement

     

     

    

 

	 	SELLER:
	 	 
	 	ALLIANCE PHYSICAL THERAPY PARTNERS, LLC
	 	 
	 	By:	/s/ Richard Leaver
	 	 	Name:	Richard Leaver
	 	 	Title:	Chief Executive Officer

  

SIgnature
Page To

MEmbership
Interest Purchase Agreement

     

     

    

 

	 	SELLER’S REPRESENTATIVE:
	 	 
	 	HIGHLINE MANAGEMENT INC.
	 	 
	 	By:	/s/ Michael Frost
	 	 	Name:	Michael Frost
	 	 	Title:	Authorized Signatory

 

SIgnature
Page To

Membership
Interest Purchase Agreement

 

     

     

    

 

	 	BUYER:
	 	 
	 	ALLIANCE PT BUYER, INC.
	 	 
	 	By:	/s/ Troy Phillips
	 	 	Name:	Troy Phillips
	 	 	Title:	President

 

Signature
Page to Membership Interest Purchase Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]